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Abstract 
 
The kynurenine pathway is thought to be involved in neurological disorders but its precise 
role and the mechanisms involved have yet to be established.  Tryptophan can be 
metabolised via this pathway to produce the neurotoxic N-methyl-D-aspartate (NMDA) 
receptor agonist, quinolinic acid (QUIN), and the direct generators of reactive oxygen 
species, 3-hydroxykynurenine (3HKYN) and 3-hydroxyanthranilic acid (3HANA), as well 
as the neuroprotective NMDA receptor antagonist, kynurenic acid (KYNA). 
High performance liquid chromatography (HPLC) methods were successfully developed 
and validated for measuring tryptophan, kynurenine, KYNA, 3HANA and anthranilic acid 
(ANA) in blood samples, using absorbance and fluorescence detection.  The method for 
determining 3HKYN using electrochemical detection was more problematic and was only 
used for tryptophan loaded samples and their respective baseline samples. 
Using HPLC, the concentrations of tryptophan, kynurenine, KYNA, 3HKYN and 3HANA 
were measured in the blood of Huntington's disease (HD) patients and patients with 
chronic brain injury, where the injury had occurred at least one year previously.  QUIN 
was also determined for these patients using gas chromatography-mass spectrometry (GC-
MS).  In addition, the dynamics of the kynurenine pathway were investigated following 
oral tryptophan depletion and loading.  In contrast to these chronic conditions, patients 
with acute stroke were also studied.  The concentrations of tryptophan, kynurenine, 
KYNA, ANA and 3HANA were determined in the blood of the stroke patients, examining 
any changes in these concentrations during the two weeks after the stroke.  The extent of 
inflammation and oxidative stress were also assessed for all patients, by measuring the 
levels of neopterin and the lipid peroxidation products, malondialdehyde and 4-
hydroxynonenal. 
Patients with late stage HD showed abnormal tryptophan metabolism via the kynurenine 
pathway, together with increased inflammation and oxidative stress.  Increased levels of 
kynurenine together with increased kynurenine: tryptophan (K:T) ratios, indicating greater 
indoleamine 2,3-dioxygenase (IDO) activity, were observed in blood samples from HD 
patients in comparison with healthy control subjects.  In conjunction with this increased 
IDO activity, there was a decrease in the ratios of KYNA: kynurenine, suggesting 
decreased kynurenine aminotransferase (KAT) activity.  Inflammation, which may be 
stimulating IDO activity, could also be decreasing KAT activity, suggested by negative 
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correlations between the KYNA: kynurenine ratios and the inflammatory marker, 
neopterin.  The inactivity of KAT suggests a small deficiency in KYNA over a long period 
of time which could cause a reduction in NMDA receptor antagonism, resulting in slow 
progressive excitotoxicity contributing to the neurodegeneration in HD.  Low KYNA: 
kynurenine ratios were observed in baseline and tryptophan depleted samples, but after 
tryptophan loading, HD patients showed similar ratios compared with control subjects.  
This suggests that loading may be beneficial for HD patients, as more of the 
neuroprotectant, KYNA can potentially be produced.  However, the results suggest that 
concentrations of the neurotoxin, QUIN, may also be increasing after tryptophan loading.  
Low concentrations of 3HKYN and 3HANA, with no change in QUIN levels, were also 
observed in the blood of HD patients.  3HANA levels continued to be decreased for the 
HD patients after loading.  This may suggest degradation of 3HKYN and 3HANA by 
autoxidation producing reactive oxygen species which could contribute to the high levels 
of oxidative stress found in these patients. 
Tryptophan loading in healthy control subjects showed significant increases in the 
inflammatory marker, neopterin, and in the lipid peroxidation products.  These results 
should be considered when tryptophan loading is used in psychiatric practice and in diets 
high in tryptophan, such as the Atkins diet. 
Patients with severe chronic brain injury showed similar alterations in kynurenine pathway 
metabolism as HD patients, at baseline and throughout the loading and depletion protocols.  
Although the brain injury had occurred at least one year previously, these patients showed 
persistent inflammation and oxidative stress, demonstrated by their increased levels of 
neopterin and lipid peroxidation products compared with healthy controls.  In baseline 
blood samples, there were increased K:T ratios indicating greater IDO activity in the 
patients.  Patients with chronic brain injury showed decreased concentrations of the 
neuroprotectant, KYNA, as well as low KAT activity, indicated by the decreased KYNA: 
kynurenine ratios.  After tryptophan loading, K:T ratios decreased and the KYNA: 
kynurenine ratios increased in patients in comparison with controls, suggesting a reversal 
in the activities of the enzymes IDO and KAT.  Similar levels of the inflammatory marker, 
neopterin, were observed in patients and controls after tryptophan loading.  This suggests 
that these changes in IDO and KAT activities may be related to inflammation.  As for the 
HD patients, patients with chronic brain injury showed lower levels of 3HKYN and 
3HANA in their blood, with no change in QUIN levels.  These metabolites may be 
undergoing autoxidation, producing reactive oxygen species which contribute to the 
ongoing oxidative stress in these patients. 
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The kynurenine pathway was activated following an acute stroke, as indicated by the 
increased K:T ratios, suggesting greater IDO activity.  Stroke patients also had raised 
levels of neopterin and lipid peroxidation products, indicating inflammation and oxidative 
stress.  There were no changes in the blood concentrations of kynurenines, neopterin or 
lipid peroxidation products during the fourteen days after a stroke.  Stroke patients had 
reduced levels of 3HANA in their blood, as observed for the HD and chronic brain injury 
patients.  There were negative correlations between the concentration of 3HANA and the 
volume of the brain lesion, measured by computed tomography (CT) scan, demonstrating 
the importance of the decreased concentrations of 3HANA.  In addition, there were 
increased levels of ANA in the blood of the stroke patients and the ratios of 3HANA: ANA 
also correlated with brain lesion volume.  Another measurement which correlated with 
lesion volume was lipid peroxidation, suggesting that oxidative stress contributes to the 
extent of the brain damage after a stroke.  This may suggest that the role of 3HANA in 
stroke is related to its autoxidation and the generation of reactive oxygen species.   
Increased concentrations of KYNA were observed in patients who died within three weeks 
of having a stroke.  These high levels of KYNA may have been produced following 
excitotoxicity and the generation of free radicals, and may cause excessive NMDA 
receptor blockade or reduced mitochondrial adenosine triphosphate (ATP) synthesis, thus 
contributing to cell death. 
The kynurenine pathway was activated and showed abnormal metabolism in all the patient 
groups, suggesting a potential role for these metabolites in neuronal dysfunction in HD, 
chronic brain injury and acute stroke.  Further work is required to elucidate the role of 
tryptophan metabolites and whether they may have a direct contribution to neuronal 
damage in neurological disorders.  
iv  
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1  Introduction 
1.1  Kynurenine Pathway 
1.1.1  General 
The first indication that kynurenines may have a role in brain function was the report by 
Lapin (1978), who observed convulsions in mice after an intracerebroventricular quinolinic 
acid (QUIN) injection.  In 1981, Stone and Perkins discovered that QUIN was a potent 
excitant of neurones in the central nervous system (CNS), by acting as an agonist at the N-
methyl-D-aspartate (NMDA) sensitive population of glutamate receptors. Intracerebrally 
injected QUIN was shown to produce excitotoxic lesions in the rat brain (Schwarcz et al., 
1983).  Kynurenic acid (KYNA) was discovered to act as an antagonist at glutamate 
receptors (Perkins and Stone, 1982) and helps to prevent the brain damage caused by 
QUIN (Foster et al., 1984a).  Other kynurenines, 3-hydroxykynurenine (3HKYN) and 3-
hydroxyanthranilic acid (3HANA), can produce neuronal damage, largely by generating 
free radical species which cause oxidative stress (Eastman and Guilarte, 1989; Okuda et 
al., 1998).  QUIN can also generate free radicals and cause oxidative cell damage (Rios 
and Santamaria, 1991).  The major components of the kynurenine pathway are shown in 
Figure 1-1.    
1.1.2  N-methyl-D-aspartate Receptor Activity 
Excitatory amino acid-mediated synaptic transmission is the most prevalent excitatory 
system within the mammalian brain.  Glutamate is the main excitatory neurotransmitter in 
the human CNS.  Glutamate is a common amino acid used throughout the human body to 
synthesise proteins (Cooper et al., 2003).  The arrival of action potentials at a synaptic 
terminal of neurones triggers the influx of Ca
2+ ions across the cell membrane from the 
extracellular space into the neuronal terminal (Stone, 1995).  Glutamate is stored in 
synaptic vesicles, and on depolarisation of the nerve terminal, it is released by calcium-
dependent exocytosis into the synaptic cleft.  Post-synaptic ionotropic receptors sensitive 
to NMDA, α-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) and kainate are 
activated.  Glutamate's removal from the synaptic cleft is by a high affinity cellular uptake 
process, back into the pre-synaptic nerve terminal and/or into glial cells.  Excessive 
stimulation of these receptors results in excitotoxicity.  Neuronal excitotoxicity usually 
refers to the death of neurones arising from prolonged exposure to high concentrations of 
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glutamate and the excessive influx of ions and water into the cell.  The resulting overload 
of calcium ions is particularly neurotoxic, leading to activation of enzymes that degrade 
proteins, membranes and deoxyribonucleic acid (DNA) (Fan and Raymond, 2007).    
The synaptic activity of NMDA receptors under normal physiological conditions controls 
cognitive functions, such as learning and memory, as well as sensory and motor abilities 
(Ikonomidou and Turski, 2002).  However, pathological activation of the NMDA receptors 
is thought to cause excitotoxic neuronal damage in ischaemia, epilepsy and Huntington’s 
disease (HD) (Swartz et al., 1990).  QUIN is an endogenous excitatory compound which 
acts as a weak agonist at NMDA receptors and has been suggested to contribute to this 
neuronal damage (Stone and Perkins, 1981; Tsuzuki et al., 1989).    
Functional NMDA receptor complexes consist of a combination of NR1, NR2 and NR3 
subunits.  Molecular studies have identified various subtypes of each of these subunits, 
which result in a range of NMDA receptors, all with distinct distribution, properties and 
regulation.  QUIN has been shown to activate some subtype combinations more than others 
(de Carvalho et al., 1996).  The NR2 subunit contains the glutamate recognition site where 
the agonist binds, and the NR1 subunit contains the glycine recognition site (Parsons et al., 
1998).  NR3 subunits decrease the magnitude of NR1/NR2 receptor-mediated currents or 
form glycine-activated channels with the NR1 subunit alone (Wada et al., 2006).  Glycine 
(or  D-serine) is a co-agonist at NMDA receptors and its binding at the glycine site is 
necessary for receptor activation by the agonist.  There is a cation binding site inside the 
channel where magnesium (Mg
2+) ions bind.  These ions block conductance through the 
channel via voltage-dependent gating.  When the glutamate binding site is occupied by an 
agonist, depolarisation results in removing the voltage-dependent Mg
2+ block within the 
ion channel, leading to Ca
2+ ion influx into the neurones.  NMDA receptors have high 
permeability to Ca
2+ ions (de Carvalho et al., 1996) and NMDA receptor-mediated 
neurotransmission occurs slowly with prolonged opening of the ion channel (Fan and 
Raymond, 2007).  Polyamines, such as spermine and spermidine, are modulators which 
enhance the activation of NMDA receptors, although at high concentrations they can also 
block the receptors (Parsons et al., 1998; St'astny et al., 1999). 
Excessive stimulation of NMDA receptors with glutamate or QUIN results in 
excitotoxicity and many studies have examined the potential role of antagonists at this 
receptor to offer neuroprotection.  Competitive antagonists, often analogues of 
dicarboxylic amino acids, can inhibit NMDA receptor activation by competing with the 
agonist for binding to the glutamate recognition site (Foster and Fagg, 1987).  There is 
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another binding site within the channel where non-competitive NMDA receptor 
antagonists such as dizocilpine (MK-801) block the NMDA channel and receptor 
activation (Foster and Fagg, 1987).  For binding of such antagonists to occur, the agonist 
must already be bound to the receptor.  A further type of antagonism for NMDA receptors 
is inhibition of the glycine binding site.  KYNA is an endogenous antagonist at this site, 
but in healthy brain, its concentration is too low to affect NMDA receptor function.  Its 
levels can be manipulated in the brain by drugs and increased levels have been shown to 
offer neuroprotection in ischaemic gerbils (Speciale et al., 1996).  As well as many other 
synthetic antagonists, 7-chlorokynurenic acid has a much higher affinity for the glycine 
site than KYNA itself (Parsons et al., 1998).    
1.1.3  Tryptophan and Indoleamine 2,3-dioxygenase  
Historically, tryptophan metabolism via the kynurenine pathway was studied in the 1950s 
and 1960s in order to understand its contribution to the synthesis of nicotinamide adenine 
dinucleotide (NAD
+), a coenzyme involved in basic cellular processes (Wolf, 1974).   
Tryptophan is an essential amino acid in the diet being required for protein biosynthesis 
and is a component of dietary proteins, plentiful in foods such as chocolate, oats, bananas, 
milk, meat, turkey and peanuts.  Tryptophan can be metabolised via another pathway to 
form serotonin (5-hydroxytryptamine, 5HT), an important neurotransmitter involved in 
many disorders including depression (Kohl and Sperner-Unterweger, 2007).  Melatonin is 
a hormone produced from tryptophan via 5HT.  It regulates circadian rhythms, with 
melatonin supplements being available for insomnia and jet lag, and is also a powerful 
antioxidant (Nowak and Zawilska, 1998).  The kynurenine pathway is the major route for 
the metabolism of non-protein tryptophan in most tissues.  This oxidative pathway is 
greatly upregulated by an inflammatory or immune response, as this activates one of the 
initial enzymes of the pathway, indoleamine 2,3-dioxygenase (IDO, EC 1.13.11.17), which 
converts tryptophan to kynurenine.      
At least two different enzymes, tryptophan 2,3-dioxygenase (TDO, EC 1.13.11.11) and 
IDO, catalyse the irreversible cleavage of the indole ring of L-tryptophan, leading to the 
formation of formylkynurenine, which is then rapidly metabolised into kynurenine.   TDO 
is a haem-dependent enzyme almost exclusively expressed in liver cells, with a half-life of 
approximately two hours in mammals and specifically oxidises L-tryptophan (Schutz et al., 
1972).  The administration of the substrate L-tryptophan (or an analogue such as α-
methyltryptophan) greatly induces its activity.  TDO activity can also be induced by 
glucocorticoids, causing a decrease in blood tryptophan levels and an increase in levels of 
3  
kynurenine, as demonstrated with hydrocortisone in the perfused rat liver (Green et al., 
1976).  Tryptophan can be transported from the blood to the brain, and hence 
glucocorticoids may cause a depletion of tryptophan in the brain which may cause a 
significant decrease in brain 5HT synthesis (Joseph et al., 1976).  TDO may therefore be 
responsible for depression found in patients chronically treated with glucocorticoids.  One 
of the kynurenine pathway metabolites, 3HANA, can reduce the efficiency of TDO 
(Schutz et al., 1972). 
Hepatic TDO activity is generally considered as the major cause of tryptophan metabolism 
via the kynurenine pathway in the body, but in response to an immune stimulation with 
pokeweed mitogen, Saito et al. (1993a) demonstrated increases in the blood levels of the 
kynurenines,  L-kynurenine and QUIN, although there was a decrease in TDO activity.  
These kynurenines were produced from tryptophan by increased activity of the enzyme 
IDO.   
IDO is a haem-containing protein able to catalyse a reaction between tryptophan and the 
superoxide anion.  With the exception of superoxide dismutase (SOD), IDO is the only 
enzyme known to require the superoxide anion radical as a substrate (Hayaishi et al., 
1977).  Due to its reaction with superoxide, the induction of IDO may be expected to be an 
antioxidant defense mechanism but the superoxide can easily reform.  The superoxide 
anion reduces the inactive ferric form of IDO to an active ferrous form, but IDO is rapidly 
autoxidised back to the ferric form, resulting in the release of superoxide (Takikawa, 
2005).  In contrast to TDO specifically acting on L-tryptophan, IDO may open the indole 
ring of all the indoleamines: 5HT, tryptamine, melatonin, D-tryptophan,  L- or D-5-
hydroxytryptophan, as well as L-tryptophan.  Whereas TDO is predominantly located in 
the liver, IDO is present in most mammalian organs, including the central nervous system, 
intestine, placenta, lung, blood mononuclear phagocytes, epididymis and endocrine system, 
but not in the liver or the kidneys.  In contrast with tryptophan inducing TDO activity, 
increased tryptophan concentrations may inhibit IDO activity, as interferon-γ (IFN-γ) 
stimulation of IDO in human cells in culture was reduced by a 10-fold increase in 
tryptophan levels from 50µM to 500µM (Werner et al., 1988). 
1.1.4  IDO Activity and the Immune System 
IDO is strongly induced by IFN-γ and other pro-inflammatory cytokines, by viruses, by 
bacterial lipopolysaccharide and other signals derived from activated T cells, while anti-
inflammatory cytokines, such as interleukin-4 (IL-4), or growth factors such as 
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transforming growth factor-β (TGF-β), suppress IDO activity (Pfefferkorn, 1984).  This 
suggests that this enzyme is under tight immunological control and that TDO is involved in 
general metabolism while IDO is related to immunological functions.  IDO is activated in a 
variety of inflammatory diseases affecting the brain, such as meningitis, hepatic 
encephalopathy, septicaemia and neurovirological disorders e.g. acquired 
immunodeficiency syndrome (AIDS) (Heyes et al., 1993). 
Munn et al. (1998) demonstrated a physiological role of IDO in the regulation of the 
immune system during pregnancy.  Placental cells express IDO, metabolise tryptophan and 
suppress maternal T cell proliferation, whereby the embryo is protected against rejection.  
Inhibition of IDO with 1-methyltryptophan was shown to cause rapid T cell-induced 
rejection of all allogeneic embryos in pregnant mice (Munn et al., 1998).  In vitro, 
macrophages, induced to express IDO in response to IFN-γ and other signals from 
activating T cells, inhibit T cell proliferation by rapidly consuming tryptophan (Mellor and 
Munn, 2004).  It is interesting that an immune response stimulates IDO activity, which in 
turn, suppresses T cell activity, showing a fine balance between IDO and the immune 
system.  To produce an enhanced immune response, IDO activity would need to be 
inhibited.  There is currently much interest in the inhibition of IDO for the treatment of 
cancer, as increased IDO activity has been implicated in the immune escape of tumour 
cells for a broad spectrum of cancers.  In a murine breast cancer model, inhibition of IDO 
has been shown to improve responses to cancer chemotherapy (Muller et al., 2005).   
Conversely, IDO activity may be useful in reducing the immune response in autoimmune 
diseases and following transplants.  Indeed, Bauer et al. (2005) showed prolonged survival 
of skin allografts in rats after treatment with kynurenine and 3HANA, metabolites that 
would be produced from increased IDO activity.  
IDO also has a role in antimicrobial defense.  Hayaishi et al. (1984) proposed that when 
viruses, bacteria or parasites invade host tissues, interferons are produced by macrophages 
and superoxide is generated by granulocytes.  IFN-γ then induces IDO and tryptophan is 
degraded and depleted.  Further growth of the viruses, bacteria or parasites is thus inhibited 
as tryptophan is an essential amino acid.  Pfefferkorn (1984) demonstrated that IFN-γ 
blocks the growth of Toxoplasmic gondii, a common parasite in humans and animals, by 
inducing IDO in the host cells to degrade tryptophan.  This effect was reversed by 
tryptophan addition in a dose-dependent manner.  Werner et al. (1987) showed that human 
macrophages degraded tryptophan by the induction of IDO by IFN-γ.  This effect was also 
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demonstrated in cultures of human astrocytes, activated by IFN-γ, with IDO inhibiting the 
growth of Toxoplasmic gondii (Oberdorfer et al., 2003).   
1.1.5  IDO and Nitric Oxide Synthase Related Activities 
As well as the kynurenine pathway, the nitric oxide synthase (NOS) pathway is also 
activated in blood monocytes and macrophages after stimulation with bacterial 
lipopolysaccharide or endogenous IFN-γ.  The pathways seem to be interrelated as nitric 
oxide inhibits IDO and the formation of the kynurenines while inhibition of NOS results in 
excessive production of kynurenines (Thomas et al., 1994).  One compound of the 
kynurenine pathway, 3HANA, has been shown to inhibit NOS activity (Sekkai et al., 
1997), while another, picolinic acid, induces its activity (Melillo et al., 1994).  Human 
astrocytes stimulated with IFN-γ increased IDO activity which caused the inhibition of  
toxoplasmal or bacterial growth (Oberdorfer et al., 2003).  However, when these human 
astrocytes were stimulated with a cytokine cocktail to also express inducible NOS (iNOS),  
there was no inhibition of toxoplasmal or bacterial growth, demonstrating that the presence 
of iNOS regulated the IDO activity in the astrocytes.  Nitric oxide is thought to be 
important for neuronal function and plasticity in the CNS, and this interaction may be 
relevant for understanding the physiology and pathology associated with the kynurenine 
pathway.    
1.1.6  Kynurenine 
The conversion of L-tryptophan to L-kynurenine by IDO is the first and rate-limiting step 
for the kynurenine pathway in the brain (Takikawa, 2005).  Infusion of kynurenine, but not 
tryptophan, into the rat brain using a microdialysis technique, increased striatal 
extracellular fluid concentrations of KYNA, demonstrating a low IDO activity in the 
healthy rat brain (Swartz et al., 1990).  Joseph et al. (1978) and Gal and Sherman (1978) 
were the first to identify L-kynurenine in brain tissue.  L-kynurenine is also present in the 
blood and peripheral organs, occurring in low micromolar concentrations.  Kynurenine 
from the periphery can cross the blood-brain barrier into the brain (Joseph and Kadam, 
1979).  About half of brain kynurenine is produced from tryptophan within the CNS, the 
rest originating as peripheral kynurenine (Forrest et al., 2005).  Stone and Connick (1985) 
showed that kynurenine does not directly modify neuronal electrical activity in rat brain 
slices or in isolated neurones.  Kynurenine can be metabolised in mammalian brain to form 
three different products: KYNA, 3HKYN and anthranilic acid (ANA).   
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1.1.7  Kynurenine Aminotransferases and Kynurenic Acid 
KYNA is a neuroprotective product of the kynurenine pathway and is present in the human 
brain (Moroni et al., 1988).  In mammalian peripheral organs, several pyridoxal phosphate-
dependent aminotransferases are able to catalyse the transamination of kynurenine to 
KYNA (Okuno and Kido, 1991).  In the rat and human brain, there are two established 
isoforms of kynurenine aminotransferases (KATs), known as KAT I (EC 2.6.1.64) and 
KAT II (EC 2.6.1.7) (Guidetti et al., 1997).  In addition, a third enzyme, mitochondrial 
aspartate aminotransferase (mitAAT, EC 2.6.1.1), has recently been identified which can 
also produce KYNA from kynurenine in the mammalian brain (Guidetti et al., 2007a).  Km 
values for the action of KAT I and KAT II, partially purified from rat brain, on kynurenine 
have been reported at high micromolar range for KAT II and low millimolar range for 
KAT I, at physiological pH (Guidetti et al., 1997).  The Km value for an enzyme is the 
concentration of substrate that permits half maximal rate of reaction.  KAT I and II differ 
substantially with regard to their pH optimum and substrate specificity.  KAT I is a soluble 
enzyme and has a pH optimum of 9.5-10, preferring pyruvate as a co-substrate and is 
potently inhibited by competing substrates, including glutamine and tryptophan.  KAT II 
acts optimally at physiological pH and preferentially recognises L-kynurenine as a 
substrate.  The KAT II enzyme has a slight preference for 2-oxoglutarate as the co-
substrate and can also transaminate α-aminoadipate and tryptophan, but not glutamine.  
Quisqualate but not tryptophan caused inhibition of KAT II activity (Guidetti et al., 1997).  
The enzyme mitAAT has a pH optimum of 8.0 and a low capacity to transaminate 
glutamine or α-aminoadipate.  This enzyme was inhibited by aspartate, glutamate and 
quisqualate (Guidetti et al., 2007a).  In the human and rat brain, KAT II is primarily 
responsible for the formation of KYNA, as KAT I is potently inhibited by physiological 
concentrations of glutamine and other abundant amino acids (Yu et al., 2004), and low 
levels of mitAAT are present.  In contrast, the enzyme mitAAT played a major role in 
mouse brain (Guidetti et al., 2007a).  KAT II activity showed regional differences in the rat 
brain, with the olfactory bulb having the highest level and the cerebellum having the 
lowest, whereas KAT I was similarly active in most brain areas.   
KYNA has been shown to reduce NMDA-, QUIN-, kainate- and quisqualate-induced 
neuronal excitation, by acting as an antagonist at all three ionotropic glutamate receptors 
(NMDA, AMPA and kainate receptors) and blocking synaptic transmission in the cerebral 
cortex, hippocampus, striatum and spinal cord (Perkins and Stone, 1982; Ganong et al., 
1983; Herrling, 1985; Perkins and Stone, 1985).  KYNA can act at the NMDA receptor as 
7  
a competitive antagonist, shown to inhibit glutamate binding at concentrations of 100μM- 
1mM, but more potently, at concentrations of 10-100μM, binds at the glycine allosteric site 
on the NMDA receptor complex to antagonise receptor function (Moroni et al., 1988; 
Kessler et al., 1989).  As increased glycine can also enhance NMDA receptor activity, the 
site may not be saturated in vivo, implying that under physiological conditions, KYNA has 
the potential to modulate the glycine site (Danysz et al., 1989).  However, concentrations 
of only 0.2-1.5μM KYNA are present in normal human brain tissue, much lower than the 
levels required to antagonise NMDA receptors (Wu et al., 2000), but human brain KYNA 
levels show marked regional differences (Turski et al., 1988).  KYNA is also a potent 
inhibitor of the α7 nicotinic acetylcholine receptor (Hilmas et al., 2001; Stone, 2007), a 
property which is likely to contribute to KYNA’s efficacy as an anti-excitotoxic agent.  
KYNA has been reported to be present in the thalamus, globus pallidus, hippocampus, 
parietal cortex and frontal cortex of the human post-mortem brain, with the highest 
concentration in the caudate nucleus and the lowest in the cerebellum (Turski et al., 1988).  
KYNA can readily enter the extracellular compartment of the brain (Swartz et al., 1990) 
and there is no evidence for enzymic degradation or cellular reuptake, indicating that 
removal from the brain is by passive efflux (Turski and Schwarcz, 1988).  Cerebral KYNA 
levels and function can be regulated by either changes in the levels of its substrate, 
kynurenine, or the activity of KAT (Wu et al., 1992).  The intracellular availability of 
kynurenine for KYNA synthesis is regulated by the large neutral amino acid transporter, 
which controls the uptake of kynurenine in astrocytes (Speciale et al., 1989a).  KYNA can 
also be formed in the brain from the enol tautomer of indole-3-pyruvic acid (IPA), the 
process requiring the presence of oxygen free radicals (Bartolini et al., 2003). 
The neuroprotective properties of KYNA have been demonstrated in several studies in 
vivo.  KYNA was shown to block the excitotoxic action of QUIN on striatal cholinergic 
neurones and prevent the resulting seizures in rats (Foster et al., 1984a).  The destruction 
of cholinergic neurones and impairments in memory-related tasks, following QUIN 
injections into the nucleus basalis magnocellularis in the rat, were prevented by co-
injection of KYNA (Wirsching et al., 1989).  Pretreatment with KYNA reduced infarct 
size and improved neurological outcome after focal cerebral ischaemia in rats (Germano et 
al., 1987). 
KYNA, at increased levels, will act as an antagonist at NMDA receptors and can therefore 
modify excitotoxic vulnerability, neurophysiological activity and behaviour.  Several 
studies have investigated the effect of increasing the concentration of KYNA by using a 
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kynurenine 3-mono-oxygenase (KMO) inhibitor, which blocks the production of the 
neurotoxic kynurenines, 3HKYN, 3HANA and QUIN (Cozzi et al., 1999; Carpenedo et 
al., 2002).  It is therefore unclear whether the beneficial effects observed in these studies 
are from the increase in KYNA or the decrease in 3HKYN, 3HANA or QUIN.  Transgenic 
mice with a genomic disruption of KAT II (Yu et al., 2004) have a transient reduction in 
cerebral KYNA levels present during the first month of life, but KYNA levels return to 
normal thereafter.  These mice were used in a novel experiment to test the hypothesis that 
KYNA reduces the vulnerability of striatal neurones to QUIN-induced neurotoxicity 
(Sapko et al., 2006).  At post-natal day 14, the mice showed a significant reduction in 
KYNA levels but normal levels of 3HKYN and QUIN.  Intrastriatal injections of QUIN 
caused significantly larger lesions than in age-matched wild-type mice, demonstrating a 
neuroprotective effect of KYNA.  Recently, the first selective KAT II inhibitor, (S)-4-
(ethylsulfonyl)benzoylalanine, has been synthesised and shown to inhibit KAT II in vitro 
and in vivo (Pellicciari et al., 2006).  Using microdialysis, this inhibitor decreased the 
levels of extracellular KYNA in the hippocampus of rats and future work with this 
inhibitor should be useful in elucidating the specific roles of KYNA in the brain.  
Elevated levels of KYNA in the brain have resulted after the administration of an 
excitotoxic compound.  QUIN-induced lesions in the rat striatum or hippocampus 
increased KAT II but not KAT I activity and increased KYNA levels (Wu et al., 1992; 
Guidetti et al., 1997; Ceresoli-Borroni et al., 1999).  Systemic administration of kainate, as 
a model for epilepsy, also increased KYNA in the brain and plasma of rats (Baran et al., 
1995).  KYNA production offers neuroprotection, acting as a defense response to the 
excitotoxic insults.  As excitotoxicity generates free radicals, one possible mechanism for 
these increases in KYNA formation is from the generation of nitric oxide, as nitric oxide 
donors have been shown to increase the production of KYNA in cortical brain slices 
(Luchowski and Urbanska, 2007).  However, other neurotoxins, 3HKYN and quisqualate 
suppress KAT II activity (Guidetti et al., 1997).  3HKYN may act by competing with 
kynurenine as the substrate for the KAT II enzyme, producing xanthurenic acid.   
KYNA levels decrease as a result of energy deprivation in rat cortical tissue slices, which 
can be reversed by the addition of 2-oxoacids, a co-substrate for KAT enzymes (Hodgkins 
and Schwarcz, 1998).  However, high concentrations of greater than 125µM KYNA also 
lower the efficacy of heart mitochondrial adenosine triphosphate (ATP) synthesis, by 
activating oxygen consumption and by lowering ATP formation (Baran et al., 2003).  The 
other kynurenines, ANA, 3HKYN and 3HANA can also affect heart mitochondria 
respiratory parameters, but concentrations need to be extremely high, above 1mM.   
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Tryptophan, kynurenine and QUIN showed no effect.  Disturbances in mitochondrial 
function have been associated with neurodegenerative diseases (Beal, 1996), which could 
be attributed to these active kynurenines, especially KYNA.  However, the high 
concentration of over 125µM KYNA needed to alter mitochondrial function is far in 
excess of that found in brain tissue (0.2-1.5μM) (Wu et al., 2000) and therefore this effect 
is unlikely to be relevant in vivo.  3HKYN and 3HANA probably have a more active role 
in impairing mitochondrial function by generating reactive oxygen species, which occurs at 
much lower concentrations (Okuda et al., 1996) than their effects on respiratory 
parameters.  Another detrimental effect of increased levels of KYNA is its potential role as 
a contributory factor in the cognitive impairment in schizophrenia, due to it causing a 
reduction in glutamate receptor function (Schwarcz et al., 2001).  
1.1.8  Kynureninase and Anthranilic Acid 
A second enzyme, kynureninase (EC 3.7.1.3), can metabolise kynurenine into ANA and is 
also responsible for converting 3HKYN to 3HANA.  As well as the KAT enzymes, 
kynureninase also requires pyridoxal phosphate (vitamin B6) and is especially sensitive to 
B6 deficiency.  Elderly subjects after a tryptophan load showed a build up of kynurenine 
and 3HKYN in their plasma and urine, which was decreased by administering vitamin B6 
(Crepaldi et al., 1975).  3HKYN levels were also markedly increased in the brain tissue of 
vitamin B6-deficient neonatal rats (Guilarte and Wagner, 1987).   
ANA is not involved in the major route of the kynurenine pathway metabolism to produce 
QUIN, as kynureninase has much lower activity than KMO, the enzyme responsible for 
converting kynurenine to 3HKYN (Bender and McCreanor, 1982).  However, following 
kynurenine administration, ANA is produced in the brain, and therefore alterations in 
kynurenine levels will also affect ANA concentrations (Chiarugi et al., 1996). 
Although ANA is generally accepted to be biologically inactive, it can interact with copper 
to form an anti-inflammatory complex.  This complex acts as a hydroxyl radical-
inactivating ligand, able to remove the highly injurious hydroxyl radicals at inflammatory 
sites (Miche et al., 1997; Gaubert et al., 2000).  The anthranilic acid-Cu
2+ complex 
increases the Fenton reactivity of copper, producing more hydroxyl radicals, but quickly 
reacts with these radicals to render them inactive, with the overall effect being the removal 
of the hydroxyl radicals.  Due to this property, the synthetic derivative of ANA, 3-
methoxyanthranilate, has been proposed as a potential anti-inflammatory drug (Halova-
Lajoie et al., 2006).  
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1.1.9  Kynurenine 3-mono-oxygenase and 3-Hydroxykynurenine 
The third and main enzyme for kynurenine metabolism, kynurenine 3-mono-oxygenase 
(KMO, kynurenine 3-hydroxylase, E.C.1.14.13.9) metabolises kynurenine to 3HKYN.   
This enzyme has a high affinity for the substrate (Km in the low micromolar range), 
suggesting that, under physiological conditions, it metabolises most of the available 
kynurenine (Bender and McCreanor, 1982).  KMO is localised in the outer mitochondrial 
membranes of brain, liver, placenta, spleen and kidney (Erickson et al., 1992).  Saito et al. 
(1993c) reported that KMO expression increases under inflammatory conditions, 
demonstrated in the ischaemic gerbil brain.   
3HKYN can be converted to xanthurenic acid by the aminotransferases, KAT I and KAT 
II, but these enzymes preferentially convert kynurenine to KYNA in the brain (Guidetti et 
al., 1997). 
1.1.10  3-Hydroxyanthranilic Acid 
3HKYN can be metabolised to form 3HANA by the enzyme, kynureninase.  It is generally 
accepted that L-kynurenine is converted to QUIN via 3HKYN and 3HANA (Bender and 
McCreanor, 1982).  In the mouse brain, Chiarugi et al. (1996) showed that 3HANA is 
predominantly produced by 3HKYN.  In blood, ANA may produce more 3HANA, 
suggested to be due to microsomal hydroxylation of ANA that occurs in the liver (Ueda et 
al., 1978).  In macrophage cultures, no labelled QUIN was formed in medium containing 
labelled ANA, but QUIN was produced in medium containing labelled tryptophan (Saito et 
al., 1993a).  However, exposure of rat cortical brain slices to high concentrations of ANA 
resulted in the rapid production of 3HANA by direct hydroxylation (Baran and Schwarcz, 
1990).  ANA produced an 11-fold higher level of 3HANA compared with the 3HANA 
produced when 3HKYN was added to the brain slices.  Biosynthesis of 3HANA from 
ANA cannot be excluded and may have a functional role in the brain.   
3HANA can also contribute to reduced activity of the immune system, by inhibiting 
proliferation of T cells.  Bauer et al. (2005) showed that kynurenine, 3HKYN and 3HANA 
strongly suppressed T cell proliferation, by causing T cell death, with immune-stimulated 
rat lymphocytes in vitro.  Similarly, kynurenine, 3HKYN and 3HANA suppressed the T 
cell response to an allogeneic stimulus in dendritic cells, and the suppressive effects of 
these compounds were additive (Terness et al., 2002).  Selective T cell apoptosis was 
demonstrated by 3HANA in vitro and in vivo (Fallarino et al., 2002).  A consequence of 
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this reduced immune response mechanism was shown in rats where a mixture of 
kynurenine and 3HANA prolonged the survival of a skin allograft (Bauer et al., 2005). 
1.1.11  Toxicity of 3-Hydroxykynurenine and 3-Hydroxyanthranilic 
Acid by Oxidative Stress 
3HKYN and 3HANA can initially act as antioxidants as they undergo oxidation.   
However, these oxidation reactions generate potent oxidising agents in vivo, and thus 
contribute to oxidative stress.  The redox behaviour of these compounds is dependent on 
the presence of other redox agents (Giles et al., 2003). 
3HKYN levels were increased in the post-mortem brains of humans with neurological 
disorders, such as HD (Pearson and Reynolds, 1992), the AIDS-dementia complex (Sardar 
et al., 1995) and hepatic encephalopathy (Pearson and Reynolds, 1991).  The brain 
concentrations of 3HKYN under these pathological conditions are estimated to be 0.3-
1.2µM, whereas in non-diseased brains, 3HKYN levels are 0.08-0.3µM. 
Intracerebroventricular administration of 3HKYN has been shown to be toxic in animals, 
and causes seizures (Lapin, 1981).  Nakagami et al. (1996) demonstrated that intrastriatal 
injection in rats of 50nmoles 3HKYN induced tissue damage around the injection site.  The 
antioxidant, N-acetyl-L-cysteine, reduced the 3HKYN damage, but the NMDA receptor 
inhibitor, MK-801, failed to protect the brain from 3HKYN toxicity.  This suggests that 
oxidative stress and not the metabolism of 3HKYN into QUIN is causing the toxicity. 
Jhamandas et al. (1990) showed that a single injection of 3HANA into the nucleus basalis 
magnocellularis in rats produced a large decrease in the survival of cholinergic neurones.  
The cause of the toxicity of 3HANA was explained as either the conversion of 3HANA 
into QUIN or the autoxidation of 3HANA producing reactive oxygen species.   
At high concentrations, 3HKYN can be toxic to neurones by generating free radicals 
(Eastman and Guilarte, 1989).  3HKYN and 3HANA were toxic to primary neuronal 
cultures, with 3HANA being much less potent than 3HKYN (Okuda et al., 1998).  Other 
metabolites of the kynurenine pathway, including kynurenine and ANA, were not toxic, 
suggesting that it is the o-aminophenol structure, common to 3HKYN and 3HANA, which 
is important for toxicity.  o-Aminophenol compounds readily undergo several steps of 
oxidation reactions initiated by their oxidative conversion to quinoneimines, which are 
highly reactive and continue to oxidise.  During these oxidation processes, various reactive 
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oxygen species are produced.  The products of 3HKYN autoxidation, including hydrogen 
peroxide and xanthommatin, contribute to oxidative stress (Hiraku et al., 1995; Vazquez et 
al., 2000). 
3HANA autoxidation has been suggested to involve 2 steps: the first producing the 
quinoneimine and converting molecular oxygen to the superoxide anion, the second 
condensation and oxidation reactions requiring molecular oxygen to form cinnabarinic acid 
and hydrogen peroxide (Dykens et al., 1987; Hiraku et al., 1995).  Under hypoxic 
treatment, there was no autoxidation of 3HANA, demonstrating that the reaction requires 
oxygen (Dykens et al., 1987). 
The potency of 3HKYN and 3HANA is a quarter to a third of the oxidising capacity of 
hydrogen peroxide, but considerably stronger than glutathione disulfide, the common 
cellular oxidant (Giles et al., 2003). 
In primary neuronal cultures from the rat striatum, 1µM 3HKYN caused toxicity resulting 
in approximately 50% cell death after 48h, with increased toxicity at 10µM and 100% cell 
death at 100µM but no toxicity at 0.1µM (Okuda et al., 1996).  3HKYN concentrations of 
1µM were comparable to those found in diseased human post-mortem brains.  Cultures 
from the striatum were chosen as this is a brain region where there is marked neuronal loss 
in HD.  3HANA required a concentration of greater than 10µM for 48h to demonstrate cell 
death (Okuda et al., 1998).  Cell lysis was shown to be a delayed effect, using hybrid 
neuronal cells in culture (Eastman and Guilarte, 1989).  Following 2 hours exposure to 
500µM 3HKYN, little cell lysis occurred, but removing the 3HKYN exposure and 
continuing to incubate the cells in fresh medium resulted in greater than 85% cell death 
after 8-12 hours.   
Transition metal ions are required for 3HKYN and 3HANA toxicity, as iron chelation with 
desferrioxamine was able to inhibit 3HKYN-induced cell lysis (Eastman and Guilarte, 
1990; Okuda et al., 1996).  Iron ions can contribute to oxidative damage either by 
catalysing the autoxidation of 3HKYN or enabling the reduction of hydrogen peroxide to 
form the highly reactive hydroxyl radical, able to cause damage to macromolecules, such 
as DNA, proteins and lipid membranes.  Goldstein et al. (2000) showed that 3HKYN and 
3HANA in phosphate buffered saline (PBS) solution can potently reduce copper (Cu
2+ ions 
forming Cu
+) and to a lesser extent iron (Fe
3+ ions forming Fe
2+) at physiological pH.  
Other kynurenines, including kynurenine, ANA, and QUIN, were unable to reduce these 
transition metal ions.  Even in the presence of trace metals in the PBS, 10µM 3HKYN and 
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3HANA could generate superoxide, but not hydrogen peroxide.  When the metal chelator, 
diethylenetriaminepentaacetic acid (DTPA), was added, neither 3HKYN nor 3HANA 
could produce superoxide, indicating that superoxide generation by 3HKYN and 3HANA 
are metal-dependent reactions.  3HKYN and 3HANA can generate hydrogen peroxide in 
the presence of Cu
2+ ions.  Both 3HKYN and 3HANA generated approximately 3-fold 
more hydrogen peroxide than was expected from the available copper.  It was suggested 
that copper may act as a catalyst, cycling between the reduced state produced by its 
reaction with 3HKYN, and the oxidised state produced by reacting with molecular oxygen.   
In biological systems, most redox-active metals are bound to protein and small 
biomolecules.  Whilst these metal ions are not free, they could still catalyse some reactions 
similar to those observed with the free ions.  With inflammation or infection, local acidosis 
occurs, which liberates copper and iron from proteins, so they are more available for redox 
reactions.  As inflammation or infection also stimulates the activity of the kynurenine 
pathway by activating IDO, increased levels of 3HKYN and 3HANA will be generated.  
Together, the free metal ions and the increased 3HKYN and 3HANA concentrations may 
well increase the production of reactive oxygen species such as superoxide and hydrogen 
peroxide (Goldstein et al., 2000).   
Several features of apoptosis were observed in 3HKYN-mediated neuronal cell death 
(Okuda et al., 1998).  Apoptosis is the mechanism of cell death known to often occur 
where cell death is induced by reactive oxygen species and has been implicated as the 
mechanism of neuronal damage in neurodegenerative diseases such as HD (Portera-
Cailliau et al., 1995).  Wei et al. (2000) demonstrated that 3HKYN induced apoptosis in 
cerebellar granule cells and neuronally-related cell lines at high concentrations (>200µM), 
mainly by producing hydrogen peroxide, thought to be formed by autoxidation of 3HKYN 
in extracellular compartments.   More evidence for a role of 3HKYN in neuronal cell death 
was shown by Jeong et al. (2004) where increased reactive oxygen species and increased 
caspase activity were involved in 3HKYN-induced apoptosis in a human neuroblastoma 
cell line.  Lee et al. (2001) demonstrated 3HKYN-induced apoptosis in neuroblastoma 
cells and identified protection from this toxicity by heat shock proteins (HSP), in 
particular, HSP90, which inhibits caspases.  Lee et al. (2004) showed that 3HKYN-
induced neuronal cell death is associated with mitochondrial dysfunction and caspase 
activity.  Following stimulation of IDO with IFN-γ, apoptosis was demonstrated in 
monocyte-derived cells in culture (Morita et al., 2001).  3HANA, but not 3HKYN or 
QUIN, induced apoptosis in these cells, and apoptosis was enhanced by the presence of 
redox-active metals
 ions.   
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The toxic effects of 3HKYN were abolished in the presence of many antioxidants, 
including catalase, glutathione, α-tocopherol,  N-acetylcysteine and spin trapping agent, 
3,3,5,5-tetramethylpyrroline N-oxide (TMPO), indicating that oxidative stress, particularly 
resulting from the production of hydrogen peroxide and the hydroxyl radical, is involved in 
3HKYN toxicity (Eastman and Guilarte, 1989; Okuda et al., 1996; Okuda et al., 1998).  It 
has been proposed that 3HKYN and 3HANA do promote the hydroxyl radical formation 
but simultaneously act as a site for hydroxyl radical attack, due to their initial antioxidant 
properties (Goldstein et al., 2000).  This suggests that continued oxidation of 3HKYN or 
3HANA occurs due to reaction with the hydroxyl radical.  3HKYN has been shown to 
scavenge hydroxyl radicals (Leipnitz et al., 2007). 
The antioxidant enzyme, SOD, was not capable of reducing 3HKYN toxicity in neuronal 
cell cultures, which suggests that superoxide is not involved in cell lysis (Eastman and 
Guilarte, 1989; Okuda et al., 1996; Okuda et al., 1998).  The superoxide anions formed 
from 3HANA autoxidation may be removed by SOD or transition metal cations.  By 
removing this product of the reaction, the reverse reaction would be prevented and would 
result in accelerated 3HANA autoxidation (Dykens et al., 1987; Ishii et al., 1990).  A 
similar mechanism may occur for 3HKYN.  With an inflammatory or immune stimulus, 
IDO activity is increased and this is expected to increase the concentrations of 3HKYN and 
3HANA.  IDO uses superoxide as a substrate and hence its removal of superoxide may 
promote the autoxidation of 3HKYN and 3HANA (Goldstein et al., 2000). 
Xanthine oxidase is also involved in 3HKYN toxicity as the addition of allopurinol, an 
inhibitor of xanthine oxidase, offered significant protection against 3HKYN toxicity 
(Okuda et al., 1996).  Xanthine oxidase may catalyse the oxidation of 3HKYN to produce 
hydrogen peroxide.  Alternatively, low concentrations of 3HKYN may stimulate xanthine 
oxidase activity, producing more free radicals from other oxidative reactions catalysed by 
this enzyme.   
3HKYN toxicity from the accumulation of hydrogen peroxide has been demonstrated to 
occur intracellularly, with catalase and desferrioxamine able to act intracellularly to 
prevent toxicity (Eastman and Guilarte, 1990) and catalase and allopurinol both able to 
reduce intracellular hydrogen peroxide (Okuda et al., 1996).  Nicotinamide adenine 
dinucleotide phosphate (NADPH) diaphorase-containing neurones were spared from 
3HKYN toxicity in cell culture, as they are in HD.  NADPH diaphorase is contained in the 
specific aspiny neuronal subpopulation, co-localised with somatostatin and neuropeptide 
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Y.  These neurones may have the ability to detoxify oxygen free radicals and are generally 
resistant to oxidative stress (Okuda et al., 1996).   
Different brain regions may demonstrate different susceptibility to 3HKYN toxicity.  In 
culture, cortical and striatal neurones were extremely vulnerable to 3HKYN toxicity, with 
hippocampal neurones being less susceptible and cerebellar neurones resistant to 3HKYN 
toxicity (Okuda et al., 1998).  Neither 3HANA nor hydrogen peroxide toxicity showed this 
regional selectivity.  Extracellular 3HKYN can be taken up by cells either by sodium- 
independent or sodium-dependent cellular uptake mechanisms (Eastman et al., 1992), but 
there was a predominant role for the sodium-dependent process for the uptake of 3HKYN 
into striatal neurones (Okuda et al., 1998).  Competitive inhibition of 3HKYN uptake by 
an excess amount of another substrate for these transport systems, such as tryptophan, 
blocked 3HKYN neurotoxicity (Okuda et al., 1998).  This suggests that the differences in 
susceptibility to 3HKYN toxicity of the neurones from different brain regions are due to a 
difference in transporter activities of these neurones.  Cerebellar neurones, with little 
sensitivity to 3HKYN toxicity, have poor ability to take up large neutral amino acids 
compared with striatal neurones with high sensitivity to 3HKYN toxicity.  This evidence 
was supported by Speciale and Schwarcz (1990) who showed that sodium-dependent 
kynurenine uptake activity was greatest in the cortex, followed by the striatum, then by the 
hippocampus, which were all much greater than uptake in the cerebellum.   
To counteract oxidative stress in vivo, there are several antioxidant defense mechanisms 
which consist of enzymes (e.g. superoxide dismutase, catalase, glutathione peroxidase), 
transition metal binding proteins and small molecular weight antioxidants (e.g. ascorbic 
acid, α-tocopherol).  Potential therapies to reduce oxidative stress induced by 3HKYN or 
3HANA include the chelation of redox-active metal ions or displacement with non-redox-
active metal ions (Goldstein et al., 2000).  
1.1.12  Antioxidant roles for 3-Hydroxykynurenine and                 
3-Hydroxyanthranilic Acid 
In contrast, 3HKYN and 3HANA have been shown to exhibit antioxidant properties.   
Christen et al. (1990) showed that low micromolar concentrations of 3HKYN and 3HANA 
scavenged peroxyl radicals with high efficiency, being more protective than equimolar 
concentrations of ascorbate or Trolox (water soluble analogue of Vitamin E).  IFN-γ 
induced kynurenine pathway metabolism in human peripheral blood mononuclear cells and 
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monocyte-derived macrophages, with physiological levels of tryptophan added.  This 
resulted in increased levels of 3HANA, which could inhibit low density lipoprotein (LDL) 
oxidation when LDL was added (Christen et al., 1994).  Further work (Thomas et al., 
1996) demonstrated that 3HANA inhibited peroxidation of LDL and proposed that 
3HANA is a localised extracellular antioxidant defense against LDL oxidation in 
inflammation.  Leipnitz et al. (2007) showed that the addition of 3HKYN and 3HANA to 
rat cerebral cortex, in vitro, and C6 glioma cells demonstrated antioxidant properties.  Both 
compounds prevented lipid peroxidation and reduced peroxyl radicals.  3HANA prevented 
spontaneous glutathione oxidation in the cerebral cortex.  3HKYN could scavenge hydoxyl 
radicals.  3HANA can also have an anti-inflammatory protective effect by inducing haem 
oxygenase-1, which could offer protection in vascular injury such as atherosclerosis (Pae et 
al., 2006).     
1.1.13  Quinolinic Acid 
3HANA is readily converted to QUIN by the enzyme, 3-hydroxyanthranilate 3,4-
dioxygenase (3HAO, EC 1.13.11.6) (Foster et al., 1986).  3HAO catalyses 3HANA into an 
intermediate product, aminocarboxymuconic semialdehyde, which then preferentially 
converts to QUIN by a non-enzymic cyclisation.  This intermediate product can also 
produce picolinic acid instead of QUIN (Forrest et al., 2005).  
Wolfensberger et al. (1983) and Moroni et al. (1984) demonstrated the presence of QUIN 
in the rat and human brain.  The endogenous concentration of QUIN in healthy mammalian 
brain tissue has been reported as being 50-100nM and in human cerebrospinal fluid (CSF) 
has been shown to  be 10-35nM (Heyes et al., 1992a; Moroni, 1999).  For patients with 
inflammatory diseases, including various types of infections, meningitis, autoimmune 
diseases and septicaemia, increased levels of QUIN have been shown in both CSF and 
post-mortem brain tissue (Heyes et al., 1992a).  In patients affected by the AIDS-dementia 
complex, the increase in QUIN levels in the CSF were over 20-fold and correlated with the 
severity of cognitive and motor disorders (Heyes et al., 1991a).  After traumatic brain 
injury (TBI), QUIN concentrations in the CSF were increased to between 5 and 50-fold, 
being higher in the patients who subsequently died (Sinz et al., 1998).  QUIN 
accumulation occurs in the brains of experimental animal models of inflammatory 
neurologic diseases such as poliovirus brain infection (Heyes et al., 1992b), cerebral 
malaria (Sanni et al., 1998) and ischaemic brain disease (Saito et al., 1993b). 
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In 1981, Stone and Perkins discovered that QUIN was a potent excitant of cortical 
neurones in the rat brain by acting as an agonist at NMDA receptors.  Administration of 
QUIN directly into the rat striatum, produced "axon-sparing" lesions, with marked 
swelling of dendrites and loss of cell structure in postsynaptic sites, but generally good 
preservation of axons and presynaptic terminals (Schwarcz et al., 1983; McGeer and 
Singh, 1984).   No loss in glial cells was observed.  Doses as low as 12nmoles QUIN 
caused neuronal loss around the injection site in the striatum (Schwarcz et al., 1983).   
Areas of the brain most sensitive to QUIN neurotoxicity are the hippocampus and striatum 
(Schwarcz and Kohler, 1983).  Within these brain areas, some neuronal cell types are more 
sensitive than others, with cholinergic neuronal death in the striatum observed following 
QUIN injection (Foster et al., 1983) and preferential susceptibility of pyramidal cells in the 
hippocampus (Schwarcz et al., 1983).  Striatal spiny neurones containing the 
neurotransmitter γ-aminobutyric acid (GABA) and substance P are also sensitive to QUIN 
toxicity, with the subclass of striatal aspiny neurones containing somatostatin and 
neuropeptide Y being preserved (Beal et al., 1986).  QUIN acts selectively at NMDA 
receptors, specifically with NMDA receptor subtypes containing the NR2A and NR2B 
subunits (de Carvalho et al., 1996), with massive calcium entry into neurones, and 
therefore it is where these receptor subtypes are present that QUIN exerts the greatest 
damage to neurones.  In rats, intrastriatal injection of QUIN resulted in an initial period of 
involuntary movements and intrahippocampal injection triggered convulsions (Foster et 
al., 1983). 
The enzyme, quinolinate phosphoribosyltransferase (QPRT, EC 2.4.2.19) metabolises 
QUIN to form nicotinic acid ribonucleotide, which can then be metabolised to NAD
+.  
QPRT is present primarily in glial cells but is often found in cytoplasmic bodies separated 
from the rest of the cell, which may prevent the enzyme from accessing and metabolising 
QUIN as it is formed (Stone and Darlington, 2002).  There are substantially fewer cells 
that contain QPRT than contain 3HAO (Kohler et al., 1988), suggesting that after 
stimulation of the kynurenine pathway, QUIN could accumulate.   
Excitotoxicity induced by QUIN causes overactivation of NMDA receptors resulting in 
excessive Ca
2+ ions entering the neurones.  Mitochondrial dysfunction was shown by the 
reduction in mitochondrial oxygen consumption and a reduction in ATP levels following 
QUIN injection into the rat striatum (Bordelon et al., 1997).  This could be caused by 
calcium loading of the mitochondria, which increases the production of free radicals.   
Mitochondrial dysfunction may be a critical event in the cell death cascade of QUIN 
excitotoxicity (Bordelon et al., 1997).  
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QUIN has been shown to cause neuronal death in human foetal brain tissue in culture at 
concentrations of 5 and 10mM, examined after 20 hours exposure (Kerr et al., 1995).  
Increases in the levels of QUIN have been observed for several inflammatory neurological 
disorders, but levels in the CSF (low micromolar) are still lower than those able to cause 
neuronal death in vitro (Heyes et al., 1992a).  However, these effects may still be relevant 
as different neuronal populations may be selectively affected by QUIN, or alternatively, 
the neurotoxic potency of low concentrations of QUIN may increase during chronic 
exposure. Chiarugi et al. (2001) demonstrated that the neurotoxic threshold concentration 
of QUIN can be decreased from 100µM to 1µM by prolonging the time of exposure from 
24 to 72 hours in primary cultures of mixed cortical cells (containing both neurones and 
glial cells).  Excitotoxic damage was also shown in cultures of a rat corticostriatal system, 
but not in cultures of caudate nucleus, exposed to 100nM QUIN for 7 weeks (Whetsell and 
Schwarcz, 1989).     
QUIN has a high in vivo potency as an excitotoxin, which cannot be fully explained by its 
activation of NMDA receptors (Foster et al., 1983).  This may be caused by a high local 
concentration of QUIN at the synapse (Schwarcz, 1993) or the absence of effective 
removal mechanisms for extracellular QUIN (Foster et al., 1984b).  However, it is likely 
that an additional mechanism is also involved (Foster et al., 1983) as QUIN is able to 
readily generate damage-producing free radicals.  High concentrations of QUIN (20-
80µM) induced an increase in lipid peroxidation of up to 50% in rat brain homogenates 
after 30 minutes (Rios and Santamaria, 1991) and in vivo, intrastriatal injection of QUIN in 
the rat increased lipid peroxidation and caused neuronal damage (Santamaria and Rios, 
1993).   
The potent antioxidant, melatonin, when co-injected with QUIN into the rat hippocampus, 
inhibited the formation of lipid peroxidation products (Behan et al., 1999).  Similarly, 
deprenyl, which scavenges free radicals and/or stimulates antioxidant enzymes, also 
prevented QUIN-induced lipid peroxidation in the rat hippocampus.  Following QUIN 
intrastriatal injections in rats, a reduction in the level of the antioxidant glutathione, with 
simultaneous increases in its product glutathione disulphide, was shown (Rodriguez-
Martinez  et al., 2000).  There was no change in glutathione peroxidase, which 
demonstrated a non-enzymatic mechanism of conversion of this endogenous antioxidant.  
Leipnitz et al. (2005) confirmed that QUIN reduced the brain non-enzymatic antioxidant 
defenses in rat brain homogenates in vitro.  In addition, Rodriguez-Martinez et al. (2000) 
showed that cytosolic copper, zinc-dependent superoxide dismutase (CuZn-SOD) activity 
decreased after QUIN intrastriatal injection but mitochondrial manganese-dependent 
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superoxide dismutase (Mn-SOD) was not affected, suggesting that the intrastriatal toxicity 
of QUIN involves cytoplasmic oxidative injury.  The antioxidant enzymes, CuZn-SOD and 
Mn-SOD can both reduce the concentrations of superoxide anions and prevent cell 
damage.   
Stipek et al. (1997) showed that iron (as Fe
2+ ions) is necessary for QUIN to demonstrate 
increased lipid peroxidation in rat brain homogenates, with the iron chelator, 
deferoxamine, completely preventing this effect.  QUIN concentrations of 0.15 - 2.5mM 
stimulated lipid peroxidation over a range of concentrations of Fe
2+ ions.  Concentrations 
higher than 3mM inhibited lipid peroxidation, but such levels are unlikely to be reached in 
vivo.  QUIN chelates Fe
2+ ions but not Fe
3+ ions, forming a QUIN-Fe
2+ complex (Stipek et 
al., 1997; Iwahashi et al., 1999).  It is interesting that the addition of Fe
2+ ions increased 
lipid peroxidation in rat brain homogenates, without any QUIN present (Zaleska and 
Floyd, 1985).  Fe
2+ ions themselves induce lipid peroxidation as they catalyse the 
production of the hydroxyl radical from hydrogen peroxide via the Fenton reaction.   
Fe
2+ + H2O2 → Fe
3+ + ·OH + OH
-    FENTON  REACTION 
The Fe
3+ ions produced can be recycled back to Fe
2+ ions by reacting with more hydrogen 
peroxide.  Both iron salts and hydrogen peroxide are available in vivo for the Fenton 
reaction.  QUIN may act like other iron chelators, such as ethylenediaminetetraacetate 
(EDTA), which can also either stimulate or inhibit iron-dependent lipid peroxidation, 
depending on their concentration (Halliwell and Gutteridge, 1984).  In phosphate buffer, 
the QUIN-Fe
2+  chelate enhanced the formation of the hydroxyl radical via the Fenton 
reaction compared with Fe
2+ ions alone (Iwahashi et al., 1999).  Further investigation of 
the mechanism has suggested that the QUIN-Fe
2+ chelate is relatively stable at 
physiological pH, with slow autoxidation, and although this initiates the generation of 
hydroxyl radicals via the Fenton reaction, a further QUIN derivative is formed, which 
enables redox cycling of Fe
2+ and Fe
3+ ions, thus maintaining hydroxyl radical formation 
(Platenik et al., 2001).  The QUIN-Fe
2+ complex was shown to be responsible for in vitro 
DNA chain breakage and lipid peroxidation mediated by hydroxyl radicals (Goda et al., 
1996).  The ratio of Fe
2+: Fe
3+ ions is critical for the initial rate and extent of lipid 
peroxidation, the most potent ratio being 1:1.  QUIN reduces this ratio by complexing the 
Fe
2+ ions, and ascorbate, or an equivalent reducing agent, increases the ratio by reducing 
Fe
3+ to Fe
2+ ions (Stipek et al., 1997).   
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Iron is normally present in the body in a highly bound state, often bound to proteins such 
as transferrin and ferritin.  However, there is a small pool of non-protein bound iron in the 
body, and free iron has been detected in the CSF (2.2μM) but not in serum or plasma 
(Halliwell and Gutteridge, 1984).  This level of free iron is sufficient to react with QUIN to 
stimulate lipid peroxidation (Stipek et al., 1997).  However, in conditions of oxidative 
stress, superoxide or other reducing agents in the body can release Fe
2+ ions from bound 
Fe
3+ ions (Halliwell and Gutteridge, 1984).  QUIN concentrations of approximately 
100μM (Stipek et al., 1997; Leipnitz et al., 2005) were required to interact with Fe
2+ ions 
and stimulate lipid peroxidation, which are much higher than the levels present in the 
human brain (<40nM in CSF), with CSF levels increasing to a mean of 1.3μM for patients 
with the AIDS-dementia complex (Heyes et al., 1991a).  However, with the activation of 
IDO activity, QUIN concentrations could potentially increase to levels which would 
stimulate lipid peroxidation in discrete brain areas (Stipek et al., 1997).   
It is still unclear whether QUIN-induced lipid peroxidation involving its chelation with 
iron is independent from QUIN activation of NMDA receptors.  Leipnitz et al. (2005) 
prepared rat cerebral cortex homogenates free of nuclei and cell debris, therefore not 
containing NMDA receptors, and still demonstrated that QUIN addition induced lipid 
peroxidation and a reduction in antioxidants.  The antioxidant, melatonin, was able to 
prevent QUIN but not NMDA neuronal damage in the rat hippocampus, showing that the 
QUIN toxicity was, at least in part, independent of NMDA receptor activation (Behan et 
al., 1999).  It is therefore unlikely that the significant induction of oxidative stress by 
QUIN was due to NMDA receptor activation causing free radical synthesis.  However, 
NMDA receptor inhibitors were shown to block QUIN-induced lipid peroxidation, with 
trace amounts of Fe
2+ ions present.  QUIN-induced lipid peroxidation was prevented by 
KYNA in vitro (Rios and Santamaria, 1991) and by the non-competitive NMDA receptor 
antagonist, MK-801, in vivo (Santamaria and Rios, 1993).  However, with added Fe
2+ ions, 
the QUIN-Fe
2+ complex inhibited the binding of radiolabelled MK-801 (St'asny et al., 
1999).  An alternative approach was used by Behan and Stone (2002) where the 
neurotoxicity of QUIN was shown to be increased when a source of free radicals were 
injected with QUIN into the rat hippocampus.  Both xanthine/xanthine oxidase mixture and 
the nitric oxide donor, S-nitroso-N-acetylpenicillamine (SNAP), as sources of free radicals, 
increased the neuronal damage produced by QUIN.  The NMDA receptor antagonist, 5,7-
dichlorokynurenic acid, prevented the damage by QUIN alone but not the damage 
produced by QUIN and xanthine/xanthine oxidase, showing that the damage was not 
simply caused by free radical enhancement of NMDA receptor activation.  It may be that 
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hydroxyl radical formation has to be instigated by hydroxyl radical attack of QUIN.  Under 
the experimental conditions in the healthy rat as described by Behan and Stone (2002), 
these initial hydroxyl radicals may result from NMDA receptor activation by QUIN, but in 
a disease state, the initial hydroxyl radicals could be from a range of sources.  In 
neurological disorders, the damage produced by QUIN is partly dependent on the 
inflammatory response, where activated microglia and macrophages infiltrate the brain and 
produce reactive oxygen species (Behan et al., 1999).  This extra contribution of reactive 
oxygen species could act with QUIN to produce neuronal damage.  Free radicals 
themselves enhance the release of glutamate from the synapse and this effect could lead to 
maintaining NMDA receptor activation.  It can be concluded that the high potency of 
QUIN toxicity to neurones is the result of synergism between the activation of NMDA 
receptors and the formation of free radicals.  The combined mechanisms may be required 
for neuronal death (Behan et al., 1999).   
In contrast to the effect of Fe
2+ ions, copper ions (Cu
2+ ions) were shown to protect against 
the neurotoxicity of QUIN in the rat striatum (Santamaria et al., 2003).  Intraperitoneal 
injection of copper sulphate 30 minutes before an intrastriatal injection of QUIN reduced 
QUIN excitotoxicity measured both as circling behaviour of the rats and depletion in 
striatal GABA content, suggesting that Cu
2+ ions were inhibiting QUIN’s activation of 
NMDA receptors.  It has been suggested that Cu
2+ ions may act on an extracellular binding 
site of the NMDA receptor, probably a redox-modulatory site.  In addition, Cu
2+  ions 
blocked the striatal lipid peroxidation and reverted the decreased levels of CuZn-SOD back 
to normal in these QUIN-treated rats.  Therefore, Cu
2+ ions also had antioxidant properties.  
Free reduced copper ions (Cu
+) are in short supply in the CNS and this may be the reason 
why copper does not participate in the Fenton reaction in a similar way to Fe
2+  ions.  
Indeed copper is almost exclusively bound to proteins (Halliwell and Gutteridge, 1984).  
Cu
2+  ions were shown to increase the ferroxidase activity of ceruloplasmin (a protein 
containing bound copper) in the CSF of rats after QUIN injection (Santamaria et al., 2003), 
suggesting an interaction between copper and iron ions, which may affect the oxidative 
activity in the brain.  This interaction has yet to be fully investigated.  It was interesting 
that the higher doses of Cu
2+ ions (7.5 and 10.0mg/kg) used in this study were toxic to the 
rats (Santamaria et al., 2003).    
QUIN excitotoxicity can be modulated by other endogenous kynurenines.  With focal 
injections into the rat nucleus basalis magnocellularis, Jhamandas et al. (1990) 
demonstrated that although KYNA was the most effective against QUIN-induced 
cholinergic damage, giving complete protection at a ratio of 1:1, picolinic acid could also 
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completely prevent such damage but at a much higher ratio of 1:4 (QUIN: picolinic acid).  
The neuroprotective effect of picolinic acid shown in this study is inconsistent with the 
results of Robinson et al. (1985), where picolinic acid was poor as an antagonist at 
synaptically evoked responses in rat hippocampal slices, which could be blocked by 
KYNA.  Indeed, picolinic acid did not effectively block QUIN-induced damage to striatal 
cholinergic neurones (Jhamandas et al., 1990).  The neuroprotective effect of picolinic acid 
does not seem to occur as an interaction with NMDA receptors.  ANA and quinaldic acid 
were shown to give partial protection against QUIN-induced neuronal damage.  In certain 
neurodegenerative disorders, the balance of endogenous excitotoxins and antagonists 
(including KYNA, picolinic acid and ANA) may influence neuronal survival.  However, 
another kynurenine metabolite, 3HKYN, enhanced QUIN toxicity (Guidetti and Schwarcz, 
1999). 
1.1.14  Synergy between 3-Hydroxykynurenine and Quinolinic                  
Acid 
In rats, intrastriatal co-injections of 5nmoles 3HKYN and 15nmoles QUIN, doses which 
caused no degeneration on their own, together showed substantial neuronal loss 4 days 
after injection, demonstrated behaviourally (apomorphine-induced rotations) and 
histologically (lesion volume) (Guidetti and Schwarcz, 1999).  This suggests that even at 
low concentrations of QUIN, there is a synergistic effect with 3HKYN, which can cause 
neurodegeneration.  The lesions were excitotoxic in nature as an NMDA inhibitor (CGP 
40116) prevented lesion formation and were qualitatively indistinguishable from those 
produced by a higher dosage of QUIN alone.  3HKYN can be converted into QUIN in the 
brain, but it was shown that this was not occurring as there was no change in QUIN or 
3HKYN levels over time.  A free radical scavenger, N-tert-butyl-α-(2-sulphophenyl)-
nitrone (S-PBN) also inhibited lesion formation, demonstrating the necessity of free 
radicals for neuronal loss.  3HKYN did not enhance the toxicity of NMDA in the rat 
striatum, when QUIN was substituted by NMDA, suggesting that there may be a joint 
effect of 3HKYN and QUIN in generating sufficient free radicals to cause the 
neurodegeneration.  Other free radical scavengers, indolepropionic acid and PNU 101033, 
were also able to reduce the increase in lesion volume caused by the addition of 3HKYN to 
a QUIN intrastriatal injection in rats (Guidetti and Schwarcz, 2003).  These free radical 
scavengers failed to block the neurotoxicity of QUIN alone.  However, the NMDA 
receptor antagonist, MK-801, completely prevented neuronal loss induced by QUIN and 
3HKYN together.  These results showed that 3HKYN potentiates striatal QUIN toxicity 
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and these compounds may act together to contribute to neuronal damage in neurological 
disorders.  This enhanced toxicity appears to be due to 3HKYN, and perhaps QUIN also, 
generating free radicals, but requires NMDA receptor activation. 
1.1.15  Mechanisms of Cell Death initiated by 3-
Hydroxykynurenine and Quinolinic Acid 
There are various contrasting opinions on the neurotoxic potency of 3HKYN and QUIN. 
Neurotoxicity of 3HKYN and QUIN were similar in vitro (Chiarugi et al., 2001).   
However, the lesion size of an intrastriatal injection in rats of 50nmoles 3HKYN was 
similar to that induced by 200nmoles QUIN (Nakagami et al., 1996). 
The mechanism for neuronal cell death caused by 3HKYN or QUIN has been investigated 
in primary mixed cortical cell cultures (Chiarugi et al., 2001).  It was suggested that QUIN 
neurotoxicity is caused by necrosis, whereas with 3HKYN toxicity, neurones die by 
apoptosis.  This confirmed the results of Okuda et al. (1998), where 3HKYN was shown to 
cause apoptosis.  NMDA receptor antagonists, neuronal NOS (nNOS) inhibitors and poly 
(adenosine diphosphate (ADP) -ribose) polymerase (PARP) inhibitors all can prevent 
QUIN-induced toxicity, but were not able to reduce 3HKYN toxicity (Chiarugi et al., 
2001).  This suggests that QUIN neurotoxicity involves NMDA receptor-mediated 
activation of nNOS, formation of DNA nicks, hyperactivation of PARP resulting in energy 
failure and finally necrotic-type cell death.  Five different free radical scavengers reduced 
3HKYN toxicity, but only three reduced QUIN toxicity, showing that free radicals are 
involved in both mechanisms of cell death.  The enzyme, caspase-3, has a key role in the 
execution phase of apoptosis and an increase in its activity is a marker for an ongoing 
apoptotic process.  With 3HKYN, cells showed an increase in caspase-3 at 24h, remaining 
elevated for up to 72h exposure, whereas with QUIN, there was no increase in caspase-3.  
The opening of the mitochondrial permeability transition pore may trigger the execution of 
the apoptotic process.  Cyclosporin can reduce the opening of this channel.  Cyclosporin 
was shown to reduce the toxicity of 3HKYN, but not of QUIN, again suggesting that 
3HKYN neurotoxicity, but not that of QUIN, involves apoptosis.  ATP availability was 
also examined after various times of exposure to the neurotoxins.  QUIN depleted the 
energetic stores more rapidly than 3HKYN, suggesting that QUIN-induced cell death was 
more likely to be by necrosis, and not by apoptosis, as ATP is required in some steps of 
apoptotic cell death (Chiarugi et al., 2001).   
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1.1.16  Location of Kynurenine Pathway Enzymes 
The enzymes of the kynurenine pathway are present in the brain, but have much lower 
activity than in the peripheral organs.  The enzymes involved in the metabolism of 
tryptophan to produce QUIN have been confirmed to be identical in the brain and the 
periphery, with the same high substrate specificity and high substrate affinity.  Although 
some enzymes show several-fold differences between brain regions, and activities are 
variable depending on species and age, no clear specific functions relating to these 
differences have emerged to date (Schwarcz and Pellicciari, 2002).    
The KAT enzymes are primarily located in astrocytes (Guillemin et al., 2001), although 
KAT has also been found in medium and large neurones in the striatum (Roberts et al., 
1992).  Recently, a new KAT II antibody has been used for immunocytochemistry, which 
has confirmed the localisation of KAT II in astrocytes, with no KAT II detected in 
neurones or microglia (Guidetti et al., 2007b).  KAT II-positive astrocytes were associated 
with select neurone populations, supporting a role for KYNA in mediating neuronal 
activity.  Intense staining for KAT II was frequently observed around brain capillaries, 
which may explain the rapid formation of KYNA in the brain when kynurenine levels are 
elevated in the blood.  
3HAO is located primarily in astrocytes in all regions of the rat brain, although some 
neurones have been shown to contain 3HAO (Okuno et al., 1987; Kohler et al., 1988).  
QPRT exists primarily in glial cells but again there is some present in neurones in the 
human striatum (Du et al., 1991).  There are substantially fewer cells that contain QPRT 
than contain 3HAO (Kohler et al., 1988), suggesting that QUIN can be produced more 
quickly than it can be metabolised.   
It is now generally established that astrocytes and microglia, rather than neurones, contain 
the enzymes required for the biosynthesis of kynurenines (Schwarcz and Pellicciari, 2002).    
Human astrocytes in cultures stimulated with a range of cytokines involved in brain 
inflammation to induce IDO, lack KMO and hence cannot convert kynurenine into 
3HKYN, and therefore produce large amounts of kynurenine and KYNA (Guillemin et al., 
2001).  These human astrocytes express most of the other kynurenine pathway enzymes, 
although there is some discrepancy between studies as to whether kynureninase is 
expressed.  With the lack of KMO, it may be expected that some kynurenine would be 
converted to ANA by kynureninase, but this was not observed by Guillemin et al. (2001).  
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Astrocytes demonstrated high QPRT activity, which completely degraded the small 
amounts of QUIN synthesised and also much of the additional QUIN (1μM) when it was 
supplied to the cell culture.   Astrocytes can therefore metabolise most of the QUIN 
formed, and therefore QUIN is not available to cause excitotoxicity.  The addition of 
kynurenine to macrophages, at the level produced by the cytokine-stimulated human 
astrocyte cultures, led to a significant production of QUIN.  As astrocytes are not isolated 
from infiltrating macrophages following an immune stimulus, the production of 
kynurenine in astrocytes can contribute to excessive QUIN production in macrophages. 
Following an immune or inflammatory response, infiltrating macrophages and resident 
microglial cells are both able to convert tryptophan into QUIN.  High concentrations of 
QUIN were produced in human blood macrophage cultures and human foetal microglia 
cultures after stimulation with IFN-γ.  In contrast, cultures of human foetal astrocytes and 
neurones, stimulated with IFN-γ produced negligible amounts of QUIN (Heyes et al, 
1996).  Guillemin et al. (2003) demonstrated the expression of kynurenine enzymes in 
human microglia and macrophages.  The enzymes KAT I, KAT II, kynureninase, KMO, 
3HAO and QPRT were all expressed in unstimulated macrophages and microglia, although 
there was no expression of IDO.  The amount of kynureninase and KMO mRNA were 10-
fold and 5-fold higher, respectively, in macrophages compared with microglia.  After IFN-
γ stimulation, IDO was found in macrophages and microglia, with macrophages expressing 
three times more IDO than microglia.  The amount of IDO transcripts was far higher than 
those of the other kynurenine pathway enzymes examined.  In microglia, stimulation with 
IFN-γ did not increase the expression of any of the other kynurenine pathway enzymes, 
however, in macrophages, there was a small increase (2-fold) in expression of KAT I, 
KAT II and kynureninase.  Substantially less QUIN (20-fold) was produced from 
microglia than from macrophages after IFN-γ stimulation, which can be attributed to the 
lower expression of IDO, kynureninase and KMO in microglia (Guillemin et al., 2003).   
1.1.17  Transport between the Brain and the Periphery 
The microvasculature of the CNS supplies blood to brain structures, with a barrier between 
its microvessels and the brain tissue.  This blood-brain barrier is composed of endothelial 
cells, functioning by their cohesive and resistance properties which require astrocytic co-
operation and vascular matrix adhesion (del Zoppo et al., 2006).   
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Fukui et al. (1991) determined the rates of cerebral uptake and mechanisms of blood-brain 
barrier transport for the main kynurenines in rats.  Tryptophan and kynurenine can readily 
cross the blood-brain barrier, being transported by the large neutral amino acid carrier (L-
system).  Kynurenine, an α-amino acid, has a free carboxyl group and an unsubstituted α-
amino group that are required for L-system activity.  Tryptophan and leucine can inhibit 
the blood-brain transport of kynurenine by at least 90%, indicating that the α-amino acids 
act competitively for this carrier.  3HKYN appeared to be transported by the same carrier, 
but the affinity for 3HKYN was lower than that of kynurenine due to the presence of the 
additional hydroxyl group.  For the other metabolites, uptake appeared to be mediated by 
passive diffusion, which occurred at a significant rate for ANA, but at a far lower rate for 
3HANA, KYNA and QUIN.   It was concluded that kynurenine crosses the blood-brain 
barrier easily, 3HKYN and ANA may also cross and contribute to cerebral levels, but 
3HANA, KYNA and QUIN cross the blood-brain barrier poorly and are not expected to 
contribute to brain pools.  However, in healthy gerbils with labelled QUIN infused 
subcutaneously, Heyes and Morrison (1997) showed that 38-49% of QUIN in the brain 
was derived from the blood.  It is therefore unclear whether blood QUIN does contribute to 
brain QUIN levels. 
Fukui et al. (1991) used normal healthy rats to examine the transport of kynurenines across 
the blood-brain barrier, but when considering neurological disorders, such as ischaemia 
and TBI, there is degradation of the blood-brain barrier (Skinner et al., 2006; Habgood et 
al., 2007).  This will enable kynurenines to pass more freely from the blood to the brain. 
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Figure 1-1  A summary of the key components of the kynurenine pathway. 
(Courtesy of T.W. Stone) 
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1.2  Neurological Disorders 
1.2.1  Neurodegeneration 
The kynurenine pathway is activated in a variety of inflammatory diseases affecting the 
brain including meningitis, septicaemia and neurovirological disorders such as the AIDS-
dementia complex (Heyes et al., 1992a) and implicated in neurological disorders, such as 
HD, epilepsy, TBI and ischaemic stroke (Stone, 2001). 
Neurodegenerative disorders have slow progression and are frequently hereditary.  These 
diseases show a selective loss of a particular subset of neurones for unknown reasons.  
Although the initial trigger of neuronal death is not clear, the consequent events can 
proceed gradually or episodically.  Each neurone has its own optimal biochemical 
conditions, such as intracellular pH, water content, concentrations of oxygen, glucose, ATP 
and calcium ions.  An imbalance in these conditions can cause neuronal damage or death. 
Apoptosis has been implicated as a possible mechanism for neuronal death in 
neurodegenerative disorders.  However, there is no direct and substantial evidence of 
apoptosis in human brains, with apoptosis in developing nervous systems being much 
quicker than the extremely slow neuronal loss in neurodegenerative disorders (Kanazawa, 
2001).   
During the normal development of the nervous system, over half of the neurones of the 
central and peripheral nervous systems die.  Neurones are lost by apoptosis, a process of 
programmed cell death.  These cells have differentiated and successfully extended their 
axons to their target cells.  The target tissue limits the number of axons attaching to it, and 
hence rejects some neurones and causes apoptosis of the whole neurone.  Surviving 
neurones must make a connection with the target cells, with the target tissue able to 
transport substances vital for neuronal survival.  Substances transported from the target 
tissue to the neuronal cell body are called neurotrophic factors and are produced by the 
target cells in limited amounts.  Nerve growth factor (NGF) and brain-derived neurotrophic 
factor (BDNF) are two of many regulatory neurotrophic factors, with each factor favouring 
the survival of a different group of neurones.  BDNF can rescue foetal motor neurones 
from naturally occurring cell death and from induced cell death by the removal of the 
target tissue (Kanazawa, 2001). 
In response to neuronal injury, glial cells alter their morphology, size and number and also 
increase the production and release of cytokines and growth factors (Aschner et al., 2002; 
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Kim et al., 2003).  This stimulation induces IDO activity and the rapid up-regulation of the 
3HKYN/QUIN branch of the kynurenine pathway within reactive microglial cells.  KYNA 
formation, which takes place mainly in astrocytes (Kiss et al., 2003), is far less affected by 
exposure to cytokines with increases in CSF QUIN: KYNA ratios occurring after immune 
activation (Heyes et al., 1992a). 
A major consequence of reactive oxygen species activity in living tissue is the oxidation of 
cell membrane lipids.  Brain neuronal cells are at particular risk from damage caused by 
free radicals, since the brain has an extremely high rate of oxygen consumption that can 
lead to increased superoxide formation and neuronal membranes have high contents of 
polyunsaturated fatty acids that are susceptible to lipid peroxidation (Okuda et al., 1996).  
In addition, the brain has modest antioxidant defences and there is high Ca
2+ ion transport 
across neuronal membranes (Leipnitz et al., 2005).  Under physiological conditions, there 
is a well-balanced equilibrium between free radical generation and various enzymatic and 
non-enzymatic antioxidant defense systems.  Oxidative stress occurs when there is an 
imbalance towards free radical accumulation and has been implicated in several 
neurodegenerative disorders (Coyle and Puttfarcken, 1993).  Cumulative damage caused 
by reactive oxygen species may explain the delayed onset and progressive characteristics 
of cell death in such diseases.  Oxidative stress can be triggered either by impairment of 
antioxidant defense mechanisms or by increased generation of reactive oxygen species.  
3HKYN has been proposed as a factor that contributes to reactive oxygen species 
generation in the brain (Okuda et al., 1998).  
Mitochondrial dysfunction and excitotoxicity appear to be closely related in 
neurodegeneration and it has been hypothesised that bioenergetic defects could lead to 
neuronal death via secondary excitotoxicity (Browne et al., 1999).  Impaired mitochondrial 
energy metabolism, reducing ATP production, can cause neurones to be more vulnerable to 
endogenous levels of excitatory amino acids and result in partial cell depolarisation.  As 
more calcium ions enter the neurones, this may trigger further free radical production, 
exacerbating the damage to cellular components.  This hypothesis has been supported with 
work demonstrating that normal levels of glutamate become toxic in the presence of, for 
example, oxidative phosphorylation inhibitors (Novelli et al., 1988), and excitatory amino 
acid antagonists such as MK-801 can reduce cerebral lesions induced by mitochondrial 
toxins (Beal et al., 1991).   It remains unresolved whether bioenergetic dysfunction or 
oxidative damage are causative factors or occur secondarily to neuronal loss in HD. 
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Neopterin is used as a marker of disease as it indicates an activated cellular immune 
system in humans (Hoffmann and Schobersberger, 2004).  Following bacterial infections, 
activated TH1-type lymphocytes release IFN-γ, which activates monocytes and 
macrophages to produce and release neopterin.  Neopterin itself, or together with 
cytokines, triggers pro-inflammatory events, including the expression of iNOS and tumour 
necrosis factor- α (TNF-α) synthesis.  One outcome of this is the excessive production of 
nitric oxide leading to oxidative stress.  Neopterin has also been shown to induce 
apoptosis, where it may (in vascular smooth muscle cells) or may not (in inflammatory 
diseases of the lung) be related to nitric oxide production.  In the alveolar epithelium, 
neopterin has also been shown to have a role in upregulating the synthesis of intracellular 
adhesion molecule-1, which mediates the migration and activation of leukocytes to the site 
of infection.  Chronically increased activities of the cellular immune system are often 
associated with anaemia.  Neopterin may also be involved in the onset of anaemia, without 
a link with oxidative stress.  Neopterin can cause an increase in intracellular Ca
2+ ions, but 
this appears to be cell-type specific.  The precise role and importance of neopterin in 
infection and inflammation remains unclear, but it appears to be stimulated by IFN-γ and 
acts as a mediator of host-defence reactions, often associated with nitric oxide (Hoffmann 
and Schobersberger, 2004). 
1.2.2  Huntington’s Disease 
1.2.2.1  General 
HD is an inherited neurodegenerative disorder that affects four to ten per 100,000 
individuals of Caucasian origin (Reddy et al., 1999).  The disease is characterised by 
neuronal loss in the striatum and cortex, although there are minor volume reductions in 
almost all brain structures, observed using magnetic resonance imaging (MRI) coronal 
scans, which occur even for individuals with early to mid-stages of HD (Rosas et al., 
2003). The symptoms are progressive chorea (involuntary body movements of the arms, 
legs, face, mouth or torso), progressive cognitive impairment leading to dementia and 
emotional disturbances.  The onset of the disease usually occurs between the ages of 35 
and 42, with symptoms becoming more severe until death, generally about 17 years after 
the first manifestation of symptoms (Martin and Gusella, 1986).  
HD is an autosomal dominant disorder, and hence a sufferer of the disease has a 50% risk 
of passing the condition on to their offspring, and both males and females can equally 
contract the condition.  The gene responsible for HD has been identified (The Huntington’s 
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Disease Collaborative Research Group, 1993) and has an expansion of CAG repeats that 
codes for the amino acid glutamine.  In the general population, the number of CAG repeats 
ranges from 6 to 35 whereas HD sufferers have between approximately 40 and 121.  This 
gene encodes the 349kDa protein, named huntingtin, where in HD, there are usually 
greater than 35 glutamine repeats at its amino terminus.  The length of the CAG repeats is 
related to the age of onset of the disorder (Reddy et al., 1999).  The earlier the age of onset 
of the disease, the faster the disease progresses and the greater the severity of the 
symptoms.  Early-onset HD is associated with paternal transmission whereas late-onset is 
most frequently linked to maternal transmission (Martin and Gusella, 1986).  Mothers may 
be able to pass on protective factors to the foetus via the placenta during pregnancy, 
thereby protecting the basal ganglia and postponing neurodegenerative changes. 
Post-mortem HD brains have been graded from grade 0 to grade 4, according to the 
neuropathological severity in the striatum (Vonsattel et al., 1985).  Brains which showed 
no gross or microscopical abnormalities in the striatum, but there had been substantial 
clinical evidence for the diagnosis of HD, were graded 0.  Grade 1 HD brains showed no 
macroscopic alterations in the striatum but microscopic examination showed 50% neuronal 
loss in the caudate nucleus.  At grade 2, atrophy at the head of the caudate nucleus was 
observed macroscopically.  Neuronal loss in the striatum increased with increasing grades.  
For grade 3 brains, the caudate nucleus was markedly shrunken, with a moderate decrease 
in the size of the putamen and globus pallidus, observed macroscopically.  By grade 4, 
brains had further degraded with the loss of 95% of the neurones in the caudate nucleus.  
The grade correlated closely with the rating of physical disability at the time of death 
(Vonsattel et al., 1985).     
1.2.2.2  The Role of the Huntingtin Protein 
The mechanisms by which huntingtin causes neuronal damage have been investigated but 
remain unresolved.  The reason for the preferential susceptibility of striatal neurones is also 
unknown.  Neurodegeneration may originate in one vulnerable brain area and nerve cells 
may become damaged independently from each other or through pathogenic cell-cell 
interactions.  Much work, which is still ongoing, has studied the roles of huntingtin 
aggregation, intranuclear inclusions and the proteolytic generation of toxic huntingtin 
fragments.  Intranuclear aggregates in small striatal neurones have been found in a 
transgenic mouse model of HD (Kanazawa, 2001).  Aggregates are also found in the post-
mortem striatum and cortex in HD.  However there does not seem to be a correlation 
between the formation of inclusion bodies and neuronal cell death in cultured neurones 
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expressing abnormal huntingtin (Saudou et al., 1998).  Proposed roles for aggregates of 
huntingtin, found in post-mortem brains, have ranged from being critical for disease 
pathogenesis, to being a benign phenomenon, and even being neuroprotective (Bates 
2003).  Yang et al. (2002) demonstrated that preformed aggregates are highly toxic when 
directed to the cell nucleus.  Consistent with this, pharmacological intervention to inhibit 
aggregate formation has shown beneficial effects in a mouse model of HD (Sanchez et al., 
2003).  Huntingtin aggregates may not directly cause neuronal damage, however, they do 
appear to have a major role in the pathogenesis of HD.  
In a transgenic HD mouse model, where the mice demonstrate neuronal inclusions, 
characteristic neuropathology and progressive motor dysfunction, it has been shown that it 
is possible to turn off the expression of the transgene with oral administration of 
tetracycline analogues.  This leads to a disappearance of inclusions and an improvement in 
the motor function of these mice (Yamamoto et al., 2000).  Although impaired surviving 
neurones are generally thought to die eventually, there is the possibility that they could 
revert to their normal healthy state (Kanazawa, 2001).  A continuous influx of the mutant 
protein is required to maintain inclusions and symptoms, suggesting that HD may be 
reversible (Yamamoto et al., 2000).  
Apoptosis has been implicated as the mechanism of cell death in HD (Portera-Cailliau et 
al., 1995) but there is no conclusive evidence of apoptosis in the HD human brain 
(Kanazawa, 2001).  Blocking apoptosis may help to halt the onset and symptoms of HD.  
The activation of caspase-1, a protease involved in triggering apoptosis in cells, has been 
shown to have the ability to cleave huntingtin.  Transgenic mice with the huntingtin 
mutation (R6/2 mice) were cross-bred with transgenic mice lacking caspase-1 activity and 
the cross-bred mice had a delayed disease onset and survived longer than mice with the 
huntingtin mutation only (Ona et al., 1999).  A caspase inhibitor was also given to the R6/2 
mice and this slowed the disease progression and delayed mortality.  This work suggested 
that the mutant huntingtin protein causes apoptosis by inducing a toxic state inside the cell 
which activates caspase-1.  Caspase-1 could cleave the mutant huntingtin, generating toxic 
huntingtin fragments and set up a feedback loop that eventually leads to cell dysfunction 
and death (Ona et al., 1999).  This idea of the toxicity building up over time could start to 
explain why the symptoms of HD do not manifest themselves until mid-life, although the 
gene is present from birth.   
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1.2.2.3  Neuronal Damage and related Animal Models of Huntington’s 
Disease 
HD neuropathology is characterised by bilateral striatal atrophy with marked neuronal loss 
and astrogliosis within the caudate and putamen (Browne et al., 1999).  The striatal cell 
type most susceptible to degeneration is the medium spiny projection neurone.  80% of 
striatal neurones are spiny neurones and these are the principal input and output neurones 
of the striatum.  The other major class of striatal neurones are the aspiny interneurones.  
NADPH-diaphorase, neuropeptide Y, somatostatin and NOS typically colocalise in 
medium aspiny neurones.  The large aspiny neurones contain acetylcholine.   
HD affects several neurotransmitter systems. One of these is a reduction in the inhibitory 
transmitter, GABA, observed within the striatal spiny neurones (Browne et al., 1999).   
This reduces GABA-mediated inhibition of the substantia nigra, and increases dopamine.  
There is then an imbalance in the dopamine-acetylcholine relationship in the striatum, 
which is thought to cause the characteristic uncontrollable choreic movements in HD 
(Martin and Gusella, 1986).  At present, one successful treatment of HD is with dopamine 
antagonists which appear to relieve the choreic symptoms.   
The original animal model for HD proposed by Coyle and Schwarcz (1976) and McGeer 
and McGeer (1976) used intrastriatal injections of kainic acid, which produced local 
specific degeneration of GABAergic neurones, with preservation of dopaminergic 
neurones.  The rats also showed similar histological and behavioural changes to those 
observed in HD. 
In the striatum in HD, there is an increase in somatostatin and neuropeptide Y, which 
results in the preservation of a subclass of striatal aspiny neurones.  Beal et al. (1986) 
demonstrated that lesions produced by QUIN resemble those of HD, with a depletion of 
GABA and substance P and selective sparing of somatostatin/ neuropeptide Y neurones.  
This could be attributed to NMDA receptor-induced excitotoxicity, as NMDA injections 
also preserved these neurones.  Lesions produced by kainic acid, ibotenic acid, quisqualic 
acid or AMPA were unlike those produced by QUIN, as they affected all cell types, 
without sparing somatostatin/ neuropeptide Y neurones (Beal et al., 1989).  Following 
QUIN excitotoxicity in the rat, cholinergic neurones in the striatum were also relatively 
spared (Davies and Roberts, 1988), although the same effect was also observed with other 
excitotoxins acting at NMDA, AMPA and kainic acid receptors (Beal et al., 1989).  In HD, 
cholinergic neurones were also relatively preserved (Ferrante et al., 1987).  These reports 
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suggested a more accurate animal model for HD is by injection of QUIN into the striatum 
rather than kainic acid.  Such a QUIN model also seems a more realistic model for HD as 
QUIN is an endogenous compound in the mammalian brain whereas kainic acid is not 
present.    
The relatively resistant medium aspiny neurones also contain NOS.  NOS-containing 
neurones in the striatum are known to be resistant to acute excitotoxic insults and nitric 
oxide toxicity which may be due to their antioxidant properties (Browne et al., 1999).  
Cultured nitric oxide-resistant neurones were found to contain elevated levels of the 
mitochondrial superoxide radical scavenging enzyme, Mn-SOD, which was critical for the 
resistance of these neurones to nitric oxide- and NMDA- toxicity (Gonzalez-Zulueta et al., 
1998).  
1.2.2.4  Quinolinic Acid Hypothesis for Huntington’s Disease 
The first hypothesis for the mechanism of neuronal loss in HD involving activation of the 
kynurenine pathway suggests an excessive stimulation of NMDA receptors by QUIN and 
then a subsequent increase of intracellular calcium (Beal et al., 1986).  This hypothesis was 
supported by Young et al. (1988) who showed that NMDA receptor binding was reduced 
by 93% in the putamen of HD post-mortem brains compared to binding in control brains, a 
significantly greater decrease than observed for other receptors in the putamen.  There was 
no effect on NMDA receptor binding in the cerebral cortex.  This work demonstrates that 
cells with high densities of NMDA receptors are preferentially lost in HD striatum.  In 
support of this finding, a significant loss in binding to the glycine site of the NMDA 
receptor complex in HD brains was observed, particularly in the caudate nucleus but also 
in the frontal cortex (Reynolds et al., 1994).  
The hypothesis suggests that brain tissue in HD will contain an elevated level of QUIN.  
Furthermore, the activity of 3HAO, the enzyme which synthesises QUIN from its 
kynurenine pathway precursor, 3HANA, has been shown to be increased in the HD brains 
(Schwarcz et al., 1988a).  However, no increase in QUIN in the CSF was found, with 
concentrations unexpectedly being slightly but not significantly lower than in control CSF 
(Heyes et al., 1991b).  Similarly, levels of QUIN appeared to be slightly lower, rather than 
higher, in HD brain tissue.  These reduced levels of QUIN were only significant in 3 out of 
the 6 areas of the cerebral cortex examined, with levels in the putamen, dentate nucleus of 
the cerebellum and other cortical regions slightly reduced but not significantly different 
from controls.  These results are in agreement with previous studies, where similar levels 
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of QUIN in CSF in HD patients were shown compared with controls (Schwarcz et al., 
1988b), and no increased levels of QUIN were found in HD brain (Reynolds et al., 1988).                 
1.2.2.5  Kynurenic Acid Hypothesis for Huntington’s Disease  
An alternative hypothesis for excessive stimulation of NMDA receptors may be a 
reduction in KYNA instead of an increase in QUIN.  KYNA acts as an antagonist at 
NMDA receptors, and neurotoxicity could occur when there is a decrease in brain KYNA 
levels.  However, Connick et al. (1989) showed increased KYNA in the motor cortex of 
post-mortem HD brains, with no differences in KYNA levels in the prefrontal cortex, the 
caudate nucleus or globus pallidus compared to controls.  It was suggested that the increase 
in KYNA may not be a primary effect, but a compensatory response to an increase in 
excitatory activity. 
Other groups however demonstrated a decrease in KYNA or a decrease in the formation of 
KYNA from its bioprecursor, kynurenine.  In post-mortem human brains with HD, there 
was a significant increase in the ratio of kynurenine: KYNA and there was also a reduced 
concentration of KYNA in the CSF of HD patients (Beal et al., 1990).  They suggested that 
if KYNA regulates by blocking NMDA receptor activation, a chronic deficiency could 
potentially lead to a slowly developing NMDA excitotoxic neurodegenerative process.   
Further work showed a decrease in the levels of KYNA in HD cerebral cortex (Beal et al., 
1992).  This effect may be important over a period of time but the reported concentrations 
of KYNA required to block NMDA receptor activation are about 100-fold greater than 
those found in the human brain (Jahr and Jessel, 1985). 
Jauch et al. (1995) measured KYNA levels in 12 brain regions from late-stage HD brains 
and the activities of the two KYNA synthesising enzymes, KAT I and KAT II.  The only 
region of the brain that showed a significant reduction in the level of KYNA was the 
caudate nucleus.  The putamen and globus pallidus also had reduced KYNA levels but 
these were not significant.  However, the only brain region which showed significantly 
reduced KAT I and KAT II activities was the putamen, which also had approximately 3-
fold higher Km for both enzymes.  These results suggest a selective impairment in KYNA 
biosynthesis, which may be due to the loss of endogenous KAT activators.  However, 
Pearson et al. (1995) found no change in KAT activity in HD brain in the caudate or 
frontal cortex. 
36  
1.2.2.6  3-Hydroxykynurenine Hypothesis for Huntington’s Disease 
Another neurotoxic metabolite of the kynurenine pathway has also been implicated in HD.  
HD post-mortem brain showed 2-3-fold increases of 3HKYN in cortical and striatal 
regions (Reynolds and Pearson, 1989; Pearson and Reynolds, 1992).  However, Beal et al. 
(1990) did not observe any changes in 3HKYN levels in HD putamen.  Acute 
intracerebroventricular injection of 3HKYN is known to have a toxic effect in animals, 
causing seizures (Lapin, 1981).  Elevated levels of 3HKYN have also been observed in 
other diseases where neurological function is impaired: hepatic encephalopathy (Pearson 
and Reynolds, 1991) and infantile spasms (Yamamoto, 1991).  There was some debate 
about the relevance of the toxicity of long-term low-dose exposure to 3HKYN in HD and 
the unknown factors which may modulate its in vivo toxicity (Guilarte and Eastman, 1993).  
The neurotoxic effects of 3HKYN have only been demonstrated using high micromolar 
concentrations in a neuronal cell line.  However, 3HKYN causes the death of neuronally- 
derived cells in culture at concentrations lower than other excitotoxins, including QUIN 
and glutamate (Eastman and Guilarte, 1989).  Together with the presence of endogenous 
ascorbic acid and iron, the toxicity of 3HKYN may be enhanced in vivo.  Guilarte and 
Eastman (1993) suggested that further work is required to demonstrate whether 3HKYN is 
an endogenous neurotoxin, relevant in HD.   
The suggestion of high levels of 3HKYN in the brain acting as a neurotoxin involved in 
HD leads to consideration of where the 3HKYN is produced.  The enzymes responsible for 
the synthesis of 3HKYN are at much lower levels in brain than in peripheral tissues, such 
as the liver and kidney (Erickson et al., 1992).  As 3HKYN can cross the blood-brain 
barrier, 3HKYN from the blood may well contribute to the cerebral pool of 3HKYN.   
Interestingly, the striatum and cortex have the highest capacity for 3HKYN uptake 
(Eastman et al., 1992) and are the same regions where elevated 3HKYN is found in the HD 
brain (Pearson and Reynolds, 1992).  Similarly, elevations of 3HKYN in the blood could 
possibly act as a peripheral marker of HD.    
1.2.2.7  Alterations in the Different Branches of the Kynurenine Pathway 
as a Hypothesis for Huntington’s Disease 
Guidetti et al. (2000) proposed a refined hypothesis for the involvement of kynurenines in 
HD:  “An increased flux through the 3HKYN/ QUIN branch compared to the KYNA 
branch of the kynurenine pathway may play a causative role in HD pathology.”  Increased 
levels of 3HKYN and KYNA were demonstrated in the striatum of post-mortem brains of 
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grade 1 HD patients who had died in the early stage of neurodegeneration.  Most of the 
previous studies examining kynurenines in HD used more readily available post-mortem 
brains from patients in the terminal stages of the disease (grades 3 and 4, as defined by 
Vonsattel  et al., 1985).  Increases in 3HKYN and KYNA were also observed in the 
cerebral cortex with the increase in 3HKYN, but not KYNA, being significant compared 
with control brains (Guidetti et al., 2000).  The increases in 3HKYN were much greater 
than the increases in KYNA and when a ratio of 3HKYN: KYNA was examined, there was 
a significantly higher ratio with HD striatum compared with controls.  To support this 
finding, 3HKYN and KYNA were measured in mice transgenic for full-length mutant 
huntingtin, which showed a similar degree of striatal neurodegeneration to that seen in 
grade 1 HD (Guidetti et al., 2000).  Large increases in 3HKYN levels and smaller 
increases in KYNA concentrations were observed in the striatum and cortex, compared 
with control mice.  Significant increases in the ratio of 3HKYN: KYNA were found in 
both the striatum and cortex, demonstrating an imbalance favouring the neurotoxin 
3HKYN over the neuroprotectant KYNA at an early stage in the disease process.  Beal et 
al. (1990) had also shown a significant increase in 3HKYN: KYNA ratio in HD post-
mortem brains, but this was not recognised as important, as the levels of 3HKYN in HD 
brains were not significantly different from control brains.  The authors put the emphasis 
on the increase in the ratio of kynurenine: KYNA, suggesting an impairment in the 
synthesis of KYNA. 
For the first time, an increase in QUIN levels was demonstrated in HD brains, but only in 
post-mortem brains of grade 1 HD patients (Guidetti et al., 2004).  There were significant 
increases in 3HKYN and QUIN only in the early grade HD brains (grade 0/1) compared 
with control brains, in both the striatum and the cerebral cortex, but not in the cerebellum.  
In post-mortem brains from presymptomatic at-risk subjects, grade 2 HD, or late stage HD 
(grades 3/4), levels of 3HKYN and QUIN were not significantly different from control 
brains.  There were no significant increases in the levels of kynurenine or KYNA at any 
stage of the disease or in any of the brain regions examined.  When ratios of 3HKYN: 
KYNA and QUIN: KYNA were calculated, there were significant increases in both these 
ratios for early stage (grade 0/1) HD, but not for the at-risk individuals.  These results 
suggest that 3HKYN and QUIN may participate in the initial phases of the 
neurodegenerative process in HD.  The concentrations of either 3HKYN or QUIN 
observed by Guidetti et al. (2004) in grade 1 HD brain are similar to those known to induce 
neuronal loss in vitro (Chiarugi et al., 2001).  As 3HKYN significantly potentiates QUIN 
neurotoxicity (Guidetti and Schwarcz, 1999), the increased levels of both metabolites may 
actually result in an elevated neuronal loss compared with that expected from the 
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concentrations of the individual compounds.  Since free radicals can be generated by both 
QUIN (Rios and Santamaria, 1991) and 3HKYN (Vazquez et al., 2000), it is proposed that 
these free radicals potentiate NMDA receptor function and have a role in HD.  The 
proposed hypothesis for kynurenine pathway involvement in HD is that ‘increased levels 
of both 3HKYN and QUIN jointly accelerate neuronal death through NMDA receptor 
activation and the generation of toxic free radicals’ (Guidetti et al., 2004). 
1.2.2.8  Glial Activation and Oxidative Stress in Huntington’s Disease 
An early participation of microglial cells in HD is suggested by abnormal microglial 
cytoarchitecture in the brain of grade 1 HD patients (Sapp et al., 2001).  Stimulated 
microglia are far more efficient in generating 3HKYN than KYNA.  Guidetti et al. (2004) 
suggested that the pathological process initiated by mutant huntingtin leads to an activation 
of glial kynurenine metabolism, where an increase in 3HKYN and QUIN, but not in 
KYNA, may accelerate neuronal damage. 
There is evidence for a role of oxidative damage in HD.  HD post-mortem brains have 
shown increased incidence of DNA strand breaks, excessive lipofuscin accumulation and 
increased immunohistochemical staining of oxidative damage products in HD striatum and 
cortex (Browne et al., 1999).  The enhanced lipofuscin deposition in both striatal and 
cortical neurones in HD brain suggests that lipid peroxidation has occurred (Tellez-Nagel 
et al., 1974).  Lipofuscin is a fluorophore which is produced by the reaction of amino 
compounds with aldehydic products of oxidative free radical-induced oxidation of, 
particularly, cell membrane lipids.  The extent of lipofuscin accumulation increases with 
neuropathological severity of the disease.  Free radical-induced oxidative damage was 
demonstrated by increased DNA strand breaks in HD striatal neurones (Butterworth et al., 
1998).  The degree of DNA fragmentation in HD striatum is positively correlated with the 
length of the polyglutamine expansion in huntingtin.  Oxidative damage can also induce 
excessive oxidation of DNA bases, such as oxidising deoxyguanosine to 8-hydroxy-
deoxyguanosine (8-OHDG).  Significant increases in the levels of 8-OHDG were detected 
in nuclear DNA in the caudate of grade 4 HD post-mortem brains (Browne et al., 1997), 
but not in other brain regions examined. 
1.2.2.9  Therapeutic Approaches for Huntington’s Disease 
There is now much evidence for altered kynurenine pathway metabolism in HD, and 
several possible therapeutic approaches have been suggested.  A possible therapy could be 
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to increase the levels of KYNA in the brain.  Probenecid is a drug which inhibits the 
excretion of KYNA by blocking the transport system for organic acid disposal.   
Administration of probenecid in rats significantly increased the levels of KYNA in the 
brain (Vecsei et al., 1992).  However, when L-kynurenine, the natural bioprecursor of 
KYNA, was administered, the levels of KYNA also increased.  There was a synergistic 
effect when both L-kynurenine and probenecid were administered, giving rise to over 50-
fold increases in KYNA in both the cerebral cortex and the striatum.  Administration of 
probenecid in humans with Parkinson’s disease or Alzheimer’s disease did significantly 
increase KYNA levels in the CSF (Vecsei et al., 1992).  However, this strategy of 
increasing kynurenine or probenecid levels would also be expected to increase the levels of 
QUIN in the brain. 
The use of kynurenine and probenecid, in conjunction with nicotinylalanine, an inhibitor of 
the enzymes, kyureninase and KMO, thus blocking QUIN synthesis, has been shown to 
attenuate QUIN-induced striatal neurotoxicity in rats, by increasing KYNA concentrations 
in the striatum (Harris et al., 1998).  Other similar studies have been attempted for striatal 
neuroprotection involving enzymatic inhibition of 3HKYN and QUIN synthesis shifting 
kynurenine metabolism towards enhanced KYNA synthesis.  Several KMO inhibitors have 
been developed and have shown neuroprotection in animal models (Speciale et al., 1996; 
Cozzi et al., 1999).  Another mechanism of inhibiting QUIN synthesis is via the powerful 
glycine/NMDA receptor antagonist, 7-chlorokynurenic acid, which can be synthesised in 
the brain by the KAT enzymes following intracerebral injection of 4-chlorokynurenine 
(Wu  et al., 1997). This novel approach has been suggested as a means of avoiding 
excessive receptor blockade and the associated clinical risks.  
One successful treatment of HD is with dopamine antagonists which appear to relieve the 
choreic symptoms (Martin and Gusella, 1986).  However, as the disease progresses, and 
the striatal cell loss increases, this relief becomes far less effective.  HD is often associated 
with depression and severe mood swings, so drugs to alleviate these symptoms are often 
prescribed.  One research approach to treatment involves the transplantation of human 
foetal striatal tissue to replace degenerated neurones in HD patients.  Five patients received 
grafts of foetal tissue and three of the group showed improvements in motor and cognitive 
functions, with these benefits persisting for at least three years, suggesting a long-term 
effect (Freeman et al., 2000). 
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1.2.3   Stroke and Ischaemia 
1.2.3.1  Ischaemic Stroke 
Stroke is the third major cause of death in industrialised countries, with a mortality rate of 
about 30% (Dirnagl et al., 1999).  Surviving stroke patients are often debilitated (including 
paralysis, speech problems and dementia, depending on the area of the brain that is 
damaged), and their care makes a significant contribution to health care costs.  Most 
strokes (approximately 85%) are ischaemic (Green and Shuaib, 2006).  Ischaemic stroke is 
caused by the blockage of a major artery in the brain which results in a decrease in blood 
flow and oxygen supply to the area of the brain around the blockage.  The majority of 
human strokes results from an occlusion of the middle cerebral artery (Green and Shuaib, 
2006), either by an embolus or by local thrombosis.  Hence, most animal models of 
ischaemic stroke are based on a middle cerebral artery occlusion (MCAO) and can be 
transient or permanent.   
Following a stroke, cells of the ischaemic core of the perfusion deficit are permanently 
damaged, with permanent depolarisation within minutes after the onset of ischaemia and 
cell death occurs rapidly (Dirnagl et al., 1999).  The cells surrounding this core (ischaemic 
penumbra or peri-infarct zone) have low blood flow, with partially preserved energy 
metabolism, and have the potential to regain their function.  After depolarisation, cells in 
the penumbra can repolarise but this uses energy and the cells may depolarise again in 
response to increased glutamate or potassium in the extracellular space.  Hence, repetitive 
depolarisations (peri-infarct depolarisations) occur, which have been observed in animal 
models and can occur several times per hour and continue for at least 6-8 hours.  After 
many depolarisations, the cells can no longer repolarise and the cells die, resulting in an 
increase in size of the ischaemic core or infarct (Mies et al., 1993).  Many neurones in the 
penumbra can survive for many hours or even days after the ischaemic insult.  Cells in the 
penumbra will ultimately die, thus expanding the ischaemic core, unless they are protected 
by reflow or by a neuroprotectant (Green and Shuaib, 2006).   
MRI scans have shown that increasing ischaemic damage in stroke patients similarly 
occurs over a period of time (Baird et al., 1997).  This suggests that neurological ability 
will also decrease over the same time.  However, patients’ symptoms tend to improve 
during the first week after the insult.  This anomaly has raised the question of the 
importance of the delayed responses to the ischaemic insult in humans.  However, this can 
be explained as the initial neurological deficit reflects the impairment of function in both 
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the core and the penumbra (Baird et al., 1997).  Over time, some parts of the penumbra 
may regain function, shown by an improvement in symptoms, while the structural lesion is 
actually still growing, as other cells of the penumbra die.  It is not until after several days 
or weeks that the structural lesion size and location more closely reflects the neurological 
deficit.  Long-term recovery of function may be explained by plasticity and tissue 
reorganisation (Dirnagl et al., 1999).  
There is a neurochemical sequence of events that occur following an ischaemic stroke.  
The major pathogenic mechanisms of this cascade are 1) excitotoxicity, 2) penumbra 
depolarisations, 3) inflammation and 4) programmed cell death (Dirnagl et al., 1999).   
1.2.3.2  Excitotoxicity after Ischaemia 
Focal reduction of cerebral blood flow restricts oxygen and glucose availability for the 
cells and impairs the energetics required to maintain ionic gradients.  This energy depletion 
causes neurones and glia to depolarise, voltage-dependent Ca
2+ ion channels become 
activated and glutamate is released into the extracellular space.  The reuptake of glutamate 
also requires energy and hence, upon energy failure, this lack of reuptake contributes to 
maintaining the high levels of extracellular glutamate. Glutamate receptors (NMDA and 
AMPA) are then activated, causing excitotoxicity, a major event for initiating ischaemic 
cell death (Dirnagl et al., 1999).  Activation of AMPA receptors causes sodium (Na
+) ions 
to enter the neurones and potassium (K
+) ions to be released into the extracellular space.  
Cell swelling occurs as the Na
+ ions influx causes water to passively enter the cells.  The 
resulting brain oedema is one of the major determinants of whether the patient survives 
beyond the first few hours after stroke.  Activation of NMDA receptors contributes to Ca
2+ 
overload.  Increased levels of Ca
2+ ions have a large impact on tissue damage including the 
breakdown of several proteins and the production of reactive oxygen species causing lipid 
peroxidation of cell membranes.   
Excitotoxicity can cause cells to die from necrosis, and can also initiate molecular events 
that lead to apoptosis.  As a trigger for post-ischaemic inflammation, excitotoxicity can 
contribute to ischaemic injury by this mechanism.  Excitotoxicity is therefore a major event 
for initiating ischaemic cell death, which has led to considerable work in this area for 
possible therapies for the treatment of stroke. 
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1.2.3.3  Oxidative Stress after Ischaemia 
Reactive oxygen species also trigger inflammation and apoptosis.  nNOS is a calcium-
dependent enzyme and hence, with excessive Ca
2+ ions, nitric oxide is synthesised which 
reacts with the superoxide anion to form the highly reactive peroxynitrite, causing further 
tissue damage.  The importance of the role of nitric oxide after acute ischaemic stroke was 
shown in patients’ CSF where increased levels of nitric oxide metabolites were associated 
with greater brain injury and early neurological deterioration (Castillo et al., 2000).   
Xanthine oxidase may also have a role in contributing to ischaemic brain damage, as 
following focal ischaemia in the rat, xanthine oxidase was shown to be involved in the 
generation of free radicals (Uemura et al., 1991), although this has been debated (Betz et 
al., 1991).  Iron-dependent free radical formation has been related to greater damage in 
cerebral ischaemia (Davalos et al., 2000) and therefore the presence of iron ions may be 
critical for oxidative damage in stroke.  The antioxidant, melatonin, has been shown to 
suppress cerebral oedema caused by MCAO in rats (Torii et al., 2004).  Mitochondria are a 
source of reactive oxygen species and when their membranes become impaired by free 
radical disruption, there is an oxygen free radical burst and cytochrome C is released, the 
latter providing a trigger for apoptosis (Kristian and Siesjo, 1998; Fujimura et al., 1998).   
1.2.3.4  Inflammation and Breakdown of the Blood-Brain Barrier after 
Ischaemia 
The increased levels of Ca
2+ ions, the increase in reactive oxygen species and the reduced 
oxygen availability all contribute to the rapid production of inflammatory mediators in the 
injured brain cells (Rothwell and Hopkins, 1995).  Although inflammation is initiated very 
quickly following a stroke, it progresses as an inflammatory cascade over many hours or 
days (Barone and Feuerstein, 1999).   
Post–ischaemic inflammation may contribute to ischaemic damage by many mechanisms 
including disruption of the blood-brain barrier (Skinner et al., 2006).  Inflamed brain tissue 
activates endothelial and glial cells of the CNS which release inflammatory mediators, 
such as cytokines, causing increased permeability of the blood-brain barrier.  This 
disruption of the blood-brain barrier allows leukocytes to infiltrate the CNS, causing the 
release of more inflammatory compounds including free radicals, resulting in further 
blood-brain barrier damage (Skinner et al., 2006).  There was evidence of leukocyte 
accumulation as early as 6-12 hours after human stroke in partially perfused brain regions 
(Aspey et al., 1989) and at 30 minutes after permanent MCAO in rats.  Leukocytes have 
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been hypothesised to be the cells responsible for the progression from tissue damage to 
cerebral infarction (Huang et al., 2006), as they trigger the production of more 
inflammatory mediators, which results in neutrophils, followed by macrophages and 
monocytes, migrating into the ischaemic brain, the latter two cell types becoming the 
predominant cells five to seven days after ischaemia (Iadecola, 1997).   
Resident brain cells are also involved in the inflammatory response: microglia are activated 
and astrocytes become enlarged, four to six hours after ischaemia.  Twenty-four hours after 
an MCAO, there is much microglial activation in the ischaemic brain, particularly in the 
penumbra (Dirnagl et al., 1999).  Activated microglia can also produce neurotoxins 
including nitric oxide and reactive oxygen species contributing to further oxidative stress.  
The production of these neurotoxins reaches a peak at least several days after ischaemia, 
although the microglia are activated earlier (Giulian and Vaca, 1993).  A recent study with 
human stroke patients showed little microglial activation until 72 hours after ischaemic 
stroke, with continued activation up to 30 days, assessed using a positron emission 
tomography (PET) technique (Price et al., 2006).   
There is evidence that post-ischaemic inflammation contributes to cerebral damage, as this 
damage can be reduced when different steps in the process are blocked, such as blocking 
the action of the crucial inflammatory mediator IL-1 (Loddick and Rothwell, 1996).  In 
stroke patients and in rodent models, infiltrating neutrophils produce iNOS which can 
generate toxic amounts of nitric oxide (Love, 1999).  Pharmacological inhibitors of iNOS 
reduce ischaemic brain injury, even when administered a few days after the ischaemic 
insult, consistent with the hypothesis that ischaemic injury develops over several days 
(Iadecola, 1997).  The cytokine, TNF-α, is produced by ischaemic neurones which can 
worsen the cerebral damage, but is also beneficial to the injured brain as it induces 
antioxidant enzymes (Skinner et al., 2006).  Inflammation may also be linked with 
apoptosis, as reduced post-ischaemic inflammation also reduced apoptosis in the ischaemic 
brain (Chopp, 1996).  In brain, as in other organs, inflammatory cells are involved in tissue 
reconstruction after injury, taking place days to weeks after ischaemia (Dirnagl et al., 
1999).  Inflammation therefore, as well as being detrimental in exacerbating cerebral 
damage following a stroke, may also be crucial for tissue repair.   
1.2.3.5  Cell Death after Ischaemia 
Brain cells, damaged by excessive glutamate receptor activation, Ca
2+ ion overload, 
oxygen radicals and mitochondrial and DNA damage, can die by either necrosis or 
44  
apoptosis.  Necrosis is predominant in the ischaemic core, with apoptosis occurring within 
the penumbra.  In ischaemia-mediated apoptosis, damaged mitochondria release 
cytochrome C resulting in activation of caspases.  Caspases are protein-cleaving enzymes 
which act on many proteins, including the DNA-repairing enzyme PARP, the cytoskeletal 
protein, gelsolin, and huntingtin (Dirnagl et al., 1999).  Neurones seem to be particularly 
susceptible to caspase-mediated cell death following focal cerebral ischaemia.  After mild 
reversible MCAO in mice, cytochrome C release and caspase effects are detected at 6 and 
9 hours respectively, with cell death prominent between 24 and 72 hours (Endres et al., 
1998).  Caspase inhibitors reduce the volume of dead tissue in focal ischaemia and also 
decrease the neurological deficit (Hara et al., 1997), demonstrating the importance of 
caspase activity in reducing the functional ability of the neuronal tissue.  Caspase 
inhibition also protects in experimental head trauma (Yakovlev et al., 1997).  However, it 
has not been concluded that apoptosis definitely occurs in human ischaemic tissue. 
1.2.3.6  Haemorrhagic Stroke 
The other 15% of strokes are haemorrhagic where a blood vessel bursts either in the brain 
or on its surface (Green and Shuaib, 2006).  Intracerebral haemorrhage produces a 
haematoma, a localised collection of clotted blood.  Following acute haemorrhage, 
prevention of haematoma expansion is key for improving the outcome.  However, there is 
a lack of proven treatments.  As with ischaemic stroke, some perihaematoma tissue may be 
able to regain function, but much of the damage occurs quickly and irreversibly, with an 
explosion of local intracranial pressure at the site of the arteriolar rupture (Greenberg, 
2007).  As with ischaemic stroke, inflammation and cell death develop after a haemorrhage 
as shown with animal models of intracerebral haemorrhage (Wagner, 2007).  In the 
perihaematoma tissue, there are infiltrating immune cells and activation of microglia.   
Elevated levels of glutamate have been measured in the brain after intracerebral 
haemorrhage (Wagner, 2007).  When the haemorrhage occurs, blood glutamate can enter 
the brain's extracellular space and, as blood contains several fold higher concentrations of 
glutamate than the brain, may contribute to the increased glutamate in the brain.  This 
increase in brain glutamate is expected to stimulate glutamate receptors and cause 
excitotoxicity.  Oxidative stress has been shown to be rapidly induced in the 
perihaematomal white and grey matter after intracerebral haemorrhage.  Oxidative stress 
contributed to DNA damage and brain injury in a rat model of intracerebral haemorrhage 
(Nakamura et al., 2005).  Nakamura et al. (2005) also showed that intracerebral infusion of 
iron (Fe
2+) ions in rats increased markers of oxidative DNA damage supporting their 
hypothesis that iron chelation can reduce brain injury following intracerebral haemorrhage.  
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Blood-derived plasma proteins, in particular, thrombin, converts fibrinogen to fibrin, which 
is thought to lead to fibrin deposition and water retaining properties in the perihaematomal 
interstitial space (Wagner, 2007).  This may contribute to the perihaematomal oedema.  
Pro-inflammatory cytokines are upregulated after intracerebral haemorrhage.  Early 
upregulation of IL-1β has been observed in the perihaematoma, localised in astrocytes and 
microglial cells.  This cytokine is known to increase blood-brain barrier permeability and 
increase oedema, and is upregulated in various brain injury models and in 
neurodegeneration (Wagner, 2007).  Clot lysis using a recombinant tissue plasminogen 
activator (rt-PA) followed by surgical aspiration reduced the clot and oedema volumes and 
prevented disruption of the blood brain barrier in a pig intracerebral haemorrhage model.  
This treatment was shown to reduce cytokine expression.  Early intervention using this 
approach is currently being examined in a clinical trial (Wagner, 2007).  Iron chelation to 
reduce DNA oxidative damage has also been proposed as a potential therapy for 
intracerebral haemorrhage (Nakamura et al., 2005). 
1.2.3.7  Kynurenines and Ischaemia 
One potential mechanism for neuronal damage following ischaemia is an increase in the 
concentrations of QUIN in the brain.  As IDO, the first enzyme of the kynurenine pathway, 
is stimulated by inflammation, the production of QUIN from tryptophan may not occur 
immediately following the ischaemic insult but only after the inflammatory response has 
been established.  The activity of the QUIN-degrading enzyme, QPRT, remains low, even 
after brain injury in rats, allowing for the accumulation of QUIN (Speciale et al., 1987).  In 
addition, QUIN’s potency is related to the absence of effective removal mechanisms for 
extracellular QUIN (Foster et al., 1984b).  Therefore, excessive QUIN production after 
ischaemia could lead to sustained activation of NMDA receptors and excitotoxicity.   
Saito et al. (1993b) demonstrated increased QUIN levels and IDO activity in the brain at 4 
days after transient global ischaemia in gerbils.  Maximum QUIN levels and IDO activity 
were observed in the hippocampus, followed by the striatum, the regions where the 
neurones are most vulnerable to ischaemia.  There were no increases in QUIN 
concentrations or IDO activity in the brain until 2 days after the ischaemic insult (Heyes 
and Nowak, 1990; Saito et al., 1993b), with levels starting to rise at 2 days, peaking at 4 
days and being reduced by 7 days.  The delayed increases in QUIN levels and IDO activity 
corresponded to the time when inflammation and local brain injury increased.  QUIN 
levels in the CSF of these gerbils, although much lower than the levels in the brain tissue, 
were also increased at 4 days after ischaemia, but there were no changes in plasma.   
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Following ischaemia, the maximum brain levels of QUIN exceeded those in the blood 
(Saito et al., 1993b), suggesting that this increase in QUIN is not due to a breakdown of the 
blood brain barrier.  Injection of labelled tryptophan into the brain was also shown to 
produce QUIN in the hippocampus of ischaemic gerbils which was not observed in control 
gerbils, indicating that the ischaemic hippocampus can produce QUIN from tryptophan, 
but the healthy brain cannot.  The brain has low IDO activity compared to that of other 
tissues.  In healthy rat brain tissue, no metabolism of tryptophan or kynurenine to produce 
QUIN has been determined (Speciale et al., 1989b).  Labelled ANA did not produce QUIN 
in the ischaemic gerbil brain, indicating that this was not an alternative pathway for QUIN 
formation.  However, 3HANA injected into the brain of control gerbils did produce QUIN 
in both the hippocampus and the cerebellum, demonstrating that there is sufficient 3HAO 
present to convert 3HANA to QUIN in the healthy brain (Saito et al., 1993b).  It was 
demonstrated that as well as increases in IDO activity in the ischaemic hippocampus, there 
were significant increases in the activities of the other major enzymes of the pathway 
required for converting tryptophan to QUIN: namely KMO, kynureninase and 3HAO.  In 
the ischaemic gerbil hippocampus, increases in kynureninase and 3HAO occurred 1 day 
post ischaemia, whereas there was no increase in KMO until day 2 and maximally at day 4, 
at the same time as the increases in IDO and QUIN were observed (Saito et al., 1993c).  It 
may be that KMO, being localised in mitochondria, and not present in the cytosol of the 
brain, may suppress an increase in its activity in the brain.  There was no change in KAT 
activity, which produces KYNA, between control and ischaemic gerbils.   
Macrophages in vitro can convert tryptophan to QUIN, suggesting that these cells contain 
kynurenine pathway enzymes (Heyes et al., 1996).  Macrophages were observed by 
immunocytochemistry in the gerbil hippocampus 4 days after ischaemia and to a lesser 
extent in the striatum, cortex and thalamus, consistent with the lower IDO and QUIN in 
these regions (Saito et al., 1993b).  The production of QUIN from tryptophan in ischaemia 
appeared to require macrophage infiltrates in the lesioned brain area, resulting from the 
inflammatory response.  It may be that macrophages are the source of kynurenine pathway 
enzymes to enable tryptophan to produce QUIN.  Infiltrating macrophages from the blood 
contain IDO, KMO, kynureninase and 3HAO, and therefore increase KMO activity 
following an inflammatory response (Saito et al., 1993c).  3HAO is localised in astrocytes 
in healthy rat brain (Okuno et al., 1987), and therefore the increases in 3HAO may also be 
due to astroglial proliferation.  However, it has been shown that there is increased 3HAO 
activity following excitotoxic lesions in the striatum of rats and in patients with HD, but 
there was no increase in QUIN in the brain.  This may suggest that it is the increased 
availability of the substrate, 3HANA, rather than the activity of 3HAO which will 
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determine QUIN production, and 3HANA may be produced in activated macrophages.  
The concentrations of tryptophan were also significantly elevated in both the hippocampus 
and the CSF at 4 days after ischaemia in the gerbil.  As there is more available substrate, 
this may enhance the production of QUIN. 
1.2.3.8  Kynurenine 3-mono-oxygenase Inhibitors and Ischaemia 
Increases in KYNA and decreases in 3HKYN and QUIN, brought about by the 
administration of KMO inhibitors, resulted in reduced ischaemic brain damage in animal 
models of ischaemia.  Both KMO inhibitors, (m-nitrobenzoyl)-alanine and 3,4-dimethoxy-
[-N-4-(nitrophenyl)thiazol-2yl]-benzenesulphonamide (Ro 61-8048) caused a dramatic 
reduction (greater than 80%) in the percentage of damaged pyramidal neurones in the 
hippocampal CA1 region of gerbils subjected to transient bilateral carotid occlusion (Cozzi 
et al., 1999).  After MCAO in rats, these compounds also significantly reduced infarct 
volume by over 60% (Cozzi et al., 1999).  The mechanisms of this neuroprotection were 
initially thought to be due to the increase in KYNA caused by inhibiting KMO.  KYNA 
levels, measured by microdialysis, increased by approximately 25-fold in the ischaemic 
gerbil brain, to a maximum of 56nM, and by approximately 5-fold in the ischaemic rat 
brain, to a maximum of 85nM, under the experimental conditions (Cozzi et al., 1999).  
However, these levels of KYNA are much lower than KYNA concentrations able to offer 
functionality as an antagonist at NMDA receptors, as the minimum concentration required 
is approximately 30μM, when administered by microdialysis (Urenjak and Obrenovitch, 
2000).  Direct application of 100nM of KYNA into the gerbil hippocampus, which was 
then subjected to transient bilateral carotid occlusion, inhibited the increased glutamate 
output induced by ischaemia (Moroni et al., 2003), suggesting an alternative mechanism 
for KYNA's neuroprotective effects.  NMDA receptor antagonists, as well as other 
glutamate receptor antagonists, are protective against ischaemic brain damage, and have 
been shown in the gerbil model by Pellegrini-Giampietro et al. (1994).   
In an in vitro model of ischaemia, rat hippocampal slices, exposed to oxygen glucose 
deprivation (OGD) and the two KMO inhibitors, (m-nitrobenzoyl)-alanine and Ro 61-
8048, reduced neuronal death and restored reduced KYNA concentrations (Carpenedo et 
al., 2002).  However, KYNA itself at concentrations up to 30μM had no neuroprotective 
effect on these hippocampal slices.  Levels of 100μM KYNA did offer neuroprotection 
which was attributed to antagonism at NMDA receptors (Carpenedo et al., 2002).  The 
mechanism for the neuroprotection of the KMO inhibitors in ischaemia therefore was not 
simply by increased KYNA concentrations.   
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KMO inhibitors also inhibit the production of 3HKYN and QUIN synthesis and a 
reduction in these neurotoxic compounds may contribute to neuroprotection.  Rat 
hippocampal slices were exposed to OGD in the presence of Ro 61-8048 and low 
concentrations (1-10μM) of either 3HKYN or QUIN inhibited the neuroprotective effect of 
Ro 61-8048 (Carpenedo et al., 2002).  These results suggest that 3HKYN and QUIN 
contribute to the loss of hippocampal neurones after ischaemia.  Indeed, a role for the 
reduced formation of 3HKYN in the mechanism for KMO inhibitors preventing ischaemic 
neuronal death has been further implicated as, in the in vitro OGD model of ischaemia, 
hippocampal slices demonstrated apoptotic features of neuronal death (Moroni et al., 2001) 
and 3HKYN is a potent apoptotic compound (Okuda et al., 1998; Chiarugi et al., 2001).  
The ability of KMO inhibitors to reduce ischaemic neuronal damage demonstrates that 
KMO inhibitors have the potential to be evaluated as therapeutic tools in the treatment of 
stroke. 
The evidence above supports a role for IDO activation and the involvement of the 
kynurenine pathway in the mechanisms contributing to brain damage following ischaemic 
stroke.  In particular, manipulating the levels of KYNA, 3HKYN and QUIN with KMO 
inhibitors has been shown to offer neuroprotection from ischaemic neuronal damage. 
1.2.3.9  Treatment for Ischaemic Stroke 
There are no effective treatments for acute ischaemic stroke, except for the thrombolytic  
rt-PA, which needs to be given within 3 hours of the onset of the stroke (Green and Shuaib, 
2006).  This drug, however, increases the risk of haemorrhage, which together with the 
need for immediate administration, results in it being given to less than 5% of stroke 
patients.  Additionally, it is not always effective as many patients do not reperfuse when 
given the drug.  There are two major approaches for the treatment of stroke: thrombolysis 
(which includes rt-PA) to try to disperse the clot and restore blood flow to the 
compromised region, and neuroprotection, using drugs to interfere with one or more of the 
mechanisms which are activated following ischaemia, to minimise the extent of tissue 
damage and hence neurodegeneration (Green and Shuaib, 2006).  Several studies have 
examined a combination of thrombolytic and neuroprotective drugs but no synergistic 
effect was demonstrated.  However, the potential neuroprotectant drug NXY-059 was 
shown to prevent the increase in haemorrhage rate produced by the thrombolytic drug, rt-
PA (Lapchak et al., 2002).  Aspirin, if started within 48hours of ischaemic stroke, has been 
shown to reduce the risk of early recurrent ischaemic stroke, without a major risk of 
haemorrhagic complications (Sandercock et al., 2003; Sherman, 2004).  It also reduces the 
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volume of brain damage after a stroke, thus improving the long-term outcome for the 
patient.  Aspirin inhibits the aggregation of blood platelets and hence enhances blood 
perfusion to the brain (Sandercock et al., 2003; Sherman, 2004).      
1.2.3.10  Neuroprotective Therapy – NMDA Receptor Antagonists 
There has been major progress in researching the mechanisms of ischaemic cell death and 
neuroprotective drugs but this has not translated into the development of suitable drugs for 
humans.  This research has been based on rat and other animal models, with permanent 
MCAO and transient MCAO.  During the 1990s, much animal work was done establishing 
excitotoxic glutamate receptor (NMDA and AMPA) antagonists which decreased the 
damage to the penumbra.  In addition to KYNA itself, two competitive NMDA receptor 
antagonists, 2-amino-5-phosphonovalerate and 2-amino-7-phosphonoheptanoate, 
depressed the ischaemia-induced accumulation of glutamate and aspartate in the rat 
striatum (Ghribi et al., 1994).  Since 2003, many pharmaceutical companies have pulled 
out of clinical trials with these neuroprotective drugs for stroke or head injury treatment, as 
they did not show therapeutic efficacy.  Glutamate is released very early after the 
ischaemic insult and drugs need to be given very quickly which is often impractical (Green 
and Shuaib, 2006).  For example, the NMDA receptor antagonist, MK-801, administered 
before or up to 2 hours after onset, reduced penumbra damage in a range of animal species 
(Park et al., 1988; McCulloch, 1992).  Another approach was to antagonise the NMDA 
receptor by inhibiting glycine from its regulatory site, thus reducing NMDA receptor 
activity.  Chen et al. (1993) had demonstrated that the potent glycine antagonist, 7-
chlorothiokynurenic acid, attenuated infarct size in rats with permanent MCAO.     
Glutamate has a physiological role as a neurotransmitter and blocking glutamate receptors 
results in serious side effects such as respiratory depression and cardiovascular 
dysregulation (Dirnagl et al., 1999).  To overcome this problem, recent trial drugs have 
examined targeting specific subunits of glutamate receptors that are upregulated in 
ischaemia.  There appears to be only one NMDA receptor antagonist (Traxoprodil) 
currently being developed with NR2B receptor subtype selectivity (Green and Shuaib, 
2006).  Other clinical trials that have not produced the neuroprotection shown in animal 
models include administering magnesium (Mg
2+ ions) to reduce activation of the NMDA 
receptor, as these ions ‘gate’ the NMDA receptor channel.  AMPA antagonists were also 
evaluated as neuroprotectants, but competitive antagonists had adverse side effects (Green 
and Shuaib, 2006).   
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1.2.3.11  Failure of Neuroprotective Drugs in Clinical Trials 
Reasons for the failure of neuroprotective drugs for treatment of stroke in humans although 
they worked well in animals, include a) poor penetration of drug from plasma to the brain, 
b) reduced dose to alleviate side effects to the cardiovascular system, c) uncontrolled 
physiology compared to animal work, e.g., blood pressure, temperature, glucose level, d) 
stroke patients are usually elderly, with a variety of other clinical problems whereas young 
healthy animals are used in animal models, e) penumbra may be smaller (unknown 
volume) and exist for a shorter period of time than in animals, f) may not have found the 
therapeutic window in human, as drugs were often given to humans at a much later time 
than they had been shown to be effective in animal models and g) may need to protect all 
brain cells including the axons and oligodendrocytes, neither of which contain NMDA 
receptor (Dirnagl et al., 1999; McCulloch and Dewar, 2001; Green and Shuaib, 2006).  To 
maximise the chance of success of a drug, guidelines have been proposed by experts from 
academia and industry, the Stroke Therapy Academic Industry Roundtable group (STAIR), 
for the information that should be collected in animal models before a drug ought to be 
considered for progression to clinical trial (Stroke Therapy Academic Industry Roundtable, 
1999).   
1.2.3.12  Neuroprotective Therapy – Reduction in Oxidative Stress 
NXY-059 is the first neuroprotective drug developed rigidly following the STAIR criteria 
before entering Phase III trials.  The first of two clinical studies (SAINT I) with acute 
stroke patients has shown that this drug significantly reduced disability (using the modified 
Rankin score) but did not improve neurological function (measured by the US National 
Institutes of Health stroke scale).  This drug was administered within 6 hours of stroke 
onset, and was well tolerated in the patients (Lees et al., 2006).  The results of the second 
trial are awaited.  NXY-059 is a nitrone which has free radical trapping properties.  Its 
trapping ability means that it forms a stable adduct with free radicals, which may suggest 
that it is less reversible than some free radical scavengers.  NXY-059 also prevents 
mitochondrial dysfunction by reducing cytochrome C release, and hence caspase 
activation, after the ischaemic insult (Green and Shuaib, 2006).  Other free radical 
scavengers and trapping agents have been investigated.  The most promising is 
stilbazulenyl nitrone (STAZN), another nitrone-derived compound, which recently 
produced effective neuroprotection in transient MCAO in the rat and has the potential 
benefit over NXY-059 in that it exhibits greater penetration of cerebral tissue (Ley et al., 
2005).  Another approach that is currently being considered for developing drugs for 
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ischaemic stroke is metal chelation, where compounds which chelate divalent metal ions, 
including calcium, copper and iron, have shown reduced infarct volumes in rat models, 
functioning in reducing free radical production.  Metal chelation also has therapeutic 
potential in haemorrhagic stroke (Nakamura et al., 2005).  Citicoline is a compound that 
has been in clinical use for many years in Europe and Japan to treat a variety of 
degenerative neurological disorders.  It is currently being considered for the treatment of 
stroke as it reduces lipid metabolism following ischaemia and hence reduces the generation 
of free fatty acids and free radicals (Green and Shuaib, 2006).   
1.2.3.13  Neuroprotective Therapy – Anti-inflammatory Approach 
As inflammation contributes to cerebral damage following a stroke, there is a strong 
rationale to use anti-inflammatory therapies (Dirnagl et al., 1999).  The production of 
cytokines, for example TNF-α, is important in the inflammatory response of the brain to 
injury.  Anti-TNF-α antibodies have been shown to inhibit ischaemia-induced damage to 
the brain in spontaneously hypertensive rats (Barone et al., 1997) and several approaches 
to reduce this TNF-α effect have been examined.  The major problem with reducing TNF-α 
is that this compound also can assist in cell survival after stroke, therefore, it has both 
beneficial and detrimental properties.  Other stroke therapies involve growth factors, which 
may be more important for long-term recovery than for neuroprotection (Green and 
Shuaib, 2006).   
1.2.4  Traumatic Brain Injury 
TBI is a closed head injury which occurs when there is a sudden blunt mechanical impact 
injury to the head, causing disruption of the brain tissue.  The leading causes of TBI are 
motor vehicle crashes and falls, with a mortality rate of 22%.  TBI is most common in 
young people, in the age range 15-24, and in the elderly, over 75 years old, and is more 
prevalent in males than females (Lovasik et al., 2001).   
The primary injury from a TBI occurs from both the direct contact force and the resulting 
translational or rotational acceleration forces in the brain which immediately follow the 
initial impact (Lovasik et al., 2001).  There is immediate damage to neurones and glia 
which lose their functionality.  Damage to the cerebral vasculature leads to progressive 
events including increased intracranial pressure, disruption of the blood-brain barrier, 
haemorrhage, ischaemia, oedema and necrosis (Stelmasiak et al., 2000).  As well as focal 
injury leading to large lesions in the brain, a TBI involving rotational acceleration causes 
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diffuse axonal injury, a scattered destruction of axons throughout the brain (Sahuquillo et 
al., 2001).  This diffuse axonal injury is the most devastating primary lesion.  Mechanical 
alteration of axons and cells leads to increased permeability and abnormal ion fluxes with 
increases in intracellular calcium, sodium and chloride ions and leakage of potassium ions, 
resulting in excitotoxicity and astrocytic swelling (Sahuquillo et al., 2001).  After diffuse 
axonal injury, reduced levels of free magnesium ions have been found, which could 
contribute to increased excitotoxicity as magnesium ions block the NMDA receptor 
channels.  
Following TBI, ruptured cerebral blood vessels allow the blood contents to escape directly 
into the brain parenchyma, which is thought to contribute to secondary brain damage.  The 
permeability of the blood-brain barrier in a mouse model of TBI showed that soon after 
trauma, both large and small molecules could enter the brain near the injury site (Habgood 
et al., 2007).  Large protein-sized molecules could no longer penetrate the blood-brain 
barrier by 4-5 hours after injury, however, much smaller molecules (<10,000Da) could still 
reach the brain tissue up to 4 days post-injury.  This demonstrated that the restoration of 
the blood-brain barrier was gradual and penetration during this restoration period was 
dependent on the size of the molecules in the blood (Habgood et al., 2007).  TBI has been 
shown to alter polyamine metabolism with activation of NMDA receptors via their 
polyamine sites, which contributes to blood-brain barrier breakdown, brain oedema and 
injury volume (Dempsey et al., 2000).  
Traumatic brain lesions are very dynamic and the mechanical injury activates multiple 
neurochemical cascades.  As in stroke, after TBI, there are areas of injured but viable brain 
tissue known as the traumatic penumbra, which, for some time after the initial injury, have 
the potential to regain their function (Sahuquillo et al., 2001).  Secondary damage occurs at 
variable times after the initial injury and mechanisms include oxidative stress, 
excitotoxicity and inflammation.  Macrophages and microglia have been reported to be 
involved in the inflammatory damage after TBI, releasing oxygen free radicals and 
cytokines (Sahuquillo et al., 2001).  For patients undergoing surgery within 24 hours after 
trauma, a biopsy of contused human brain tissue was removed and a very limited 
inflammatory response was detected.  However, brain tissue from TBI patients having 
surgery 3-5 days after trauma showed a massive inflammatory response, involving 
macrophages and reactive microglia (Holmin et al., 1998).  Similarly, the inflammatory 
marker, neopterin, has been shown to gradually increase in CSF and serum during the first 
week after human TBI (Lenzlinger et al., 2001).   
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One of the major secondary effects of TBI is ischaemia.  TBI-induced ischaemia can be 
caused by decreases in global cerebral blood flow due to increased intracranial pressure or 
reduced blood flow due to vasospasm or brain herniation (where the arteries are 
compressed by the herniated tissue) (Sahuquillo et al., 2001).  Although the causes of 
ischaemia are different compared with ischaemic stroke, the resulting effects are the same: 
excitotoxicity, oedema, oxidative stress and inflammation.  Ischaemic damage has been the 
main therapeutic target for both experimental and clinical trials for TBI and many of the 
pharmacological agents trialled for TBI were similar to those used in ischaemic stroke 
trials.  As for stroke, clinical trials with drugs that were very promising in experimental 
animal models of TBI have yielded disappointing results, suggesting that for head-injured 
patients, neuroprotection cannot be achieved as simply as in animal models (Sahuquillo et 
al., 2001). 
1.2.4.1  Kynurenines in Traumatic Brain Injury 
The involvement of excitotoxicity and inflammation in TBI suggests that the kynurenine 
pathway may be involved in the resulting brain damage.  Sinz et al. (1998) determined 
there was a rise in QUIN in the CSF during the first week after severe TBI in humans with 
QUIN levels being higher in patients who died as a result of their injury.  QUIN 
concentrations in the CSF increased over time, reaching a maximum, averaging 463nM, at 
72-83 hours after the TBI, compared to normal concentrations of QUIN in the CSF of less 
than 50nM.  The time course of this increase mirrors that of infiltration of macrophages 
into the injured brain (Holmin et al., 1997).  Children with severe TBI also showed high 
levels of QUIN in their CSF, which increased over time after injury and was higher in 
children who died (Bell et al., 1999).   
In animal studies, a traumatic compression injury to the spinal cord of guinea pigs resulted 
in increased QUIN levels in the spinal cord and CSF and caused progressive neurological 
deficits in the animals (Blight et al., 1995).  This study showed that peak tissue levels of 
QUIN occurred at 12 days after injury.  The 3HAO inhibitor, 4-chloro-3-
hydroxyanthranilate, reduced QUIN accumulation and reduced the functional deficits, 
demonstrating QUIN's role in causing neuronal dysfunction.  Further work showed that 
this improvement in the guinea pigs' neurological function was not caused by the 3HAO 
inhibitor resulting in an increase in the neuroprotectant, KYNA, as there was no change in 
the concentration of this metabolite (Yates et al., 2006). 
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With a rat model of TBI (lateral fluid-percussion brain injury), the neuroprotective effects 
of KYNA were demonstrated, with KYNA administered 15 minutes post-injury. KYNA 
dramatically reduced the trauma-induced cognitive dysfunction, improved neurologic 
motor deficits,  reduced oedema formation and attenuated calcium concentrations in the rat 
brain (Smith et al., 1993).  This model causes the selective loss of neurones in the 
hippocampal CA3 region, observed after two weeks, which was greatly reduced by the 
KYNA treatment (Hicks et al., 1994). 
  
1.3  Aims 
The literature suggests that the kynurenine pathway may have a role in HD, stroke and 
TBI, contributing to the neuronal damage in each of these disorders.    
The initial aim of this PhD project was to determine whether concentrations of kynurenines 
are altered in the blood of patients with different causes of brain injury: HD, chronic brain 
injury and acute stroke.  The project then aimed to investigate the kinetics of tryptophan 
metabolism via the kynurenine pathway following tryptophan depletion or loading for HD 
and chronic brain injury patients compared with healthy controls.  For stroke patients, the 
project aimed to determine any changes in the kynurenines during the 14 days following 
the stroke. 
The overall aim was to hypothesise mechanisms for changes in kynurenines in each 
disorder and compare kynurenine pathway metabolism in neurodegeneration (HD), chronic 
brain injury and acute brain injury (stroke). 
This project also aimed to develop high performance liquid chromatography (HPLC) 
methods to accurately measure kynurenines in human blood. 
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2  Materials and Methods 
2.1  Materials 
2.1.1  Chemicals 
Sigma-Aldrich Company Ltd., Poole, Dorset, UK:  L-tryptophan (T-0254), L-kynurenine 
(K-8625), kynurenic acid (K-3375), 3-hydroxy-DL-kynurenine (H-1771), 3-
hydroxyanthranilic acid (H-9391), anthranilic acid (A8,985-5), 3-nitro-L-tyrosine (N-
7389),  L-ascorbic acid, ethylenediaminetetraacetic acid disodium salt (EDTA), 3,4-
dihydroxybenzylamine hydrobromide, 4-amino-3-hydroxybenzoic acid. 
VWR International Ltd., Lutterworth, Leicestershire, UK: glacial acetic acid (100%), 
orthophosphoric acid (85%), perchloric acid (70%), sodium acetate trihydrate, sodium 
chloride, triethylamine (HiPerSolv for HPLC), zinc acetate, potassium hydroxide pellets, 
disodium hydrogen orthophosphate (anhydrous), sodium dihydrogen orthophosphate 
dihydrate. 
Fisher Scientific UK, Loughborough, Leicestershire, UK: citric acid, 1-heptane sulphonic 
acid (sodium salt, HPLC grade), hydrochloric acid (37%), sodium hydroxide pellets, 
HPLC grade acetonitrile, HPLC grade methanol. 
Rathburn Chemical Company, Walkerburn, Scotland, UK: HPLC grade water. 
Millipore (UK) Limited, Watford, Hertfordshire, UK: Milli-Q synthesis system producing 
ultrapure water for HPLC, fed by the Millipore Elix 10 water system.  Water purity was 
18.2mΩ. 
BOC Gases, Guildford, Surrey, UK: helium gas, oxygen-free nitrogen gas. 
All chemicals were stored at the appropriate temperature, as recommended by the 
suppliers.   
2.1.2  Laboratory Consumables 
General laboratory consumables (eppendorf tubes, pipette tips, pasteur pipettes, universal 
and bijou containers, glassware) were obtained from a variety of sources based on 
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availability in the University Biomedical Research (IBLS) Stores.  Autosampler total 
recovery vials were purchased from Waters Limited (Elstree, Hertfordshire, UK). 
Polypropylene pellet pestles (for homogenising residues in 1.5ml eppendorf tubes) were 
from VWR. 
2.1.3  Filtration of Solutions 
All HPLC mobile phases were filtered under vacuum through 0.2μm nylon filter 
membranes (Phenomenex, 47mm diameter), using filtration glassware from Phenomenex.  
All solutions prior to injection on to the HPLC were filtered by centrifuging using 0.2μm 
VectaSpin Micro Anopore filter tubes (Whatman International, Maidstone, Kent, UK) or 
0.2μm PVDF Micro-Spin filter tubes (Alltech Associates Applied Science Ltd., Carnforth, 
Lancashire, UK). 
2.1.4  Laboratory Equipment 
Sanyo, Loughborough, Leicestershire, UK: Harrier 18/80, MSB080.CR2.K refrigerated 
centrifuge, with a 24 x 1.5ml angle rotor (43117-612). 
Thermo Electron Corporation, Milford, MA, USA: Modulyo freeze-dryer. 
2.1.5  HPLC Instrumentation 
The HPLC system was from Waters Ltd., consisting of a Waters 600 quaternary pump, a 
Waters 717plus autosampler, a column heater, a Waters 2487 dual wavelength absorbance 
detector and a Waters 474 fluorescence detector.  Flow was through the absorbance 
detector followed by the fluorescence detector, the detectors being connected in series.  
Alternatively a Waters Concorde electrochemical detector was used instead of the 
absorbance and fluorescence detectors.  Waters Millennium software (version 3.20) was 
used to run the HPLC system, collect the data and process the chromatograms.  Helium gas 
was used to degas all mobile phases continuously at a sparge rate of 20ml/min. 
2.1.6  HPLC Columns 
The HPLC columns used were Kingsorb, a standard C18 column (250mm x 4.6mm I.D., 
particle size 5μm,) and Synergi Hydro-RP 80A C18 column (250mm x 4.6mm I.D., 
particle size 4μm) both from Phenomenex, Macclesfield, Cheshire, UK.  The Synergi 
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Hydro column contains a C18 bonded phase endcapped with a polar group to provide good 
retention of both hydrophobic and polar compounds with 100% aqueous mobile phase.  
Phenomenex SecurityGuard Cartridges (4 x 3.0mm) were used as pre-columns, the general 
C18 cartridge with the Kingsorb column and the polar endcapped C18 cartridge for the 
Synergi Hydro column. 
2.1.7  Solid Phase Extraction (SPE) 
A 24-position vacuum manifold (Phenomenex) was used for SPE.  Oxygen-free nitrogen 
gas was used for drying samples in organic solvents and a Modulyo freeze-dryer was used 
for drying aqueous samples.   
Various SPE cartridges were assessed: Waters SepPak (500mg/3cc), Waters SepPak 
(200mg/3ml), Waters Oasis HLB (30mg/1ml), Phenomenex Strata (2g/12ml), Phenomenex 
Strata-X (30mg/1ml), Varian (Walton-on-Thames, Surrey, UK) Focus (20mg/3ml), 
Phenomenex Strata-X-C (60mg/3ml), Varian Bond Elut SCX (500mg/3ml), Varian Bond 
Elut SCX (50mg/1ml), Phenomenex Strata-X-C (30mg/1ml), Supelco (Sigma-Aldrich) 
Discovery DSC-MCAX (100mg/1ml) and Waters Oasis MCX (30mg/1ml). 
2.2  HPLC Technique 
Reverse phase HPLC was used in this project.  It is a commonly used type of liquid 
chromatography, where separation of an analyte (or analytes) in a solution containing 
several different compounds is achieved based on its polarity.  The HPLC columns are 
often C18 columns where the column matrix, usually silica particles, are coated with 
straight hydrocarbon chains containing 18 carbon atoms.  The mobile phase is relatively 
polar in comparison, usually comprising an aqueous buffered salt solution, with the 
addition of a small amount of organic solvent.  When the sample is injected on to the 
column, the more non-polar components interact with the column packing material and are 
retained for longer by the column, whereas the more polar compounds pass easily through 
the column and are eluted more quickly.  On elution of the analyte in the mobile phase it 
passes through a detector which produces a signal, the intensity of which corresponds to 
the quantity of analyte present.  The detector used depends on the properties of the analyte, 
with absorbance detectors commonly used at ultraviolet and visible wavelengths and 
fluorescence and electrochemical detectors are often used for increased sensitivity, when 
the analytes can fluoresce, or are redox-active.  Mass spectrometry detection has been used 
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more recently, with this detection system having the added advantage of confirming the 
identity of the analyte as it is detected. 
2.3  Methods (carried out by others) 
Quinolinic acid was analysed using gas chromatography-mass spectrometry (GC-MS) at 
West Park Biochemistry Laboratories, Epsom General Hospital, Epsom, Surrey, UK and 
the standard clinical assays, erythrocyte sedimentation rate (ESR) and C-reactive protein 
(CRP), were analysed by the Haematology and Immunology Laboratories, Epsom General 
Hospital, Epsom, Surrey.  In addition, neopterin and lipid peroxidation products were 
detemined by Dr C.M. Forrest and Ms L. Oxford at the University of Glasgow. 
Method details are given in the Appendix.  
3  HPLC Method Development 
3.1  Sample Preparation 
3.1.1  Method Development for Sample Preparation 
A simple extraction procedure using perchloric acid (PCA) to deproteinise the plasma 
samples was examined, based on the extraction described by Hervé et al. (1996).   
A single extraction released only a proportion of the kynurenines from plasma, and as the 
levels of some kynurenines in plasma are in the low nanomolar range and difficult to 
detect, it was important to try to extract all of the kynurenines present.  Repeated 
extractions were examined to try to extract more kynurenines.   
The first extraction procedure used a minimum amount of extraction solvent (total volume 
of 700μl).  In a 1.5ml eppendorf tube, 500μl plasma was added to 100μl 240μM 3-
nitrotyrosine (internal standard) and 50μl 2mM ascorbic acid and the mixture was 
vortexed.  50μl 4M PCA was added and vortexed immediately for 30 seconds.  The 
samples were centrifuged at 5000g for 10 minutes at 4°C and the resulting supernatant 
frozen overnight at -40°C.   
Another procedure involved a single extraction again with extracts being prepared as 
above, except that a larger volume of extraction solution (total volume of 1ml) was used.  
200μl water was added to the plasma and the volume of 4M PCA was increased to 150μl, 
compared with the original 50μl.   
To release kynurenines from plasma using a repeated extraction method, the first 
extraction procedure was used and after collecting the supernatant from the centrifugation 
step, the residue was then homogenised with 200μl water and 100μl 4M PCA, using pellet 
pestles.  This mixture was vortexed and then centrifuged at 5000g for 10 minutes at 4°C.  
The resulting supernatant was combined with the initial supernatant.   
A method involving three extractions was also examined by washing the residue produced 
on centrifugation twice.  The method from the repeated extraction procedure was followed 
using volumes for the first wash of 100μl water and 50μl 4M PCA, with a repeated 
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washing step using a further 100μl water and 50μl 4M PCA.  The three resulting 
supernatants were combined.   
The total volumes for the two and three extraction methods were both 1ml.  The following 
day extracts were defrosted and filtered through Anopore filter tubes by centrifuging at 
10,000g for 10 minutes at 4°C.   
Four plasma samples were used to determine the best extraction procedure for measuring 
tryptophan, kynurenine and KYNA.  Tryptophan, kynurenine and KYNA were determined 
by the HPLC method described in Section 3.2.3.  The concentration in plasma was 
determined by multiplying the results from the calibration curve by 2, where the plasma 
had been diluted from 500μl into a total volume of 1ml.  The results from the calibration 
curve for the concentrated extracts have been multiplied by 700/500 as 500μl plasma was 
diluted in a total volume of 700μl.  The internal standard or recovery factors have not been 
applied to these results as it is the actual quantities of the individual metabolites that are 
important here.  The results are shown in Tables 3-1 to 3-3. 
Another four plasma samples were extracted by the four different extraction methods 
detailed above and the amounts of ANA and 3HANA were determined by the method 
described in Section 3.3.3.  The results are in Tables 3-4 and 3-5. 
Four plasma samples taken 7 hours after subjects had consumed a tryptophan load were 
extracted using the same four extraction procedures.  The results for the determination of 
3HKYN using the method described in Section 3.5.3 are shown in Table 3-6. 
In general, the more concentrated extract and the other extract from a single extraction 
procedure resulted in lower concentrations of all six metabolites compared with the 
repeated extractions.  For kynurenine and ANA, the concentrated extracts were lower than 
when a larger volume of extraction solvent was used in a single extraction.  The different 
volumes of extraction solvent showed little effect for the other metabolites.  Increasing the 
number of extractions in general increased the levels of all the metabolites, although there 
was only a small improvement with three extractions compared with two.  Kynurenine 
seemed to be the least affected by the number of extractions.  The results suggest that 
increasing the number of extractions beyond three would not extract much more of the 
metabolites and hence the three extraction procedure was chosen for use throughout this 
work. 
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The kynurenines, 3HKYN and 3HANA, are unstable and light sensitive, but can be 
stabilised by the addition of the antioxidant, ascorbic acid (Pearson and Reynolds, 1991).   
Ascorbic acid was added to standard solutions and during extraction of plasma samples to 
maintain a concentration of 100μM in all solutions, to try to prevent breakdown of these 
compounds.  All standards and plasma samples were defrosted in the dark and kept on ice 
once defrosted.  
3.1.2  Final Sample Preparation Method 
Samples of EDTA plasma were defrosted in the dark and kept on ice during sample 
preparation.  To 100μl 240μM 3-nitrotyrosine (internal standard), 500μl plasma and 50μl 
2mM ascorbic acid were added, followed by 50μl 4M PCA.  Samples were vortexed for 30 
seconds immediately after acid addition, centrifuged at 5000g for 10 minutes at 4°C, and 
the supernatant collected.  The precipitated proteins were homogenised with 100μl water 
and 50μl 4M PCA using pellet pestles, the mixture vortexed for 30 seconds and 
centrifuged at 5000g for 10 minutes at 4°C.  Again the supernatant was collected.  This 
washing and centrifugation step was repeated and the supernatants combined.  After 
vortexing, the extracts were split into two samples and stored at -40°C prior to analysis. 
Defrosted sample supernatants were filtered through Anopore or Alltech filter tubes by 
centrifugation at 10,000g for 10 minutes at 4°C.  Filtrates were transferred to Waters total 
recovery vials and placed in the autosampler at 4°C.  A volume of 100μl was injected on to 
the HPLC column.  
Table 3-1  Effect of increasing the volume of extraction solvent and increasing the 
number of extractions on the levels of tryptophan in four plasma samples. 
 
 
Tryptophan (μM) 
 
 
Plasma 1  Plasma 2  Plasma 3  Plasma 4 
One extraction 
(conc) 
20.7 
 
51.2 38.7 34.4 
One extraction 
 
20.5  52.1 38.8 34.5 
Two extractions 
 
23.6  59.2 44.9 39.7 
Three  
extractions 
24.6  60.7 45.6 40.7 
 
Table 3-2    Effect of increasing the volume of extraction solvent and increasing the 
number of extractions on the levels of kynurenine in four plasma samples. 
 
 
Kynurenine (μM) 
 
 
Plasma 1  Plasma 2  Plasma 3  Plasma 4 
One extraction 
(conc) 
1.43  1.69 1.24 1.16 
One extraction 
 
1.61  2.12 1.47 1.31 
Two extractions 
 
1.73  2.10 1.51 1.38 
Three  
extractions 
1.71  2.17 1.61 1.38 
 
Table 3-3  Effect of increasing the volume of extraction solvent and increasing the 
number of extractions on the levels of kynurenic acid in four plasma samples. 
 
 
Kynurenic Acid (nM) 
 
 
Plasma 1  Plasma 2  Plasma 3  Plasma 4 
One extraction 
(conc) 
44.4  22.0 16.8 25.1 
One extraction 
 
41.6  26.2 17.9 21.9 
Two extractions 
 
57.8  28.9 19.0 28.0 
Three  
extractions 
56.0  28.6 22.3 29.6 
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Table 3-4  Effect of increasing the volume of extraction solvent and increasing the 
number of extractions on the levels of anthranilic acid in four plasma samples. 
 
 
Anthranilic Acid (nM) 
 
 
Plasma 5  Plasma 6  Plasma 7  Plasma 8 
One extraction 
(conc) 
26.6 111.4  12.6  12.2 
One extraction 
 
40.0 118.9  19.7  18.4 
Two extractions 
 
47.6 132.5  19.9  18.2 
Three  
extractions 
52.2 136.5  20.3  20.8 
 
Table 3-5  Effect of increasing the volume of extraction solvent and increasing the 
number of extractions on the levels of 3-hydroxyanthranilic acid in four plasma samples 
(analysed using HPLC with fluorescence detection). 
 
 
3-Hydroxyanthranilic Acid (nM) 
 
 
Plasma 5  Plasma 6  Plasma 7  Plasma 8 
One extraction 
(conc) 
18.0 0  20.8  23.7 
One extraction 
 
18.7 0.9  20.5 24.2 
Two extractions 
 
17.4 1.4  23.1 26.7 
Three  
extractions 
25.3 0.9  23.5 27.4 
 
Table 3-6  Effect of increasing the volume of extraction solvent and increasing the 
number of extractions on the levels of 3-hydroxykynurenine in four plasma samples. 
 
 
3-Hydroxykynurenine (μM) 
 
 
Plasma 9  Plasma 10  Plasma 11  Plasma 12 
One extraction 
(conc) 
1.08  0.75 0.70 0.60 
One extraction 
 
1.12  0.64 0.69 0.57 
Two extractions 
 
1.21  0.76 0.73 0.67 
Three  
extractions 
1.30  0.78 0.74 0.68 
  
3.2  Quantification of Tryptophan, Kynurenine and KYNA 
3.2.1  Determination of Tryptophan, Kynurenine and KYNA 
Introduction 
Tryptophan and kynurenine have been determined in human serum (Hervé et al., 1996) 
Kynurenine was detected by absorbance at wavelength 365nm, and tryptophan by either 
absorbance at 230nm or fluorescence at excitation wavelength (λex) of 254nm and emission 
wavelength (λem) of 404nm.  Widner et al. (1997) also measured tryptophan and 
kynurenine in human serum, using 3-nitrotyrosine as the internal standard.  Kynurenine 
and 3-nitrotyrosine were determined by absorbance at 360nm.  Tryptophan was detected 
using fluorescence with λex=285nm and λem=365 nm.  The use of 3-nitrotyrosine is not 
ideal as an internal standard as it can be produced in the body under conditions of oxidative 
stress.  Widner et al. (1997) used 3-nitrotyrosine in samples at a concentration of 45µM, 
which exceeds pathophysiological amounts by at least two orders of magnitude, and hence 
3-nitrotyrosine was regarded suitable for use as an internal standard. 
The concentration of KYNA in biological fluids is low and a sensitive method of detection 
is required.  Endogenous concentrations of KYNA in the serum of healthy humans are 
between 23nM and 59.6nM (Heyes et al., 1994; Hervé et al., 1996; Ilzecka et al., 2003; 
Fukushima  et al., 2007).  This concentration is not detectable using absorbance or 
fluorescence detection, nor is it electrochemically active, therefore electrochemical 
detection is not appropriate.  However, Shibata (1988) demonstrated that KYNA could be 
detected by enhancing its fluorescence with zinc ions (Zn
2+).  KYNA was separated using 
reverse phase HPLC, with up to 1M zinc acetate post-column derivatisation, resulting in a 
50-fold increase in the fluorescence of KYNA.  The fluorescence λex was 344nm and λem 
was 398nm.  Hervé et al. (1996) incorporated zinc acetate into the mobile phase at a 
concentration of 250mM and successfully measured KYNA in human serum.  This group 
also measured tryptophan and kynurenine in the same run but using absorbance detection, 
showing that the zinc acetate does not interfere with the detection of these metabolites.   
3.2.2  Method Development for Tryptophan, Kynurenine and 
KYNA  
The mobile phase chosen was based on that of Hervé et al. (1996) and comprised 50mM 
acetic acid, 250mM zinc acetate and 5% acetonitrile, with kynurenine, tryptophan, 3-
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nitrotyrosine and KYNA all eluting within 20 minutes.  However, with the large number of 
samples involved in each study, continuous running of this mobile phase was impractical 
as the HPLC pump frequently blocked due to precipitation of zinc acetate.  The best 
compromise was using a mobile phase composed of 50mM acetic acid, 100mM zinc 
acetate and 3% acetonitrile, which resulted in a retention times of 10.2 minutes for 
kynurenine, 16.2 minutes for 3-nitrotyrosine, 20.5 minutes for tryptophan and 25 minutes 
for KYNA using the Kingsorb HPLC column.  The standard C18 Kingsorb column is not 
ideal for use with mobile phases containing less than 5% organic modifier, as the C18 
phase may collapse, and therefore it was replaced by a Synergi Hydro HPLC column, 
containing a C18 bonded phase endcapped with a polar group, which can be used with 
completely aqueous mobile phases.  When the column was changed to the Synergi Hydro 
column for these measurements, the acetonitrile concentration was reduced to 1.5% to 
produce similar chromatograms, with retention times of 10.2 minutes for kynurenine, 16.4 
minutes for 3-nitrotyrosine, 20.7 minutes for tryptophan and 29.6 minutes for KYNA.  The 
method was run isocratically as running a gradient would involve increasing the 
concentration of the organic modifier, acetonitrile, which may cause zinc acetate 
precipitation in the pump. 
Patients who had high lipid peroxidation results were compared with controls to check that 
they did not produce detectable levels of 3-nitrotyrosine, which would interfere with the 3-
nitrotyrosine internal standard peak on the chromatograms.  Two patients with extremely 
high levels of lipid peroxidation products (11.6µM and 12.3µM), one from the HD study 
and the other from the chronic brain injury study were compared with two patients with 
high lipid peroxidation in the stroke study (lipid peroxidation 1.28µM and 1.79µM) and 
two stroke controls (lipid peroxidation 0.20µM and 0.21µM).  Samples were prepared by 
the standard extraction method (Section 3.1.2), using 100µl water instead of 100µl 3-
nitrotyrosine.  Samples were analysed using the 100mM zinc acetate mobile phase.  There 
were no peaks for 3-nitrotyrosine in any of the samples assessed.  The limit of detection 
(LoD) of 3-nitrotyrosine was 100nM, with an injection volume of 100µl.  As no 3-
nitrotyrosine could be detected in the samples, 3-nitrotyrosine was considered to be a 
suitable internal standard for this analysis. 
The concentration of internal standard, 3-nitrotyrosine, used was 24µM, as this gave a 
large peak at both 250nm and 365nm, which could be analysed on the same scale as peaks 
for the metabolites being measured.  3-Nitrotyrosine peak height was comparable with the 
peak height for 40µM tryptophan and 12µM kynurenine.  The structure of 3-nitrotyrosine 
is shown in Figure 3-1 and has some similarities with the structure of kynurenine.  It was 
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assumed that any losses in metabolites were similar to losses in 3-nitrotyrosine on 
extraction.   
Standard solutions of 3HKYN, 3HANA and ANA could also be measured with this mobile 
phase.  However, with plasma samples, there were other peaks interfering with peaks for 
3HANA and ANA, even when the fluorescence wavelengths were optimised to 
λex=320nm, λem=420nm for these compounds.  For 3HKYN standards, the retention time 
was 5.4 minutes, which in plasma samples, interfered with lots of compounds eluting at 
about the same retention time and also the LoD was high with only concentrations of 
above 100nM able to be detected at either 250nm or 365nm.  3HKYN concentrations in 
healthy human serum have been reported as 32nM (Pearson and Reynolds, 1991).  In 
summary, it was not possible to quantify 3HANA, ANA or 3HKYN in human blood 
samples using this mobile phase.  
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Figure 3-1  Comparison of the structure of 3-nitrotyrosine (internal standard) with the 
structure of kynurenine.   
(Courtesy of TW Stone)  
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3.2.3  Final Method for the Determination of Tryptophan, 
Kynurenine and KYNA 
Isocratic reverse phase HPLC was performed at 37°C.  Separation was achieved using a 
Kingsorb C18 column or a Synergi Hydro C18 column and the detection system included 
both the dual wavelength absorbance detector (250nm and 365nm) and the fluorescence 
detector, connected in series.  The mobile phase, pumped at a flow rate of 1ml/min, was 
50mM acetic acid, 100mM zinc acetate containing 3% acetonitrile.  The pH of the zinc 
acetate buffer was 4.7.  With the Synergi Hydro column the concentration of acetonitrile 
was reduced to 1.5%.  Tryptophan was determined by absorbance detection at a 
wavelength of 250nm and kynurenine and 3-nitrotyrosine were detected at 365nm.  KYNA 
was determined by fluorescence detection (λex=344nm, λem=390nm). 
A volume of 100μl of filtered sample extract or standard was injected on to the HPLC. 
Calibration curves were analysed with the samples at least twice weekly when running 
continuously.  A new calibration curve was run after any shutdown of the HPLC.  A 
standard solution was also analysed after each block of 10 runs to check for any drift in the 
retention times of the metabolites.  A blank, containing only water, ascorbic acid and PCA 
was run with each calibration curve to ensure the baseline was completely flat at the 
retention times for the peaks.    
Example chromatograms are shown in Figure 3-2.                                                                                 
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Figure 3-2  Example chromatograms of an extracted plasma sample from a patient 
showing peaks for (A) tryptophan at 250nm, (B) kynurenine and 3-nitrotyrosine at 365nm 
and (C) kynurenic acid by fluorescence at λex=344nm, λem=390nm.  
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3.2.4  Preparation of Tryptophan, Kynurenine and KYNA 
Standards  
2mM tryptophan and 1mM kynurenine solutions were prepared from the pure powders by 
dissolving in HPLC grade water.  KYNA required sodium hydroxide to solubilise and to 
prepare 1mM KYNA, the pure powder was dissolved in 10mM sodium hydroxide solution.  
KYNA was further diluted in HPLC grade water, by serial dilutions of 1 in 10, to achieve 
10µM.  1ml aliquots of 2mM tryptophan, 1mM kynurenine and both 1mM and 10µM 
KYNA were frozen at -40°C.   For the stroke study, a mixed standard solution 1 was 
prepared by defrosting these individual standard solutions (using 10µM KYNA) and 
diluting with HPLC grade water to produce a solution of 200µM tryptophan, 8µM 
kynurenine and 100nM KYNA.  This mixed standard solution was also aliquoted into 
volumes of 1ml and frozen at -40°C until required to prepare a standard curve.  Standard 
solutions were kept for up to 12 months at -40°C.  Stability of these standard solutions at -
40°C was examined and is discussed in Section 3.4.   
A 240µM solution of the internal standard, 3-nitrotyrosine, was prepared by solubilising in 
10mM hydrochloric acid, prepared using HPLC grade water.  This solution was frozen in 
aliquots of 100µl in 1.5ml eppendorf tubes, which were then used directly for sample or 
standard preparation.  These internal standard aliquots were also kept at -40°C for up to 12 
months.  
3.2.5  Calibration Curves for Tryptophan, Kynurenine and KYNA 
To prepare a calibration curve for the stroke study, 2ml mixed standard 1 and 8 aliquots of 
3-nitrotyrosine were defrosted.  The mixed standard 1 was diluted 1 in 5 with HPLC grade 
water to prepare mixed standard 2 (40µM tryptophan, 1.6µM kynurenine and 20nM 
KYNA).  Various volumes of mixed standard and water were added to each of the 
eppendorfs containing 3-nitrotyrosine (Table 3-7).  50µl of 2mM ascorbic acid and 150µl 
of PCA were added, to ensure their compositions were comparable with the sample 
extracts.  A blank was also prepared, containing water, ascorbic acid and PCA only.   The 
resulting concentrations of the 8 standard solutions are shown in Table 3-8.   
For the HD and chronic brain injury studies, samples were analysed after tryptophan 
depletion and loading, and hence calibration curves over a much wider range of 
concentrations were required.  A mixed standard (3) of 800µM tryptophan, 200µM 
kynurenine and 20µM KYNA was prepared from the frozen individual standards.   This 
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was serially diluted tenfold to produce mixed standard 4 (80µM tryptophan, 20µM 
kynurenine and 2µM KYNA), mixed standard 5 (8µM tryptophan, 2µM kynurenine and 
200nM KYNA) and mixed standard 6 (0.8µM tryptophan, 0.2µM kynurenine and 20nM 
KYNA).  These mixed standards were used to prepare 14 standards of varying 
concentrations, each being mixed with HPLC grade water, 240µM 3-nitrotyrosine, 2mM 
ascorbic acid and 4M PCA as shown in Table 3-9.  The resulting concentrations of the 
standards are shown in Table 3-10. 
As with the plasma extracts, the standard solutions of various concentrations and the blank 
were filtered through Anopore or Alltech filter tubes using centrifugation at 10,000g for 10 
minutes at 4°C.  Filtrates were transferred to Waters total recovery vials and placed in the 
autosampler at 4°C.  A volume of 100μl was injected on to the HPLC column. 
Calibration curves were prepared from chromatogram peak areas of these mixed standard 
solutions.  For kynurenine, determined at the absorbance wavelength of 365nm, the 
internal standard was included in the calibration curve and in quantifying the samples.  
This compensates for any loss in recovery of the metabolites during sample extraction.  For 
absorbance detection at 250nm and fluorescence detection, quantified results were later 
corrected for recovery, using a recovery factor calculated from the area of 3-nitrotyrosine 
at 365nm in each extract.  The mean area of 3-nitrotyrosine in the 8 standards was divided 
by the area of 3-nitrotyrosine in each extract.  This gives a recovery factor which can be 
multiplied by the result for tryptophan and KYNA to compensate for any losses on 
extraction.  This recovery factor showed more than 100% recovery.  This was due to a 
concentration effect, as after protein precipitation and washing the precipitate, the volume 
of extract containing the kynurenines was approximately 800μl, although calculations are 
based on a volume of 1ml.  Actually the recovery factor and the use of the internal standard 
calibration accounts for the losses on extraction and the concentration effects for each 
extract. 
The results for the plasma extracts from the calibration curves were multiplied by 2 to give 
the concentration in the original plasma sample and then multiplied by the recovery factor 
for that sample, to produce the final concentration of tryptophan and KYNA in the plasma 
samples.  For kynurenine, the results from the calibration curves were multiplied by 2 only, 
as the internal standard is included in the calibration.  
 
Table 3-7  Preparation of standard solutions for calibrations curves of tryptophan, 
kynurenine and kynurenic acid for the stroke study. 
Standard 
Code 
Mixed 
Std 
Volume  
Mixed Std 
(μl) 
 
Volume 
Water (μl) 
Volume 2mM 
Ascorbic Acid (μl) 
Volume IS 
(μl) 
Volume 
PCA (μl) 
Std1  2 200  500  50  100  150 
Std2  2 300  400  50  100  150 
Std3  2 400  300  50  100  150 
Std4  1 100  600  50  100  150 
Std5  1 200  500  50  100  150 
Std6  1 300  400  50  100  150 
Std7  1 400  300  50  100  150 
Std8  1 500  200  50  100  150 
BLANK   0  800  50  0  150 
 
Standard (Std), 240μM 3-nitrotyrosine internal standard (IS), 4M perchloric acid (PCA) 
 
 
Table 3-8  Concentrations of tryptophan, kynurenine, kynurenic acid and 3-
nitrotyrosine in standards for calibration curves for the stroke study. 
  Concentration 
  Tryptophan (μM)  Kynurenine 
(μM) 
 
Kynurenic Acid 
(nM) 
3-Nitrotyrosine 
(μM) 
Std1  8 0.32 4  24 
Std2  12 0.48  6  24 
Std3  16 0.64  8  24 
Std4  20 0.8 10 24 
Std5  40 1.6 20 24 
Std6  60 2.4 30 24 
Std7  80 3.2 40 24 
Std8  100 4  50 24 
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Table 3-9  Preparation of standard solutions for calibrations curves of tryptophan, 
kynurenine and kynurenic acid for the Huntington’s disease and chronic brain injury 
studies. 
Standard 
Code 
Mixed 
Std 
Volume  
Mixed Std 
(μl) 
Volume 
Water (μl) 
Volume 2mM 
Ascorbic Acid 
(μl) 
 
Volume IS 
(μl) 
Volume 
PCA (μl) 
Std1  6 100  600  50  100  150 
Std2  6 250  450  50  100  150 
Std3  6 500  200  50  100  150 
Std4  5 100  600  50  100  150 
Std5  5 250  450  50  100  150 
Std6  5 500  200  50  100  150 
Std7  4 100  600  50  100  150 
Std8  4 200  500  50  100  150 
Std9  4 400  300  50  100  150 
Std10  4 500  200  50  100  150 
Std11  3 100  600  50  100  150 
Std12  3 250  450  50  100  150 
Std13  3 400  300  50  100  150 
Std14  3 500  200  50  100  150 
BLANK   0  800  50  0  150 
 
Standard (Std), 240μM 3-nitrotyrosine internal standard (IS), 4M perchloric acid (PCA) 
 
 
Table 3-10  Concentrations of tryptophan, kynurenine, kynurenic acid and 3-
nitrotyrosine in standards for calibration curves for the Huntington’s disease and chronic 
brain injury studies. 
  Concentration 
  Tryptophan  
(μM) 
Kynurenine (μM) Kynurenic Acid 
(nM) 
 
3-Nitrotyrosine 
(μM) 
Std1  0.08 
not detectable 
0.02  
not detectable 
2 24 
Std2  0.2 0.05  5  24 
Std3  0.4 0.1 10  24 
Std4  0.8 0.2 20  24 
Std5  2 0.5  50 24 
Std6  4 1  100  24 
Std7  8 2  200  24 
Std8  16 4  400  24 
Std9  32 8  800  24 
Std10  40 10  1,000  24 
Std11  80 20  2,000  24 
Std12  200 50  5,000  24 
Std13  320 80  8,000  24 
Std14  400 100  10,000  24 
  
3.2.6  Method Validation for the HPLC Method for Tryptophan, 
Kynurenine and KYNA 
3.2.6.1  Linearity of HPLC Response for Tryptophan, Kynurenine and 
KYNA  
Tryptophan, kynurenine and KYNA standards all demonstrated a linear HPLC response 
with increasing concentrations.  This was observed across the full range of concentrations 
used in the calibration curves from 0.2µM to 400µM for tryptophan, from 0.05µM to 
100µM for kynurenine and from 2nM to 10,000nM for KYNA. 
3.2.6.2  Limit of Detection (LoD) for Tryptophan, Kynurenine and KYNA 
The LoD is the smallest amount of the analyte that can be identified as a peak on the 
chromatogram, distinguishable from the baseline, defined as a signal/noise ratio of 3.   
Dilutions of standard solutions of tryptophan, kynurenine and KYNA were analysed to 
determine the LoD for standards, using the injection volume of 100µl.  The LoD for this 
method was 0.2µM (20pmoles on column) for tryptophan, 0.03µM (3pmoles on column) 
for kynurenine and 1nM (0.1pmoles on column) for KYNA.  When the Kingsorb HPLC 
column was replaced with the Synergi Hydro column, the LoD was the same for 
tryptophan and kynurenine, but was 2nM (0.2pmoles on column) for KYNA, probably due 
to the later elution time. 
Tryptophan depleted samples from the HD and chronic brain injury studies were used to 
determine the LoD for kynurenine and KYNA in plasma samples.  The LoD for 
kynurenine in plasma was 0.1µM, and for KYNA was 4nM, accounting for the plasma 
being diluted 2-fold for this method and with an injection volume of 100µl.  The LoD for 
tryptophan in plasma could not be determined as even the tryptophan depleted samples had 
tryptophan levels that were easily detectable, with the lowest level measured being 3.2µM. 
3.2.6.3  Recoveries for Tryptophan, Kynurenine and KYNA 
To ensure that no metabolite was lost during the extraction process, which is not accounted 
for by the use of the internal standard (or recovery factor calculated from it), a spike of 
mixed standard solution was added to a plasma sample before extraction.  Consistent 
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recoveries demonstrate the accuracy of the method.  Three plasma samples were used, each 
spiked at three different concentrations of a mixed standard (Table 3-11).   
Samples were extracted using the standard method described in Section 3.1.2, with the 
exceptions that 20μl of spike solution was added to the plasma before extraction, and the 
volume in which the precipitated proteins were resuspended was changed to 90μl water 
and 50μl 4M PCA for each wash. 
The percentage recovery for each spike is calculated as follows: 
Recovery (%) =  Conc. of Spiked Plasma – Conc. of Original Plasma   x 100% 
Conc. of Standard Spike 
Recoveries for all three metabolites ranged from 90% to 109% (Table 3-12), showing that 
the method is accurate, with the results giving a true measure of the quantity of tryptophan, 
kynurenine and KYNA present.  The internal standard or recovery factor calculated from 
the internal standard peak was used to adjust samples for recoveries as described in Section 
3.2.5 and not the percentage recoveries calculated here. 
3.2.6.4  Intra-Assay and Inter-Assay Precision for Tryptophan, 
Kynurenine and KYNA 
To determine intra-assay precision or repeatability, a sample of serum was pooled from the 
stroke control subjects.  8 aliquots of pooled serum were extracted by the standard method 
(Section 3.1.2).  After freezing the extracts overnight at -40°C, all 8 extracts were analysed 
by HPLC.  Tryptophan concentrations were 51.7 ± 0.87 µM (mean ± standard deviation 
(SD)) with CV = 1.7%.  The mean concentration of kynurenine was 2.09 ± 0.05 µM, CV = 
2.5%.  KYNA concentrations were 36.6 ± 2.7 nM, CV = 7.4%. 
For inter-assay precision or reproducibility, a sample was pooled from the control serum 
for the stroke study.  8 samples were extracted by the standard method and the extracts 
frozen at -40°C, at least overnight.  One inter-assay sample was analysed each day for the 
following 8 days together with other samples being analysed.  This involved 3 different 
calibration curves being used to calculate the results.  The mean concentration of 
tryptophan was 54.6 ± 0.66 µM, CV = 1.2%, kynurenine was 2.09 ± 0.06 µM, CV = 2.9%, 
and KYNA was 41.9 ± 2.12 nM, CV = 5.1%. 
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The coefficient of variation (CV) is calculated by dividing the standard deviation by the 
mean and expressing the result as a percentage.  A CV of below 10% for inter-assay 
variability was acceptable for these HPLC analyses. 
3.2.6.5  Confirmation of Peak Identity for Tryptophan, Kynurenine and 
KYNA 
HPLC with absorbance and fluorescence detection produce chromatographic peaks which 
are identified as the analyte by retention time alone.  It is possible that another compound 
may be present in the sample which elutes at the same time as the analyte of interest.  The 
detector absorbance wavelength or the fluorescence wavelengths may be specific enough 
for only the analyte of interest to be detected, however, it is possible the other compound 
could also be detected and be mistaken as the analyte, leading to erroneous concentrations 
of the analyte being calculated.  An advantage of using a mass spectrometer as the detector 
with HPLC or GC is that the chromatographic peaks are specifically identified as the 
analyte of interest.   
To ensure that the peaks measured are pure metabolite, tryptophan, kynurenine and KYNA 
were detected by 2 different detection methods, as it is highly unlikely that another 
compound would give the same response by both methods.  Tryptophan can be detected at 
the fluorescence wavelengths used for KYNA detection (λex=344nm,  λem=390nm).  
Kynurenine can be measured by absorbance at 250nm, although there is often interference 
with the kynurenine peak from other compounds at this wavelength.  It is difficult to 
determine the low levels of KYNA in plasma using alternative detection, but KYNA in the 
tryptophan loaded samples were detectable with absorbance at 250nm.  Results for 6 
samples of each metabolite analysed by the different detection methods are shown in Table 
3-13.   
The average percentage change in the results using the alternative detection was 5% for 
tryptophan, 6% for kynurenine and 9% for KYNA.  Tryptophan and KYNA results from 
the alternative method were sometimes lower and sometimes higher than the standard 
results, but all 6 kynurenine results were higher by the alternative method.  This may 
suggest that even in these kynurenine samples where there was minimal interference, there 
may still be a little interference at 250nm.  This clarified that the peaks being measured 
were indeed tryptophan, kynurenine and KYNA.  
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Table 3-11  Concentrations of standard solutions of tryptophan, kynurenine and 
kynurenic acid (KYNA) used to spike plasma to determine recoveries. 
 
 
  Spike conc. for 
20μl spike 
Conc. of spike as if in 
plasma 
Low level  500  20 
Medium level  1000  40 
Tryptophan (μM) 
High level  1500  60 
      
Low level  20  0.8 
Medium level  40  1.6 
Kynurenine (μM) 
High level  80  3.2 
      
Low level  500  20 
Medium level  1000  40 
KYNA (nM) 
High level  1500  60 
 
 
Table 3-12  Recoveries for tryptophan, kynurenine and kynurenic acid (KYNA), using 3 
different plasma samples spiked with 3 concentrations of each metabolite. 
  Plasma 1  Plasma 2  Plasma 3 
 
Spike 
Conc as if 
in plasma  
Conc in 
plasma 
 
Recovery 
(%) 
Conc in 
plasma 
 
Recovery 
(%) 
Conc in 
plasma 
 
Recovery 
(%) 
  59.1   53.1  57.2  
20 78.0  94 72.6 98 75.2 98 
40 95.1  90 90.1 93 94.0 92 
Tryptophan 
(μM) 
60 117.0  96 110.1 95 116.3 90 
          
 2.46   2.29  2.04  
0.8  3.24  98 3.08 98 2.87  104 
1.6 3.91  91  3.96 104 3.68 102 
Kynurenine 
(μM) 
3.2  5.65 100  5.24 92 5.40  105 
          
 38.3   39.2  41.6  
20 60.2 109  58.9 99 61.8  101 
40 75.4  93 76.4 93 79.3 94 
KYNA (nM) 
60 96.3  97 94.3 92 95.7 90 
 
 
Table 3-13  Measurement of tryptophan, kynurenine and kynurenic acid (KYNA) using 
an alternative method to check that the peaks identified are indeed pure metabolite. 
Plasma 
Sample 
Tryptophan (μM)  Plasma 
Sample 
Kynurenine (μM)  Plasma 
Sample* 
 
KYNA (μM) 
 standard 
method 
250nm 
FL 
 
 standard 
method 
365nm 
absorbance 
250nm 
 standard 
method 
FL 
absorbance 
250nm 
1  61.5 58.9  7  2.99 3.15  13  1.37 1.25 
2  75.4 81.7  8  1.80 1.91  14  2.32 2.33 
3  61.4 65.5  9  2.86 3.19  15  0.70 0.64 
4  57.2 58.9  10  1.88 1.88  16  4.03 4.38 
5  22.5 22.8  11  2.26 2.36  17  0.80 0.90 
6  44.5 42.2  12  3.44 3.73  18  1.60 1.82 
 
standard method 250nm or 365nm is with absorbance detection 
FL – fluorescence at excitation 344nm/ emission 390nm 
* - plasma samples taken after tryptophan loading 
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3.3  Measurement of 3HANA and ANA by fluorescence 
detection 
3.3.1  Determination of 3HANA and ANA Introduction 
For the HD and chronic brain injury studies, 3HANA was measured using electrochemical 
detection (Section 3.5), but the sensitivity was low, with levels only just detectable in 
baseline control and patient bloods (LoD was 40nM for plasma samples).  A method which 
increased the sensitivity of 3HANA was sought.  The method by Cannazza et al., 2003, 
describes quantification of 3HANA and ANA in rat brain dialysate by reverse phase HPLC 
with fluorescence detection.  This method used a mobile phase consisting of 25mM sodium 
acetate/acetic acid buffer at pH 5.5 and 10% methanol.  The mobile phase used for 
fluorescence detection of KYNA is 100mM zinc acetate/ 50mM acetic acid buffer at pH 
4.7 and 1.5% acetonitrile (Section 3.2.3).  The sensitivity of 3HANA with these two 
mobile phases was compared.  For fluorescence detection of 3HANA and ANA, several 
references had suggested the optimum λex of approximately 320nm and λem of 
approximately 420nm. (Cannazza et al., 2003; Hervé et al., 1996; Chiarugi et al., 1996).  
These wavelengths were compared with the wavelengths used for KYNA measurement 
(λex=344nm, λem=390nm).  It would also be useful to determine ANA in the same run, as 
there was interference with this peak using the zinc acetate mobile phase.   
3.3.2  Method Development for 3HANA and ANA 
A sodium acetate mobile phase was prepared using 25mM sodium acetate trihydrate with 
the addition of acetic acid until the pH reached 5.5.  Using standards of 2μM, and 40nM 
3HANA (just detectable by electrochemical detection), a comparison of zinc acetate 
mobile phase pH 4.7 (Section 3.2.3) without acetonitrile, with sodium acetate mobile phase 
pH 5.5, without methanol was made.  40nM 3HANA was detected using both mobile 
phases, but the sodium acetate mobile phase produced a much larger peak.  All 
measurements were made using fluorescence detection (λex=320nm, λem=420nm). 
The electrochemical method for measuring 3HANA used a mobile phase at pH 3.1.  The 
retention time was 18 minutes.  The sodium acetate mobile phase for the fluorescence 
method had a pH of 5.5, which gave a retention time of 10.3 minutes.  A reason for this 
change may be that at the higher pH, 3HANA will be in an ionised form, as opposed to 
being non-ionised, and hence be retained on the column for a shorter time.   
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The 40nM 3HANA standard was measured at λex=320nm, λem=420nm and at λex=344nm, 
λem=390nm, the fluorescence wavelengths used for KYNA measurement.  The former 
wavelengths produced a larger peak than the latter. 
The sodium acetate mobile phase with fluorescence detection at λex=320nm, λem=420nm 
was the most sensitive method for measuring 3HANA. 
To ensure that endogenous 3-nitrotyrosine could not be detected in the plasma samples 
using this mobile phase, samples with high lipid peroxidation and controls were assessed 
as described previously (Section 3.2.2).  No 3-nitrotyrosine could be detected in any of the 
samples.  The LoD for 3-nitrotyrosine was 100nM using this sodium acetate mobile phase.  
The use of 24µM 3-nitrotyrosine was suitable as the internal standard.  
3.3.3  Final Method for the Determination of 3HANA and ANA 
Using a Synergi Hydro column with isocratic reverse phase HPLC at 30°C, 3HANA and 
ANA were measured by fluorescence detection at λex=320nm, λem=420nm.  The internal 
standard, 3-nitrotyrosine, was determined by the absorbance detector at 365nm, which was 
connected in series with the fluorescence detector.  The mobile phase of 25mM sodium 
acetate buffer (containing 2mM acetic acid) at pH5.5, containing no organic modifier was 
pumped at a flow rate of 1ml/min. 
The injection volume of filtered sample extract or standard solution was 100μl. 
Calibration curves were analysed with the samples at least twice weekly when running 
continuously.  A new calibration curve was run after any shutdown of the HPLC.  A blank, 
containing only water, ascorbic acid and PCA was run with each calibration curve to 
ensure the baseline was completely flat at the retention times for the peaks.  A standard 
was run through the HPLC after every 10 samples, to check for any drift in the retention 
times of the metabolites. 
An example chromatogram is shown in Figure 3-3.  
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Figure 3-3  Example chromatogram of an extracted serum sample from a patient 
showing peaks for 3-hydroxyanthranilic acid and anthranilic acid by fluorescence detection 
at λex=320nm, λem=420nm. 
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3.3.4  Preparation of 3HANA and ANA standards 
3HANA and ANA would not solubilise in water alone, requiring hydrochloric acid and 
sodium hydroxide, respectively, to enable solubilisation.  2mM 3HANA was prepared 
from the pure powder by dissolving in 40mM hydrochloric acid and 2mM ANA was 
prepared using 10mM sodium hydroxide.  As 3HANA is an unstable compound which 
may autoxidise, the hydrochloric acid and the sodium hydroxide solutions both were 
prepared using 100μM ascorbic acid (in HPLC grade water) as an antioxidant.  These stock 
standard solutions were divided into 1ml aliquots, which were frozen at -40°C for up to 12 
months.  The stability of these standard solutions in the freezer was assessed and the results 
discussed in Section 3.4. 
3.3.5  Calibration Curves for 3HANA and ANA 
To prepare a calibration curve for the stroke study, 2mM 3HANA and 2mM ANA were 
defrosted, as were 8 x 100μl aliquots of 240μM 3-nitrotyrosine (prepared as described in 
Section 3.2.4).  3HANA and ANA were mixed and diluted by serial dilutions, using 
100μM ascorbic acid throughout, to produce mixed standard 1 (200nM 3HANA and 
800nM ANA), mixed standard 2 (40nM 3HANA and 160nM ANA) and mixed standard 3 
(5nM 3HANA and 20nM ANA).  Various volumes of these mixed standards were added to 
the internal standard, 3-nitrotyrosine, and diluted with 100μM ascorbic acid.  4M PCA was 
added to each of these standards, and extra ascorbic acid was added to compensate for the 
3-nitrotyrosine and PCA not containing ascorbic acid, to maintain a concentration of 
100μM ascorbic acid in the final solutions.   A blank of ascorbic acid and PCA was also 
prepared.  The preparation of standards and their final concentrations are shown in Tables 
3-14 and 3-15. 
The standards and the blank were filtered through Anopore or Alltech filter tubes using 
centrifugation at 10,000g for 10 minutes at 4°C.  Filtrates were transferred to autosampler 
vials and maintained in the autosampler at 4°C.  A volume of 100μl was injected on to the 
HPLC column. 
Calibration curves were prepared from chromatogram peak heights, as the peak for ANA 
in plasma often had slight interference from an adjacent peak, so peak areas would not be 
accurate.  3HANA and ANA were determined by fluorescence detection.  At the 
absorbance wavelength of 365nm, the mean area for the internal standard 3-nitrotyrosine 
from the 8 standards was used to calculate a recovery factor for each sample from its area 
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of 3-nitrotyrosine, as described in Section 3.2.5.  The results for the plasma extracts from 
the calibration curves were multiplied by 2 to give the concentration in the original plasma 
sample and then multiplied by the recovery factor for that sample, to produce the final 
concentration of 3HANA and ANA in the plasma samples. 
 
Table 3-14  Preparation of standard solutions for calibrations curves of 3-
hydroxyanthranilic acid and anthranilic acid for the stroke study. 
Standard 
Code 
Mixed 
Std 
Volume  
Mixed 
Std (μl) 
 
Volume 100μM 
Ascorbic Acid 
(μl) 
Volume 600μM 
Ascorbic Acid 
(μl) 
Volume 
IS (μl) 
Volume 
PCA (μl) 
Std1  3 100  600  50  100  150 
Std2  3 400  300  50  100  150 
Std3  2 100  600  50  100  150 
Std4  2 150  550  50  100  150 
Std5  2 200  500  50  100  150 
Std6  2 300  400  50  100  150 
Std7  2 400  300  50  100  150 
Std8  1 100  600  50  100  150 
BLANK   0  800  50  0  150 
 
Standard (Std), 240μM 3-nitrotyrosine internal standard (IS), 4M perchloric acid (PCA) 
 
 
Table 3-15  Concentrations of 3-hydroxyanthranilic acid and anthranilic acid and 3-
nitrotyrosine in standards for calibration curves for the stroke study. 
  Concentration 
  3-Hydroxyanthranilic Acid 
(nM) 
Anthranilic Acid 
(nM) 
3-Nitrotyrosine 
(μM) 
 
Std1  0.5 2  24 
Std2  2 8  24 
Std3  4 16  24 
Std4  6 24  24 
Std5  8 32  24 
Std6  12 48  24 
Std7  16 64  24 
Std8  20 80  24 
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3.3.6  Method Validation for the HPLC Method for 3HANA and 
ANA 
3.3.6.1  Linearity of HPLC Response for 3HANA and ANA  
3HANA and ANA standards showed a linear HPLC response with increasing 
concentrations.  This was observed across the range of concentrations in the calibration 
curves from 0.5nM to 20nM for 3HANA and from 2nM to 80nM for ANA. 
3.3.6.2  LoD for 3HANA and ANA 
Standard solutions of 3HANA and ANA were diluted to determine the LoD for these 
standards, with a signal/noise ratio of 3.  The LoD for 3HANA standard solution was 
0.1nM (10fmoles on column), for an injection volume of 100μl.  The LoD for ANA was 
0.2nM, again for an injection volume of 100μl, which equates to 20fmols on column. 
In the stroke study, where this method was used, as both 3HANA and ANA were easily 
detected in serum samples, a LoD for serum samples for this method could not be 
determined.  Levels as low as 0.75nM 3HANA and 8.9nM ANA in serum were detectable. 
3.3.6.3  Recoveries for 3HANA and ANA 
Three samples of serum from healthy controls for the stroke study were spiked with mixed 
standard solutions of 3HANA and ANA.  All three samples were spiked at three different 
concentrations of 3HANA and ANA, prior to extraction, and were compared with the three 
original unspiked samples.   
The method for preparing the samples and the calculation for recovery was as described in 
Section 3.2.6.3.  
Mixed standard solutions of 3HANA and ANA were prepared by defrosting and diluting 
stock solutions of 2mM individual standards and mixing them to give the appropriate 
concentrations of each standard for a 20μl spike, for each level of spike (Table 3-16).  All 
standard solutions were prepared in 100μM ascorbic acid.  The concentration of plasma 
was determined in the usual way, multiplying the result from the calibration curve by 2, 
and by the recovery factor.   
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The recoveries varied from 92% to 107% for 3HANA and from 96% to 107% for ANA 
(Table 3-17), demonstrating that this method of extraction, with the subsequent analysis, 
accurately quantifies the levels of 3HANA and ANA. 
 
Table 3-16  Concentrations of standard solutions of 3-hydroxyanthranilic acid and 
anthranilic acid used to spike plasma to determine recoveries. 
  
 
Spike conc. for 
20μl spike 
(nM) 
Conc. of spike if had 
been in plasma 
(nM) 
Low level  250  10 
Medium level  500  20 
3-Hydroxyanthranilic 
Acid 
High level  1000  40 
      
Low level  1000  40 
Medium level  2000  80 
Anthranilic Acid 
High level  4000  160 
 
 
Table 3-17  Recoveries of 3-hydroxyanthranilic acid (3HANA) and anthranilic acid 
(ANA) using 3 different plasma samples spiked with 3 concentrations of each metabolite. 
  Plasma 1  Plasma 2  Plasma 3 
 
Spike 
Conc 
as if in 
plasma 
(nM) 
Conc 
in 
plasma
(nM) 
Recovery 
(%) 
Conc 
in 
plasma
(nM) 
Recovery 
(%) 
Conc 
in 
plasma
(nM) 
Recovery 
(%) 
  5.4   15.1  11.8  
10  15.3 100 25.5 104 21.0  92 
20  25.3 100 36.4 107 31.9 101 
3HANA 
40  46.4 102 56.4 103 52.9 103 
          
  24.7  26.8  24.4  
40  67.5 107 67.2 101 62.8  96 
80  109.1 106 107.6 101 104.5 100 
ANA 
160  190.3 104 188.8 101 188.2 102 
 
  
3.3.6.4  Intra-Assay and Inter-Assay Precision for 3HANA and ANA 
Several plasma samples from healthy controls for the stroke study were pooled to produce 
a sample for repeatability.  The sample was extracted 8 times by the standard procedure 
(Section 3.1.2), and extracts were frozen at -40°C.  8 extracts were defrosted and analysed 
together in the same run, to obtain a measure of repeatability.  The concentrations of 
3HANA were 34.1 ± 0.81 nM (mean ± SD), with CV = 2.4%, and for ANA, the mean 
concentration was 29.9 ± 1.7 nM, CV = 5.5%.  
Similarly, plasma samples from healthy controls for the stroke study were pooled for a 
sample for reproducibility.  8 aliquots were extracted on the same day and frozen at -40°C. 
One sample was then analysed each day, together with other samples being analysed on 
that day, for the following 8 days.  These 8 repeats were analysed using 3 different 
calibration curves.  The concentrations for 3HANA were 24.5 ± 2.2 nM (mean ± SD), with 
CV = 9.0%, and for ANA, the mean concentration was 26.3 ± 2.1 nM, CV = 8.1%. 
3.3.6.5  Confirmation of Peak Identity for 3HANA and ANA 
To clarify that the 3HANA peak identified by this method was indeed pure 3HANA, 6 
plasma samples were also measured using the electrochemical mobile phase with 
electrochemical detection (Section 3.5).  The results are shown in Table 3-18.  The mean % 
change in the results was 8% for 3HANA.  The electrochemical method produced some 
higher and some lower results than the original as expected due to normal variability.  
Concentrations determined were similar by either method, confirming that the peaks were 
pure 3HANA. 
ANA can also be determined using the zinc acetate mobile phase method (Section 3.2.3) 
with the fluorescence wavelengths changed to those optimised for ANA (λex=320nm, 
λem=420nm).  The results for six plasma samples analysed by both the original and this 
alternative method are shown in Table 3-18.  The mean % change in the results is 7%.  
Both methods gave similar results, confirming that the peaks were pure ANA.   
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Table 3-18  Measurement of 3-hydroxyanthranilic acid and anthranilic acid using an 
alternative method to check that the peaks identified are indeed pure metabolite. 
Plasma 
Sample 
3-Hydroxyanthranilic Acid 
(nM) 
Plasma 
Sample 
Anthranilic Acid (nM) 
 standard  method 
FL 
 
ECD 
+0.65V 
 standard  method 
FL 
FL  
zinc acetate 
mobile 
phase 
1  149 151  7  20.2 16.6 
2  57 50  8  28.3 26.1 
3  48 47  9  23.8 26.7 
4  1351 1452  10  41.4 39.5 
5  57 46  11  42.4 42.5 
6  134 125  12  78.9 77.3 
 
FL – fluorescence at excitation 320nm/ emission 420nm 
ECD – electrochemical detection 
  
3.4  Stability of Standard Solutions and Plasma Samples 
Stored at -40ºC 
3.4.1  Storage of Standard Solutions at -40ºC 
It would be ideal if standard solutions of tryptophan, kynurenine, KYNA, 3HANA and 
ANA could be kept in the freezer at -40ºC for at least 12 months.   
To determine the stability of mixed standard solution 1, containing 200μM tryptophan, 
8μM kynurenine and 100nM KYNA, aliquots of this standard solution were prepared as 
described in Section 3.2.4 and were stored at -40ºC for 12 months.  Mixed standard 
solution 1 was freshly prepared from freshly prepared individual standards again as 
described in Section 3.2.4 and was frozen at -40ºC and used within one week.  For both the 
stored and freshly prepared mixed standard, 6 aliquots were diluted to prepare 6 sets of 8 
standards similar to those normally used for calibration.  A calibration curve, required for 
analysing the standards as if they were samples, was prepared from one set of freshly 
prepared standards.  A similar analysis was carried out comparing standard solutions of 
2mM 3HANA and 2mM ANA, which had been stored for 12 months at -40ºC, with freshly 
prepared solutions, which had been frozen for up to one week.  Two way analysis of 
variance (ANOVA) (using the General Linear Model), with a Tukey multiple comparisons 
post test, was used to evaluate if the stored standards were significantly different from the 
freshly prepared standards.   
Tryptophan levels were significantly higher for solutions which had been stored for 12 
months, at 7 of the 8 different concentrations (Figure 3-4A).  Levels of kynurenine were 
also significantly higher at the highest three concentrations for the solutions which had 
been stored for 12 months (Figure 3-4B).  The concentrations of KYNA did not change 
significantly on storage at -40ºC (Figure 3-4C). 
The concentrations of ANA were not significantly different after storage at -40ºC for 12 
months, except at the concentration of 32nM, where higher ANA was determined for the 
stored standards (Figure 3-5A).  The two way ANOVA showed an overall decrease in 
3HANA concentrations with 12 months storage.  Individually this decrease was only 
significant at 2 of the 8 concentrations and a significant increase was shown at 32nM 
(Figure 3-5B). 
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The only metabolite to show an overall decrease on storage, which would indicate 
degradation, was the 3HANA standard, but this was not consistent at every concentration.  
From these results, standards of 3HANA were not stored for 12 months, but prepared at 
least every 6 months for calibration curves used in this project.  The significantly higher 
levels of tryptophan and kynurenine measured in the frozen standards may be due to a 
difference in the initial stock solution of these standards.  The mixed standand 1 
(tryptophan, kynurenine and KYNA) and ANA standards were kept for up to 12 months 
for use in the calibration curves in this project. 
3.4.2  Stability of Plasma Samples at -40ºC 
Blood samples for each study were stored frozen often for several months before analysis.  
Plasma extracts were also stored frozen for a few months before analysis, as it was 
practical to extract a large batch of samples and then later analyse them by HPLC.  It was 
therefore important to evaluate if the kynurenines were stable in plasma stored at -40ºC for 
up to 12 months and if the kynurenines in plasma extracts were stable at -40ºC for up to 6 
months.  
Blood samples from six healthy subjects were collected into EDTA vacutainers.  Blood 
samples were kept on ice for a few minutes and centrifuged at 3000g for 15 minutes at 4ºC.  
4 aliquots of approximately 1ml of the resulting plasma were taken for each subject and 
were frozen at -40ºC.   
Extractions (Section 3.1.2) and HPLC analyses of the first aliquot were carried out within 1 
month of collecting the bloods.  Further extractions of the other 3 plasma aliquots were 
carried out after 3, 6 and 12 months storage of the plasma at -40ºC.  On each occasion, 
plasma extracts (in PCA) were frozen at -40ºC in 4 aliquots of 175μl and 2 aliquots were 
analysed within a week and the remaining 2 after either 1, 3 or 6 months.  All were 
analysed using the HPLC method for tryptophan, kynurenine and KYNA (Section 3.2.3) 
and a second aliquot of extract analysed using the method for 3HANA and ANA (Section 
3.3.3).  Repeated measures ANOVA with a Dunnett’s multiple comparisons post test was 
carried out for the plasma samples to evaluate if there was any change in the results on 
storage compared with the initial measurement.  The extracts were analysed by paired t 
tests to examine the effect of storing the extracts for 1, 3 or 6 months.  There was only 
enough extract from each sample to analyse at one further time point and therefore extracts 
after 1, 3 and 6 months were from different original extractions. 
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The results for the stability of plasma samples at -40ºC are shown in Figures 3-6 and 3-7.  
Tryptophan and kynurenine concentrations were stable in the plasma samples stored for 3 
and 6 months, but were significantly higher than the original after 12 months storage.  
KYNA levels were stable at all time points.  The ANA and 3HANA results were more 
variable with storage time, with higher levels of ANA after 6 months storage, which had 
returned to original levels after 12 months storage.  The 3HANA concentrations in the 
plasma samples were seen to decrease at 3 months storage, increase at 6 months storage 
and return to the original levels after 12 months.  Storing plasma samples for up to 12 
months did not show any indication that these 5 kynurenines degrade over time as there 
were no significant reductions in their levels over the 12 month period.  The increases 
observed with tryptophan and kynurenine after 12 months storage were relatively small.  It 
was concluded that plasma could be stored in the freezer at -40ºC for up to 12 months. 
The stability of PCA extracts are shown in Figures 3-8 and 3-9.  Storing the PCA extracts 
at -40ºC, decreased the concentrations of tryptophan at 1 and 6 months, increased the 
levels of kynurenine at 3 and 6 months and increased the level of KYNA at 1 month.  
Levels of ANA were increased significantly at all 3 storage times and 3HANA levels were 
reduced at 1 and 3 months storage.  Although there was not a greater change with 
increased length of storage time, there were several significant changes in concentrations 
of most of the kynurenines, suggesting that the PCA extracts should be stored at -40ºC for 
a minimum length of time.  Alternatively it may be acceptable if all the extracts for a study 
were stored at -40ºC for the same length of time.     
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Figure 3-4  Effect of storing stock mixed standard solutions containing 200μM 
tryptophan, 8μM kynurenine and 100nM kynurenic acid (KYNA) for 12 months at -40ºC.  
Results are for standards diluted as used in calibrations.  Values are mean ± SEM (n=6).  
Significant differences on storage: * p<0.05, ** p<0.01, *** p<0.001.  
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Figure 3-5  Effect of storing stock standard solutions of 2mM anthranilic acid (ANA) 
and 2mM 3-hydroxyanthranilic acid (3HANA) for 12 months at -40ºC.  Results are for 
standards diluted as used in calibrations.  Values are mean ± SEM (n=6).  Significant 
differences on storage: ** p<0.01, *** p<0.001. 
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Figure 3-6   Effect of storing plasma at -40ºC for different periods of time on the levels 
of tryptophan (A), kynurenine (B) and kynurenic acid (C).  Values are mean ± SEM (n=6).  
Significant differences: ** p<0.01.  
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Figure 3-7  Effect of storing plasma at -40ºC for different periods of time on the levels 
of anthranilic acid (A) and 3-hydroxyanthranilic acid (B).  Values are mean ± SEM (n=6).  
Significant differences: * p<0.05, ** p<0.01. 
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Figure 3-8  Effect of storing perchloric acid extracts of plasma at -40ºC for different 
periods of time on the levels of tryptophan (A), kynurenine (B) and kynurenic acid (C).  
Values are mean ± SEM (n=6).  Significant differences: * p<0.05, ** p<0.01, *** p<0.001. 
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Figure 3-9  Effect of storing perchloric acid extracts of plasma at -40ºC for different 
periods of time on the levels of anthranilic acid (A) and 3-hydroxyanthranilic acid (B).  
Values are mean ± SEM (n=6).  Significant differences: ** p<0.01. 
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3.5  Measurement of 3HKYN and 3HANA using 
electrochemical detection 
3.5.1   Determination of 3HKYN and 3HANA Introduction 
The levels of 3HKYN in plasma were often lower than 100nM, which was the LoD with 
absorbance (Section 3.2.2) and hence a more sensitive method was sought.  The aim was to 
set up a method to measure the low concentrations of 3HKYN in plasma using HPLC with 
electrochemical detection, based on the methods described by Heyes and Quearry (1988) 
and Pearson and Reynolds (1991), where 3HKYN levels of less than 10nM could be 
detected.  Using their method, Pearson and Reynolds (1991) were also able to quantify 
3HANA in cortical tissue, although in plasma, there were other peaks interfering with the 
3HANA peak.  3HKYN and 3HANA are both susceptible to oxidation when a low 
potential is applied, and therefore potentially could both be measured using 
electrochemical detection in a single analysis. 
3.5.2  Method Development for 3HKYN and 3HANA 
A Synergi Hydro HPLC column was used, as this column contains a C18 bonded phase 
endcapped with a polar group, which increases the retention of polar compounds compared 
to the standard C18 Kingsorb column, and can be used with completely aqueous mobile 
phases.  One of the problems with measuring 3HKYN using the method described in 
Section 3.2.3 was that 3HKYN is extremely polar in comparison with the other metabolites 
of interest and was eluted early in the chromatogram at a similar retention time as many 
other compounds. 
Adjusting the mobile phase to increase the retention time for 3HKYN to allow its 
separation from interfering components, would also result in increasing the retention times 
for all the other detectable compounds in plasma and the analysis time would be extremely 
long.  A mobile phase containing the ion pair reagent, heptane sulphonic acid, was 
examined.  The carbon chain of the heptane sulphonic acid, associates with the C18 chains 
of the stationary phase of the column, and allows the SO3
- ion to be free to form an ionic 
bond with the NH3
+ ion of weak base analytes, such as 3HKYN, which are ionised at a low 
pH.  Using the ion pair reagent should retain 3HKYN on the column for a longer time and 
should avoid the need for long analysis times to elute all the other components of plasma 
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which are also electrochemically active at the oxidation voltage used.  This ion pair reagent 
should not affect the retention of 3HANA.   
A mobile phase recommended by Waters for electrochemical detection was examined, 
comprising 50mM phosphoric acid, 50mM citric acid, 60µM sodium EDTA, 0.5mM 
heptane sulphonic acid and 2mM sodium chloride, with the pH adjusted to 3.1 with 5M 
potassium hydroxide and the addition of 5% methanol.  This mobile phase resulted in 
plasma samples showing interference with the 3HKYN peak.  
As heptane sulphonic acid is present at a low concentration (0.5mM) in this mobile phase, 
increasing the concentration of the ion pair reagent to several higher concentrations was 
examined to increase the retention time for 3HKYN in an attempt to separate 3HKYN 
from the interfering compounds in plasma.  The retention time for 3HKYN was increased 
from 15.5 minutes to 20.0 minutes by increasing the concentration of heptane sulphonic 
acid from 0.5mM to 8mM.  The levels of methanol in the mobile phase were also adjusted 
to achieve the best separation of 3HKYN.  The optimised mobile phase for 3HKYN and 
3HANA was with 8mM heptane sulphonic acid and 5% methanol, which resulted in 
retention times of 20.0 minutes for 3HKYN and 25.0 minutes for 3HANA. 
Peak oxidation voltage for 3HKYN is +0.65-0.70V but Heyes and Quearry (1988) used 
+0.55 to +0.60V, and Pearson and Reynolds (1991) used +0.60V, to ensure minimal 
interference in the brain samples being analysed.  For 3HANA, Christen and Stocker 
(1992) used an oxidation voltage of +0.50V.  As the oxidation voltage was decreased from 
+0.65V to +0.60V and +0.55V, the sensitivity for 3HKYN and 3HANA decreased, with no 
benefit of reduced interference.  Hence, the oxidation voltage of +0.65V was used.   
This mobile phase was used for the HD and chronic brain injury studies but was not ideal, 
as the LoD was high for both metabolites.  This lack of sensitivity was due to the mobile 
phase having a high background current of approximately 6nA.  Even with the ion pair 
reagent in the mobile phase, an analysis time of 70 minutes was necessary to elute all the 
non-polar compounds in the plasma samples, otherwise large broad interfering peaks were 
present in chromatograms due to carry over from the previous run. 
For the HD and chronic brain injury studies, 3HKYN and 3HANA could be detected in the 
majority of baseline plasma samples and in all the plasma samples following tryptophan 
loading.  
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3.5.3  Final Method for the Determination of 3HKYN and 3HANA 
3HKYN and 3HANA were determined using a Synergi Hydro column and electrochemical 
detection at the oxidation voltage of +0.65V.  The reverse phase HPLC was run 
isocratically at 37ºC, and the electrochemical detection was also performed at 37ºC.  The 
mobile phase was 50mM phosphoric acid, 50mM citric acid, 60µM EDTA, 8mM heptane 
sulphonic acid and 2mM sodium chloride, with the pH adjusted to 3.1 with 5M potassium 
hydroxide and the addition of 5% methanol.  A flow rate of 1ml/min was used. 
A volume of 150µl, 50µl or 10µl of filtered sample extract or filtered standard was 
injected.  Standard solutions were also analysed after every 10 sample runs to check for 
any drift in the retention times of the metabolites.  Calibration curves were analysed with 
the samples at least twice weekly when running continuously.  A new calibration curve 
was run after any shutdown of the HPLC.  A blank, containing only water, ascorbic acid 
and PCA was run with each calibration curve to ensure the baseline was completely flat at 
the retention times for the peaks of interest. 
An example chromatogram is shown in Figure 3-10. 
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Figure 3-10  Example chromatogram of an extracted plasma sample from a patient after 
tryptophan loading, showing peaks for 3-hydroxykynurenine and 3-hydroxyanthranilic 
acid by electrochemical detection at +0.65V. 
  
3.5.4  Preparation of 3HKYN and 3HANA Standards 
2.4mM 3HKYN solution was prepared by dissolving the pure powder in HPLC grade 
water.  To enable solubilisation, 2.4mM 3HANA was prepared by dissolving in 40mM 
hydrochloric acid.  These stock solutions were frozen in aliquots of 1ml at -40°C.  
3.5.5  Calibration Curves for 3HKYN and 3HANA 
The frozen stock solutions of standards of 3HKYN and 3HANA were defrosted and mixed 
together using serial dilutions of up to 1 in 20.  Mixed standards of equal concentration for 
both metabolites of 24μM, 4.8μM, 2.4μM and 0.24μM were prepared.  Various volumes of 
these standards were diluted with water, ascorbic acid and PCA, so that they are 
comparable with the plasma samples.  In the HD and chronic brain injury studies, as the 
concentrations of 3HKYN varied greatly between baseline samples and tryptophan loaded 
samples, 3 calibration curves were prepared using different injection volumes (150μl, 50μl 
and 10μl).  3HKYN could only just be detected with an injection volume of 150μl for 
baseline samples, whereas some loaded samples required an injection volume of 10μl.  For 
one sample, an injection volume of 10μl was still off-scale for 3HKYN, and a dilution of 1 
in 10 was made and 10μl injected.  A blank of ascorbic acid and PCA was also prepared. 
The standards and the blank were filtered through Anopore or Alltech filter tubes using 
centrifugation at 10,000g for 10 minutes at 4°C.  Filtrates were transferred to autosampler 
vials and maintained in the autosampler at 4°C.   The preparation of standard solutions for 
the calibration curves at the various injection volumes are shown in Tables 3-19, 3-20 and 
3-21.  The concentrations of 3HKYN and 3HANA in the final standard solutions are given 
in Table 3-22. 
Calibration curves were prepared from chromatogram peak areas.  The sample extracts 
were from the same extraction as those analysed for tryptophan, kynurenine and KYNA 
(Section 3.1.2), and the recovery factors calculated from the areas of 3-nitrotyrosine for 
each extract (Section 3.2.5) were used for these electrochemical measurements.  The 
results for the plasma extracts from the calibration curves were multiplied by 2 to give the 
concentration in the original plasma sample and then multiplied by the recovery factor for 
that sample, to produce the final concentration of 3HKYN and 3HANA in the plasma 
samples. 
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Table 3-19  Preparation of standard solutions for calibrations curves of 3-
hydroxykynurenine and 3-hydroxyanthranilic acid, using a 150μl injection volume, for the 
Huntington’s disease and chronic brain injury studies. 
Standard 
Code 
Conc of each Std 
in Stock Solution 
(μM) 
 
Volume  
Mixed Std 
(μl) 
Volume 
Water (μl) 
Volume 2mM 
Ascorbic Acid 
(μl) 
Volume 
PCA (μl) 
Std1  0.24 100  510 40 150 
Std2  0.24 200  410 40 150 
Std3  0.24 300  310 40 150 
Std4  0.24 400  210 40 150 
Std5  0.24 500  110 40 150 
Std6  2.4 100  510 40  150 
Std7  2.4 150  460 40  150 
Std8  2.4 170  440 40  150 
Std9  2.4 200  410 40  150 
Std10  2.4 250  360 40  150 
BLANK   0  610  40  150 
 
Standard (Std), 4M perchloric acid (PCA) 
 
Table 3-20  Preparation of standard solutions for calibrations curves of 3-
hydroxykynurenine and 3-hydroxyanthranilic acid, using a 50μl injection volume, for the 
Huntington’s disease and chronic brain injury studies. 
Standard 
Code 
Conc of each Std 
in Stock Solution 
(μM) 
 
Volume  
Mixed Std 
(μl) 
Volume 
Water (μl) 
Volume 2mM 
Ascorbic Acid 
(μl) 
Volume 
PCA (μl) 
Std1  0.24 500  110 40 150 
Std2  2.4 75  535  40  150 
Std3  2.4 100  510 40  150 
Std4  2.4 150  460 40  150 
Std5  2.4 200  410 40  150 
Std6  2.4 300  310 40  150 
Std7  2.4 400  210 40  150 
Std8  2.4 500  110 40  150 
Std9  4.8 300  310 40  150 
Std10  4.8 350  260 40  150 
BLANK   0  610  40  150 
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Table 3-21  Preparation of standard solutions for calibrations curves of 3-
hydroxykynurenine and 3-hydroxyanthranilic acid, using a 10μl injection volume, for the 
Huntington’s disease and chronic brain injury studies. 
Standard 
Code 
Conc of each Std 
in Stock Solution 
(μM) 
Volume  
Mixed Std 
(μl) 
Volume 
Water (μl) 
Volume 2mM 
Ascorbic Acid 
(μl) 
Volume 
PCA (μl) 
Std1  2.4 250  360  40  150 
Std2  2.4 400  210  40  150 
Std3  2.4 500  110  40  150 
Std4  4.8 400  210  40  150 
Std5  24 100  510  40 150 
Std6  24 150  460  40 150 
Std7  24 200  410  40 150 
Std8  24 300  310  40 150 
Std9  24 350  260  40 150 
Std10  24 500  110  40 150 
BLANK   0  610  40  150 
 
 
 
Table 3-22  Concentrations of 3-hydroxykynurenine and 3-hydroxyanthranilic acid in 
standards for calibration curves for the Huntington’s disease and chronic brain injury 
studies. 
  Conc of each standard (μM) 
  150μl injection  50μl injection  10μl injection 
Std1  0.03 0.15  1.2 
Std2  0.06 0.225  1.5 
Std3  0.09 0.3  2.4 
Std4  0.12 0.45  3 
Std5  0.15 0.6  4.5 
Std6  0.3 0.9  6 
Std7  0.45 1.2  7.5 
Std8  0.51 1.5  9 
Std9  0.6 1.8  10.5 
Std10  0.75 2.1  15 
  
3.5.6  Method Validation for the HPLC Method for 3HKYN and 
3HANA 
3.5.6.1  Linearity of HPLC Response for 3HKYN and 3HANA 
3HKYN and 3HANA standards showed a linear response from the electrochemical 
detector with increasing concentrations.  This was observed across the range of 
concentrations in the calibration curves from 30nM to 750nM when an injection volume of 
150μl was used, from 0.15μM to 2.1μM when an injection volume of 50μl was used and 
from 1.2μM to 15μM when an injection volume of 10μl was used, for both 3HKYN and 
3HANA. 
3.5.6.2  LoD for 3HKYN and 3HANA 
Standard solutions of 3HKYN and 3HANA were diluted to determine the LoD at a signal 
to noise ratio of 3, using the highest injection volume for this method of 150μl.  The LoD 
was 10nM for 3HKYN and 3HANA standards, which equates to 1.5pmoles on column.   
Tryptophan depleted samples from the HD and chronic brain injury studies were examined 
to determine the LoD for plasma samples.  The LoD with plasma samples was 40nM for 
3HKYN and 40nM for 3HANA.  These are the levels in the original plasma, having 
accounted for the 2-fold dilution of the plasma prior to analysis.  
3.5.6.3  Recoveries for 3HKYN and 3HANA 
Three samples of plasma were spiked with three mixed standard solutions, each containing 
the same concentrations of 3HKYN and 3HANA and were compared with the three 
original unspiked samples.   
Mixed standard solutions of 3HKYN and 3HANA were prepared by defrosting and 
diluting stock solutions of 2mM individual standards and mixing them to give the 
appropriate concentrations of each standard for a 20μl spike, for each level of spike (Table 
3-23).  All standard solutions were prepared in 100μM ascorbic acid.   
Samples were extracted using the method described for recoveries in Section 3.2.6.3, 
where recovery calculations are also shown.  The injection volume was 50μl for standards 
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and samples.  The concentration of plasma was determined by multiplying the result from 
the calibration curve by 2, and multiplying by the recovery factor. 
The recoveries for 3HKYN were between 103% and 108% and for 3HANA were between 
101% and 109% (Table 3-24).  These results show that this electrochemical method 
accurately quantifies 3HKYN and 3HANA concentrations in plasma. 
 
Table 3-23  Concentrations of a mixed standard solution containing equal 
concentrations of 3-hydroxykynurenine and 3-hydroxyanthranilic acid used to spike 
plasma to determine recoveries. 
 
 
Spike conc. for 
20μl spike 
(μM) 
 
Conc. of spike if had been in 
plasma 
(μM) 
Low level  20 0.8 
Medium level  40 1.6 
High level  60 2.4 
 
 
Table 3-24  Recoveries of 3-hydroxykynurenine and 3-hydroxyanthranilic acid using 
three different plasma samples spiked with three concentrations of each metabolite.  
  Plasma 1  Plasma 2  Plasma 3 
 
Spike Conc 
as if in 
plasma (μM) 
Conc in 
plasma 
(μM) 
 
Recovery 
(%) 
Conc in 
plasma 
(μM) 
Recovery 
(%) 
Conc in 
plasma 
(μM) 
Recovery 
(%) 
 0.052    0.065    0.623   
0.4  0.483  108  0.479  104 1.045 105 
0.8  0.889  105  0.920  107 1.469 106 
3HKYN 
(μM) 
 
1.2  1.302  104  1.302  103 1.866 104 
             
 0.126    0.343    0.611   
0.4  0.530  101  0.778  109 1.041 107 
0.8  0.941  102  1.211  109 1.474 108 
3HANA 
(μM) 
1.2  1.372  104  1.613  106 1.838 102 
  
3.5.6.4  Intra-Assay and Inter-Assay Precision for 3HKYN and 3HANA 
From the HD study, several plasma samples from healthy controls, 7 hours after 
consuming a tryptophan load, were pooled to produce a sample for repeatability (intra-
assay) and a sample for reproducibility (inter-assay).   
One sample was extracted 8 times by the standard procedure (Section 3.1.2), and extracts 
frozen at -40°C.  8 samples were analysed together in the same run, to obtain a measure of 
repeatability.  The concentrations of 3HKYN were 3.71 ± 0.072 μM (mean ± SD), with 
CV = 2.0% and for 3HANA, the mean concentration was 0.186 ± 0.005 μM, CV = 2.6%.  
For reproducibility, 8 aliquots of pooled plasma were extracted on the same day and frozen 
at -40°C.  One sample was then analysed each day, together with other samples being 
analysed on that day, for the following 8 days.  These 8 repeats were analysed using 3 
different calibration curves.  The concentrations for 3HKYN were 3.83 ± 0.097 μM (mean 
± SD), with CV = 2.5%, and for 3HANA, the mean concentration was 0.41 ± 0.020 μM, 
CV=4.9%. 
The CV results were all below 5% indicating good precision for this method. 
3.5.6.5  Confirmation of Peak Identity for 3HKYN 
To clarify that the 3HKYN peak identified by this method was indeed pure 3HKYN, 6 
tryptophan loaded plasma samples were also measured using the absorbance detection at 
365nm.  The results are shown in Table 3-25.  There was on average a 5% difference 
between methods, showing that the peaks were indeed 3-hydroxykynurenine.  The 
alternative method produced some higher and some lower results than the original method 
as expected due to normal variability. 
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Table 3-25  Measurement of 3-hydroxykynurenine using an alternative method to check 
that the peak identified is indeed pure metabolite. 
Plasma Sample  3-Hydroxykynurenine 
(μM) 
 standard  method 
ECD +0.65V 
 
absorbance 365nm 
1  2.56 2.59 
2  4.21 3.98 
3  1.40 1.29 
4  2.35 2.44 
5  3.38 3.11 
6  1.70 1.65 
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3.6  Measurement of 3HKYN using Solid Phase 
Extraction with Electrochemical Detection 
3.6.1  Solid Phase Extraction for 3HKYN Measurement 
Introduction 
A sensitive method is required to determine 3HKYN in plasma samples.  The method 
described in Section 3.5 was not ideal, firstly, as sensitivity was low with the LoD being 
close to the level of 3HKYN in control plasma samples and, secondly, an HPLC run time 
of 70 minutes was required to elute non-polar compounds which had much longer retention 
times than the polar 3HKYN.  Solid phase extraction (SPE) is a technique used to clean up 
a sample, by selectively extracting and purifying target analytes, prior to HPLC analysis.  
This is achieved using syringe barrels packed with a sorbent (often reverse phase or ion 
exchange), where some components of the sample will be absorbed on to the sorbent and 
others will pass through the sorbent.  Different solutions of varying polarity or pH can be 
drawn through the cartridges at low flow rates (under vacuum using a SPE vacuum 
manifold) to specifically remove different compounds from the sorbent.  For measuring 
3HKYN in plasma, a sample clean up stage using SPE would be useful to remove the non-
polar components of plasma prior to HPLC analysis, and may give the additional benefit of 
removing peaks which could interfere with the 3HKYN peak on the chromatogram.  SPE 
may offer a means of concentrating the samples, either by using a low volume to elute the 
3HKYN from the SPE cartridge or by using an elution solvent which could subsequently 
be concentrated by evaporation under nitrogen (for organic solvents) or freeze-drying (for 
aqueous solvents). 
The mobile phase chosen for the determination of 3HKYN was based on that described by 
Heyes and Quearry (1988) and consisted of 0.27mM sodium EDTA, 2mM sodium 
chloride, 8.9mM heptane sulphonic acid, 100mM phosphoric acid, 0.9% triethylamine and 
1.5% acetonitrile.  This mobile phase was preferred to that used for the previous 
determination of 3HKYN (Section 3.5.3) as it gave a reduced background current of 
approximately 3nA with an oxidation voltage of +0.65V using the electrochemical 
detector.  Isocratic reverse phase HPLC was performed using a Synergi Hydro column at 
30ºC.  The retention time for 3HKYN with this mobile phase was 23 minutes.  Initially, 
electrochemical detection at an oxidation voltage of +0.65V at 30ºC was used.  The LoD 
for 3HKYN standards using this method was 5nM. 
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3.6.2  Solid Phase Extraction using C18 cartridges 
To separate components of different polarities, a C18 based SPE sorbent can be used with 
elution in a relatively polar solvent.  The more polar compounds would be eluted first, 
while the non-polar material would remain on the cartridge.  Several samples of mixed 
plasma were used for this work.  Plasma samples (500μl) were spiked with various 
concentrations of 3HKYN solutions and proteins were precipitated with 400μl 0.2M PCA 
prior to SPE.  Waters SepPak (500mg/3cc) cartridges were used, and elution of 3HKYN 
was with methanol.   
The oxidation potential for the electrochemical detector was reduced to +0.55V from 
+0.65V, which omitted a peak found in some plasma samples close to the retention time 
for 3HKYN and flattened the baseline, without reducing the size of the 3HKYN peak.  An 
oxidation voltage of +0.55V also reduced the number of late eluting peaks in the 
chromatograms. 
It was found that reducing the organic content of the SPE elution solvent from 100% 
methanol to 10% methanol and 90% water eluted all the 3HKYN and left more non-polar 
material absorbed on the SPE cartridge. 
Plasma could be concentrated by a factor of 2, with no losses in 3HKYN, by removing the 
10% methanol in the elution solvent by drying under nitrogen and then freeze-drying the 
remainder.  The dried extract, derived from 500µl plasma was then reconstituted in 250µl 
mobile phase. 
The major problem with this method was very variable recoveries with both plasma 
samples spiked with 3HKYN and the 3HKYN standards themselves.  Several attempts 
were made to improve recoveries.  One included using different SPE cartridges all based 
on reverse phase sorbents from various suppliers.  Waters SepPak (200mg/3ml), Waters 
Oasis HLB (30mg/1ml), Phenomenex Strata (2g/12ml), Phenomenex Strata-X (30mg/1ml) 
and Varian Focus (20mg/3ml) cartridges were assessed.  This work suggested that the 
variable recoveries for the SepPak cartridges was that much of the 3HKYN was being lost 
in the water wash prior to elution in 10% methanol.  The Oasis HLB cartridges appeared to 
be the most promising with only a small amount of 3HKYN lost in the water wash 
(approximately 5%), but recoveries were still variable for spiked samples, ranging from 
75% to 120%.  When plasma samples were analysed in triplicate before and after spiking, 
the recoveries were greatly improved when calculated from the mean results.   
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The use of an internal standard would be ideal when recoveries are variable.  The internal 
standard used by Heyes and Quearry (1988), dihydroxybenzylamide and an isomer of 
3HANA, 4-amino-3-hydroxybenzoic acid, were evaluated.  Both were able to be measured 
by electrochemical detection using the same HPLC conditions as for 3HKYN.  Neither 
were completed eluted in 10% methanol on SPE and hence were both unsuitable for use as 
an internal standard. 
3.6.3  Solid Phase Extraction using Cation Exchange Cartridges 
An alternative SPE method for sample clean up is to use a cation exchange SPE cartridge.  
3HKYN contains two amino groups and hence at low pH, below the pKa of 3HKYN, these 
groups will be present in their ionised form (NH3
+).  This ionised compound will be 
retained on a cation exchange cartridge at low pH, but can be eluted by increasing the pH 
and therefore changing 3HKYN to its non-ionised form.  Pearson and Reynolds (1991) 
reported a SPE method using cation exchange for measuring 3HKYN in brain tissue and 
blood plasma. 
A SPE procedure similar to that of Pearson and Reynolds (1991), was attempted using 
Phenomenex Strata-X-C (60mg/3ml) and Varian Bond Elut SCX (500mg/3ml) cartridges.  
After an initial extraction of 500μl plasma with 50μl 1M PCA, samples were loaded on to 
the SPE sorbent at pH 2.5 and eluted at pH 7 with 0.1M sodium phosphate buffer.  At least 
2ml of pH 7 buffer was required to elute all the 3HKYN from the SPE cartridge.  The 
concentration of 3HKYN in this eluate was too dilute to quantify levels normally found in 
plasma.   
To elute all the 3HKYN in a minimum volume, smaller sorbent sizes were examined.  
Bond Elut SCX (50mg/1ml) cartridges were compared to mixed mode cation exchange 
cartridges, namely Strata-X-C (30mg/1ml), Supelco Discovery DSC-MCAX (100mg/1ml) 
and Waters Oasis MCX (30mg/1ml), with elution in 1ml 0.1M phosphate buffer pH 7.  
Very poor recoveries were obtained for all 4 cartridge types for both 3HKYN standards 
and plasma samples. 
Another approach was to concentrate the 3HKYN eluted from the SPE in a larger volume 
of eluate, by freeze-drying.  3HKYN was eluted from SPE cartridges in 2ml 0.1M pH 7 
buffer, which was then freeze-dried.  There was a large amount of crystallised phosphate 
buffer present in the dried eluates, which required 1ml mobile phase to resolubilise for 
HPLC, which somewhat defeated the purpose of concentrating the sample.   
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3.6.4  Solid Phase Extraction Summary 
SPE using Oasis HLB cartridges and eluting in 10% methanol was a promising method of 
sample preparation for measuring 3HKYN in plasma but variable recoveries resulted in the 
method not being used.  The use of an internal standard would be ideal when recoveries are 
variable.  However a suitable internal standard which matches the behaviour of 3HKYN 
through SPE was not found.  Alternatively, analysing all samples in triplicate and checking 
each SPE run with triplicate spikes was shown to produce good recoveries but this is 
impractical for the large numbers of samples present in the patient studies in this project. 
Cation exchange based SPE was also attempted, but the SPE eluate was too dilute to detect 
the 3HKYN levels present from the plasma.  As this is a more specific SPE separation, it 
would be worth pursuing in the future, using a elution solvent of the same pH but with a 
lower molarity which could be concentrated by freeze-drying.  This method of sample 
clean up, together with the improved mobile phase for electrochemical detection, has the 
potential as a future method for determining 3HKYN concentrations in plasma.    
4  Huntington's Disease 
4.1  Introduction 
There is much evidence for altered kynurenine pathway metabolism in post-mortem brain 
tissue from HD patients, with Guidetti et al. (2004) demonstrating increases in the levels of 
QUIN and 3HKYN, with no change in the levels of KYNA, in early stage HD.  Post 
mortem brain tissue at later stages of the disease do not appear to have increased QUIN 
levels, but have shown a significant increase in the ratio kynurenine: KYNA (Beal et al., 
1990) and increases in the levels of 3HKYN (Pearson and Reynolds, 1992).  There is also 
evidence of oxidative stress in post-mortem HD brains (Browne et al., 1999). 
In this study, the patients were at the late stages of HD and blood samples were analysed to 
assess changes in the kynurenine pathway.  The dynamics of the kynurenine pathway in 
these living patients was examined by acutely depleting tryptophan from the diet and 
giving a single tryptophan load.  This demonstrated how the kynurenine pathway functions 
under extreme lack or excess of tryptophan and may give a clearer understanding of how 
this pathway differs between HD patients and healthy control subjects.  In addition, 
tryptophan depletion should reduce the production of the neurotoxic kynurenines, QUIN, 
3HKYN and 3HANA, and, although tryptophan is an essential amino acid in the diet, an 
appropriate diet with a reduced tryptophan content may offer some benefit for HD patients 
(Pascoe, 1993).  However potential drugs able to block the production of neurotoxic 
products of the kynurenine pathway may be more suitable and offer much more benefit 
than a low tryptophan diet.  Tryptophan loading is expected to increase metabolism via the 
kynurenine pathway and hence increase the levels of all the kynurenines.  The balance 
between the neuroprotective KYNA and the neurotoxic kynurenines is expected to be 
important for neurotoxicity (Guidetti et al., 2000).  Tryptophan loading could lead to 
increased oxidative stress as more of the neurotoxic products able to produce reactive 
oxygen species (3HKYN, 3HANA and QUIN) are formed.   
As the kynurenine pathway is the major metabolic pathway for tryptophan in most tissues 
after protein synthesis, oral tryptophan depletion and loading is expected to produce large 
changes in the levels of kynurenines.    Manipulating tryptophan will also affect other 
tryptophan pathways including the pathway which produces 5HT.  Oral tryptophan 
depletion and loading have been used as tools to reduce or increase 5HT in the brain to 
examine the role of 5HT in depression and other behavioural disorders.  In addition, blood 
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tryptophan concentrations will affect the entry of other large neutral amino acids into the 
brain, as this group of amino acids are in competition for the same active transport system 
to cross the blood-brain barrier. 
The mechanism for the tryptophan deficient amino acid mixture to deplete tryptophan from 
the blood was due to its induction of protein synthesis.  A large decrease in tryptophan 
levels in both plasma and brain tissue of rats following administration of the tryptophan 
depleting mixture was demonstrated, which did not occur after pretreating the rats with a 
protein synthesis inhibitor, cycloheximide (Moja et al., 1991).   
Our depletion protocol, involving ingestion of 100g of a tryptophan deficient amino acid 
mixture, after an overnight fast, has been used in several studies which have demonstrated 
the time for a maximum depletion in plasma tryptophan was 5 hours, falling by 80-90% in 
healthy males (Young et al., 1996).  The changes associated with tryptophan depletion are 
transient and resolve within 24 hours (Reilly et al., 1997) and in our study, tryptophan 
loading was given at 24 hours after the depletion mixture, when kynurenine levels were 
expected to have returned to normal.   
A normal Western diet contains about 0.5g of tryptophan daily.  The single tryptophan load 
in our study was 6g tryptophan.  Previous work has used doses of tryptophan of 3g (Joseph 
and Risby, 1975), 5g (Huether et al., 1992) or 10.3g (Bjork et al., 1999), again having been 
studied with regard to depression and behavioural disorders.  Plasma tryptophan levels 
were shown to have returned to their original levels by 8 hours after a 3g tryptophan load 
(Joseph and Risby, 1975). 
Tryptophan loading stimulates metabolism along the different tryptophan metabolic 
pathways, and also increases the rate of protein synthesis, utilising other amino acids in 
peripheral tissues (Huether et al., 1992).   
Previous work on the role of kynurenines in HD has focused on post-mortem human brains 
and on animal models of the disease.  This study examines the levels of kynurenines in the 
blood of living HD patients.  If kynurenine levels in the blood reflect results from post-
mortem brains and the hypotheses developed for HD, blood samples would provide much 
more readily attainable samples for further studies of this disease and may provide useful 
markers of the disease.  As there are no adequate treatments for HD available at present, 
this study may indicate if modulation of the kynurenine pathway would be useful for 
potential therapeutic openings in HD.  
113  
Tryptophan, kynurenine, KYNA and QUIN were determined for baseline, tryptophan 
depleted and tryptophan loaded blood samples for each subject.  3HKYN, 3HANA, 
neopterin and lipid peroxidation were measured in baseline and tryptophan loaded samples.  
ESR and CRP were determined for the baseline samples. 
4.2  Methods 
4.2.1  Patients and Samples 
All the patients were at an advanced stage of HD and required permanent hospitalisation in 
the Royal Hospital for Neuro-disability.  11 patients (3 males, 8 females; age 60 ± 1.7 
(mean ± SEM)) and 15 healthy control subjects (4 males, 11 females; age 43 ± 2.2 (mean ± 
SEM)) completed the full experimental protocol and were included in the results of the 
study.  Originally, 3 extra patients and 3 extra controls (all 6 were female) were included, 
but they either consumed less than 80% of the tryptophan depleting or loading mixtures or 
vomited within 2 hours of consumption, and hence were removed from the study results.  
None of the patients or controls were taking any drugs known to interfere with tryptophan 
metabolism, such as glucocorticoids.  Permission for the study was obtained from the 
Ethical Committee of the Epsom and St Helier University Hospitals NHS Trust and from 
the Riverside Ethical Committees of the Royal Hospital for Neuro-disability.  Patients and 
controls were enrolled by obtaining their informed written consent or the consent of their 
next of kin. 
All subjects were fasted overnight before a baseline blood sample was taken.  Immediately 
after this initial blood sample, the subjects consumed an amino acid mixture (100g) 
containing all the essential amino acids, except tryptophan.  This was given in the form of 
a fruit flavoured drink.  Figure 4-1 shows the time plan for the tryptophan depletion and 
loading experiment.  Further blood samples were taken 5 and 7 hours later, at times when 
the blood was expected to contain the minimum levels of tryptophan (Young et al., 1996).  
Subjects then resumed a normal diet containing tryptophan for the remainder of the day but 
again fasted overnight.  At 24 hours after the initial baseline blood sample, when 
tryptophan levels were expected to have returned to normal (Reilly et al., 1997), a second 
baseline blood sample was taken immediately before the tryptophan load was 
administered.  The tryptophan load (6g) was again taken orally as a fruit flavoured 
solution.  Further blood samples were taken after 5 and 7 hours when levels of tryptophan 
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were expected to be at a maximum (Heuther et al., 1992).  All subjects were closely 
monitored by a physician throughout the study. 
EDTA plasma was prepared using EDTA vacutainers to collect the blood which was then 
centrifuged at 1000g for 10 minutes.  Serum samples were prepared by allowing blood 
samples to clot before centrifuging at 1000g for 10 minutes.  All samples were protected 
from light and frozen within two hours of venesection.  Samples were kept frozen while 
being transported from Epsom General Hospital to the University of Glasgow and then 
stored at -40ºC prior to analysis.  
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Figure 4-1  Time plan for the tryptophan depletion and loading protocols indicating 
time points when blood samples were taken, together with the pattern of expected changes 
in blood tryptophan concentrations. 
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4.2.2  Kynurenines by HPLC 
Samples of EDTA plasma were extracted as described in Section 3.1.2.  Mrs R McMillan 
helped with some of the extractions.  Tryptophan, kynurenine and KYNA were analysed 
by HPLC using absorbance and fluorescence detection (Section 3.2.3).  3HKYN and 
3HANA were determined by HPLC with electrochemical detection (Section 3.5.3).  The 
levels of 3HKYN and 3HANA in tryptophan depleted samples could not be detected and 
therefore results were only compiled for the second baseline sample and the loaded 
samples. 
4.2.3  Quinolinic acid by GC-MS 
Samples of EDTA plasma were analysed for QUIN using GC-MS by West Park 
Biochemistry Laboratories at Epsom General Hospital by the method described in the 
appendix.   
4.2.4  Neopterin and Lipid Peroxidation 
Neopterin and lipid peroxidation were determined in serum by Dr C.M. Forrest at the 
University of Glasgow using the methods described in the appendix.  Only baseline and 
loaded samples were analysed. 
4.2.5  Clinical Analyses - ESR and CRP 
ESR and CRP, standard clinical analyses, were determined for only the first baseline 
sample at Epsom General Hospital.  The methods are briefly described in the appendix. 
4.2.6  Data Analysis and Statistics 
GraphPad InStat statistics package was used for all the statistical analysis, except for the 
correlations where NCSS97 software was used.   
Comparisons between patients and controls were made using unpaired two-tailed t tests.  A 
Welch correction or a non-parametric Mann-Whitney test was used if necessary.   
A repeated measures ANOVA, followed by a Student-Newman-Keuls multiple comparison 
post test, was used when comparing measurements from the same patients or control 
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subjects at different time points during the depletion or loading protocols.  Depletion 
samples were compared with baseline 1, with a separate ANOVA for baseline 2 and loaded 
samples.  Two separate ANOVAs were required as the extremely large differences 
between depleted levels and loaded levels may mask significant differences between 
baseline and depleted samples.  Comparison of original baseline and baseline 24 hours 
after depletion for the same patients or control subjects was determined using a paired two-
tailed t test.   
In addition to statistically analysing the levels of the kynurenines measured in the bloods of 
patients with HD and healthy controls, the ratios between different kynurenines were also 
calculated.  These ratios demonstrate how much metabolite was produced from its 
substrate, which gives an indication of the activity of the enzyme catalysing the reaction.  
Differences between patients and controls in the ratios of QUIN: KYNA and 3HKYN: 
KYNA also show if the pathway has changed to favour one route more than another.  In 
addition, the ratios are advantageous in that they indicate pathway activity, rather than 
actual levels of metabolites which can be quite variable in human subjects.  Ratios were 
analysed using the same statistical tests as the metabolites themselves. 
Another means of data analysis, primarily to overcome any masking of significant 
differences due to the natural variability between human subjects, was to calculate, by 
subtraction, the change in the levels of kynurenines from baseline to depleted or from 
baseline to loaded for individual subjects.  This demonstrates differences between patients 
and controls due to the effect of the same depleting and loading mixture given to each 
subject, independent of the initial baseline levels.  The mean change for control subjects 
and patients with HD have then been compared at each time point using a two-tailed t test.   
In all cases a significance threshold of 5% (P<0.05) was employed.   
Correlations between the kynurenines, the ratios of the kynurenines, neopterin, lipid 
peroxidation, ESR and CRP were assessed using a correlation matrix and the statistics 
package NCSS97.  Spearman correlations were made as some of the data were non-
parametric.  
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4.3  Results  
4.3.1  Kynurenines 
4.3.1.1  Tryptophan 
Baseline levels of tryptophan were not significantly different between patients and 
controls.  The only significant difference between tryptophan levels in patients and 
controls was at 5h after depletion, where there was more tryptophan in patients' blood 
compared with controls (Figure 4-2A).  The loaded samples showed no significant 
differences between patients and controls at either 5 or 7 hours after loading (Figure 4-2B).   
The depletion mixture, as expected reduced the levels of tryptophan in the bloods of both 
patients and controls (Figure 4-2A).  This reduction in tryptophan was highly significant at 
both 5 and 7 hours after the subjects were given the tryptophan depleting mixture, with 
tryptophan levels remaining similar (not significantly different) at 5 and 7 hours.  The 
tryptophan load produced significantly higher levels of tryptophan in the bloods of both 
patients and controls at both 5 and 7 hours after loading (Figure 4-2B).  The levels at 7 
hours were beginning to return to normal, being significantly lower at 7 hours compared 
with 5 hours after loading for both patients (p<0.001) and controls (p<0.001).  At the 
second baseline, 24 hours after depletion, tryptophan levels had returned to levels similar 
to that of baseline 1 for both patients and controls (Figure 4-2A). 
When the changes in tryptophan levels between baseline and depleted samples were 
calculated for each subject and the means compared, the reduction in tryptophan on 
depletion was significantly less in patients compared with controls at both 5 and 7 hours 
after depletion (Figure 4-3A).  There were no significant differences between patients and 
controls when the increases in tryptophan on loading were assessed (Figure 4-3B). 
4.3.1.2  Kynurenine 
Kynurenine levels were significantly higher in patients than controls at baselines 1 and 2, 
at both 5 and 7 hours after depletion (Figure 4-4A) and at 5 hours after loading (Figure 4-
4B).  This trend was still seen 7 hours after loading, although it was not significant.  
As with tryptophan, the levels of kynurenine were significantly lower at both 5 and 7 hours 
after depletion compared with baseline levels for patients and controls (Figure 4-4A).   
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There was also a significantly lower level of kynurenine at 7 hours after depletion 
compared with 5 hours, only in the patient group (p<0.05), suggesting that on depletion, 
kynurenine levels in the patients may take longer to reach a minimum level than in the 
controls.  In control subjects, the initial baseline was not significantly different from 
baseline 2, 24 hours after depletion, but for patients, the second baseline was significantly 
higher than the first.  For patients the effect of this tryptophan depletion may actually 
stimulate the pathway activity once a normal diet has been resumed. 
After tryptophan loading, levels of kynurenine were significantly higher than baseline for 
both patients and controls (Figure 4-4B).  Both patients (p<0.001) and controls (p<0.01) 
showed significant decreases in kynurenine levels between 5 and 7 hours after loading. 
The changes between baseline levels and depleted or loaded levels were calculated and are 
shown in Figure 4-5, with the decrease in kynurenine concentrations being significantly 
greater for patients compared with controls at 7 hours after depletion.  This is due to the 
much higher level of kynurenine at baseline.  None of the other changes in kynurenine 
levels due to depletion or loading resulted in a significant difference between patients and 
controls.  
4.3.1.3  Kynurenine: Tryptophan ratio 
The ratio of kynurenine: tryptophan (K:T) is recognised as an indicator of IDO/TDO 
activity, and was calculated for all results of this study.  HD patients had significantly 
higher K:T ratios than controls at both the first and second baseline samples and also at 5 
hours after depletion (Figure 4-6A).  There was no difference between the K:T ratios of 
patients and controls at 7 hours after depletion and at 5 and 7 hours after loading (Figure 4-
6). 
There seemed to be a different effect between patients and controls after depletion, with 
controls at 5 hours having a significantly lower K:T ratio, but patients having a 
significantly higher K:T ratio, compared with their respective baseline samples (Figure 4-
6A).  Similar K:T ratios were observed at 7 hours after depletion.  As with the original 
kynurenine levels, the K:T ratio for patients was significantly higher at the second baseline 
compared with the initial baseline, suggesting increased pathway activation following the 
depletion protocol.  On loading, the K:T ratios were significantly increased in both patients 
and controls, with levels being similar after 5 and after 7 hours (Figure 4-6B). 
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4.3.1.4  Kynurenic acid 
There were no significant differences between KYNA concentrations in patients and 
controls at any of the time points (Figure 4-7).  Tryptophan depletion caused a significant 
reduction in KYNA levels for both patients and controls at both 5 and 7 hours after 
depletion, with KYNA levels having returned to baseline values by 24 hours after 
depletion (baseline 2).  Similarly, tryptophan loading resulted in a significant increase in 
the levels of KYNA at 5 hours after loading, which had significantly reduced by 7 hours 
after loading for both patients (p<0.001) and controls (p<0.001). 
When the change in KYNA levels due to depletion or loading were calculated, there were 
no significant differences between patients and controls (Tables 4-1 and 4-2).  There seems 
to be a trend that there is more of an increase in KYNA concentrations in patients after 
loading than in controls (Table 4-2), similar to the trend in the raw KYNA results (Figure 
4-7B). 
4.3.1.5  Kynurenic acid: Kynurenine ratio 
The ratio of KYNA with its substrate, kynurenine (KYNA: KYN) was calculated for each 
subject at each time point, to indicate the activity of the KAT enzymes.  At both baselines, 
the KYNA: KYN ratios were significantly lower for patients compared with controls 
(Figure 4-8A).  A lower ratio was also observed for patients 7 hours after the tryptophan 
depletion.  The kynurenine levels in many of the controls at 5 hours after depletion were 
undetectable and determined as zero kynurenine, and hence a ratio could not be calculated.  
This resulted in too few ratios to calculate a valid KYNA: KYN ratio for this time point, 
and therefore no data are shown on the graph for 5 hours after depletion in the controls.  
There were no differences between patients and controls after loading (Figure 4-8B). 
The ratio was significantly lower for controls at 7 hours after depletion compared with 
baseline 1, but depletion did not reduce the ratios in the patients' samples.  On loading, the 
KYNA: KYN ratio was significantly increased after 5 hours for both patients and controls 
and remained increased for the patients 7 hours after loading.  There was a significant 
decrease in the KYNA: KYN ratio between 5 and 7 hours after loading for both patients 
(p<0.001) and controls (p<0.001). 
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4.3.1.6  3-Hydroxykynurenine 
The levels of 3HKYN in all the depleted samples were below the LoD of the method and 
therefore only baseline 2 and the loaded samples were considered.  The levels of 3HKYN 
were significantly lower in HD patients compared with controls at baseline (Figure 4-9A), 
although there were no significant differences after loading.  The levels of 3HKYN were 
significantly higher after loading in the patients' samples at both 5 and 7 hours and in the 
control samples at 5 hours after loading.  There was also a significant decrease in the levels 
of 3HKYN between 5 and 7 hours after loading for patients (p<0.01) and for controls 
(p<0.05).  When the change in the levels of 3HKYN were calculated, there were no 
significant differences between patients and controls at either 5 or 7 hours after loading 
(Table 4-2). 
4.3.1.7  3-Hydroxyanthranilic acid 
The levels of 3HANA in all the depleted samples were lower than the LoD of the method 
and therefore only the second baseline and the loaded samples were assessed.   At baseline 
2 and at both 5 and 7 hours after tryptophan loading, levels of 3HANA were significantly 
lower in patients compared with controls (Figure 4-9B).  For both patients and controls, the 
loaded samples at 5 and 7 hours were significantly higher than baseline samples, with 
levels significantly lower after 7 hours than after 5 hours (patients p<0.05, controls 
p<0.01).  When the change in 3HANA levels between baseline and loading were 
calculated, no significant differences were observed between patients and controls, 
although the change in the patient group appeared to be slightly less than for the controls 
(Table 4-2). 
4.3.1.8  3-Hydroxykynurenine: Kynurenine ratio 
The ratios of 3HKYN: kynurenine (3HKYN: KYN) appeared lower for patients compared 
with controls (Figure 4-10A), being significant at 5 hours after loading.  
4.3.1.9  3-Hydroxykynurenine: Kynurenic acid ratio 
As in the case of 3HKYN: KYN, the ratio of 3HKYN: KYNA was significantly lower in 
patients at 5 hours after loading than in controls (Figure 4-10B). 
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4.3.1.10  3-Hydroxyanthranilic acid: 3-Hydroxykynurenine ratio 
There were no significant differences between the ratio of 3HANA: 3HKYN for patients 
and controls, at baseline or at 5 or 7 hours after loading. 
4.3.1.11  Quinolinic acid 
There was a large variability in the QUIN results for both controls and HD patients, which 
made it difficult to interpret the results statistically.  In both the HD patients and the 
controls at baseline, there was approximately a 1000-fold difference between subjects' 
QUIN concentrations.  There was no known reason to expect any subject to have a high 
level of QUIN in their blood.  
The only significant difference between patients and controls for QUIN was at 7 hours 
after depletion, when the patients had a lower level than the controls (Figure 4-11A).   
Tryptophan depletion did not result in a significant decrease in QUIN levels after either 5 
or 7 hours.  Although not significant, it appeared that QUIN levels were lower at 24 hours 
after depletion (baseline 2) than at the initial baseline, suggesting that the effect of the 
depleting mixture may still be affecting the subjects' QUIN concentrations.  There was a 
significant increase in QUIN at 5 hours after loading for both patients and controls, which 
appeared to remain similar at 7 hours for the controls, but may still be increasing at 7 hours 
for the patients (Figure 4-11B).  However, this difference between 5 and 7 hours after 
loading for the patients was not significant. 
To attempt to overcome the large variability in QUIN levels, the change between baseline 
and depleted or loaded samples were examined.  However the changes also produced no 
significant differences between patients and controls, except that patients showed a 
significantly lower decrease in QUIN at 7 hours after depletion (Figure 4-12), similar to 
the result with the raw data.  The changes also suggest that the increase in QUIN 
concentration at 7 hours after loading was higher in patients than in controls but again was 
not significant. 
4.3.1.12  Quinolinic acid: 3-Hydroxyanthranilic acid ratio 
There were no significant differences between the ratios of QUIN: 3HANA between 
patients and controls, although the mean ratio was higher for the patients at all 3 time 
points (Figure 4-13). 
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4.3.1.13  Quinolinic acid: Kynurenic acid ratio 
There were no significant differences in the QUIN: KYNA ratios between patients and 
controls at any of the time points during depletion and loading, but it was noted that the 
initial QUIN: KYNA ratio was higher in patients than controls at the initial baseline and 
that on loading, the ratios were lower for patients than controls (Figure 4-14).  The ratios 
reflect the delayed response of QUIN compared with KYNA following depletion and 
loading. 
4.3.2  Neopterin 
Neopterin levels were significantly higher in patients compared with controls at baseline 
(Figure 4-15A).  On loading, neopterin levels in the controls were significantly increased at 
both 5 and 7 hours after loading.  Neopterin levels had decreased in patients at 7 hours 
after loading compared to baseline. 
4.3.3  Lipid Peroxidation 
The levels of lipid peroxidation for patients were significantly higher at baseline and at 5 
and 7 hours after loading compared with controls (Figure 4-15B).  As with neopterin, the 
level of lipid peroxidation in controls increased on loading, being significantly higher than 
at baseline at both 5 and 7 hours after loading.  There was little change in lipid 
peroxidation in the patients on loading.  
4.3.4  ESR and CRP 
Baseline ESR levels were not significantly different between HD patients and controls 
(Figure 4-16A).  The baseline CRP level in patients was significantly higher than in 
controls (Figure 4-16B).   
4.3.5  Correlations 
As the number of HD patients was only 11, and control subjects only 15, fewer significant 
correlations than would be observed with a larger group were expected.  However 
significant correlations were observed between some of the kynurenines in HD patients 
and in controls.  The more meaningful or interesting significant correlations are described.   
124  
125 
For HD patients, there was a significant positive correlation between neopterin and the K:T 
ratio (p<0.05) at baseline.  Neopterin also correlated negatively with the KYNA: KYN 
ratio (p<0.05) at baseline, demonstrating that although inflammation increased the K:T 
ratio, it may inhibit the formation of KYNA from kynurenine.  There were also significant 
negative correlations after depletion between the K:T ratio and KYNA levels (p<0.05 at 5 
hours after depletion, p<0.05 at 7 hours after depletion).  In contrast, controls at the first 
baseline showed a positive correlation between K:T ratio and KYNA (p<0.05).    
Controls showed positive correlations between K:T ratio and 3HANA at both 5 and 7 
hours after loading (p<0.01, p<0.05 respectively), not observed for the patients.   
In controls, there was a positive correlation between age and neopterin at 5 hours after 
loading (p<0.05), but no similar correlations for the HD patients.  Interestingly there were 
positive correlations between age and KYNA levels, for controls at both baselines (p<0.05 
at baseline 1 and p<0.05 at baseline 2) and for HD patients at the second baseline (p<0.05) 
and at 5 hours after depletion (p<0.05). 
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Figure 4-2  Effect of tryptophan depletion and loading on tryptophan levels in the 
plasma of controls and HD patients, (A) at the initial baseline 1, following depletion of 
tryptophan and at baseline 2 (24h after depletion) and (B) at baseline 2 and following 
tryptophan loading.  Values are mean ± SEM.  Significant differences between patients and 
controls:  * p<0.05.  Effect of depletion compared with baseline 1, effect of loading 
compared with baseline 2 or differences between baselines 1 and 2: +++ p<0.001.   
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Figure 4-3  Changes in the levels of tryptophan following tryptophan depletion or 
loading for plasma from HD patients and controls.  Dep1 is 5 hours after depletion, dep2 is 
7 hours after depletion, load1 is 5 hours after loading and load2 is 7 hours after loading.  
Values are mean ± SEM for differences between the depleted or loaded sample and the 
relevant baseline.  Significant differences between patients and controls:  * p<0.05, ** 
p<0.01. 
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Figure 4-4  Effect of tryptophan depletion and loading on kynurenine levels in the 
plasma of controls and HD patients, (A) at the initial baseline 1, following depletion of 
tryptophan and at baseline 2 (24h after depletion) and (B) at baseline 2 and following 
tryptophan loading.  Values are mean ± SEM.  Significant differences between patients and 
controls: * p<0.05, ** p<0.01, *** p<0.001.  Effect of depletion compared with baseline 
1, effect of loading compared with baseline 2 or differences between baselines 1 and 2: ++ 
p<0.01, +++ p<0.001.  
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Figure 4-5  Changes in the levels of kynurenine following tryptophan depletion or 
loading for plasma from HD patients and controls.  Dep1 is 5 hours after depletion, dep2 is 
7 hours after depletion, load1 is 5 hours after loading and load2 is 7 hours after loading.  
Values are mean ± SEM for differences between the depleted or loaded sample and the 
relevant baseline.  Significant differences between patients and controls:  ** p<0.01.  
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Figure 4-6  Effect of tryptophan depletion and loading on kynurenine:tryptophan (K:T) 
ratio in the plasma of controls and HD patients, (A) at the initial baseline 1, following 
depletion of tryptophan and at baseline 2 (24h after depletion) and (B) at baseline 2 and 
following tryptophan loading.  Values are mean ± SEM.  Significant differences between 
patients and controls: *** p< 0.001.  Effect of depletion compared with baseline 1, effect 
of loading compared with baseline 2 or differences between baselines 1 and 2: + p<0.05, 
+++ p<0.001. 
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Figure 4-7  Effect of tryptophan depletion and loading on kynurenic acid levels in the 
plasma of controls and HD patients, (A) at the initial baseline 1, following depletion of 
tryptophan and at baseline 2 (24h after depletion) and (B) at baseline 2 and following 
tryptophan loading.  Values are mean ± SEM.  No significant differences between patients 
and controls.  Effect of depletion compared with baseline 1, effect of loading compared 
with baseline 2 or differences between baselines 1 and 2: ++ p<0.01, +++ p<0.001.    
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Figure 4-8  Effect of tryptophan depletion and loading on kynurenic acid: kynurenine 
ratio (KYNA: KYN) in the plasma of controls and HD patients, (A) at the initial baseline 
1, following depletion of tryptophan and at baseline 2 (24h after depletion) and (B) at 
baseline 2 and following tryptophan loading.  Values are mean ± SEM.  Significant 
differences between patients and controls: *  p<0.05, ** p<0.01.  Effect of depletion 
compared with baseline 1, effect of loading compared with baseline 2 or differences 
between baselines 1 and 2: ++ p<0.01, +++ p<0.001.  (Many control kynurenine levels 
were 0 at 5h after depletion and KYNA: KYN ratios could not be calculated, therefore 
were omitted from the graph.) 
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Figure 4-9  Effect of tryptophan loading on the levels of 3-hydroxykynurenine (A) and 
3-hydroxyanthranilic acid (B) in the plasma of controls and HD patients at baseline 2 (24h 
after depletion) and at 5 and 7 hours after loading.  Values are mean ± SEM.  Significant 
differences between patients and controls: * p<0.05.  Effect of loading compared with 
baseline 2: + p<0.05, ++ p<0.01, +++ p<0.001.  
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Figure 4-10  Effect of tryptophan loading on 3-hydroxykynurenine: kynurenine 
(3HKYN: KYN) ratio (A) and 3-hydroxykynurenine: kynurenic acid (3HKYN: KYNA) 
ratio (B) in the plasma of controls and HD patients.  Values are mean ± SEM.  Significant 
differences between patients and controls: * p< 0.05.   
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Figure 4-11  Effect of tryptophan depletion and loading on the levels of quinolinic acid 
in the plasma of controls and HD patients, (A) at the initial baseline 1, following depletion 
of tryptophan and at baseline 2 (24h after depletion) and (B) at baseline 2 and following 
tryptophan loading.  Values are mean ± SEM.  Significant differences between patients and 
controls: *** p<0.001.  Effect of depletion compared with baseline 1, effect of loading 
compared with baseline 2 or differences between baselines 1 and 2: + p<0.05, ++ p<0.01. 
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Figure 4-12   Changes in the levels of quinolinic acid following tryptophan depletion or 
loading for plasma from HD patients and controls.  Dep1 is 5 hours after depletion, dep2 is 
7 hours after depletion, load1 is 5 hours after loading and load2 is 7 hours after loading.  
Values are mean ± SEM for differences between the depleted or loaded sample and the 
relevant baseline.  Significant differences between patients and controls:  * p<0.05. 
 
136  
137 
 
baseline 2 load +5h load +7h
Q
U
I
N
:
 
3
H
A
N
A
 
r
a
t
i
o
0
5
10
15
20
25
30
Controls
Patients
 
 
Figure 4-13  Effect of tryptophan loading on quinolinic acid: 3-hydroxyanthranilic acid 
ratio (QUIN: 3HANA) in the plasma of controls and HD patients.  Values are mean ± 
SEM.  No significant differences between patients and controls.    
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Figure 4-14  Effect of tryptophan depletion and loading on quinolinic acid: kynurenic 
acid ratio (QUIN: KYNA) in the plasma of controls and HD patients, (A) at the initial 
baseline 1, following depletion of tryptophan and at baseline 2 (24h after depletion) and 
(B) at baseline 2 and following tryptophan loading.  Values are mean ± S E M .   N o  
significant differences between patients and controls.  Effect of depletion compared with 
baseline 1, effect of loading compared with baseline 2 or differences between baselines 1 
and 2: ++ p<0.01. 
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Figure 4-15  Effect of tryptophan loading on the levels of neopterin (A) and lipid 
peroxidation products (B) in the serum of controls and HD patients at baseline 2 (24h after 
depletion) and at 5 and 7 hours after loading.  Values are mean ± SEM.  Significant 
differences between patients and controls: *  p<0.05, ** p<0.01, *** p<0.001.  Effect of 
loading compared with baseline 2: + p<0.05, ++ p<0.01, +++ p<0.001. 
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Figure 4-16  Comparison of ESR and CRP between HD patients and controls at baseline.  
Values are mean ± SEM.  Significant differences: ** p<0.01.  
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Table 4-1  Changes in the levels of kynurenines following tryptophan depletion.   
Values are mean ± SEM.  Comparisons between HD patients and controls: not significant: 
ns. 
  Dep+5h - Base1  Dep+7h - Base1 
  Controls Patients  Controls Patients 
Kynurenic acid (nM) 
 
-35.9 ± 4.8  -29.5 ± 9.4 
ns 
 
-36.2 ± 4.8  -32.2 ± 9.6 
ns 
 
Note: Changes for tryptophan, kynurenine and quinolinic acid are shown graphically. 
 
 
Table 4-2   Changes in the levels of kynurenines following tryptophan loading.  Values 
are mean ± SEM.  Comparisons between HD patients and controls: not significant: ns. 
 
  Load+5h - Base2  Load+7h - Base2 
  Controls Patients Controls Patients 
Kynurenic acid (nM)  5237 ± 988 
 
8409 ± 1525 
ns 
 
1227 ± 291  2073 ± 473 
ns 
3-Hydroxykynurenine (μM)  12.1 ± 3.8  8.0 ± 2.3 
ns 
 
4.5 ± 1.8  3.5 ± 1.0 
ns 
3-Hydroxyanthranilic 
acid (μM) 
1.53 ± 0.28  0.87 ± 0.18 
ns 
 
0.80 ± 0.25  0.47 ± 0.12 
ns 
 
Note: Changes for tryptophan, kynurenine and quinolinic acid are shown graphically.
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4.4  Discussion 
4.4.1  Tryptophan Depletion and Loading 
The tryptophan depletion and loading protocols produced the desired effects of 
significantly reducing or increasing, respectively, the tryptophan levels in the bloods of 
both HD patients and healthy control subjects, at both 5 and 7 hours after the depleting or 
loading mixtures were administered.  Tryptophan levels at 24 hours after depletion had 
returned to baseline levels for both patients and controls.  Tryptophan depletion also 
reduced the levels of kynurenine and KYNA, although QUIN levels appeared to take at 
least 7 hours or perhaps longer for the reduction to occur, with levels at 24 hours after 
depletion (baseline 2) still appearing to be lower than at the initial baseline.  However, 
there were no significant differences in these QUIN levels due to the large variability in the 
results.  For tryptophan, kynurenine, KYNA, 3HKYN and 3HANA, tryptophan loading 
produced increased levels after 5 hours with levels starting to reduce back to normal after 7 
hours.  With QUIN, the levels at 7 hours after loading appeared to be similar or perhaps 
even increasing in patients compared with 5 hours after loading.  Unfortunately, no further 
blood samples were taken at a later time point to investigate whether QUIN levels 
continued to rise in the patients with HD. 
4.4.2  Tryptophan, Kynurenine and IDO/TDO activity 
While there was no significant difference in baseline levels of tryptophan between patients 
with HD and controls in this study, the much higher baseline levels of kynurenine in the 
patients demonstrated increased metabolism via the kynurenine pathway.  These high 
kynurenine levels resulted in higher K:T ratios in the patients' baseline samples, also 
indicating enhanced IDO/TDO activity.  Increased kynurenine pathway activity was 
observed throughout the depletion and loading protocols as the kynurenine levels remained 
significantly higher in the patients at 5 of the 6 time points.  IDO activity may be 
upregulated in the HD patients due to the increased inflammation observed, as the levels of 
the inflammatory marker, neopterin, was significantly higher in patients than in controls at 
baseline, as was the level of CRP.  Indeed, there was a significant correlation between 
neopterin and the K:T ratio.  In human macrophages, stimulation by the pro-inflammatory 
cytokine, IFN-γ, activates IDO and in parallel, induces the enzyme, GTP-cyclohydrolase I, 
which enhances neopterin formation (Schroecksnadel et al., 2005).  The inflammatory 
response causes the activation of macrophages and microglia, both of which express IDO 
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(Heyes et al., 1996).  In addition, the increased oxidative stress, shown by the increase in 
lipid peroxidation products in this study, may result in the production of superoxide in HD 
patients, which would contribute to stimulating IDO activity as superoxide acts as a co-
substrate for IDO.   
At 5 hours after depletion, patients showed less reduction in tryptophan levels than 
controls, although there was more IDO/TDO activity (higher kynurenine and K:T ratios).  
This suggests that patients require less tryptophan for other metabolic processes, and hence 
depleting tryptophan has less of an effect on blood tryptophan levels.  Depletion did not 
reduce the IDO/TDO activity in patients, reflected by the K:T ratios, which remained high 
at 5 and 7 hours after depletion.  With more available tryptophan after loading, IDO/TDO 
activity increased in patients and also in controls.  As IDO is not expected to be very active 
in controls, much of this increase in K:T ratios on loading may be due to TDO activity in 
the liver.  Indeed, tryptophan is known to stimulate TDO activity (Schutz et al., 1972).  
The level of kynurenine was still significantly higher in patients than in controls at 5 hours 
after loading, suggesting that even after loading, IDO activity still appears to be 
contributing to the activation of the kynurenine pathway in patients. 
4.4.3  Kynurenic Acid and KAT activity 
There are conflicting reports on the levels of KYNA in the brain of HD patients.  Connick 
et al. (1989) showed increased KYNA in the motor cortex of post-mortem HD brains, with 
no differences in KYNA levels in the prefrontal cortex, the caudate nucleus or globus 
pallidus compared to controls.  Reduced concentrations of KYNA were demonstrated in 
the CSF of HD patients (Beal et al., 1990) and in HD cerebral cortex (Beal et al., 1992).  In 
addition, a significant increase in the ratio kynurenine: KYNA was demonstrated in HD 
post-mortem brains (Beal et al., 1990).  Out of 12 brain regions from late-stage HD brains, 
the only region of the brain that showed a significant reduction in the level of KYNA was 
the caudate nucleus (Jauch et al., 1995).  The putamen and globus pallidus also suggested 
reduced KYNA levels but these were not significant.  These three regions are all part of the 
striatum, which is the brain region most susceptible to neuronal damage in HD, with the 
cortex being the next most susceptible region.  It was hypothesised that if KYNA regulates 
by blocking NMDA receptor activation, a chronic deficiency could potentially lead to a 
slowly developing NMDA excitotoxic neurodegenerative process (Beal et al., 1990).   
However, the reported concentrations of KYNA required to block NMDA receptor 
activation are about 100-fold greater than those found in the human brain (Jahr and Jessel, 
1985). 
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In this study, the levels of KYNA were similar for patients and controls throughout the 
depletion and loading protocols.  However, when the ratios of KYNA: kynurenine 
(KYNA: KYN) were compared, these were lower for the patients at baseline and following 
depletion, demonstrating that the much higher levels of kynurenine in patients could not 
produce increased levels of KYNA.  In addition, negative correlations were observed 
between the K:T ratio and KYNA at both time points after depletion.  In contrast, the 
healthy controls showed a positive correlation between K:T ratio and KYNA at the first 
baseline.  This suggests that the KAT enzymes are not functioning optimally in the 
patients.  Neopterin also correlated negatively with KYNA: KYN ratio at baseline in HD 
patients, suggesting that the inflammatory response may inhibit KAT activity.  There is no 
clear evidence for a decrease in KAT activity in HD brains.  Jauch et al. (1995) showed 
that the only brain region out of the 12 regions examined from HD brains, with 
significantly reduced KAT I and KAT II activities was the putamen, which also had 
approximately 3-fold higher Km for both enzymes.  Similarly, Pearson et al. (1995) found 
no change in KAT activity in HD brain in the caudate or frontal cortex.  However, on 
tryptophan loading in our study, the KYNA: KYN ratios are similar for patients and 
controls, with the patients actually having a mean level slightly higher than the controls, 
showing that the activity of the KAT enzymes has increased in the patients to levels similar 
to the controls.  This suggests that tryptophan loading may offer neuroprotection to HD 
patients due to their ability to produce increased amounts of KYNA.  
4.4.4  3-Hydroxykynurenine, 3-Hydroxyanthranilic Acid and 
Oxidative Stress 
3HKYN and 3HANA have the potential to cause neuronal damage by generating reactive 
oxygen species such as hydrogen peroxide, with the resulting oxidative stress inducing 
apoptosis (Eastman and Guilarte, 1989; Eastman and Guilarte, 1990; Okuda et al., 1996; 
Okuda et al., 1998).  The highly significant increases in lipid peroxidation observed in 
baseline and loaded patients' samples demonstrate increased oxidative stress in the HD 
patients.  Levels of 3HKYN and 3HANA were significantly lower in the bloods of patients 
compared with controls at baseline.  For 3HANA, patients also had lower levels at both 5 
and 7 hours after loading.  In addition, controls, but not patients, showed positive 
correlations between K:T ratio and 3HANA at both 5 and 7 hours after loading, suggesting 
that normal kynurenine pathway metabolism would increase the levels of 3HANA in the 
blood.  Furthermore, when the ratios of 3HKYN: kynurenine and 3HKYN: KYNA were 
examined, they were both significantly lower at 5 hours after loading.  This may suggest 
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that 3HKYN and 3HANA are being utilised, perhaps being autoxidised resulting in the 
formation of reactive oxygen species.  The resulting products of several oxidation steps in 
autoxidation produce hydrogen peroxide and superoxide (Dykens et al., 1987; Ishii et al., 
1992; Hiraku et al., 1995).  The superoxide could induce further kynurenine pathway 
metabolism as IDO requires superoxide as a co-substrate.  These results are the opposite to 
the findings of Pearson and Reynolds (1992) and Guidetti et al. (2000), where 3HKYN 
levels were shown to be increased in post-mortem HD brain and the ratio of 3HKYN: 
KYNA increased.  Although in some studies 3HKYN levels in HD brains were not 
significantly increased (Beal et al., 1990), there was no evidence for decreased levels of 
brain 3HKYN in HD patients.  This study measured peripheral levels rather than those in 
the brain.  As both kynurenine and 3HKYN can cross the blood-brain barrier using the 
large neutral amino acid transporter (Fukui et al., 1991), the levels of 3HKYN in the brain 
may still be higher in the HD patients.  The areas of the brain most affected by HD, the 
striatum and cerebral cortex, are where elevated levels of 3HKYN have been shown to be 
present and also have the highest capacity for 3HKYN uptake.  As 3HKYN is metabolised 
in the brain either by autoxidising or producing 3HANA, 3HKYN uptake from the blood 
may increase, thus depleting the 3HKYN and the production of 3HANA in the blood.   
Alternatively, as 3HKYN and 3HANA can autoxidise, the initial oxidation can, depending 
on the presence of other redox-active species, allow them to act as antioxidants (Christen et 
al., 1990; Leipnitz et al., 2007).  The lower levels of 3HKYN and 3HANA in the blood of 
HD patients in this study may reduce their ability to act as free radical scavengers and 
hence these compounds are unable to control the increased oxidative stress in these 
patients.  This may be due to less 3HKYN being produced, which in turn would produce 
less 3HANA.  The lower 3HKYN production could contribute to the increased kynurenine 
levels observed and may suggest inhibition of the enzyme, KMO, which produces 3HKYN 
from kynurenine. 
4.4.5  Quinolinic Acid 
A hypothesis that has been developed over the past 20 years is that the mechanism for 
neuronal loss in HD is an excessive stimulation of NMDA receptors by QUIN.  This 
hypothesis has been supported by QUIN injections into the brain producing very similar 
lesions to those observed in HD, in particular the selective sparing of somatostatin/ 
neuropeptide Y neurones in the striatum (Beal et al., 1986; Beal et al., 1989) and also as 
cells with high densities of NMDA receptors are preferentially lost in HD striatum (Young 
et al., 1988).  However, only recently has an increase in QUIN been observed in HD post-
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mortem brains and this was for patients with early grade HD (Guidetti et al., 2004).  In the 
same study, QUIN levels were not elevated in brain tissue from at-risk patients, or patients 
with grades 2, 3 or 4 HD.   
In this study, there was much variability in the levels of QUIN and the only significant 
difference between patients and controls was a decrease in QUIN levels for patients at 7 
hours after depletion.  To try to reduce the effect of the high variability in QUIN levels 
within both the patient and control groups, the changes in QUIN levels on depletion or on 
loading were calculated and compared, but this did not result in any additional significant 
effects.  Little difference in blood QUIN concentrations between patients with late stage 
HD and controls is in agreement with previous studies with brain tissue from later grades 
of HD which showed that there was no increase in QUIN levels in these brains or CSF 
(Reynolds et al., 1988; Schwarcz et al., 1988b; Heyes et al., 1991b).  Heyes et al. (1991b) 
actually showed reduced levels of QUIN, significantly lower in some areas of the cerebral 
cortex.  It is unlikely that prevention of QUIN production in HD patients is caused by 
insufficient activity of the enzyme, 3HAO, which converts 3HANA into QUIN, as its 
activity has been shown to be increased in HD brain (Schwarcz et al., 1988a).  The present 
results actually suggest that there may be increased 3HAO activity, as the lower baseline 
levels of 3HANA in patients produce similar levels of QUIN compared to controls.  When 
the ratios of QUIN: 3HANA were calculated, the differences between patients and controls 
were not significant but the trend at both baseline and after loading suggested higher 
amounts of QUIN may be produced from 3HANA in the patients.   
4.4.6  Inflammation: Neopterin, ESR and CRP 
Levels of neopterin and CRP were significantly increased at baseline in HD patients 
compared to controls, consistent with evidence of activated microglia in HD (Sapp et al., 
2001).  Inflammation and raised levels of neopterin are often associated with increased 
activity of reactive oxygen species (Murr et al., 2002) and although both neopterin levels 
and lipid peroxidation were increased in the HD patients, no correlations between them 
were observed.  The raised serum neopterin levels in HD patients is consistent with the 
study of Leblhuber et al. (1998), where increased neopterin and decreased tryptophan in 
HD patients were associated with loss of cognitive function.  The correlation between 
neopterin and the K:T ratio at baseline is in agreement with observations in other human 
diseases and suggests that the pro-inflammatory cytokine, IFN-γ, has activated both 
neopterin and IDO (Schroecksnadel et al., 2005).  
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4.4.7  Lipid Peroxidation and Oxidative Stress 
It has been proposed that mitochondrial dysfunction plays a role in the pathogenesis of 
HD.  Oxidative damage is one of the major consequences of defects in energy metabolism.  
There is evidence of oxidative damage in HD brain (Browne et al., 1999; Polidori et al., 
1999) and in animal models of HD (Perez-Severiano et al., 2000; Bogdanov et al., 2001). 
The lipid peroxidation was significantly higher in HD patients than in controls, showing 
that oxidative stress was present in HD patients and remained elevated with tryptophan 
loading.  There were no correlations between the kynurenines and lipid peroxidation levels.  
In particular, there were no correlations with the potential generators of reactive oxygen 
species, 3HKYN, 3HANA and QUIN.  This may suggest that 3HKYN and 3HANA are not 
contributing to lipid peroxidation, although it must be recognised that the correlations may 
not be significant due to the small number of patients in the study. 
4.4.8  Tryptophan Loading and Oxidative Stress 
An unexpected result was that tryptophan loading increased the lipid peroxidation levels in 
the control subjects.  Levels had increased significantly from baseline at both time points 
after loading.  Tryptophan loading induces TDO activity (Schutz et al., 1972), and TDO 
activity in the liver can account for the high levels of the kynurenines produced in the 
blood of control subjects.  The increased levels of QUIN after loading could have activated 
NMDA receptors, which induces free radical formation.  This may have been limited as the 
NMDA receptor antagonist, KYNA, was also significantly increased after tryptophan 
loading.  In addition, the increased oxidative stress may be due to the high levels of 
3HKYN, 3HANA and QUIN directly generating reactive oxygen species, including 
superoxide, hydrogen peroxide and the hydroxyl free radical (Goda et al., 1996; Goldstein 
et al., 2000).     
However, there was no significant increased lipid peroxidation in the HD patients on 
loading, although levels did increase slightly.  As the pathway was already stimulated in 
the HD patients, mechanisms producing increased oxidative stress were already active and 
therefore there could be less of a contribution to oxidative stress from the tryptophan load. 
In conjunction with the increase in lipid peroxidation, neopterin levels were also 
significantly increased after tryptophan loading in the healthy controls.  An increase in 
reactive oxygen species contributes to the production of inflammatory mediators and 
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excitotoxicity which can trigger inflammation (Dirnagl et al., 1999), and therefore whether 
the increased lipid peroxidation was produced by 3HKYN, 3HANA and/or QUIN directly 
generating free radicals or by QUIN’s excessive activation of the NMDA receptors, it is 
not surprising that the neopterin levels were also increased after tryptophan loading.  This 
increase in inflammation suggests that IDO activity may well contribute to the high levels 
of kynurenine metabolites produced on loading. 
4.4.9  Conclusions 
Abnormal metabolism of tryptophan via the kynurenine pathway has been demonstrated in 
the blood of patients with late stage HD, together with increased inflammation and 
oxidative stress.  In HD, increased activity of the initial enzyme of the pathway, IDO, was 
associated with inactivity of KAT, the enzyme which produces the neuroprotectant, 
KYNA.  The lower levels of 3HKYN and 3HANA either suggest that less is produced, due 
to lowered activity of KMO, or that 3HKYN and 3HANA are autoxidising at a higher rate 
than they can be produced.  Alternatively, there may be significant uptake of 3HKYN from 
the blood into the brain, thus depleting the levels in the blood.  The lower levels of 
3HKYN and 3HANA did not change the levels of QUIN in HD patients. 
The differences in the levels of tryptophan metabolites between patients and controls were 
similar at baseline and after tryptophan depletion.  Depletion of tryptophan therefore did 
not appear to have a beneficial effect compared to a normal diet.  On loading, however, 
many of these differences were no longer present.  Indeed, for the HD patients, there was a 
change from the apparent inhibition of KAT at baseline (reduced KYNA: KYN ratio) and 
on depletion to significant KAT activity on loading.  This suggests that tryptophan loading 
may be beneficial for HD patients.  However, the results suggest a possible build up of 
QUIN over time after loading in HD patients and therefore tryptophan loading cannot be 
justified as a neuroprotective measure. 
Tryptophan loading in healthy control subjects resulted in increased inflammation and 
oxidative stress, suggesting that a tryptophan load may be harmful. 
  
5  Chronic Brain Injury 
5.1  Introduction 
TBI, particularly when severe, can cause major disruption of brain tissue, and involves 
excitotoxicity, oxidative stress and inflammation (Sahuquillo et al., 2001).  Indeed 
Lenzlinger et al. (2001) showed an increase in the inflammatory marker, neopterin, in the 
CSF and serum of patients during the first week after TBI.  Increased levels were 
maintained in the CSF during the following 2 weeks, but began to decrease in the serum 
during the third week.  Inflammation produces free radicals and cytokines which can 
activate the kynurenine pathway.  Activation of the kynurenine pathway has been 
suggested as the levels of QUIN in the CSF rose following TBI in humans (Sinz et al., 
1998).  In addition, KYNA greatly reduced hippocampal neuronal loss in a rat model of 
TBI (Hicks et al., 1994). 
This study investigated whether the kynurenine pathway continues to be activated in 
patients with severe chronic brain injury, where the injury was sustained at least one year 
previously.  To study the pathway in more detail, the effects of tryptophan depletion and 
loading on kynurenine concentrations in blood from clinically stable patients and normal 
healthy controls were examined.  In addition to measuring the kynurenines, the levels of 
the inflammation marker neopterin and lipid peroxidation products, malondialdehyde and 
4-hydroxynonenal, as markers of oxidative stress were also determined.  ESR and CRP 
measurements were also examined. 
5.2  Methods 
5.2.1  Patients and Sampling 
Fifteen patients (9 males, 6 females; age 48 ± 3.8 (mean ± SEM)) with severe chronic brain 
injury, sustained between 1 and 35 years prior to this study, now in a clinically stable 
condition, were recruited from the Royal Hospital for Neuro-disability.  Patients had 
sustained brain insults severe enough to require long term care in a specialist brain injury 
unit, and include 8 involved in road traffic accidents, 2 with head injury, 3 patients who 
had suffered hypoxia, one with cerebral infarcts and another had a history of a subdural 
haematoma.  There were no clear parameters which distinguished any patient or sub-group 
of patients from the others, irrespective of the cause of the injury or the duration since the 
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injury.  Fifteen healthy subjects (4 males, 11 females; age 43 ± 2.2 (mean ± SEM)) acting 
as controls were also enrolled in the study.  Patients were recruited after obtaining ethical 
permission from the Ethical Committee of the Epsom and St Helier NHS Trust and from 
the Riverside Ethical Committee of the Royal Hospital for Neuro-disability.  Informed 
written consent was obtained from all subjects or their next of kin.  None of the patients 
was on any medication that was known to have any effect on tryptophan or the 
kynurenines. 
The tryptophan depletion and loading protocol was the same for these patients and controls 
as for the Huntington's patients (Section 4.2.1).   
Blood samples were protected from light throughout.  EDTA plasma and serum samples 
were prepared by centrifugation at 1000g for 10 minutes, and frozen within two hours of 
venesection.  Samples were kept frozen while being transported from Epsom General 
Hospital to the University of Glasgow and then stored at -40ºC prior to analysis. 
5.2.2  Kynurenines by HPLC 
Samples of EDTA plasma were extracted for HPLC (Section 3.1.2).  Mrs R McMillan 
helped with some of the extractions.  Tryptophan, kynurenine and kynurenic acid were 
analysed by RP-HPLC described in Section 3.2.3, using absorbance and fluorescence 
detection for baseline, tryptophan depleted and tryptophan loaded samples.  3-
hydroxykynurenine, 3-hydroxyanthranilic acid and xanthurenic acid levels were measured 
in baseline samples and following tryptophan loading using RP-HPLC with 
electrochemical detection as described in Section 3.5.3.    
5.2.3  QUIN by GC-MS 
Samples of EDTA plasma were analysed for QUIN by West Park Biochemistry 
Laboratories by the method described in the appendix for baseline, tryptophan depleted 
and tryptophan loaded samples.   
5.2.4  Neopterin and Lipid Peroxidation 
Neopterin and lipid peroxidation were determined by Dr C.M. Forrest at the University of 
Glasgow using the methods described in the appendix.  Only baseline and loaded serum 
samples were analysed. 
150  
5.2.5  Clinical Analyses - ESR and CRP 
ESR and CRP, standard clinical analyses, were determined for only the first baseline 
sample at Epsom General Hospital.  The methods are briefly described in the appendix. 
5.3  Data Analysis and Statistics 
GraphPad InStat statistics package was used for all the statistical analysis, except for the 
correlations where NCSS97 software was used. 
Comparisons between patients and controls were made using unpaired two-tailed t tests. A 
Welch correction or a non-parametric Mann-Whitney test was used if necessary.   
A repeated measures ANOVA, followed by a Student-Newman-Keuls multiple comparison 
post-test, was used when comparing measurements from the same patients or control 
subjects at different time points during the depletion or loading protocols.  Depletion 
samples were compared with baseline 1, with a separate ANOVA for baseline 2 and loaded 
samples.  Two separate ANOVAs were required as the extremely large differences 
between depleted levels and loaded levels may mask significant differences between 
baseline and depleted samples.  Comparison of original baseline and baseline 24 hours 
after depletion for the same patients or control subjects was determined using a paired two-
tailed t test.   
The ratios between different kynurenines were also calculated to demonstrate how much 
metabolite was produced from its substrate, which may indicate the activity of the enzyme 
catalysing the reaction.  Differences between brain injury patients and controls in the ratios 
of QUIN: kynurenic acid and 3-hydroxykynurenine: kynurenic acid also show if the 
pathway has changed to favour one route more than another.  In addition, the ratios are 
advantageous in that they indicate pathway activity, rather than actual levels of metabolites 
which can be quite variable in human subjects.  Ratios were analysed using the same 
statistical tests as the metabolites themselves. 
To overcome any masking of significant differences due to the natural variability between 
human subjects, the changes in the levels of kynurenines from baseline to depleted or 
loaded for individual subjects were calculated.  The mean change for control subjects and 
patients with brain injury have then been compared at each time point using a two-tailed t 
test.   
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In all cases a significance threshold of 5% (P<0.05) was employed.   
Correlations between tryptophan, kynurenines, ratios of kynurenines, neopterin, lipid 
peroxidation, ESR and CRP were assessed using a correlation matrix.  Spearman 
correlations were used as some of the data were non-parametric.  
5.4  Results 
5.4.1  Kynurenines 
5.4.1.1  Tryptophan 
There was no difference between the baseline levels of tryptophan for control and patient 
samples at both baseline 1 and 2 (Figure 5-1A).  At 5 hours after tryptophan depletion, 
there was a significantly higher level of tryptophan in the patient samples compared with 
the controls.  Tryptophan levels were similar for patients and controls by 7 hours after 
depletion (Figure 5-1A).  After tryptophan loading, patient tryptophan levels were 
significantly higher at both 5 and 7 hours after loading compared with the controls (Figure 
5-1B). 
The tryptophan depleting mixture, as expected, produced a major reduction of blood 
tryptophan concentrations at both 5 and 7 hours for controls and patients (Figure 5-1A).  At 
the second baseline, 24 hours after tryptophan depletion, tryptophan levels had returned to 
levels similar to the original baseline levels for both controls and patients.  Following the 
tryptophan load, both patients and controls showed a large increase in tryptophan levels at 
5 and 7 hours.  There were also significant decreases in tryptophan concentrations between 
5 and 7 hours after loading for both controls and patients (both p<0.001).   
When the changes in tryptophan levels on depletion were compared, tryptophan levels 
decreased to a similar extent for patients as for controls (Figure 5-2A).  However, on 
loading, the levels of tryptophan increased more for the patients than the controls (Figure 
5-2B).  This suggests that when given a tryptophan load, the patients maintain a higher 
proportion of the tryptophan in their blood whereas in controls more of the tryptophan load 
is metabolised.      
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5.4.1.2  Kynurenine 
The initial baseline kynurenine levels were significantly higher for patients than for 
controls and continued to be higher in patients at five hours after depletion (Figure 5-3A).  
At 7 hours after depletion, there was no difference between patients and controls, nor was 
there any difference at the second baseline.  The levels of kynurenine remained similar 
between patients and controls after loading, suggesting that the higher levels of tryptophan 
in the patients is not being metabolised to kynurenine(Figure 5-3B).  
As with tryptophan, the levels of kynurenine fell following depletion and increased after 
loading for both controls and patients.  No significant difference between the original 
baseline sample and the second baseline sample was observed for either controls or 
patients.  There was a decrease in kynurenine levels between 5 and 7 hours after loading, 
however this was only significant for the controls (p<0.001). 
When the changes in kynurenine concentrations were examined, there was a significantly 
greater decrease in kynurenine levels for patients than controls at 7 hours after depletion 
(Figure 5-4A).  Changes after loading were similar for controls and patients (Figure 5-4B). 
5.4.1.3  K:T Ratio 
As shown in Figure 5-5A, the K:T ratio at baseline 1 was significantly higher in patients 
than in control subjects and remained higher 5 hours after depletion.  This suggests that the 
kynurenine pathway was activated in the patient group, as the K:T ratio indicates 
IDO/TDO activity.  However, on loading, patients had a lower K:T ratio compared with 
controls, which was significant at 7 hours after loading, suggesting that there was more 
metabolism via the kynurenine pathway in the controls compared with the patients after 
loading.  The K:T ratios after loading were significantly higher for both patients and 
controls.     
5.4.1.4  Kynurenic Acid 
Brain injury patients had a significantly lower level of the neuroprotectant KYNA in the 
initial baseline blood samples compared to controls, which still appeared to be lower, but 
not significantly, at baseline 2 (Figure 5-6A).  Otherwise, KYNA levels were not 
significantly different between patients and controls throughout the depletion and loading 
protocol (Figure 5-6). 
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As with tryptophan and kynurenine, the levels of KYNA decreased following depletion 
and increased after loading for both patients and controls.  There was a decrease in KYNA 
levels between 5 and 7 hours after loading, however this was only significant for the 
controls (p<0.001). 
When the changes in KYNA were examined, there was significantly less of a decrease in 
KYNA for patients compared with controls following depletion at both 5 and 7 hours 
(Figure 5-7A), due to the lower level of baseline KYNA.  The increases in KYNA on 
loading were not significantly different between patients and controls (Figure 5-7B). 
5.4.1.5  Kynurenic Acid: Kynurenine Ratio  
The KYNA: KYN ratio was significantly lower for patients at baseline 1 compared with 
controls suggesting that a lower proportion of the available kynurenine was being 
converted into KYNA in the patients by the KAT enzymes (Figure 5-8A).  There was a 
similar trend at baseline 2 but this was not significant.  However, following loading, the 
KYNA: KYN ratio was higher in patients, becoming significant after 7 hours (Figure 5-
8B).   
For controls, the KYNA: KYN ratio decreased on depletion (significant at 7 hours) and 
increased on loading (significant at 5 hours).  The KYNA: KYN ratios for patients 
remained low until after loading when there was a large increase, suggesting a significant 
activation of KAT after loading.   
5.4.1.6  3-Hydroxykynurenine 
Levels of 3HKYN became undetectable during the tryptophan depletion protocol in control 
and patient groups, so only baseline 2 and tryptophan loaded samples were assessed.   
Baseline levels of 3HKYN and levels 5 hours after loading were significantly lower in the 
patients compared with the controls (Figure 5-9A).   
Compared with baseline samples, 5 hours after tryptophan loading there was a significant 
increase in 3HKYN levels in patients and controls.  There was a decrease in 3HKYN levels 
between 5 and 7 hours after loading, being significant only for the controls (p<0.05) 
(Figure 5-9A). 
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The change in the concentrations of 3HKYN at 5 hours after loading was significantly less 
for the patients than for the controls, but there was no significant difference at 7 hours after 
loading (Figure 5-10A). 
5.4.1.7  3-Hydroxyanthranilic Acid 
Levels of 3HANA also became undetectable during the tryptophan depletion protocol in 
control and patient groups, therefore only baseline 2 and tryptophan loaded samples were 
assessed.  Patients had lower baseline levels of 3HANA compared with controls, which 
remained significantly lower at 5 hours after loading (Figure 5-9B).   
At both 5 and 7 hours after tryptophan loading, the 3HANA levels were significantly 
increased for both the patient and control groups (Figure 5-9B), with a decrease between 5 
and 7 hours (p<0.01 for both patients and controls). 
The change in 3HANA levels due to tryptophan loading showed no significant differences 
between patients and controls (Figure 5-10B). 
5.4.1.8  3-Hydroxykynurenine: Kynurenine ratio 
The ratios of 3HKYN: KYN were significantly lower at baseline and at 5 hours after 
loading for patients compared with controls (Figure 5-11A), suggesting that patients 
produce less 3HKYN from the available kynurenine than controls. 
5.4.1.9  3-Hydroxykynurenine: Kynurenic Acid ratio 
As for the ratios of 3HKYN: KYN, there was a lower ratio of 3HKYN: KYNA for patients 
compared with controls at baseline and at 5 hours after loading (Figure 5-11B). 
5.4.1.10  3-Hydroxyanthranilic Acid: 3-Hydroxykynurenine ratio 
There were no significant differences between the ratios of 3HANA: 3HKYN  for patients 
and controls at baseline or at 5 or 7 hours after loading. 
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5.4.1.11  Quinolinic Acid 
The large variability in the QUIN concentrations for both controls and patients resulted in 
no significant differences between patients and controls at any time point during the 
depletion and loading protocols (Figure 5-12).   
Levels of QUIN appeared to be decreasing slowly for both patients and controls after 
tryptophan depletion, with levels at their lowest at 24 hours after depletion, the time point 
for the second baseline (Figure 5-12A).  Levels of tryptophan, kynurenine and KYNA all 
decreased much more quickly after depletion, with significant decreases at 5 hours after 
depletion, with levels of these compounds returning to baseline at 24 hours after depletion.  
There was a significant increase in QUIN levels at both 5 and 7 hours after loading for 
controls and at 7 hours for patients.  QUIN concentrations remained similar between 5 and 
7 hours after loading for the controls, but appeared to increase for the patients.  This 
increase however was not significant.  All the other kynurenines measured showed a 
decrease between 5 and 7 hours after loading.  These results suggests that there is a lag 
time for QUIN responses to depletion and loading compared to the other kynurenines.  
In an attempt to reduce the large variability in the raw QUIN data, the change in QUIN 
levels were examined and compared.  There were still no significant differences between 
patients and controls (Figure 5-13). 
5.4.1.12  Quinolinic Acid: 3-Hydroxyanthranilic Acid ratio 
The ratio of QUIN: 3HANA appeared higher in patients compared with controls at 
baseline and after loading, but this was only significant at 7 hours after loading (Figure 5-
14). This suggests more activity of the enzyme, 3HAO, which converts 3HANA to QUIN, 
for patients after loading.   
5.4.1.13  Quinolinic Acid: Kynurenic Acid ratio 
The ratios of QUIN: KYNA were calculated over the depletion and loading protocols.  
There were no significant differences between patients and controls at any of the time 
points, but it was noted that the initial QUIN: KYNA ratio was higher in patients than 
controls at the initial baseline and that on loading, the ratios were lower for patients than 
controls (Figure 5-15). 
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5.4.1.14  Neopterin 
At baseline, the level of neopterin was significantly higher for patients than for controls 
(Figure 5-16A).  At 5 and 7 hours after loading, neopterin levels were similar for patients 
and controls.  Unexpectedly, neopterin levels in the controls at both 5 and 7 hours after 
loading were significantly higher than at baseline, suggesting an increase in inflammation 
in healthy controls after tryptophan loading.  There was no change in neopterin levels after 
loading for the patients. 
5.4.1.15  Lipid Peroxidation 
Patients had significantly higher levels of lipid peroxidation products than controls at 
baseline and at both 5 and 7 hours after loading (Figure 5-16B).  Similar to the neopterin 
results, the levels of lipid peroxidation increased in the controls after tryptophan loading, 
being significantly higher than baseline levels at both 5 and 7 hours after loading.  Patient 
lipid peroxidation levels did not significantly increase after loading. 
5.4.1.16  ESR and CRP 
The ESR was significantly elevated in patients compared to controls at baseline (Figure 5-
17A).  The concentration of CRP in the blood of patients was significantly higher than 
those of controls at baseline (Figure 5-17B). 
5.4.1.17  Correlations  
As there were only 15 brain injury patients and 15 control subjects, fewer significant 
correlations were expected than if there had been larger groups.  However there were many 
significant correlations between the kynurenines as they are all part of the dynamic 
kynurenine pathway.  The most interesting correlations observed, which may have 
implications for understanding the biology of the kynurenines are discussed. 
For brain injury patients at baseline 1, there was a correlation between the K:T ratio and 
ESR (p<0.05) and a negative correlation between CRP and the KYNA: KYN ratio 
(p<0.01).  The K:T ratio correlated negatively with the KYNA: KYN ratio at 5 hours after 
depletion (p<0.05).  The K:T ratio correlated with neopterin at baseline 2 (p<0.05).  These 
results suggest activation of IDO and inhibition of KAT activity.  In the patient group, 
neopterin correlated with QUIN (p<0.05) at 5 hours after loading and with kynurenine 
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(p<0.05) at 7 hours after loading.  In controls, the K:T ratio correlated with CRP (p<0.05) 
at baseline. 
Within the brain injury patient group, at 5 hours after loading there were positive 
correlations for the K:T ratio with KYNA (p<0.01), with 3HKYN (p<0.05) and with QUIN 
(p<0.05).  Similar correlations were also observed at 7 hours after loading (K:T ratio with 
KYNA p<0.01, with 3HKYN p<0.05, with QUIN p<0.01), but no such correlations were 
found for the baseline samples.  For controls after loading, there were similar correlations 
between K:T ratio and KYNA (p<0.001 at 5 hours and p<0.01 at 7 hours) and K:T and 
3HKYN (p<0.05 at 5 hours and p< 0.001 at 7 hours), but no correlation with QUIN at 
either time point. 
For the patients and not the controls, the K:T ratio after loading also correlated with the 
QUIN: 3HANA ratio (p<0.05 at 5 hours and p<0.01 at 7 hours).  At 7 hours after loading 
but not at 5 hours, QUIN correlated positively with 3HKYN (p<0.05) and 3HANA 
(p<0.001). 
Lipid peroxidation correlated negatively with 3HANA at 5 hours after loading in patients 
(p<0.05) whereas there was a positive correlation in the controls at 5 hours (p<0.05).   
The ages of the patients correlated with ESR (p<0.01) at baseline 1 and with neopterin at 
baseline 2 (p<0.05) and at 5 and 7 hours after loading (p<0.01 for both).  In the controls, 
age correlated with neopterin only at 5 hours after loading (p<0.05). 
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Figure 5-1  Effect of tryptophan depletion and loading on tryptophan levels in the 
plasma of controls and Brain Injury patients, (A) at the initial baseline 1, following 
depletion of tryptophan and at baseline 2 (24h after depletion) and (B) at baseline 2 and 
following tryptophan loading.  Values are mean ± SEM.  Significant differences between 
patients and controls: ** p<0.01, *** p<0.001.  Effect of depletion compared with baseline 
1, effect of loading compared with baseline 2 or differences between baselines 1 and 2: 
+++ p<0.001. 
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Figure 5-2  Changes in the levels of tryptophan following tryptophan depletion (A) or 
loading (B) for plasma from Brain Injury patients and controls.  Dep1 is 5 hours after 
depletion, dep2 is 7 hours after depletion, load1 is 5 hours after loading and load2 is 7 
hours after loading.  Values are mean ± SEM for differences between the depleted or 
loaded sample and the relevant baseline.  Significant differences between patients and 
controls:  ** p<0.01. 
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Figure 5-3  Effect of tryptophan depletion and loading on kynurenine levels in the 
plasma of controls and Brain Injury patients, (A) at the initial baseline 1, following 
depletion of tryptophan and at baseline 2 (24h after depletion) and (B) at baseline 2 and 
following tryptophan loading.  Values are mean ± SEM.  Significant differences between 
patients and controls: * p<0.05, ** p<0.01.  Effect of depletion compared with baseline 1, 
effect of loading compared with baseline 2 or differences between baselines 1 and 2: ++ 
p<0.01, +++ p<0.001.  
dep1 - base1 dep2 - base1
c
h
a
n
g
e
 
i
n
 
k
y
n
u
r
e
n
i
n
e
 
(
μ
M
)
-2.5
-2.0
-1.5
-1.0
-0.5
Controls
Patients
load1 - base2 load2 - base2
c
h
a
n
g
e
 
i
n
 
k
y
n
u
r
e
n
i
n
e
 
(
μ
M
)
0
20
40
60
80
B
A
 **
 
Figure 5-4  Changes in the levels of kynurenine following tryptophan depletion (A) or 
loading (B) for plasma from Brain Injury patients and controls.  Dep1 is 5 hours after 
depletion, dep2 is 7 hours after depletion, load1 is 5 hours after loading and load2 is 7 
hours after loading.  Values are mean ± SEM for differences between the depleted or 
loaded sample and the relevant baseline.  Significant differences between patients and 
controls:  ** p<0.01. 
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Figure 5-5  Effect of tryptophan depletion and loading on kynurenine:tryptophan (K:T) 
ratio in the plasma of controls and Brain Injury patients, (A) at the initial baseline 1, 
following depletion of tryptophan and at baseline 2 (24h after depletion) and (B) at 
baseline 2 and following tryptophan loading.  Values are mean ± SEM.  Significant 
differences between patients and controls: * p< 0.05, ** p< 0.01.  Effect of depletion 
compared with baseline 1, effect of loading compared with baseline 2 or differences 
between baselines 1 and 2: + p<0.05, +++ p<0.001. 
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Figure 5-6  Effect of tryptophan depletion and loading on kynurenic acid levels in the 
plasma of controls and Brain Injury patients, (A) at the initial baseline 1, following 
depletion of tryptophan and at baseline 2 (24h after depletion) and (B) at baseline 2 and 
following tryptophan loading.  Values are mean ± SEM.  Significant differences between 
patients and controls: ** p< 0.01.  Effect of depletion compared with baseline 1, effect of 
loading compared with baseline 2 or differences between baselines 1 and 2: + p<0.05, +++ 
p<0.001. 
164  
dep1 - base1 dep2 - base1
c
h
a
n
g
e
 
i
n
 
k
y
n
u
r
e
n
i
c
 
a
c
i
d
 
(
n
M
)
-50
-40
-30
-20
-10
Controls
Patients
load1 - base2 load2 - base2
c
h
a
n
g
e
 
i
n
 
k
y
n
u
r
e
n
i
c
 
a
c
i
d
 
(
n
M
)
0
2000
4000
6000
8000
10000
B
A
 **  **
 
Figure 5-7  Changes in the levels of kynurenic acid following tryptophan depletion (A) 
or loading (B) for plasma from Brain Injury patients and controls.  Dep1 is 5 hours after 
depletion, dep2 is 7 hours after depletion, load1 is 5 hours after loading and load2 is 7 
hours after loading.  Values are mean ± SEM for differences between the depleted or 
loaded sample and the relevant baseline.  Significant differences between patients and 
controls:  ** p<0.01. 
 
165  
baseline 1 dep +5h dep +7h baseline 2
K
Y
N
A
:
 
K
Y
N
 
r
a
t
i
o
0.00
0.02
0.04
0.06
0.08
0.10
0.12
Controls
Patients
baseline 2 load +5h load +7h
K
Y
N
A
:
 
K
Y
N
 
r
a
t
i
o
0.00
0.02
0.04
0.06
0.08
0.10
0.12
0.14
  +
    ++
   +++
  ++
B
A
 **
  *
 ++
Figure 5-8  Effect of tryptophan depletion and loading on kynurenic acid: kynurenine 
ratio (KYNA: KYN) in the plasma of controls and Brain Injury patients, (A) at the initial 
baseline 1, following depletion of tryptophan and at baseline 2 (24h after depletion) and 
(B) at baseline 2 and following tryptophan loading.  Values are mean ± SEM.  Significant 
differences between patients and controls: *  p<0.05, ** p<0.01.  Effect of depletion 
compared with baseline 1, effect of loading compared with baseline 2 or differences 
between baselines 1 and 2: + p<0.05, ++ p<0.01, +++ p<0.001.  (Many control kynurenine 
levels were 0 at 5h after depletion and KYNA: KYN ratios could not be calculated, 
therefore were omitted from the graph). 
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Figure 5-9  Effect of tryptophan loading on the levels of 3-hydroxykynurenine (A) and 
3-hydroxyanthranilic acid (B) in the plasma of controls and Brain Injury patients at 
baseline 2 (24h after depletion) and at 5 and 7 hours after loading.  Values are mean ± 
SEM.  Significant differences between patients and controls: * p<0.05, ** p<0.01.  Effect 
of loading compared with baseline 2: ++ p<0.01, +++ p<0.001. 
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Figure 5-10  Changes in the levels of 3-hydroxykynurenine (A) and 3-hydroxyanthranilic 
acid (B) following tryptophan loading for plasma from Brain Injury patients and controls.   
Load1 is 5 hours after loading and load2 is 7 hours after loading.  Values are mean ± SEM 
for differences between the loaded sample and baseline 2.  Significant differences between 
patients and controls:  * p<0.05. 
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Figure 5-11  Effect of tryptophan loading on 3-hydroxykynurenine: kynurenine 
(3HKYN: KYN) ratio (A) and 3-hydroxykynurenine: kynurenic acid (3HKYN: KYNA) 
ratio (B) in the plasma of controls and Brain Injury patients.  Values are mean ± SEM.  
Significant differences between patients and controls: * p< 0.05. 
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Figure 5-12  Effect of tryptophan depletion and loading on the levels of quinolinic acid 
in the plasma of controls and Brain Injury patients, (A) at the initial baseline 1, following 
depletion of tryptophan and at baseline 2 (24h after depletion) and (B) at baseline 2 and 
following tryptophan loading.  Values are mean ± SEM.  No significant differences 
between patients and controls.  Effect of depletion compared with baseline 1, effect of 
loading compared with baseline 2 or differences between baselines 1 and 2: ++ p<0.01. 
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Figure 5-13    Changes in the levels of QUIN following tryptophan depletion (A) or 
loading (B) for plasma from Brain Injury patients and controls.  Dep1 is 5 hours after 
depletion, dep2 is 7 hours after depletion, load1 is 5 hours after loading and load2 is 7 
hours after loading.  Values are mean ± SEM for differences between the depleted or 
loaded sample and the relevant baseline.  No significant differences between patients and 
controls. 
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Figure 5-14  Effect of tryptophan loading on QUIN: 3-hydroxyanthranilic acid ratio 
(QUIN: 3HANA) in the plasma of controls and Brain Injury patients.  Values are mean ± 
SEM.  Significant differences between patients and controls: * p< 0.05. 
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Figure 5-15  Effect of tryptophan depletion and loading on QUIN: kynurenic acid ratio 
(QUIN: KYNA) in the plasma of controls and Brain Injury patients, (A) at the initial 
baseline 1, following depletion of tryptophan and at baseline 2 (24h after depletion) and 
(B) at baseline 2 and following tryptophan loading.  Values are mean ± S E M .   N o  
significant differences between patients and controls.  Effect of depletion compared with 
baseline 1, effect of loading compared with baseline 2 or differences between baselines 1 
and 2: ++ p<0.01, +++ p<0.001.   
173  
baseline 2 load +5h load +7h
n
e
o
p
t
e
r
i
n
 
(
n
g
/
m
l
)
0
1
2
3
4
Controls
Patients
baseline 2 load +5h load +7h
l
i
p
i
d
 
p
e
r
o
x
i
d
a
t
i
o
n
 
(
μ
M
)
0
1
2
3
   +++
++
B
A
  ++
  *
***
  ***
 ***
  +++
 
Figure 5-16  Effect of tryptophan loading on the levels of neopterin (A) and lipid 
peroxidation products (B) in the plasma of controls and Brain Injury patients at baseline 2 
(24h after depletion) and at 5 and 7 hours after loading.  Values are mean ± SEM.   
Significant differences between patients and controls: *  p<0.05, *** p<0.001.  Effect of 
loading compared with baseline 2: ++ p<0.01, +++ p<0.001. 
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Figure 5-17  Comparison of ESR and CRP between Brain Injury patients and controls at 
baseline.  Values are mean ± SEM.  Significant differences: * p<0.05,  ** p<0.01.
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5.5  Discussion 
5.5.1  Tryptophan Depletion and Loading 
The depletion and loading protocols produced similar effects in the brain injury patients as 
they did for the HD patients, with QUIN levels in the blood taking longer to respond to the 
depletion or loading than the other kynurenines.  It was interesting that QUIN levels 
appeared to be higher in brain injury patients than in controls at 7 hours after loading, as 
they did in HD patients, but in neither case were these increases significant due to the large 
variability in the QUIN results.  In retrospect, it would have been useful to measure the 
QUIN levels in the blood at later time points, but no further blood samples had been taken. 
Even without an inflammatory stimulus, tryptophan loading activates the kynurenine 
pathway in controls, suggesting increased activity of TDO in the liver.  Indeed, tryptophan 
has been shown to activate TDO (Schutz et al., 1972).  Tryptophan loading for the patients 
showed increased metabolism through all the branches of the pathway, as the K:T ratio 
correlated with KYNA, 3HKYN and QUIN.  For controls after loading, there were similar 
correlations between K:T and 3HKYN and KYNA but interestingly no correlations with 
QUIN, suggesting restricted production of the neurotoxin, QUIN, in healthy controls.  
5.5.2  Tryptophan, Kynurenine and IDO/TDO Activity 
There was no difference between the levels of baseline tryptophan in patients and controls, 
in agreement with Aquilani et al. (2003), where the patient group had been in hospital for 
two months after severe TBI.  In our study, the higher level of tryptophan at 5 hours after 
depletion and the larger changes in tryptophan on loading for the patients suggest that the 
brain injury patients used less tryptophan for other metabolic processes (such as protein 
synthesis) than the controls. 
The higher K:T ratios for patients at baseline and at 5 hours after tryptophan depletion 
suggest increased activity of IDO, which occurs in conjunction with increased levels of the 
inflammatory marker, neopterin.  Patients with increased elevation in their inflammatory 
status demonstrated greater activation of the pathway, as the patient group showed 
significant correlations between the K:T ratio and ESR at baseline 1 and between the K:T 
ratio and neopterin at baseline 2.  Elevated K:T ratios have also been associated with a 
reduction in cognitive performance of patients with Alzheimer’s disease (Widner et al., 
2000). 
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However, at 7 hours after loading, there was a lower K:T ratio in the patients compared 
with the controls, which was due to the patients’ higher tryptophan levels.  As kynurenine 
levels were similar after loading, this may suggest the tryptophan was at such a high level 
in both patients and controls that IDO/TDO was working at its maximum rate for both 
groups.  There was still a relationship between inflammatory status and increased 
activation of the pathway for the patients, as there were correlations between neopterin and 
both kynurenine and QUIN after loading.   
5.5.3  Kynurenic Acid and KAT Activity 
For patients with chronic brain injury, the lower level of the neuroprotectant KYNA in 
their blood may have contributed to the brain damage in these patients and may be a factor 
in preventing recovery or causing further brain damage.  The importance of KYNA was 
demonstrated in two studies using a rat model of TBI, as KYNA treatment dramatically 
reduced the cognitive dysfunction (Smith et al., 1993) and reduced the neuronal damage in 
the hippocampus (Hicks et al., 1994).   
Together with the lower levels of KYNA, there was also a significantly lower KYNA: 
KYN ratio for patients at the initial baseline, suggesting low KAT activity with little 
conversion of kynurenine to KYNA compared with controls.  However, after loading, the 
KYNA: KYN ratio was higher in patients than controls, becoming significant at 7 hours 
after loading, suggesting that with a tryptophan load, KAT becomes more activated in 
patients than in controls.  The changes in KAT activity in patients throughout the depletion 
and loading protocols were the opposite to those of IDO/TDO activity.  At baseline and 5h 
after depletion, the increased kynurenine present in patients and, hence, the increased K:T 
ratios, may be partly due to very low activity of KAT.  Indeed, there was a negative 
correlation between the K:T ratio and the KYNA: KYN ratio at 5 hours after depletion for 
patients.  The KYNA: KYN ratio also correlated negatively with CRP.  As the K:T ratio 
correlated with the inflammatory markers, neopterin and ESR at baselines, increased 
inflammation together with increased pathway activity is linked with a decrease in the 
production of KYNA from kynurenine.  The lower K:T ratio in patients with tryptophan 
loading may indeed be partly a reflection of the higher KYNA: KYN ratio, as more 
kynurenine was converted to KYNA.  It is interesting that significant effects in both ratios 
are seen only at 7 hours following the tryptophan load, showing that differences in enzyme 
activities, between patients and controls, are becoming more pronounced at 7 hours. These 
results suggest that for patients with chronic brain injury, a diet high in tryptophan would 
177  
stimulate production of the neuroprotectant, KYNA, and may have a contribution in 
limiting further brain damage. 
5.5.4  3-Hydroxykynurenine and 3-Hydroxyanthranilic acid and 
Oxidative Stress 
Increased levels of 3HKYN have been shown in the brains of HD patients, but not in 
Alzheimer’s disease brains (Pearson and Reynolds, 1992).  Both 3HKYN and 3HANA can 
generate reactive oxygen species such as hydrogen peroxide, causing oxidative stress, 
resulting in neuronal damage and apoptosis (Eastman and Guilarte, 1990, Okuda et al., 
1996).  However, in this study the chronic brain injury patients showed lower levels of 
both 3HKYN and 3HANA than controls at baseline and 5 hours after loading, although 
levels of lipid peroxidation products were higher.  In addition, the ratios of 3HKYN: KYN 
and 3HKYN: KYNA were both lower for patients at baseline and at 5 hours after loading, 
suggesting that for patients, less 3HKYN was being produced from kynurenine and that 
there was even less 3HKYN being produced compared to the other branch of the pathway 
producing KYNA, where activity was also lower for patients. 
Both 3HKYN and 3HANA could have autoxidised, resulting in the formation of reactive 
oxygen species (Dykens et al., 1987; Ishii et al., 1992; Hiraku et al., 1995), which may 
have contributed to the increased oxidative stress.  The low levels of 3HKYN and 3HANA 
may suggest that these metabolites have been metabolised more quickly than they were 
produced. 
Alternatively, the low levels of 3HKYN and 3HANA in the patient group may be a 
protective compensatory response to the presence of a high level of reactive oxygen 
species.  Another explanation may be that as 3HKYN and 3HANA are redox-active, they 
can act as antioxidants, which is dependent on the presence of other redox-active 
compounds, such as transition metal ions (Christen et al., 1990; Leipnitz et al., 2007).  The 
lower levels of 3HKYN and 3HANA present in the blood of brain injury patients would 
then suggest that there was less antioxidant activity to inhibit the oxidative stress.  These 
hypotheses suggest that mechanisms other than the direct generation of reactive oxygen 
species from the kynurenine pathway metabolites may cause oxidative stress in chronically 
brain injured patients.  Such other mechanisms may include macrophages and microglia 
releasing free radicals or activation of NMDA receptors with calcium influx into the cells, 
resulting in the production of reactive oxygen species (Sahuquillo et al., 2001).   
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5.5.5  Quinolinic Acid 
For TBI, Sinz et al. (1998) reported a large increase in QUIN in the CSF in humans.  
Following transient cerebral ischaemia in the gerbil, increases in IDO activity and QUIN 
levels were measured in the brain but blood QUIN and L-kynurenine levels remained 
unchanged (Saito et al., 1993b).  In our study, no significant differences in QUIN between 
patients and controls were observed throughout, although there was a trend showing that 
QUIN may be accumulating in patients after loading.  Indeed, the ratio of QUIN: 3HANA 
was significantly higher at 7 hours after loading in the patients, showing increased 
metabolism of QUIN from its substrate, 3HANA.  It may have been expected that there 
would be lower levels of QUIN produced after loading for the patients, as there were 
significantly lower levels of its precursors, 3HKYN and 3HANA, at baseline 2 and 5 hours 
after loading.  This may have been overcome by increased activity of 3HAO, as shown by 
the trend for increased QUIN: 3HANA ratios in patients.  Although there was no increase 
in QUIN levels for the patients, the QUIN: KYNA ratio was slightly higher for patients 
than controls at the initial baseline, although this was not significant, suggesting there may 
have been a slight shift towards QUIN production in the patients. 
The changes in the levels of QUIN in response to tryptophan depletion and loading appear 
to occur over a longer timescale than for the other kynurenines.  This can account for the 
significantly lower ratio of QUIN: KYNA at baseline 2 and at 5 hours after loading for 
both patients and controls.  KYNA but not QUIN levels have returned to baseline levels 
following depletion by baseline 2 and KYNA levels but not QUIN are close to maximum 
at 5 hours after loading.  This suggests that QUIN formation occurs more slowly than the 
other kynurenines, which may be associated with the activity of the enzyme, 3HAO, which 
synthesises QUIN. 
After loading, the K:T ratio correlated with QUIN and the QUIN: 3HANA ratio, 
suggesting that patients with higher activation of the pathway also produced higher levels 
of QUIN.  Higher K:T ratios are associated with a higher inflammatory status and 
interestingly neopterin also correlated with QUIN at 5 hours after loading for the patients. 
These effects were observed after loading, which may be expected as loading produced 
increased levels of all the kynurenine metabolites.  As these correlations were not observed 
for the controls, these results are consistent with the view that inflammation induces the 
kynurenine pathway which produces the neurotoxin, QUIN. 
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5.5.6  Inflammation: Neopterin, ESR and CRP 
Levels of neopterin, ESR and CRP were significantly increased at baseline in patients with 
brain injury compared with controls, demonstrating persistent inflammation in these 
patients several years after the brain injury.  During the first week after TBI, Lenzlinger et 
al. (2001) showed an increase in serum neopterin concentrations to a maximum of approx. 
4.5ng/ml.  After maintaining this high neopterin level for 1 week, patients showed a 
decrease in the levels of neopterin during the third week to just above 3ng/ml, although by 
the end of the third week neopterin levels were still slightly elevated in patients compared 
with their upper normal limit (2.5ng/ml).  However, for CSF, once increased, high 
neopterin levels were maintained throughout the second 2 weeks of the study.  It is 
interesting that in our study with patients who had sustained the brain injury at least 1 year 
previously, the mean serum neopterin level was still at 3.3ng/ml for patients compared 
with 2.2ng/ml in controls at baseline.  Inflammation is often associated with oxidative 
stress but no correlations between neopterin and lipid peroxidation were observed. 
5.5.7    Lipid Peroxidation and Oxidative Stress 
The levels of lipid peroxidation products, malondialdehyde and 4-hydroxynonenal, 
continued to be elevated for the patients with chronic brain injury, where the injury was 
sustained at least one year prior to this study.  In contrast, early onset lipid peroxidation 
after severe human TBI has been demonstrated in the CSF (Cristofori et al., 2001).  The 
levels of the lipid peroxidation product, malondialdehyde, were high for patients on 
admission (on average 3 hours after trauma), but by 48 hours levels had reduced 
considerably but were still higher than in controls.  CSF samples from infants and children 
who had suffered severe TBI showed increased markers of oxidative stress at maximum 
levels at day 1 and a reduced total antioxidant reserve maximal on the last time point at 5-7 
days (Bayir et al., 2002).  Pratico et al. (2002) demonstrated that moderate experimental 
TBI induced widespread brain lipid peroxidation, which was accompanied by a similar 
increase in lipid peroxidation in urine and plasma.  
5.5.8  Conclusions 
Patients with severe chronic brain injury, sustained between 1 and 35 years prior to this 
study, showed the presence of inflammation and an activated kynurenine pathway.  The 
correlations show that increases in inflammatory indicators (neopterin, ESR and CRP) 
were linked to increases in kynurenine pathway metabolites for the brain injury patients 
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and not for the controls, consistent with the view that activation of the kynurenine pathway 
is a consequence of inflammation. 
Activation of the kynurenine pathway, determined by the increased K:T ratio, was 
demonstrated at the initial baseline and at 5 hours after depletion.  Following the depletion 
protocol, the second baseline sample showed no significant increase in the K:T ratio for the 
brain injury patients.  The lower KYNA level at the initial baseline together with low 
KYNA: KYN ratios indicates low activity of KAT.  However, after loading, the patients 
showed lower K:T ratios and increased KAT activity, suggesting that tryptophan loading 
has a neuroprotective effect.  The trend for accumulating QUIN after loading indicates that 
the neuroprotective benefit of increased KAT activity may be outweighed by the 
production of the neurotoxin, QUIN.    
The levels of 3HKYN and 3HANA were significantly lower in patients with chronic brain 
injury than in controls.  These effects were continued after loading and were similar to 
those shown with the HD patients.  These metabolites are redox-active and therefore are 
likely to influence the oxidative stress in these patients, especially at their elevated levels 
after loading.  The levels of lipid peroxidation were much higher in patients compared with 
controls, but there were no significant increases in lipid peroxidation after loading. 
  
6  Stroke 
6.1  Introduction 
Many patients who experience a stroke suffer consequent brain damage.  One factor which 
may contribute to brain damage is the production of neurotoxic kynurenine metabolites, 
such as the NMDA receptor agonist, QUIN.  The involvement of NMDA receptors in 
stroke is well established as glutamate activation of these receptors results in 
excitotoxicity, a major event for initiating ischaemic cell death (Dirnagl et al., 1999), and 
many NMDA receptor antagonists have shown neuroprotection in animal models of 
ischaemia (McCulloch, 1992; Chen et al., 1993; Pellegrini-Giampietro et al., 1994). 
Enhanced NMDA receptor activity may result from the activation of the kynurenine 
pathway, which has been suggested as a secondary inflammatory response to tissue 
damage in stroke (Heyes and Nowak, 1990), with the levels of kynurenines expected to 
rise in the initial days after the stroke and then plateau or decrease in the following weeks.  
There is evidence for kynurenine pathway activity in ischaemia, as increased levels of IDO 
activity and QUIN concentrations were observed following transient global ischaemia in 
gerbils (Saito et al., 1993b).  In addition, neuroprotection in animal models of ischaemia 
has been demonstrated by increases in the brain levels of KYNA, with decreases in 
3HKYN, 3HANA and QUIN concentrations, when KMO inhibitors were administered 
(Cozzi et al., 1999).  These observations suggest that neurotoxic kynurenines in stroke 
have the potential to induce permanent damage in the penumbra.   
This investigation was undertaken to determine if a stroke causes changes in the 
kynurenine pathway.  If the kynurenines are altered, there is the potential for therapies to 
be developed to interfere with the pathway which could lead to reducing brain damage 
after a stroke.  Blood samples were examined, which may reflect the status of the 
kynurenines in the brain.  As a stroke usually affects one main area of the brain, the 
kynurenines are likely to be higher in this area of damage, and therefore changes in the 
peripheral levels of kynurenines may only be observed to a lesser extent.  The use of blood 
samples, as opposed to post-mortem brains, enabled the levels of the kynurenines to be 
monitored for the same patients at different time points after the stroke.  
In this study, the levels of kynurenine pathway metabolites in the days immediately 
following a stroke, and then after 7 and 14 days were examined.  Tryptophan and 
kynurenine concentrations were determined to demonstrate activation of the kynurenine 
182  
pathway.  Levels of KYNA, ANA and 3HANA were also determined to examine changes 
in different branches of the pathway.  These metabolites were measured in the serum of 
stroke patients and healthy controls.  In addition, to assess the state of inflammation in 
these patients, neopterin concentration and ESR were determined.  Lipid peroxidation 
products, malondialdehyde and 4-hydroxynonenal, were also measured as markers of 
oxidative stress. 
6.2  Methods 
6.2.1  Patients and Samples 
Fifty patients (23 males, 27 females, ages ranging from 54 to 98 (mean ± SEM, 80 ± 1.6)) 
who were diagnosed as having suffered a stroke were recruited from Epsom General 
Hospital, together with thirty five healthy subjects (11 males, 24 females, ages ranging 
from 46 to 81 (mean ± SEM, 67 ± 1.7)) to act as controls.  Patients were recruited after 
obtaining ethical permission from the Ethical Committee of the Epsom and St Helier 
University Hospitals NHS Trust.  Informed written consent was obtained from all subjects 
or from their next of kin. 
Once patients had been recruited for the study, blood samples were taken as soon as 
possible.  Usually the first blood sample was taken one day after the patient had the stroke, 
but for some patients the first blood sample was delayed by a day or two, while the patient 
was being recruited.  For patients, samples taken 1, 2, 3, 4, 7 and 14 days after the stroke 
were assessed.  For control samples, bloods were collected at three time points over a two 
week period (initial sample, after 7 days and after 14 days).  After the blood had been 
allowed to clot, serum samples were prepared by centrifugation at 1000g for 10 minutes, 
and frozen within two hours of venesection.  Samples were kept frozen while being 
transported from Epsom General Hospital to the University of Glasgow and then stored at -
40ºC prior to analysis. 
Patients had a computed tomography (CT) head scan, a few days after the stroke which 
determined whether the stroke was ischaemic or haemorrhagic.  The severity of the stroke 
varied between patients but no established severity scale was used for these patients and 
therefore the most useful way to define severity was to group the patients according to 
whether they died during the study or immediately afterwards (within 3 weeks of the 
stroke), remained in hospital for the duration of the study, or were discharged from hospital 
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within the 14 days of the study.  Data were assessed for differences between ischaemic and 
haemorrhagic stroke and also for differences depending on the severity of the stroke. 
Some patients were given aspirin (75mg daily), which may interfere with the kynurenine 
pathway and therefore this subgroup of patients were compared with others not taking 
aspirin.  A number of patients were also taking glucocorticoids and antidepressants which 
may interfere with the kynurenine pathway.  Again, these subgroups of patients were 
compared with patients not taking these drugs.  Many patients were also taking drugs 
which were considered to have minimal effect on the kynurenine pathway: anticoagulants 
(30%), antibiotics (42%), statins (22%) and drugs to reduce blood pressure (β-blockers, 
ACE inhibitors, diuretics) (48%).  Patients also taking paracetamol as required, asthma 
inhalers, laxatives, drugs for nausea and insomnia were noted. 
6.2.2  Kynurenines by HPLC  
Samples of serum were extracted following the method described in Section 3.1.2.  Ms L 
Oxford helped with some of the extractions.  Tryptophan, kynurenine and KYNA were 
measured by HPLC using the zinc acetate mobile phase, with absorbance and fluorescence 
detection (Section 3.2.3).  3HANA and ANA were determined by fluorescence detection 
following HPLC using the sodium acetate buffer (pH 5.5) as the mobile phase (Section 
3.3.3). 
6.2.3   Neopterin, Lipid Peroxidation and ESR 
Serum samples were analysed using the methods for determining neopterin and the lipid 
peroxidation products, malondialdehyde and 4-hydroxyalkenals described in the appendix 
and were carried out by Dr CM Forrest and Ms L Oxford at the University of Glasgow.  
The ESR was measured at Epsom General Hospital, for patients on admission and for ten 
controls for comparison at day 1.  The method outline is described in the appendix. 
6.2.4  CT scans 
The CT scans for the stroke patients were carried out at Epsom General Hospital by Dr CD 
George, Consultant Radiologist, to determine whether the stroke was ischaemic or 
haemorrhagic.  Wherever possible, the scan was performed between 4-6 days after the 
stroke, as this is the optimal time for an infarct to be observed on the scan.  Scans were not 
conducted on 5 patients, who were too ill for the scan to be performed.   
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Dr George estimated the total volume (ml) of the damaged brain from the CT scans.  This 
was calculated from the infarct dimensions.  If a patient had two acute infarcts, the 
volumes of each were calculated and summed to give a total volume.  With the 
haemorrhagic patients, the total volume for the bleed was estimated. 
6.2.5  Data Analysis and Statistics 
GraphPad InStat statistics package was used for all the statistical analysis, except for the 
correlations where NCSS97 software was used.   
As well as assessing the concentrations of kynurenine metabolites in the blood, the ratios 
between different kynurenines were also calculated.  The K:T ratio and the ANA: KYN 
ratio demonstrate how much metabolite was produced from its substrate, which indicate 
the activity of the enzymes catalysing these reactions.  The ratio of 3HANA: ANA may 
indicate the extent of direct hydroxylation of ANA, although 3HANA is usually produced 
from 3HKYN.  In addition, the ratios are advantageous in that they indicate pathway 
activity, rather than actual levels of metabolites which can be quite variable in human 
subjects.  Ratios were analysed using the same statistical tests as the metabolites 
themselves. 
Comparisons between patients and controls were made using unpaired two-tailed t tests at 
1, 7 and 14 days after the stroke.  A Welch correction or a non-parametric Mann-Whitney 
test was used if necessary.  The sample numbers (n) for controls and patients at each day of 
the study are shown in Table 6-1.  One-way ANOVA, followed by a Student-Newman-
Keuls multiple comparison post test, was used when comparing measurements from 
patients on different days during the study.  When required, a Kruskal-Wallis 
nonparametric ANOVA with a Dunn's multiple comparison post test was used.  The data 
were also tested for linear trends occurring with time after the stroke.  (Ideally a repeated 
measures ANOVA would have been performed but, since several patients did not start the 
study until day 2 or day 3 and several died during the study, this reduced the n numbers 
considerably.  In addition, there were also some samples missing at various time points as 
bloods could not always be collected as patients had gone home or were too ill for blood to 
be taken.  One-way ANOVA was chosen as the most appropriate, as much of the data was 
not repeated measures at the same time points.)  For 32 of the control patients, there were 
blood samples at 1, 7 and 14 days, and therefore repeated measures ANOVA was used to 
assess variability in the controls.  
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For ESR, patients (data available for 28 patients only) were compared with ten controls 
using an unpaired two-tailed t test. 
For both patients and controls, correlations between the concentrations of all the 
kynurenines, neopterin levels, lipid peroxidation measurements, ESR, subject age and CT 
scan lesion volume were made at each time point.  Spearman correlations were used as 
many sets of data were nonparametric.  
Ischaemic and haemorrhagic patients were compared using unpaired two-tailed t tests at 1, 
2, 3, 4, 7 and 14 days after the stroke.  A Welch correction or a nonparametric Mann-
Whitney test was used if necessary.  There were 36 patients who had suffered an ischaemic 
stroke and 9 a haemorrhagic stroke.  The sample numbers at each day of the study for 
ischaemic and haemorrhagic patients are shown in Table 6-1.  At days 1, 7 and 14, the 
ischaemic and haemorrhagic subgroups were compared with controls, using an ANOVA, 
followed by a Student-Newman-Keuls multiple comparison post test.  When required, a 
Kruskal-Wallis nonparametric ANOVA with a Dunn's multiple comparison test was used.  
To check if either subgroup showed any effect over time, ANOVA, followed by a Student-
Newman-Keuls multiple comparison post test was used for parametric data or if 
nonparametric, Kruskal-Wallis ANOVA with a Dunn's multiple comparison test was used.  
Correlations between CT scan lesion volumes for the ischaemic patients only were 
compared to correlations for the complete set of patients.  
Similar comparisons were made when the data was grouped according to severity of the 
stroke.  12 patients died during or immediately after the study (within 3 weeks of the 
stroke), 12 were discharged from hospital during the study and 26 remained in hospital.  
The n numbers for these subgroups of patients are shown in Table 6-1.  The same 
comparisons were made again when ischaemic patients were subgrouped into those taking 
aspirin throughout the study (n=14) and those not taking aspirin (n=11).  The individual 
sample numbers at each day of the study are shown in Table 6-2.  For severity and aspirin 
effects, day 14 (and day 4 for aspirin) results were not assessed as the sample numbers 
were very small. 
Patients taking glucocorticoids (n=5) were compared with those not on glucocorticoids.  
Similarly, patients taking antidepressants (n=6) were compared to the other patients.   
Comparisons were made using unpaired two-tailed t tests at 1, 2, 3, 4, 7 and 14 days after 
the stroke, when the sample number was at least 3.  The sample numbers for patients 
taking these drugs at each day of the study are shown in Table 6-2.  
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In all cases a significance threshold of 5% (p<0.05) was employed. 
 
Table 6-1  Sample numbers at each day of the study for patients and controls, when 
subgrouped into ischaemic and haemorrhagic patients and when subgrouped for severity 
into those who died within 3 weeks of the stroke, patients who remained in hospital and 
those who were able to go home during the 2 week study.  Not applicable as not enough 
data for analysis: na. 
      Patient Subgroups  Patient Subgroups 
  Controls All 
Patients 
Ischaemic Haemorrhagic Died  Stayed 
in 
Hospital 
Home 
TOTAL  35 50  36  9  12  26 12 
             
DAY 1  35 32  25  4  8 15 9 
DAY 2  na 40  30  7  9 19 12 
DAY 3  na 43  31  9  10  23 10 
DAY 4  na 16  10  4  5  8  3 
DAY 7  32 30  23  5  8 17 5 
DAY14  34 24  17  5  na  na na 
 
 
Table 6-2  Sample numbers at each day of the study for ischaemic patients taking 
aspirin or not throughout the study and for patients taking other drugs.  Not applicable as 
not enough data for analysis: na. 
  Ischaemic Patients Only  Patient Subgroups taking other drugs 
  Aspirin No  Aspirin  Glucocorticoids  Antidepressants 
TOTAL  14 11  5  6 
        
DAY 1  11 6  na  4 
DAY 2  14 8  5  6 
DAY 3  11 10  5  6 
DAY 4  na na  3  na 
DAY 7  8 7  5  5 
DAY14  na na  na  3  
6.3  Results 
6.3.1  Patients and Controls 
6.3.1.1  Kynurenines 
Tryptophan levels were significantly lower in patients compared with controls at 1, 7 and 
14 days after the stroke (Figure 6-1A).  Kynurenine levels were higher in patients 
compared with controls but these were only significant at day 1, 1 day after the stroke 
(Figure 6-2A).  As expected from these results, the K:T ratio was significantly higher for 
patients than for controls at day 1, 7 and 14 (Figure 6-1B), indicating activation of the 
kynurenine pathway following a stroke.  There was no significant difference between 
patients and controls for KYNA (Figure 6-2B).  The ratios of KYNA: KYN were 
calculated, but were not significantly different from controls.  Levels of ANA were 
significantly higher for patients compared with controls at days 1 and 7, but this difference 
was not significant at day 14 (Figure 6-3A).  When the ratios of ANA: KYN were 
calculated, these were higher in patients compared with controls, but only significant at 
day 1.  This suggests that more ANA is being produced from kynurenine immediately after 
the stroke than normally occurs in healthy subjects.  3HANA concentrations were 
significantly lower for patients compared with controls at days 1, 7 and 14, with p<0.001 at 
all three time points clearly indicating a change in 3HANA levels (Figure 6-4A).  The ratio 
of 3HANA: ANA (Figure 6-4B) was significantly lower for patients compared with 
controls at each time point (days 1, 7 and 14).   
There were no significant changes in the levels of tryptophan, kynurenine, KYNA, 
3HANA and ANA during the 14 days following the stroke, nor were there any linear 
trends over time.  Controls samples did not show any significant variability between day 1, 
day 7 and day 14 for any of the kynurenines. 
6.3.1.2  Lipid Peroxidation and Neopterin 
Lipid peroxidation was higher in patients' samples than in controls at day 1, day 7 and day 
14 (Figure 6-5A).  Although ANOVA did not show any significant differences in lipid 
peroxidation over the 14 days following the stroke, there was a significant linear trend 
(p<0.05), indicating that lipid peroxidation was decreasing with time after the stroke.   
Levels of neopterin were significantly higher for patients compared with controls at days 1, 
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7 and 14 (Figure 6-5B).  There was no evidence of neopterin levels falling over the 14 days 
after the stroke, with levels remaining elevated. 
For controls, there was no significant variability in neopterin between days 1, 7 and 14.  
However, lipid peroxidation at day 7 was significantly higher than lipid peroxidation at day 
1 and at day 14.  This may be due to the error bars at each time point being very small.  
This result is of little importance for the study as the lipid peroxidation results for the 
controls at day 7 were still much lower than for the patients (Figure 6-5A). 
6.3.1.3  ESR 
On admission to hospital, patients had a significantly higher ESR (26.23 ± 4.45 mm/h, 
n=28) compared with controls (12.10 ± 4.09 mm/h, n=10) (p<0.05). 
6.3.1.4  CT Scans 
The estimated total volume of brain damage varied from 0 to 158ml, with a mean volume 
of 26.3ml (n=40).  For ischaemic patients the lesion volume varied from 0 to 135ml, with a 
mean of 25.6ml (n=34) and for haemorrhagic patients the lesion volume was between 1 
and 158ml, with a mean volume of 30.3ml (n=6).  Some patients had very small areas of 
infarction which were too small to be seen on the CT scan and were attributed a volume of 
0 for comparison with the other volumes.  
6.3.1.5  Correlations 
The significant correlations between the estimated total volume of brain damage from the 
CT scans and the kynurenines, neopterin, lipid peroxidation and ESR are shown in Table 
6-3.  The volume of brain damage was greater when the levels of 3HANA in the blood 
were lower, correlations being significant at 3 of the 6 time points.  When brain damage 
was correlated with 3HANA: ANA ratio, the correlations were significant at 4 time points.  
Significant correlations were also observed with lipid peroxidation at 2 time points. 
For stroke patients many correlations were observed between the kynurenines as expected, 
as they are all metabolites of the dynamic kynurenine pathway (Table 6-4).  Increased 
levels of kynurenine produced increases in both KYNA and ANA, as kynurenine 
correlated with KYNA and ANA at days 1, 2, 3, 7 and 14.  The K:T ratio also correlated 
with KYNA (at days 1, 2, 3 and 7) and ANA (at days 1, 3 and 7), demonstrating that 
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increased activation of the pathway increases the levels of both KYNA and ANA in stroke 
patients.  There was also a positive correlation between ANA and KYNA at days 1, 2, 3 
and 7.  It was however expected that there would be a negative correlation between 
3HANA and ANA, as the patient group had a lower level of 3HANA and a higher level of 
ANA, with the ratio 3HANA: ANA also showing significant differences between patients 
and controls, but 3HANA and ANA only correlated at day 1.  There was a negative 
correlation between the K:T ratio and the 3HANA: ANA ratio at days 2 and 3, showing 
that activation of the pathway does influence this ratio.  For at least 4 of the 6 time points, 
neopterin correlated negatively with tryptophan, positively with kynurenine and the K:T 
ratio, and positively with KYNA.  Neopterin also correlated with ANA at 2 time points.  
ESR also correlated with the K:T ratio at day 1, giving more evidence that inflammation 
and kynurenine pathway activation are related in stroke patients.  A correlation between 
neopterin and lipid peroxidation may be expected, but no correlation was observed.  Lipid 
peroxidation correlated negatively with the 3HANA: ANA ratio at days 2, 3 and 7, but 
only correlated negatively with 3HANA itself at 1 time point and correlated positively with 
ANA at 2 time points.  A lower 3HANA: ANA ratio may suggest increased oxidative 
stress in the stroke patient, indicated by the higher level of lipid peroxidation products. 
For the control subjects, the K:T ratio correlated with KYNA and neopterin at all 3 time 
points and with ANA at 2 time points (Table 6-5).  KYNA and ANA also correlated.  This 
demonstrates that in healthy subjects, even small increases in inflammatory status occur in 
conjunction with increased metabolism via the kynurenine pathway. 
There were correlations between age and neopterin for 3 of the 6 days for stroke patients 
(Table 6-4) and for all 3 days for the controls (Table 6-5).  There were also correlations 
between age and K:T ratio for 3 out the 6 time points for patients and for 2 of the 3 time 
points for controls.  KYNA also correlated with age but at fewer time points: significant 
correlations at day 2 for patients and at days 7 and 14 for controls. 
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Figure 6-1  Changes in the levels of tryptophan (A) and in the kynurenine: tryptophan 
(K:T) ratio (B) over the 14 days following the stroke for patients or over a period of 14 
days for controls.  Values are mean ± SEM.  Significant differences between patients and 
controls:  * p<0.05, ** p<0.01, *** p<0.001. 
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Figure 6-2  Changes in the levels of kynurenine (A) and kynurenic acid (B) over the 14 
days following the stroke for patients or over a period of 14 days for controls.  Values are 
mean ± SEM.  Significant differences between patients and controls:  * p<0.05.  
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Figure 6-3  Changes in the levels of anthranilic acid (A) and in the anthranilic acid : 
kynurenine (ANA: KYN) ratio (B) over the 14 days following the stroke for patients or 
over a period of 14 days for controls.  Values are mean ± SEM.  Significant differences 
between patients and controls:  * p<0.05, ** p<0.01. 
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Figure 6-4  Changes in the levels of 3-hydroxyanthranilic acid (A), and in the 3-
hydroxyanthranilic acid: anthranilic acid (3HANA: ANA) ratio (B) over the 14 days 
following the stroke for patients and over a period of 14 days for controls.  Values are 
mean ± SEM.  Significant differences between patients and controls: *** p<0.001. 
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Figure 6-5  Changes in the levels of lipid peroxidation products (A) and neopterin (B) 
over the 14 days following the stroke for patients and over a period of 14 days for controls.  
Values are mean ± SEM.  Significant differences between patients and controls: * p<0.05, 
** p<0.01, *** p<0.001.  
 
Table 6-3  Spearman correlations between the estimated volume of brain damage from 
the CT scans and levels of the kynurenines, neopterin and lipid peroxidation for stroke 
patients.  Significant correlations: *p<0.05,  **p<0.01.  No significant correlation: ns.   
Where there were no significant correlations at any of the time points, the results were not 
tabulated. (TRYPT - tryptophan, NEOPT - neopterin, LP - lipid peroxidation). 
 
Positive (+) and Negative (-) 
Correlations with estimated 
volume of brain damage from 
CT scans: 
 
Day 1  Day 2  Day 3  Day 4  Day 7  Day 14 
TRYPT 
 
+  ns ns *  ns ns ns 
3HANA 
 
-  * **  ns ns *  ns 
3HANA: ANA 
 
-  * ** * ns  *  ns 
NEOPT 
 
-  *  ns ns ns ns ns 
LP 
 
+  ns ns * *  ns ns 
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Table 6-4  Spearman correlations between the kynurenines and neopterin, lipid 
peroxidation and age for stroke patients.  Significant correlations: *p<0.05,  **p<0.01, 
***p<0.001.  No significant correlation: ns.  Where there were no significant correlations 
at any of the time points, the results were not tabulated, unless a correlation was expected.  
(KYN - kynurenine) 
Positive (+) and Negative (-) 
Correlations between: 
 
Day 1  Day 2  Day 3  Day 4  Day 7  Day 14 
KYN 
 
KYNA  +  *** *** **  ns  *** * 
KYN 
 
ANA  +  *** ** *** ns  *** ** 
K:T 
 
KYNA  +  *** *** **  ns  ***  ns 
K:T 
 
ANA  +  *  ns  ***  ns  **  ns 
KYNA 
 
ANA  +  *** * ** ns  **  ns 
3HANA ANA 
 
-  *  ns ns ns ns ns 
K:T 
 
3HANA: 
ANA 
-  ns  * ***  ns ns ns 
NEOPT 
 
TRYPT 
 
-  ** 
 
* 
 
** 
 
ns 
 
ns 
  * 
NEOPT 
 
KYN  +  * * *  ns  *** * 
NEOPT 
 
K:T  +  *** *** ***  *  *** *** 
ESR 
 
K:T  +  **       
NEOPT 
 
KYNA  +  * * *  ns  * * 
NEOPT 
 
ANA  +  ns ns *  ns  *  ns 
NEOPT 
 
LP  ns  ns ns ns ns ns ns 
LP 
 
3HANA: 
ANA 
-  ns  * ***  ns  *  ns 
LP 3HANA 
 
-  ns  *  ns ns ns ns 
LP 
 
ANA  +  ns ns  ***  ns  *  ns 
AGE 
 
K:T  +  * *  ns  *  ns ns 
AGE KYNA 
 
+   ns  *  ns ns ns ns 
AGE NEOPT 
 
+  ns  ** *** ns  *  ns 
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Table 6-5  Spearman correlations between the kynurenines and neopterin, lipid 
peroxidation and age for controls.  Significant correlations: *p<0.05,  **p<0.01, 
***p<0.001.  No significant correlation: ns.  Where there were no significant correlations 
at any of the time points, the results were not tabulated, unless a correlation was of 
particular interest.   
Positive (+) and Negative (-) 
Correlations between: 
 
Day 1  Day 7  Day 14 
KYN 
 
KYNA  +  *** ** ** 
KYN 
 
ANA  +  ns ns * 
K:T 
 
KYNA  +  * **  *** 
K:T 
 
ANA  +  **  ns  ** 
KYNA 
 
ANA  +  ns  ** ** 
3HANA ANA 
 
ns ns  ns  ns 
K:T 
 
3HANA: 
ANA 
-  *  ns ns 
NEOPT 
 
TRYPT 
 
+  ns  * * 
NEOPT 
 
KYN  +  *** *** *** 
NEOPT 
 
K:T  +  ** * ** 
NEOPT 
 
KYNA  ns ns  ns  ns 
NEOPT 
 
ANA  +  ns ns * 
NEOPT 
 
LP  ns ns  ns  ns 
LP 
 
3HANA: 
ANA 
-  *  ns ns 
LP 3HANA 
 
-  ns ns ** 
LP 
 
ANA  ns ns  ns  ns 
AGE 
 
K:T  +  ** * * 
AGE 
 
KA  +  ns  * * 
AGE 
 
NEOPT  + 
 
*** 
 
* 
 
*** 
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6.3.2  Comparison of Ischaemic and Haemorrhagic Patients 
The results were split into the subgroups, ischaemic (n = 36) and haemorrhagic stroke (n = 
9), and the two groups compared.  It was unfortunate that the 2 groups contained such 
different numbers of patients, but a statistical comparison was still regarded as useful to 
determine any large differences between the 2 groups.  For tryptophan, there was a trend 
for ischaemic patients to have higher tryptophan levels than the haemorrhagic patients but 
this was only significant at day 7 (Figure 6-6A).  Ischaemic and haemorrhagic patients had 
lower tryptophan levels than the controls, but now that the data has been split into smaller 
groups, this was only significant at day 7 for ischaemic patients and at days 7 and 14 for 
the haemorrhagic group.  When K:T ratios were examined, there were no significant 
differences between the ischaemic and haemorrhagic groups, and ratios remained 
significantly higher than the controls for both subgroups at each time point (day 1, 7 and 
14) (Figure 6-6B).   
There were no significant differences between the ischaemic and haemorrhagic groups for 
kynurenine, KYNA, 3HANA and ANA.  However when the 3HANA: ANA ratio was 
examined, the haemorrhagic patients had a significantly lower ratio than the ischaemic 
patients at days 1 and 2 after the stroke (Figure 6-6C).  The 3HANA: ANA ratios for both 
subgroups remained significantly lower than the controls throughout the study.  There were 
also no significant differences between the ischaemic and haemorrhagic groups for lipid 
peroxidation and neopterin. 
ANOVA showed that there were no significant effects with time after stroke for either the 
ischaemic or haemorrhagic groups, for all the analytes. 
Both the ischaemic and haemorrhagic groups showed the same trends as the combined 
patients group compared with controls for all the measurements. 
For the ischaemic patients only, correlations between the lesion volumes from the CT 
scans and the kynurenines, neopterin, lipid peroxidation and ESR were examined.  The 
correlations which were significant were very similar to those that were significant for the 
combined patient group.  There were significant correlations with lesion volume for 
3HANA at days 2 and 7, for 3HANA: ANA ratio at days 1, 2 and 7 and for lipid 
peroxidation at day 3.  
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Figure 6-6   Comparison of ischaemic and haemorrhagic patients for tryptophan levels 
(A), kynurenine: tryptophan (K:T) ratios (B) and 3-hydroxyanthranilic acid: anthranilic 
acid (3HANA: ANA) ratios (C).  Values are mean ± SEM.  Significant differences 
between patients and controls: * p<0.05, ** p<0.01, *** p<0.001.  Significant differences 
between ischaemic and haemorrhagic groups: + p<0.05, ++ p<0.01. 
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6.3.3  Severity of the Stroke 
Patients were divided into three subgroups: those who died within 3 weeks of the stroke 
(n=12), those who were discharged from hospital during the study (n=12) and those who 
remained in hospital for the duration of the study (n=26).  The levels of tryptophan were 
not significantly different between the 3 groups.  At day 1, patients who were able to go 
home during the study had lower kynurenine levels than patients who died or remained in 
hospital (Figure 6-7A).  There was a trend that patients who died after the stroke had 
higher kynurenine levels at the other time points, although these differences were not 
significant.  Kynurenic acid levels were significantly higher for the patients who died 
(Figure 6-7B).  At days 1 and 3, these KYNA levels were significantly higher compared 
with those who went home during the study, and at days 3 and 7, significantly higher than 
for the patients who remained in hospital.  At day 1, patients who died also had higher 
KYNA levels than the controls.  Anthranilic acid levels also tended to be higher for 
patients who died (Figure 6-8A).  Similar to the kynurenine results, this was only 
significant at day 1, where patients who died had higher ANA levels than those who were 
discharged.  Also at day 1, the patients who died and those who remained in hospital had 
higher ANA levels than controls, while the patients who went home were not significantly 
different from controls.  Patients who died also tended to have lower 3HANA levels at 
days 1, 2, 3 and 4, but this was only significant at day 4, with both the patients who died 
and those who remained in hospital having lower 3HANA levels than those who went 
home.  All subgroups remained significantly lower in 3HANA concentrations than the 
controls at both day 1 and day 7.  Neopterin and lipid peroxidation levels were not 
significantly different between these subgroups. 
The subgroups of patients who died, those who were discharged and those who remained 
in hospital were further divided depending on whether the stroke was ischaemic and 
haemorrhagic, resulting in very small sample numbers.  There were no effects that could be 
specifically attributed to the ischaemic or haemorrhagic group. 
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Figure 6-7  Effect of severity of the stroke on the levels of kynurenine (A) and 
kynurenic acid (B).  Values are mean ± SEM.  Significant differences compared with 
controls: * p<0.05.  Significant differences compared with patients who were able to go 
home during the study: + p< 0.05.  Significant differences compared with patients who 
stayed in hospital during the study: X p<0.05.  
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Figure 6-8  Effect of the severity of the stroke on the levels of anthranilic acid (A) and 
3-hydroxyanthranilic acid (B).  Values are mean ± SEM.  Significant differences compared 
with controls: * p<0.05, ** p<0.01, *** p<0.001.  Significant differences compared with 
patients who were able to go home during the study: + p< 0.05.   
6.3.4  Effect of Ischaemic Patients taking Aspirin on the Levels 
of Kynurenines, Neopterin and Lipid Peroxidation 
Products 
Ischaemic patients who were taking aspirin (n = 14) were compared with those who were 
not (n = 11), using unpaired two-tailed t tests, for samples taken 1, 2, 3 and 7 days after the 
stroke.  For tryptophan, kynurenine, KYNA, 3HANA, ANA and lipid peroxidation, there 
were no significant effects of taking aspirin at each time point.  It appears that there were 
lower levels of neopterin for patients taking aspirin compared with those not taking aspirin, 
at 1, 2 and 3 days after the stroke, significant at day 3 (Figure 6-9).  Neopterin is a marker 
of inflammation, so this result may be expected as aspirin has anti-inflammatory 
properties.  However, a much higher dose of aspirin than was administered to these 
patients is expected to be required before it has anti-inflammatory properties.  There are 
extremely large error bars for neopterin levels in patients not taking aspirin at days 1, 2 and 
3 (Figure 6-9).  On closer examination of the data, there are 3 patients with extremely high 
neopterin levels of between 12 and 34 ng/ml, which are skewing the data and suggesting 
this effect of aspirin on neopterin levels.  Details of these 3 patients were studied, and it 
was noted that none of them died during the study, but all 3 were on antibiotics and 
therefore may have had a severe infection.  However many other patients were also taking 
antibiotics.  The effect that patients not taking aspirin have higher neopterin levels is 
skewed by the results from 3 patients and therefore is unlikely to be valid.    
6.3.5  Effect of Other Drugs on the Levels of Kynurenines, 
Neopterin and Lipid Peroxidation Products 
5 patients were taking glucocorticoids and 6 were taking antidepressants.  For both 
subgroups, t tests were carried out to examine if there were any differences in tryptophan, 
kynurenine, KYNA, 3HANA, ANA, neopterin and lipid peroxidation between patients 
taking these drugs and the other patients.  Neither of these drugs caused significant 
differences in any of the measurements. 
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Figure 6-9  Comparison between the neopterin levels for ischaemic patients who were 
taking aspirin throughout the study and those who were not taking aspirin.  Values are 
mean  ± SEM.  Significant differences compared with controls: * p<0.05.  Significant 
differences between patients who were taking aspirin and those who were not: + p< 0.05.   
6.4  Discussion   
6.4.1  Tryptophan, Kynurenine and IDO Activity  
The results of the stroke study, in particular the higher K:T ratios for patients compared 
with controls, suggest that the kynurenine pathway was activated within 24 hours of the 
stroke occurring.  Within the first 24 hours, neopterin and lipid peroxidation products were 
also elevated compared with controls.  The elevated neopterin indicates that the 
inflammatory response was increased within 24 hours of the stroke and therefore pro-
inflammatory cytokines could have activated IDO, the initial enzyme of the kynurenine 
pathway.  Neopterin levels correlated with the K:T ratio at all 6 time points after the stroke, 
suggesting that a stroke patient with greater inflammation showed increased activation of 
IDO.  This is in agreement with other human diseases where increased neopterin levels 
correlated with increased IDO activity, both neopterin and IDO being stimulated by the 
pro-inflammatory cytokine, IFN-γ (Schroecksnadel et al., 2005). 
Activation of the kynurenine pathway, via induced IDO activity, was apparent throughout 
the 14 days of the study, as the K:T ratio remained significantly elevated in patients, 
demonstrating that more kynurenine was being produced from the available tryptophan.  
However, it is possible that tryptophan levels in the blood are lower in the patients due to 
dietary intake, as patients after a stroke are likely to be eating less than the healthy 
controls.  In an ideal study, diet would have been monitored.  However, lower tryptophan 
levels in patients would be expected to produce less kynurenine and increased or similar 
levels of kynurenine were determined.  Additional evidence for activation of the pathway 
was the significantly higher levels of ANA measured in the patient samples. 
6.4.2  Inflammation in Stroke 
The high levels of neopterin support the view that inflammation occurs rapidly after a 
stroke (Barone and Feuerstein, 1999; Skinner et al., 2006).  The continued elevation of 
neopterin demonstrates that the inflammatory cascade occurs for many hours or days 
following a stroke, which may be important as there is much evidence that inflammation 
contributes to delayed brain injury (Dirnagl et al., 1999).  Activated monocytes and 
macrophages produce and release neopterin and therefore neopterin levels reflect the 
degree of macrophage activation.  Neopterin itself can trigger pro-inflammatory events and 
has been related to the production of nitric oxide resulting in oxidative stress (Hoffmann 
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and Schobersberger, 2004).  However, there were no correlations between neopterin and 
lipid peroxidation in this study. 
6.4.3  Timescale for Kynurenine Pathway Activation 
MRI scans for stroke patients have shown that substantial enlargement of the ischaemic 
lesion can occur later than 24 hours after onset, although enlargement often occurs earlier 
(Baird et al., 1997).  In human PET studies, potentially viable penumbra was present up to 
48 hours after stroke (Heiss et al., 1992).  In rats, after an MCAO, neurones in the 
penumbra showed accelerated ischaemic damage between 8 and 12 hours after occlusion, 
with complete loss of neurones after 10 days (Dereski et al., 1993).  The levels of all the 
kynurenines in our study, as well as neopterin and lipid peroxidation, remained similar 
throughout the 14 days after the stroke.   
The activated kynurenine pathway within 24 hours of the stroke is not as expected from the 
gerbil model of ischaemia, where no increases in IDO activity or QUIN levels were 
observed in the brain until at least 2 days following the ischaemic insult, with maximum 
levels after 4 days (Saito et al., 1993b).  This was suggested to be due to the infiltrating 
macrophages having high levels of IDO, and maximum macrophage levels were present in 
the gerbil brain 4 days after ischaemia.  Inflammation results in neutrophils, followed by 
macrophages and monocytes migrating from the blood into the ischaemic brain, the latter 
two cell types becoming the predominant cells five to seven days after ischaemia in animal 
models (Dirnagl et al., 1999).  Resident brain cells are also involved in the inflammatory 
response:  microglia are activated and astrocytes become enlarged, four to six hours after 
ischaemia.  Twenty-four hours after an MCAO, there is much microglial activation in the 
ischaemic brain, particularly in the penumbra (Dirnagl et al., 1999).  Activated microglia 
also express elevated levels of kynurenine pathway enzymes, including IDO, and, as well 
as macrophages, are able to produce QUIN from tryptophan in the brain (Heyes et al., 
1996).  As macrophage activation in the blood has been shown to occur earlier than in the 
brain, demonstrated by the elevated neopterin levels at 24 hours after the stroke, IDO 
activity would also be expected to increase in the blood at the same time.  The discrepancy 
between the timescale of IDO activation in this study and in the gerbil ischaemic model 
may also be due to the species difference between humans and gerbils. 
The results of this study could suggest that macrophage activation following a stroke 
results in increased IDO activity.  However, as IDO activity appears to be activated at the 
first timepoint in the study, it cannot be ruled out that the kynurenine pathway may be 
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activated before the stroke and contribute to the stroke occurring.  Humans are more 
susceptible to stroke if they have high blood pressure, atherosclerosis, heart disease, high 
cholesterol or diabetes and these underlying pathologies may include an activated 
kynurenine pathway.  This contrasts with animal models of stroke where healthy animals 
are given an ischaemic insult, and the brain damage then starts to develop.  
6.4.4  Kynurenic Acid 
There was no significant increase in KYNA levels following the strokes, showing 
similarity with the gerbil ischaemic stroke model, where neither KYNA nor KAT were 
elevated (Saito et al., 1993b).   
6.4.5  3-Hydroxyanthranilic Acid, Lipid Peroxidation and 
Oxidative Stress 
The increased levels of lipid peroxidation in stroke patients are consistent with substantial 
evidence that oxidative stress is involved in the cerebral tissue damage occurring after 
ischaemia (Love, 1999; Chan, 2001).  Oxidative stress was also shown to contribute to 
DNA damage and brain injury in a study of experimental intracerebral haemorrhage in rats 
(Nakamura  et al., 2005).  Macrophages and microglia, activated by inflammation, can 
produce neurotoxins including nitric oxide and reactive oxygen species (Dirnagl et al., 
1999), which may be contributing to the increased lipid peroxidation.   
Of particular interest in this study was the decreased levels of 3HANA in the stroke 
patients.  3HANA is redox-active and can generate free radicals, contributing to oxidative 
stress.  In human monocyte-derived cells in culture, apoptosis has been shown to be 
induced by IDO activity stimulated with IFN-γ (Morita et al., 2001).  It was shown that 
3HANA, but not 3HKYN or QUIN, induced apoptosis in these cells, and apoptosis was 
enhanced by the presence of redox-active metals (Fe
2+ or Mn
2+ ions).  It was suggested that 
different cell types are susceptible to toxicity by different kynurenine pathway metabolites.  
3HANA can undergo autoxidation which ultimately produces reactive oxygen species 
(Dykens  et al, 1987), oxidative stress and apoptosis (Okuda et al., 1998).  Such 
metabolism of 3HANA may cause the decreased concentration of this metabolite in the 
blood and may contribute to the increased lipid peroxidation in the stroke patients.   
The redox activity of 3HANA depends on the presence of other redox-active compounds, 
and in some situations, 3HANA can also act as a scavenger of peroxyl radicals, as in the 
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initial step of autoxidation, 3HANA is oxidised (Christen et al., 1990; Leipnitz et al., 
2007).  This suggests an alternative hypothesis in which the lower levels of 3HANA offer 
less antioxidant activity, resulting in less protection against oxidative stress for the stroke 
patients.  The lower levels of 3HANA may also suggest that increased levels of QUIN 
have been formed, depleting its substrate, 3HANA.  However, there is evidence for 
abundant 3HAO in normal brain tissue (Saito et al., 1993b) and therefore this should not 
limit the production of QUIN from 3HANA in the controls.  It may be more likely that 
higher levels of 3HANA would produce more QUIN.  This cannot be clarified here as the 
levels of QUIN were not determined in this study. 
The importance of the reduced levels of 3HANA in stroke patients was emphasised by the 
correlations between 3HANA and the volume of brain damage observed in the CT scan at 
3 of the 6 time points in the study.  
6.4.6  Anthranilic Acid 
Activation of the kynurenine pathway may be expected to increase the concentration of 
ANA, as ANA can be produced from kynurenine by the enzyme, kynureninase.  However, 
the preferred route for kynurenine metabolism under physiological conditions has been 
established as being via 3HKYN, as the enzyme involved in this reaction, KMO, has a high 
affinity for the substrate, kynurenine (Bender and McCreanor, 1982).  3HKYN can then be 
converted to 3HANA.  ANA may produce 3HANA but no enzyme for this metabolism has 
been identified so the only possible mechanism is by direct hydroxylation.  This has only 
been demonstrated in a single study where a high level of ANA added to rat cortical brain 
slices was shown to produce 3HANA (Baran and Schwarcz, 1990).  In the stroke patients, 
the high levels of ANA and the low levels of 3HANA may suggest that this metabolism is 
blocked, although most of the 3HANA would be expected to be produced from 3HKYN.  
Unfortunately 3HKYN was not measured in this study, as levels were expected to be close 
to the LoD of the method.  Knowledge of the concentrations of 3HKYN in stroke patients 
would have helped to clarify the possible metabolic routes involved.  There was only a 
correlation between 3HANA and ANA in patients at day 1, making it unclear whether 
these metabolites behave independently or not.   
ANA has been shown to demonstrate some neuroprotective properties by partially 
blocking QUIN toxicity when co-injected with QUIN into the rat brain (Jhamandas et al., 
1990), but to a much lesser extent than the NMDA receptor antagonist, KYNA.  The 
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increased levels of ANA in the stroke patients may be a compensatory response to the 
neurotoxic damage to the cells of the penumbra in the stroke patients.  
ANA can also interact with copper to form an anti-inflammatory complex.  This complex 
acts as a hydroxyl radical-inactivating ligand, able to remove the highly injurious hydroxyl 
radicals at inflammatory sites (Miche et al., 1997; Gaubert et al., 2000).  The high levels of 
ANA generated following stroke may be an anti-inflammatory response, offering some 
protection from oxidative stress.     
6.4.7  3-Hydroxyanthranilic Acid : Anthranilic Acid 
Interestingly, in other work by our group for patients with osteoporosis, decreases in the 
levels of 3HANA and increases in the levels of ANA in blood were also observed (Forrest 
et al., 2006).  These changes were reversed after 2 years of drug treatment to levels similar 
to controls, which suggests the potential for drug treatment to reverse these changes in the 
stroke patients.   
The correlations with lipid peroxidation are stronger for the 3HANA: ANA ratio 
(significant at 3 out of the 6 time points) than for the 3HANA levels themselves (only 
significant at 1 time point), suggesting that the ratio is key.  Similarly, the 3HANA: ANA 
ratio changes appear to result from the activation of the kynurenine pathway as the ratios 
correlated with the ratios of K:T at days 2 and 3 in patients.  The importance of the ratio of 
3HANA: ANA in this stroke study is demonstrated by the significant correlations with the 
volume of brain damage from the CT scans, at 4 of the 6 time points, being significant at 
one more time than 3HANA itself.   
Interestingly, 3HANA: ANA, 3HANA itself and lipid peroxidation showed the most 
significant correlations with the volume of brain damage from the CT scans, suggesting 
that these are important parameters involved in the brain damage caused by stroke.  The 
correlations of brain damage with lipid peroxidation were not at any of the same time 
points as the correlations with 3HANA and only at one of the same time points with 
3HANA: ANA ratio.  The relationship between lipid peroxidation and 3HANA or the 
3HANA: ANA ratio was not entirely clear from these correlations.  
One possible mechanism for the increased levels of ANA and decreased levels of 3HANA 
is that there may be a lack of the enzyme, KMO, which produces 3HKYN followed by 
3HANA from kynurenine.  This could also account for the higher ANA levels measured, 
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as kynurenine could not be metabolised via its preferred route to 3HKYN and could 
therefore be metabolised via ANA by the enzyme, kynureninase.  Such increased 
metabolism was significant at day 1 after the stroke when the ratio of ANA: KYN was 
higher in patients compared with controls.  KMO availability has been demonstrated to be 
a potential variable in kynurenine pathway metabolism.  When a systemic immune 
stimulus was given to gerbils, there was a lack of KMO in the brain and hence QUIN could 
not be produced from tryptophan or kynurenine within the brain (Saito et al., 1993c).  
However, KMO inhibition has been shown to increase KYNA concentrations (Cozzi et al., 
1999), and KYNA levels were similar in stroke and control patients.  A reduction in KMO 
activity suggests that 3HKYN and QUIN would also be lower after stroke, and therefore 
does not suggest a role for any of these three neurotoxic products of the pathway.   
However, several KMO inhibitors have shown neuroprotection in animal models of 
ischaemia (Cozzi et al., 1999), suggesting that KMO activity is high in stroke.  Therefore, 
it is unlikely that reduced KMO activity was the cause of the high levels of ANA and low 
levels of 3HANA in the blood.  
The 3HANA: ANA ratio may not be important, with the altered concentrations of 3HANA 
and ANA in stroke patients occurring independently of each other.  A more plausible 
explanation for the increased ANA in stroke patients may be an increased kynureninase 
activity. 
6.4.8  Ischaemic and Haemorrhagic Stroke 
Patients with symptoms of stroke and who were diagnosed with stroke were included in the 
study to achieve the maximum number of samples at all 6 time points examined.  The CT 
scan clarified whether the stroke was ischaemic or haemorrhagic.  The differences in 
severity of the stroke for the ischaemic patients gave further variability in the patient 
group.  In an ideal study, a large number of patients with ischaemic stroke of similar 
severity would be used.  However, such a group of patients were not available for this 
work.  As this study is a preliminary study for examining if the kynurenine pathway is 
altered in human stroke, further studies would have to be more carefully controlled. 
Although an ischaemic stroke involves a blockage of a major brain artery and a 
haemorrhagic stroke involves a blood vessel bursting in the brain, many of the same 
mechanisms of brain damage occur for both: excitotoxicity, oxidative stress, inflammation 
and cell death.  Both have an area surrounding the core site of damage which may be able 
to regain function: the penumbra in ischaemic stroke (Dirnagl et al., 1999) and the 
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perihaematoma in haemorrhagic stroke (Greenberg, 2007).  There is also a serious risk of 
oedema in both types of stroke. 
The results from this study show that there are very few differences between the ischaemic 
and haemorrhagic groups, which gives some justification for using the combined patient 
group.  Both groups showed the same differences compared with controls.  The trend for 
lower tryptophan in the haemorrhagic group may be because these patients were generally 
more severely affected by the stroke and therefore there was more activation of the 
kynurenine pathway.  The severity may also account for the lower 3HANA: ANA ratios at 
days 1 and 2 in the haemorrhagic group.  Four of the nine (44%) haemorrhagic patients 
died within 3 weeks of the stroke, with none of the other five being sent home during the 
study.  For the larger ischaemic group, patients were less severely affected, with only 14% 
(5 patients) dying within 3 weeks of the stroke and 12 patients able to go home during the 
study, with the remaining 19 staying in hospital. 
6.4.9  Severity of Stroke 
The severity of the stroke resulted in changes in the levels of the kynurenines.  In 
particular, patients who died within 3 weeks of the stroke had high levels of KYNA.   
Although the haemorrhagic patients tended to be more severely affected by the stroke, the 
ischaemic group, when analysed separately, still showed significant increases in KYNA 
levels for patients who died.  As well as the neuroprotective properties of KYNA, this 
metabolite also has been shown to have detrimental physiological characteristics.  High 
KYNA levels have been shown to lower the efficacy of mitochondrial ATP synthesis 
(Baran  et al., 2003).  This effect was demonstrated in rat heart tissue, but the 
concentrations of KYNA affecting mitochondria function were 125μM, much higher than 
the increased levels of KYNA in the stroke patients, which were up to 100nM.  However, 
these concentrations of 100nM are in blood and there is the possibility that local 
intracellular levels in the brain may be much higher.  Disturbances in mitochondrial 
function have been shown to be involved in stroke (Dirnagl et al., 1999).   
Patients more severely affected by the stroke, dying within 3 weeks, appeared to have a 
more activated kynurenine pathway compared to those who were discharged within 2 
weeks of the stroke.  There were trends suggesting that kynurenine and ANA levels were 
elevated in patients who died, compared with those who went home.  The 3HANA 
concentrations also tended to be lower for the patients who died compared to those who 
were discharged.  These differences in kynurenine, ANA and 3HANA concentrations were 
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only significant at one of the 5 time points examined.  The lack of significance may be due 
to the small sample numbers resulting from subgrouping the patients.  The differences 
observed between the total patient group and controls were exaggerated in the patients who 
died.  However, the concentrations of neopterin and lipid peroxidation did not change.  The 
changes in other kynurenines suggest that the increase in KYNA in patients who died was 
due to abnormal kynurenine pathway metabolism.  However, it is feasible that KYNA was 
produced by a different route, possibly from indole-3-pyruvic acid (IPA).  In the presence 
of free radicals, the enol tautomer of IPA can form KYNA (Bartolini et al., 2003).  There 
was no evidence for the presence of increased free radicals for patients who died, as there 
was no change in lipid peroxidation.  
6.4.10  Aspirin and Other Drugs 
Aspirin (acetylsalicylic acid), at low doses (approximately 75mg daily), is often given to 
stroke patients to try to enhance blood perfusion after a stroke, acting by inhibiting the 
aggregation of blood platelets.  Sherman (2004) examined the results from two very large 
clinical trials where the role of aspirin administration after acute ischaemic stroke was 
evaluated.  It was concluded that aspirin has a significant benefit in reducing stroke 
recurrence when given within 48 hours.  
Aspirin however can also be used as a non-steroidal anti-inflammatory drug, but a much 
higher dose is required for the anti-inflammatory effect (usually 1-4g daily (British 
Medical Association and Royal Pharmaceutical Society of Great Britain, 1999)).  Anti-
inflammatory drugs, such as aspirin, can interfere with the kynurenine pathway, as they 
can modulate cytokine production and reduce IDO stimulation by cytokines 
(Schroecksnadel et al., 2005).  Sodium salicylate has been shown to inhibit TDO activity 
in the liver and hence reduce kynurenine pathway activity (Badawy, 1982).  However, high 
levels of aspirin (1.8 – 2.7g) cause a significant increase in the concentration of free 
tryptophan by displacing the amino acid from serum albumin and thus increasing 
kynurenine pathway activity resulting in lower plasma tryptophan levels (Smith and 
Lakatos, 1971; Cotlier, 1981).  It was therefore unclear if aspirin would affect the 
kynurenine pathway in our study.  
It was concluded that the potential artefact of the study, that some patients were taking 
aspirin and others were not, was not significantly affecting the measurements made.  Both 
patients taking aspirin and those not taking aspirin showed similar differences between 
patients and controls as was observed with the complete patient set, for all the analytes.   
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Glucocorticoids are also used to suppress inflammation, and therefore may alter cytokine 
production, IDO activation and kynurenine pathway metabolism.  In this study, there was 
no evidence that glucocorticoids affected the kynurenines measured.  
Antidepressants could potentially interfere with metabolism via the kynurenine pathway as 
many antidepressants inhibit TDO activity and kynurenine pathway metabolism, resulting 
in elevated brain tryptophan concentrations and increased 5HT synthesis in rats (Badawy 
and Evans, 1982).  Some antidepressants are selective serotonin re-uptake inhibitors 
(SSRI) and hence maintain elevated levels of 5HT.  This may have an impact in the 
production of 5HT from tryptophan and could therefore affect the concentrations of 
tryptophan and its availability for kynurenine pathway metabolism.  In our study, there was 
no evidence for patients taking antidepressants having different levels of kynurenines in 
their blood. 
6.4.11  Conclusions 
It has been shown that the kynurenine pathway is activated following a stroke, in 
conjunction with increased inflammation and oxidative stress.  A major finding from this 
study is the much decreased concentrations of 3HANA in the blood of the stroke patients.  
This is possibly related to the increased levels of ANA.  The concentrations of 3HANA 
and the 3HANA: ANA ratio correlated negatively with the stroke lesion volumes, 
demonstrating that these kynurenine changes in the blood are related to the brain damage 
caused by the stroke.  3HANA and the 3HANA: ANA ratio also correlated negatively with 
lipid peroxidation, suggesting that 3HANA may be depleted due to autoxidation which can 
contribute to oxidative stress.  Alternatively, as 3HANA is redox-active and can also act as 
an antioxidant, less 3HANA may be produced from ANA in stroke patients, resulting in 
less free radical scavenging ability and less protection from oxidative stress.  Patients who 
died within 3 weeks of having a stroke showed higher concentrations of KYNA in their 
blood, which suggests that KYNA may either act as an NMDA receptor antagonist 
attempting to compensate for the excitotoxic damage in the brain, or act in reducing 
mitochondrial ATP synthesis, hence contributing to neuronal cell death.  
7  General Discussion 
7.1  Alterations of the Kynurenine Pathway in the Blood 
of Patients with Huntington’s Disease, Chronic Brain 
Injury and Acute Stroke 
In HD, there is much evidence that the activation of the kynurenine pathway is involved in 
the mechanisms of neurodegeneration, investigated primarily in human post-mortem brain 
tissue (Beal et al., 1990; Pearson and Reynolds, 1992; Guidetti et al., 2004).  There is 
much less published literature about the role of kynurenines in TBI or stroke, although 
after TBI, human CSF had high levels of QUIN (Sinz et al., 1998), and the kynurenine 
pathway was altered in animal models of ischaemic stroke (Saito et al., 1993b; Cozzi et al., 
1999).   
The results from all three studies showed alterations in kynurenine pathway metabolism, 
measured in the blood.  The inflammatory marker, neopterin, was increased in all three 
studies, with levels being higher in the acute stroke patients than for the patients with 
chronic disorders (HD and chronic brain injury).  As may be expected, this demonstrates a 
greater inflammatory response immediately after acute injury.  As neopterin levels were 
increased, changes in the kynurenine pathway were assumed to be related to IDO activity 
and not TDO activity, as IDO was activated in response to an inflammatory stimulus and 
TDO activity was expected to be more constant (Heyes et al., 1993).  In each study, there 
was evidence for increased IDO activity, by significant increases in the K:T ratio at 
baseline for the HD and chronic brain injury patients, and after stroke.  Interestingly, the 
difference between the K:T ratios for patients and controls in each study was 
approximately 0.02, demonstrating a similar degree of activation of IDO immediately after 
an acute stroke compared with late stage neurodegeneration (HD) or chronic brain injury.  
However, the mechanism for the increased IDO activity differs, as the results from HD and 
chronic brain injury patients demonstrated an increase in kynurenine concentrations in the 
blood, with no change in tryptophan levels, whereas the stroke patients showed a decrease 
in tryptophan levels, with an increase in kynurenine levels only at day 1.  This suggests a 
difference between acute and chronic injury.  A possible explanation is that in acute injury, 
tryptophan is degraded by IDO and quickly metabolised down the pathway, compared with 
in chronic injury, where there has been sustained IDO activity which may produce a build 
up of kynurenine, with tryptophan levels having had time to renormalise.  
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Although there was increased IDO activity, there were no similar increases in KYNA 
levels in the blood in any of the three studies.  For stroke patients, the general trend was for 
increased KYNA concentrations in the blood, although this was not significant, and there 
was no change in KAT activity.  The chronic brain injury patients, however, had KYNA 
levels which were lower than controls at the initial baseline.  For the chronic disorders (HD 
and chronic brain injury), there was low KAT activity in the patients, as the higher levels 
of kynurenine did not produce higher levels of KYNA.  This is in agreement with Beal et 
al. (1990), where a significant increase in the ratio KYN: KYNA was demonstrated in the 
post-mortem brains of HD patients.  In addition, the activity of the KAT II enzyme was 
decreased, with its Km increased 3-fold, in the putamen of HD post-mortem brains, 
although the decreases in KYNA levels were not significantly different from control brains 
(Jauch et al., 1995).  In our HD and chronic brain injury studies, the decreased KAT 
activity was very clearly accompanied by increased IDO activity.  The inflammatory 
response, which increased IDO activity, may be the cause of KAT inactivation, and this 
was supported by the negative correlations between the KYNA: KYN ratio and neopterin 
at baseline in HD patients and the KYNA: KYN ratio and CRP in the chronic brain injury 
patients.  The inactivity of KAT in these chronic disorders suggests a slow progressive 
deficiency in KYNA over time.  As KYNA can block NMDA receptor activation, KYNA 
deficiency could induce excitotoxicity, potentially leading to slowly developing 
neurodegeneration, as hypothesised by Beal et al. (1990).   
One of the most interesting and unexpected findings of this work was the significantly 
reduced levels of 3HANA in the blood of patients with HD, chronic brain injury and acute 
stroke, compared with their respective controls.  Lower levels of 3HKYN were also found 
in the blood of the HD and chronic brain injury patients, but 3HKYN was not measured in 
the stroke study.  It has been established in several studies that 3HKYN is increased in 
post-mortem striatum and cerebral cortex in late stage HD (Pearson and Reynolds, 1992; 
Guidetti et al., 2000).  Therefore, it was unexpected to find decreased levels of 3HKYN 
and 3HANA in the blood of the HD patients.  To maintain high levels of 3HKYN in the 
brain, blood pools of 3HKYN may have been depleted.  Indeed, 3HKYN can cross the 
blood-brain barrier via the large neutral amino acid transporter (Fukui et al., 1991) and 
3HKYN has selective uptake into certain brain regions, particularly the striatum (Okuda et 
al., 1998), where much of the neurodegeneration in HD occurs.  In the brain, 3HANA is 
produced from 3HKYN, as 3HANA does not easily cross the blood-brain barrier (Fukui et 
al., 1991).  The reduced levels of 3HANA in the blood may be due to reduced production 
from the low levels of 3HKYN.  If indeed high levels of 3HKYN and 3HANA were 
present in the brain, they could have led to increased autoxidation of these metabolites 
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which resulted in enhanced production of reactive oxygen species. As the pathway is 
dynamic, it may be expected that more 3HKYN and 3HANA would form after their 
degradation by autoxidation, or otherwise, more could be taken up from the blood. 
Alternatively, the low levels of 3HKYN and 3HANA in the blood may have been the 
consequence of degradation via autoxidation in the periphery.  3HKYN and 3HANA may 
have autoxidised at a faster rate than they could be produced.  As autoxidation of 3HKYN 
or 3HANA produces the superoxide anion (Dykens et al., 1987; Goldstein et al., 2000), 
such autoxidation may promote further IDO activity as IDO uses the superoxide anion as a 
co-substrate.  The removal of the superoxide product of 3HANA autoxidation has been 
shown to accelerate the reaction (Dykens et al., 1987), and hence if IDO removes the 
superoxide anion, the autoxidation process will be promoted.  This would result in 
continuing activation of the kynurenine pathway and continuing production of reactive 
oxygen species in these three disorders.  3HKYN and 3HANA toxicity results in neuronal 
cell death by apoptosis (Chiarugi et al., 2001; Morita et al., 2001).  As apoptosis has been 
implicated as a major process of neuronal cell death in HD (Portera-Cailliau et al., 1995; 
Ona et al., 1999), in stroke (Hara et al., 1997; Moroni et al., 2001) and in TBI (Yakovlev 
et al., 1997), oxidative stress induced by 3HKYN and 3HANA is a possible mechanism for 
neuronal damage in HD, chronic brain injury and stroke.  The large 3-4 fold increases in 
lipid peroxidation levels in all three disorders studied, suggested that oxidative stress was 
an important mechanism of neuronal damage. 
The major effect of 3HKYN and 3HANA in vivo is toxicity caused by oxidative stress.  
Intracerebroventricular administration of 3HKYN has been shown to be toxic in mice, and 
causes seizures (Lapin, 1981).   Nakagami et al. (1996) demonstrated that intrastriatal 
injection of 3HKYN induced tissue damage in rats.  The antioxidant, N-acetyl-L-cysteine, 
reduced the 3HKYN damage, but the NMDA receptor inhibitor, MK-801, failed to protect 
the brain from 3HKYN toxicity.  This suggests that oxidative stress, and not the 
metabolism of 3HKYN into QUIN, is causing the toxicity.  Jhamandas et al. (1990) 
showed that a single injection of 3HANA into the nucleus basalis magnocellularis in rats, 
produced a large decrease in the survival of cholinergic neurones.  Transition metal ions 
are required for 3HKYN and 3HANA toxicity (Eastman and Guilarte, 1990; Okuda et al., 
1996), and even at trace levels of these ions, 3HKYN and 3HANA have been shown to 
generate superoxide (Goldstein et al., 2000).  In vivo, the low levels of transition metal 
ions that are required for 3HKYN and 3HANA toxicity should be available.  Inflammation 
has been shown in all three disorders studied, and as it induces acidosis which liberates 
copper and iron from proteins, may increase the availability of iron and copper to enhance 
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the 3HKYN and 3HANA toxicity (Goldstein et al., 2000).  As the antioxidant properties of 
3HKYN and 3HANA have been demonstrated only in vitro, it is more probable that the 
3HKYN and 3HANA effects in our studies were related to their pro-oxidant activity.       
For the stroke study, ANA was also measured and showed increased concentrations in the 
blood of the stroke patients.  ANA can react with copper and the resulting anthranilic acid-
Cu
2+ complex has anti-inflammatory properties, which can remove the highly injurious 
hydroxyl radicals at inflammatory sites (Miche et al., 1997; Gaubert et al., 2000).  ANA 
has also been shown to partially protect against QUIN–induced neuronal damage 
(Jhamandas et al., 1990), which may indeed be due to the ability of ANA to remove 
hydroxyl radicals, as these are produced during QUIN-induced toxicity (Goda et al., 1996).  
The stroke patients showed positive correlations between ANA and lipid peroxidation, 
suggesting that higher levels of lipid peroxidation induced ANA synthesis.  The increase in 
ANA levels in the stroke patients may be a compensatory response to the neurotoxicity, 
which could offer protection from oxidative stress.   
The importance of the low levels of 3HANA in the stroke patients has been demonstrated 
by the negative correlations between 3HANA concentrations and the lesion volumes from 
the CT scans.  Lipid peroxidation correlated positively with lesion volumes in the stroke 
patients, suggesting that oxidative stress was a major factor in neuronal cell death in stroke.   
The high concentrations of ANA together with the low levels of 3HANA in the blood of 
the stroke patients suggested that the metabolism of ANA to produce 3HANA was 
blocked.  However, most of the 3HANA produced was expected to be metabolised from 
3HKYN (Bender and McCreanor, 1982).  The ratios of 3HANA: ANA, which may 
indicate the extent of direct hydroxylation of ANA, showed negative correlations with lipid 
peroxidation and lesion volume at more time points than for 3HANA alone.  In addition, 
the K:T ratio correlated negatively with the 3HANA: ANA ratio but not with 3HANA or 
ANA themselves, indicating that the extent of kynurenine pathway activation was related 
to decreased 3HANA: ANA ratios.  One possible mechanism for the increased levels of 
ANA and decreased levels of 3HANA is reduced activity of the enzyme, KMO, which 
produces 3HKYN, followed by 3HANA, from kynurenine.  This could also account for the 
higher ANA levels measured, as kynurenine could not be metabolised via its preferred 
route to 3HKYN and would therefore be metabolised to ANA by the enzyme, 
kynureninase.  This hypothesis suggests that the levels of 3HANA and ANA would be 
closely related but these metabolites only correlated at 1 of the 6 time points in the stroke 
study, indicating that they may behave more independently of each other.  It was 
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unfortunate that 3HKYN and QUIN were not measured for the stroke patients, as the HD 
and brain injury results suggest that 3HKYN concentrations in the blood may also have 
been reduced. 
It is possible that the reduced levels of 3HKYN and 3HANA contribute to increased 
activity of the immune system, as both metabolites can regulate the immune system by 
suppressing T cell proliferation (Bauer et al., 2005).  Enhancing the immune response 
would include increased activation of microglia, which are thought to be instrumental in 
producing brain damage in HD (Sapp et al., 2001), stroke (Dirnagl et al., 1999) and TBI 
(Sahuquillo et al., 2001).  In addition, more macrophages would be able to infiltrate the 
brain and contribute to the neuronal damage in stroke and TBI (Dirnagl et al., 1999; 
Sahuquillo  et al., 2001).  Activated microglia and macrophages produce neurotoxins 
including cytokines, nitric oxide and reactive oxygen species. 
Guidetti et al. (2004) demonstrated that QUIN was increased in post-mortem brains from 
patients with grade 1 HD but not in brains of later stages of HD.  This suggests that the 
neurotoxicity is initiated by the excitotoxin, QUIN.  Our results agreed with this work as 
there was no change in QUIN in the blood of patients at late stage HD.  However it was 
unexpected that the reduced levels of 3HKYN and 3HANA in the blood of HD and chronic 
brain injury patients did not reduce the levels of QUIN produced.  This supports the 
hypothesis that 3HKYN and 3HANA are produced in the blood following activation of the 
kynurenine pathway, but are rapidly transported (3HKYN only) to the brain, autoxidised or 
metabolised to QUIN, resulting in low levels being detected.   
There is some evidence from our studies to support the hypothesis of Guidetti et al. (2000) 
for HD, which states that increased metabolism through the 3HKYN/QUIN branch 
compared with the KYNA branch is involved in HD neurodegeneration.  At the initial 
baseline for both HD and chronic brain injury, the QUIN: KYNA ratios were slightly 
higher in patients compared with controls, although they were not significant.  These 
higher QUIN: KYNA ratios, together with the highly significant reduction in KAT activity 
for both studies, offer some support for this HD hypothesis.     
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7.2  Kinetics of Tryptophan Metabolism in Huntington’s 
Disease and Chronic Brain Injury Patients 
As the kynurenine pathway is the major metabolic pathway for tryptophan in most tissues, 
after protein synthesis, oral tryptophan depletion and loading resulted in large changes in 
all the kynurenine metabolites measured in the blood.     
With the small number of samples in the HD and chronic brain injury studies, there will be 
fewer significant effects than would be expected with a larger sample group.  However, it 
was remarkable that the HD patients and the chronic brain injury patients showed 
extremely similar tryptophan metabolism and kinetics of the kynurenine pathway on 
depletion and loading.  Indeed, even the neopterin and lipid peroxidation responses were 
very similar at baseline and after loading.  These studies have demonstrated strong 
similarities in kynurenine pathway metabolism between the neurodegenerative HD and 
chronic brain injury, mainly initiated by a traumatic injury.     
Both HD and chronic brain injury patients may use less tryptophan for other metabolic 
processes, such as protein synthesis, than controls, as both groups of patients had higher 
levels of tryptophan at 5 hours after trytophan depletion.  Further evidence of this was 
observed in the chronic brain injury patients, where the tryptophan load also produced 
higher levels of tryptophan than the controls.  Although it was only at these extreme 
conditions of depletion or loading that this difference in tryptophan metabolism was 
observed, the increased tryptophan metabolism to kynurenine would be expected to have 
the opposite effect and lower the tryptophan levels in these patients’ samples.  Therefore, it 
is hypothesised that HD and chronic brain injury patients use less tryptophan for other 
metabolic processes, such as protein synthesis. 
The HD patients demonstrated increased IDO activity (measured as K:T ratios) throughout 
the depleting and loading protocols, although the significance was lost after loading, but 
tryptophan depletion caused the K:T ratios for the chronic brain injury patients to become 
much more similar to controls at the second baseline and lower than controls after loading.  
This suggests that there is a stronger link with kynurenine pathway activity in HD than in 
chronic brain injury.  Although neopterin levels were higher in HD and chronic brain 
injury patients than in controls at baseline, there were no significant differences between 
neopterin levels after loading, suggesting that this similar level of inflammation after 
loading will produce similar IDO activity in both patients and controls.  Werner et al. 
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(1988) demonstrated that increasing tryptophan concentrations from 50 to 500µM inhibited 
IDO activity in human cells in culture.  Tryptophan loading may inhibit IDO in the chronic 
brain injury patients to a greater extent than in the HD patients.  A tryptophan load will 
enhance TDO activity (Schutz et al., 1972), but this would be expected to be similar for 
both patients and controls.   
The hypothesis that inflammation may be inactivating KAT in the patients with these 
chronic disorders was suggested by the increased neopterin levels in the patients at 
baseline.  The KAT activity in the chronic brain injury patients, which had been inactivated 
at baseline, was increased compared with controls after loading.  On loading, this increase 
in KAT activity paralleled decreases in IDO activity, confirming the strong relationship 
between the activities of these enzymes.  For HD, the low KAT activity at baseline and 
after depletion was returned to levels similar to the controls after loading.  After loading, 
where there was no inactivation of KAT, neopterin levels were similar in patients and 
controls, supporting the hypothesis that inflammation may be inactivating KAT. 
It was interesting that the elevated levels of 3HKYN and 3HANA after the tryptophan 
loading, remained lower than controls for both the HD and chronic brain injury patients, 
although there were marked changes in IDO and KAT activity.   
For HD and chronic brain injury patients after an oral tryptophan load, there was a delayed 
response for increases in QUIN compared with all the other kynurenine metabolites, 
including KYNA.  In agreement with this effect, Jauch et al. (1993) demonstrated that 
serum QUIN levels rose much more slowly than KYNA levels with intravenous 
administration of kynurenine in rhesus monkeys.  KYNA levels peaked within 10 minutes 
of the kynurenine load, and then gradually declined over the remainder of the 4 hours of 
the study, whereas the QUIN concentrations increased steadily to reach a maximum after 
approximately 90 minutes, with levels being maintained at this maximum until the end of 
the study at 4 hours.  The decline in KYNA levels in the blood was suggested to be due to 
efficient urinary excretion.  The rapid decline in KYNA levels observed in the blood for 
these monkeys may suggest that for our study, the maximum levels of all the tryptophan 
metabolites in the blood may not occur at 5 or 7 hours after oral loading.  However, there 
were significant increases at 5 hours after the tryptophan load, with concentrations having 
decreased between 5 and 7 hours for all the kynurenines measured, with the exception of 
QUIN.  This suggests similar response times to the tryptophan load for the measured 
kynurenines except QUIN.   
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Often the differences in the levels of tryptophan metabolites between patients and controls 
were similar at baseline and after tryptophan depletion.  Depletion of tryptophan therefore 
did not appear to have a beneficial effect compared to a normal diet.  Tryptophan loading 
increases the levels of the neurotoxic tryptophan metabolites in both patients and controls, 
but it is the balance between the neurotoxic kynurenines (QUIN, 3HKYN and 3HANA) 
and the neuroprotective KYNA, that may be more important than the actual concentrations. 
After tryptophan loading, the potentially detrimental effects of increased IDO activity and 
reduced KAT activity were lost for both the HD and chronic brain injury patients.  This 
suggests that tryptophan loading may be beneficial for HD and chronic brain injury 
patients.  However, the QUIN data indicated a possible build up of QUIN over time after 
loading in HD patients and therefore tryptophan loading cannot be justified as a 
neuroprotective measure. 
7.3  Tryptophan Loading Induces Oxidative Stress 
An unexpected result from the HD and chronic brain injury studies was an increase in lipid 
peroxidation after tryptophan loading in the healthy control subjects.  Tryptophan 
administration has previously been reported to increase lipid peroxidation in rats (Aviram 
et al., 1991).  In conjunction with this, an increase in the inflammatory response was also 
shown after loading in the healthy controls.  These results suggest that tryptophan loading 
may be harmful and therefore care should be taken if tryptophan loading is being used to 
investigate the effects of increasing 5HT in the brain in relation to depression, or in a diet 
such as the Atkins diet, which involves a chronically raised intake of tryptophan.  It should 
be noted that the high dose of 6g tryptophan resulted in increased lipid peroxidation in this 
study, whereas much lower doses (1g tryptophan taken three times a day) are more 
common for use in depression studies (Shaw et al., 2002).  A tryptophan load can be used 
in the treatment of depression as patients seek the use of a ‘natural alternative’ to 
prescribed antidepressants, but has the side effects of nausea and gastrointestinal distress 
(Shaw et al., 2002).  Tryptophan ingestion has been associated with Eosinophilia –Myalgia 
Syndrome, which affected nearly 1500 people in 1989 and led to over 30 deaths.   
However, this outbreak was traced to a contaminant in the biotechnologically 
manufactured tryptophan from one manufacturing source (Simat et al., 1999) and there 
remains no evidence for toxicity associated with tryptophan ingestion. 
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7.4  Changes in Kynurenines with Time and Severity of 
Stroke 
The initial alterations in the kynurenine pathway observed one day after the stroke did not 
change over the next 14 days.  In addition, the elevated neopterin levels and lipid 
peroxidation remained very similar, although there was a trend for the lipid peroxidation to 
decrease slightly over time.  From animal studies, a delay in the maximum kynurenine 
pathway activity was expected, which peaked at 4 days and then returned to normal within 
14 days (Saito et al., 1993b) but this was not seen in our study.  As macrophages 
infiltrating the brain have been implicated as a major contributor to the increased IDO 
activity and increased levels of QUIN in the brain following ischaemia in animals (Saito et 
al., 1993c), macrophage activation may take place earlier in the blood and therefore 
changes in kynurenine pathway activity in the brains of the patients may still be delayed.  
The immediate effect of the alterations in the kynurenine pathway for stroke patients is 
consistent with the failure of NMDA antagonists in stroke clinical trials.  One reason for 
the failure was attributed to these drugs not being able to be administered to the patients 
until many hours after the stroke, as time had elapsed between the stroke occurrence and 
the patients reaching hospital (Green and Shuaib, 2006).  Alternatively, as IDO activity 
was demonstrated in the initial blood sample one day after stroke, patients may have 
greater IDO activity before the stroke occurred, which may contribute to the patients’ 
susceptibility to stroke.   
Various excitotoxic compounds, including the NMDA receptor agonist QUIN, have been 
shown to induce KYNA synthesis in response to excitotoxicity (Wu et al., 1992; Guidetti 
et al., 1997; Ceresoli-Borroni et al., 1999).  Increased excitotoxicity may be a possible 
explanation for the higher levels of KYNA in the blood of patients who died within 3 
weeks of having a stroke.  As excitotoxicity generates free radicals, one possible 
mechanism for these increases in KYNA formation is from the generation of nitric oxide, 
as nitric oxide donors have been shown to increase the production of KYNA in cortical 
brain slices (Luchowski and Urbanska, 2007).  Indeed, neopterin, which was elevated in 
this study, has been implicated in the production of nitric oxide, although neopterin levels 
were not increased in the patients who died.  In addition, in the presence of oxygen free 
radicals, KYNA can be produced from IPA (Bartolini et al., 2003).  Elevated levels of 
KYNA can cause excessive NMDA receptor blockade which may be related to the 
cardiovascular side effects observed with NMDA receptor inhibitors in stroke clinical trials 
(Dirnagl et al., 1999).  Extremely high levels of KYNA (greater than 125µM) can reduce 
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mitochondrial ATP synthesis (Baran et al., 2003) and although much lower levels were 
observed in the patients who died in our study (mean at day 1 was 83nM), it is possible 
that local levels in the brain in these patients may be high enough to cause this effect.   
7.5  Relationship Between Blood and Brain Levels of 
Kynurenines 
Clearly, there are drawbacks to studying kynurenine pathway metabolites in the blood 
when it is their action in the CNS that is of primary concern.  It is likely that the 
concentrations of kynurenines in the blood are partly due to tryptophan metabolism in the 
liver.  However, if changes in kynurenine pathway activity can be observed in the blood in 
neurological disorders, blood samples would provide much more readily obtainable 
samples for further studies of these disorders and may provide useful markers for the 
disorders.  It is important to examine living patients as opposed to post-mortem brains or 
animal models of a disease because potential therapies that could be developed from the 
results of this study would be applicable to living patients.  Ideally, CSF would have been 
used in these studies but we could not justify ethically taking CSF from these patients.    
Tryptophan, kynurenine and 3HKYN can be transported between the plasma and the brain 
by the large neutral amino acid carrier (Fukui et al., 1991).  With healthy primates (rhesus 
monkeys), intravenous administration of kynurenine was shown to increase levels of 
KYNA and QUIN in both the serum and the CSF (Jauch et al., 1993).  This demonstrates 
that all the enzymes required to synthesis QUIN and KYNA from kynurenine were active 
in both the periphery and the brains of healthy primates.  Since the synthesis of QUIN and 
KYNA were elevated in proportion to the dose of kynurenine (maximum 200mg/kg), none 
of the enzymes were saturated with substrate, suggesting that the availability of kynurenine 
is the main determinant for the production of QUIN and KYNA in both the periphery and 
the brain, in agreement with IDO/TDO being the rate-limiting step of the kynurenine 
pathway.  A systemic tryptophan load can produce large increases in QUIN in the rat brain 
(Heyes and Markey, 1988; During et al., 1989).  KYNA is known to be readily produced 
from kynurenine in the human brain (Okuno and Kido, 1991).  As systemic administration 
of tryptophan and kynurenine has been shown to alter the kynurenine pathway in both the 
blood and brain, and tryptophan, kynurenine and 3HKYN can be transported between the 
blood and the brain, the levels of kynurenine metabolites in the blood were expected to 
reflect the levels in the brain.     
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A difference between the concentrations of kynurenines in the blood and brain was shown 
by the different rates of KYNA and QUIN production and excretion in the blood of rhesus 
monkeys (Jauch et al., 1993).  Following intravenous kynurenine administration, the 
steady decline in KYNA concentrations in the blood was attributed to efficient urinary 
excretion of KYNA.  There is also active organic acid efflux out of the CNS, which 
maintains the lower levels of kynurenines in the brain than in the blood, and has been 
demonstrated to reduce the concentrations of KYNA and QUIN in the brain (Miller et al., 
1992; Morrison et al., 1999).  With breakdown of the blood-brain barrier, which has been 
demonstrated in ischaemia and TBI (Skinner et al., 2006; Habgood et al., 2007), the small 
kynurenines would be able to pass more freely from the blood to the brain, particularly in 
the areas of brain damage.  Organic acid efflux and breakdown of the blood-brain barrier 
may influence the proportional relationship between the kynurenine levels in the blood and 
brain.  
Tryptophan in the blood can be free or bound to plasma albumin.  It has a very high level 
of protein binding (about 95%) (Reilly et al., 1997).  Most of the kynurenines may also 
bind to albumin in plasma.  There have been contrasting reports for kynurenine binding, 
with Joseph and Kadam (1979) and Cangiano et al. (1999) showing that kynurenine did 
bind to albumin but Fukui et al. (1991) demonstrated no significant binding to plasma 
protein.  The acids of the kynurenine pathway (KYNA, QUIN, ANA, 3HANA) have also 
been shown to bind to plasma albumin, however, at physiological pH and temperature, 
QUIN, but not the other acids, was in a free state (Fukui et al., 1991).  Only unbound 
tryptophan and kynurenine pathway metabolites are available for transport across the 
blood-brain barrier (Fukui et al., 1991). 
7.6  Comparison with Reported Concentrations of 
Kynurenines in Healthy Human Blood 
The concentrations of kynurenines in healthy human blood measured in this project were 
compared with concentrations quoted in the literature.  The mean tryptophan levels for the 
control plasma samples for the HD and chronic brain injury studies was 73.6 ± 3.5 μM 
(mean ± SEM), very similar to levels quoted in many papers in the literature (Heyes et al., 
1994; Widner et al., 2000; Pertovaara et al., 2006).  For the stroke study, the tryptophan 
levels were lower in the healthy controls (mean 54.0 ± 2.1 μM), but were still within the 
range quoted in the literature (Saito et al., 2000; Frick et al., 2004).  The range of reported 
kynurenine concentrations in healthy human blood was from 1.35μM to 3.27μM (Joseph 
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and Risby, 1975; Heyes et al., 1994; Hervé et al., 1996), which was slightly higher than the 
mean level of 1.13 ± 0.28 μM for the control plasma samples for the HD and chronic brain 
injury patients, with the concentration of 2.28 ± 0.10 μM in the serum of the stroke 
controls being very similar to literature values.  Levels of KYNA in healthy controls were 
46.7 ± 0.6 nM and 37.5 ± 2.9 nM for the HD/chronic brain injury and stroke studies 
respectively, compared with reported serum KYNA levels of between 23nM and 59.6nM 
(Heyes et al., 1994; Hervé et al., 1996; Ilzecka et al., 2003; Fukushima et al., 2007).  The 
reported concentration of 3HKYN in healthy human plasma was 32nM and another report 
quoted 383nM in human plasma (Pearson and Reynolds, 1991; Heyes et al., 1994).  The 
method used in the HD and chronic brain injury studies showed a concentration of 232 ± 
47 nM for healthy controls.  The concentration of 3HANA in healthy controls for the 
HD/chronic brain injury studies was 177 ± 49 nM using the electrochemical method, but 
23.7 ± 1.6 nM using the fluorescence method for the stroke controls.  Literature levels of 
3HANA in healthy human serum were 79nM and 24.2nM (Hervé et al., 1996; Arbatova et 
al., 2005).  There are, therefore, some discrepancies between the levels of 3HKYN and 
3HANA in human plasma or serum both in the literature and from the results of this 
project, which is likely to be due to the use of different methods of analysis.  The 
electrochemical method used in this project for the determination of 3HKYN and 3HANA 
for the HD and chronic brain injury studies had low sensitivity and was superceded by the 
fluorescent method for measuring 3HANA concentrations for the stroke study.  The levels 
of QUIN measured for the healthy controls in the HD and chronic brain injury studies was 
1540 ± 830 nM, higher than reported concentrations of 432nM and 267nM (Heyes et al., 
1991a; Vogelgesang et al., 1996).  This high mean level of QUIN may have been due to 
the high variablility in the QUIN measurements for the HD and chronic brain injury 
studies. 
7.7  Effect of Age 
An additional observation from this study is that the age of the subjects correlated with the 
K:T ratio and KYNA concentrations, as well as with neopterin.  Blood neopterin and K:T 
ratio have been shown to increase with the age of the subject (Frick et al., 2004).  It was 
suggested that ageing in healthy people is associated with immune activation.  In our work, 
age and neopterin correlated for the healthy controls in the stroke study and for the stroke 
and chronic brain injury patients.  Similarly, there were correlations between age and the 
K:T ratio (a measure of IDO activity) for the stroke controls and patients at several time 
points.  The stroke study incorporated a larger group of patients and controls than the HD 
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and chronic brain injury studies, which accounts for more correlations observed with age 
from this study.  In addition, the patients and controls in the stroke study were older than in 
the HD and chronic brain injury studies, which suggests that old age may increase 
neopterin and K:T ratios at a faster rate than for younger people.  In a study with 
nonagenarians, IDO activity, measured by the K:T ratio in the blood, was shown to be 
markedly increased and higher IDO levels were shown in the subjects who died in the 
following four years (Pertovaara et al., 2006).  Increased IDO activity was suggested as a 
mechanism involved in the decline of T cell responses with old age. 
Interestingly, there were correlations between age and KYNA levels, for HD and chronic 
brain injury controls and for stroke controls.  This correlation was also observed for stroke, 
HD and brain injury patients but at fewer time points than for the controls.  This agrees 
with Moroni et al. (1988) who reported that brain and blood levels of KYNA increase with 
age in rats.  In human healthy controls for a stroke study where the subjects were elderly, 
serum KYNA levels correlated with age (Urbanska et al., 2006).  As it was only the K:T 
ratio and KYNA levels that correlated with age at several time points, it suggests that on 
ageing, increased kynurenine is produced which is converted to KYNA rather than   
metabolising via the other branches of the kynurenine pathway.  This is in direct contrast 
with the apparent inhibition of KAT by IDO shown in the HD and chronic brain injury 
studies.  However, levels of QUIN in the CSF have also been reported to increase with age 
(Heyes et al., 1992a).  The correlations with age demonstrate the importance of having age 
matched patients and controls in studies of the kynurenine pathway.     
7.8  Future Work 
One of the major findings of this work was the decreased concentrations of 3HKYN and 
3HANA in the blood of patients with HD and chronic brain injury.  There is much 
evidence demonstrating that 3HKYN is elevated in HD post-mortem human brain (Pearson 
and Reynolds, 1992; Guidetti et al., 2000), and an increase in 3HKYN was expected in the 
blood of HD patients.  Most reported studies on kynurenines in HD have focused on post-
mortem brain from human HD sufferers, although more recently the use of transgenic 
animal models of HD has begun (Guidetti et al., 2006).  Little is known about blood levels 
of the kynurenines in HD.  Future work is required to clarify if 3HKYN and 3HANA 
concentrations are elevated in the brain but decreased in the blood in HD.  There are 
several genetic mouse models of HD, and using one of these would be useful to measure 
kynurenines in both blood and brain tissue.  Guidetti et al. (2006) showed that 3HKYN 
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was increased in the striatum and cortex of three HD mouse models: transgenic R6/2 mice 
(expressing a short mutant htt fragment), YAC128 mice (expressing full length human htt) 
and Hdh
Q92 and Hdh
Q111 knock-in mice (expressing mutant htt with 92 or 111 glutamines 
respectively).  The use of one of these mouse models would be ideal as 3HKYN has been 
shown to be increased in these brains, as it is in human HD brains.  In addition to 
measuring 3HKYN and 3HANA, determining the levels of tryptophan, kynurenine and 
KYNA as before in both the blood and brains of a transgenic HD mouse model would be 
useful to examine changes occurring throughout the pathway.  As there was a significant 
increase in ANA for the stroke patients, it would also be useful to measure ANA in the 
transgenic HD mouse model.  Furthermore, other pathway metabolites, which have not 
been determined previously may also be important, in particular, 5-hydroxyanthranilic acid 
and picolinic acid.   5-Hydroxyanthranilic acid, as well as 3HANA, can be produced from 
ANA, and this may be especially relevant as the 3HANA levels decreased in HD patients' 
blood.  Concentrations of picolinic acid, but not quinolinic acid, were significantly 
elevated in a mouse model of cerebral malaria (Clark et al., 2005), and it would be 
interesting to investigate if picolinic acid is important in HD.  5-Hydroxyanthranilic acid 
can be measured using HPLC and fluorescence detection and picolinic acid is determined 
by GC-MS. 
As the ANA concentrations increased in the stroke study, bloods of the HD and chronic 
brain injury patients will be re-extracted and ANA levels will be determined, to investigate 
whether ANA was also increased for these patients. 
It is ethically unjustifiable to take CSF from any of the patients involved in this work.  
Further studies using patients’ blood samples would be useful to clarify the observations 
made in this project.  The stroke study was a preliminary study and as abnormalities in the 
kynurenine pathway were observed, further work in patients with acute ischaemic stroke 
would be useful.  Stroke patients are accessible and a large patient group, with ischaemic 
stroke of similar severity, could be assessed, with measurements taken at one specific time 
point within two weeks of the stroke.  To determine if the lower levels of 3HKYN in blood 
from patients is due to less 3HKYN being produced by KMO from kynurenine, white 
blood cells, collected as the mononuclear cell layer, could be used to determine the 
expression of KMO in patients and healthy controls using Western blotting.  The low 
levels of 3HKYN and 3HANA in patients may be due to autoxidation at a high rate, and to 
investigate this hypothesis, the products of autoxidation could be measured, involving 
HPLC with mass spectrometry for product identification.  Oxidation products of 3HKYN 
that could be determined are xanthommatin, hydroxyxanthommatin and 4,6-
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dihydroxyquinolinequinonecarboxylic acid (DHQCA) (Vazquez et al., 2000).  Similarly, 
five oxidation products of 3HANA including cinnabarinic acid can be determined 
(Iwahashi, 1999).   HPLC methods for these compounds could be developed in our 
laboratory. 
This project has shown the potential importance of 3HKYN in neurological disorders, and 
therefore developing a more sensitive HPLC method for its determination would be very 
valuable.  Further work will continue to pursue the SPE route for sample preparation for 
3HKYN measurement in serum.  3HKYN levels could then be measured in the serum of 
the stroke patients. 
QUIN levels appeared to be increasing at 7 hours after a tryptophan load was administered 
to HD and chronic brain injury patients, but no further blood samples were taken to 
determine if this increase continued.  It would be interesting to assess if QUIN levels 
continued to rise in patients after a tryptophan load at later time points and to determine 
when QUIN levels started to decrease or return to normal.  This would indicate how long 
the neurotoxin, QUIN, remains elevated in these patients after ingesting high 
concentrations of tryptophan.  
7.9  Conclusions 
It was interesting to compare patients with the neurodegenerative disease, HD, with others 
who were suffering brain injury, both those in a clinically stable condition with severe 
chronic brain injury, mainly caused by a traumatic injury, and those immediately after 
acute stroke. 
Methods were developed and validated for the determination of the concentrations of 
tryptophan, kynurenine, KYNA, ANA, 3HKYN and 3HANA in plasma or serum.  The 
method for 3HKYN had low sensitivity. 
This project has demonstrated increased IDO activity, measured by an increase in the K:T 
ratio, in the blood of HD, chronic brain injury and stroke patients.  The increased IDO 
activity indicates activation of the kynurenine pathway, and alterations in the 
concentrations of kynurenines have been observed for all three disorders.  
After oral tryptophan depletion, the differences in the concentrations of kynurenines 
observed at baseline, between HD or chronic brain injury patients and controls, were 
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maintained.  Tryptophan loading increased the levels of all the kynurenine metabolites and 
there were fewer differences between patients and controls.  Tryptophan loading may be 
detrimental for healthy subjects as it was shown to induce lipid peroxidation and 
inflammation. 
There were no changes in the levels of any of the kynurenines in the 14 days following an 
acute stroke.  Patients who died during the study or immediately afterwards (within 3 
weeks of the stroke) had high levels of KYNA in their blood.  
The increase in IDO activity was accompanied by an increase in the inflammatory marker, 
neopterin, for each disorder, suggesting that IDO may be activated by inflammatory 
mediators.  Neopterin was significantly increased in the chronic disorders (HD and chronic 
brain injury) showing that inflammation persists several years after the original brain injury 
and that inflammation is involved in late stage HD.  The high lipid peroxidation for the HD 
and chronic brain injury patients suggested that high levels of oxidative stress were 
contributing to progressive neurodegeneration in HD and to continuing brain damage in 
chronic brain injury. 
In the HD and chronic brain injury patients, there was low KAT activity, suggesting a lack 
of production of the neuroprotectant, KYNA, which may be triggered by chronic 
inflammation and increased IDO activity. 
The most interesting and novel result from this project was the low levels of 3HANA 
determined in all three disorders, and the associated low levels of 3HKYN in the HD and 
chronic brain injury patients.  Unfortunately, 3HKYN was not measured in the stroke 
patients.  The increased levels of ANA and the 3HANA: ANA ratio may also be of key 
importance in stroke.     
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Appendix 
Methods carried out by others 
Quinolinic Acid by GC-MS  (Dr J. Christofides and Dr M. Egerton, 
West Park Biochemistry Laboratories, Epsom General Hospital, 
Epsom, Surrey, UK)  
Levels of quinolinic acid were measured by GC-MS of the t-butyldimethylsilyl derivative, 
after sample clean up using SPE.  1ml plasma was mixed with dipicolinic acid (the internal 
standard) and acetate buffer at pH 2.0-2.2.  SPE sample cleanup was with a Waters SepPak 
C18 cartridge, with quinolinic acid being eluted in 2% ammonia in methanol.  Prazepam 
was added to the sample eluate as an extra recovery standard and the mixture was dried.  
Derivatisation was achieved by adding N-methyl-N-(tert-
butyldimethylsilyl)trifluoroacetamide and 1% tert-butyldimethylchlorosilane and 
incubating for 2h at 90°C.  The derivatised extract was analysed by GC-MS using a 
Thermo GC8000 and MD800 quadrupole mass detector.  1μl sample was injected using 
splitless injection at 190°C on to a 30m x 0.2mm RTX5 GC column.  The GC oven 
temperature was increased from 120°C to 230°C over 5 minutes followed by a rise to 
260°C over 16 minutes. The detector, using electron impact at 70eV, was set to maximum 
voltage monitoring ions at mass/charge ratio (m/z) of 338.1 and 380.1 with a dwell time of 
0.3 seconds. 
Standard clinical assays – ESR and CRP (Haematology and 
Immunology Laboratories, Epsom General Hospital, Epsom, 
Surrey, UK) 
Erythrocyte sedimentation rate (ESR) was determined as a marker of inflammation.  ESR 
is measured as the distance a column of anticoagulated blood will fall under gravity in 1 
hour.  Red blood cells have a surface charge which prevents them from coming too close to 
each other.  With infection or inflammation, there is increased production of fibrinogen 
and other large charged molecules that allow the red blood cells to come closer to each 
other and fall faster in an ESR test.  ESR was measured by a StaRRsed Automated ESR 
machine (RR Mechatronics) which utilises the method recommended by the International 
Council for Standardization in Haematology (1933).  
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C-reactive protein (CRP) is another measure of acute inflammation.  In blood, levels of 
CRP, an acute phase reactant, rise dramatically with inflammation.  CRP was measured 
using a Behring Turbitimer. 
 
Neopterin assay (Dr C.M. Forrest and Ms L. Oxford, NABS, IBLS, 
University of Glasgow, Glasgow, UK) 
Neopterin levels were measured in 10μl aliquots of serum using an enzyme linked 
immunosorbent assay (ELISA) kit (Immunobiological Laboratories, Germany). The assay 
was a competitive ELISA where a peroxidase-conjugated neopterin competed with sample 
neopterin for a fixed number of antibody binding sites.  Peroxidase- conjugated neopterin-
antibody complexes bind to the wells of the plate, coated with another antibody.  The plate 
is incubated with shaking to enable the reactions to occur.  Unbound peroxidase-
conjugated neopterin is removed by washing using a plate washer.  Following incubation 
with substrate solution, colour developed depending on the level of bound peroxidase 
complexes.  The optical density is inversely proportional to the neopterin concentration of 
the sample.  The optical density was read at 450nm using a plate reader.  Neopterin 
standards of known concentrations were assayed together with the samples, and were used 
to prepare a calibration curve for quantifying the samples.  All samples were analysed in 
duplicate. 
 
Lipid peroxidation products (Dr C.M. Forrest and Ms L. Oxford, 
NABS, IBLS, University of Glasgow, Glasgow, UK) 
The concentrations of the lipid peroxidation products malondialdehyde and 4-
hydroxyalkenals in serum samples were measured using a Bioxytech LPO-586 
colorimetric assay (Biostat).  Lipid peroxidation products in 100μl of serum, stabilised 
with BHT, were reacted with N-methyl-2-phenylindole in methanesulfonic acid at 45ºC to 
form a stable chromogenic indolic dimer.  The reaction mixture was centrifuged in 
Anopore filter tubes to clarify the solutions.  The absorbance was measured 
spectrophotometrically at 595nm and malondialdehyde and 4-hydroxyalkenals quantified 
from a calibration curve of 4-hydroxynonenal standards.  All samples were tested in 
duplicate. 
 